hypothesis,evidences,label
"Patients with cytologically confirmed breast cancer, who's Locally recurrent disease is amenable to radiation with curative intent are not eligible for NCT00656019, but are eligible for NCT01506609.","[""Inclusion Criteria:"", ""  Histologically or cytologically confirmed breast cancer that is either locally recurrent or metastatic."", ""  Locally recurrent disease must not be amenable to surgical resection or radiation with curative intent.""]",Contradiction
"Women with leptomeningeal metastases are unfortunately excluded from NCT00627978, as it would prevent them from giving informed consent to study entry.","[""  Exclusion Criteria"", ""  Patients with known and active brain and/or leptomeningeal metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.""]",Contradiction
Cohort 1 of NCT02513472 produced better Objective Response Rate results than cohort 2.,"[""Outcome Measurement: "", ""  Objective Response Rate (ORR)"", ""  ORR was defined as percentage of participants with confirmed best overall response (BOR) of complete response (CR) or partial response (PR) using independent imaging review (IIR) based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. BOR of CR and PR was confirmed by a subsequent CR assessment and CR or PR assessment, respectively at least 4 weeks later. CR: disappearance of all measurable, non-measurable lesions and no unequivocal new lesions. Any pathological lymph nodes (target or non-target) had to be reduced in short axis to less than (<) 10 millimeter (mm). PR: at least a 30 percent (%) decrease in sum of diameters (SOD) of target lesions, taking as reference the baseline SOD and there are no unequivocal new lesions, and no progression of non-target disease. The 2-sided 95% confidence interval (CI) calculated by Clopper-Pearson method. As planned, data up to the primary completion date only were analyzed."", ""  Time frame: From date of first dose of study drug administration to date of first documentation of disease progression or death, whichever occurred first (up to 3 years 11 months)"", ""Results 1: "", ""  Arm/Group Title: Stratum 1: Eribulin Mesylate + Pembrolizumab"", ""  Arm/Group Description: Participants with mTNBC who were never treated with systemic anticancer therapy in the metastatic setting received eribulin mesylate 1.4 mg/m^2, intravenous infusion on Days 1 and 8 and pembrolizumab 200 mg, intravenous infusion on Day 1 in Treatment Cycle 1 (safety run-in, Phase 1b) and then continued in each 21-days Treatment Cycles in the presence of clinical benefit until confirmed disease progression, development of unacceptable toxicity, participant request, withdrawal of consent, or study termination by the sponsor in Phase 2 in the Stratum 1."", ""  Overall Number of Participants Analyzed: 66"", ""  Measure Type: Number"", ""  Unit of Measure: percentage of participant  25.8        (15.8 to 38.0)"", ""Results 2: "", ""  Arm/Group Title: Stratum 2: Eribulin Mesylate + Pembrolizumab"", ""  Arm/Group Description: Participants with mTNBC previously treated with 1 to 2 lines of systemic anticancer therapy in the metastatic setting received eribulin mesylate 1.4 mg/m^2, intravenous infusion on Days 1 and 8 and pembrolizumab 200 mg, intravenous infusion on Day 1 in Treatment Cycle 1 (safety run-in, Phase 1b) and then continued in each 21-days Treatment Cycles in the presence of clinical benefit until confirmed disease progression, development of unacceptable toxicity, participant request, withdrawal of consent, or study termination by the sponsor in Phase 2 in the Stratum 2."", ""  Overall Number of Participants Analyzed: 101"", ""  Measure Type: Number"", ""  Unit of Measure: percentage of participant  21.8        (14.2 to 31.1)""]",Entailment
NCT01237327 and NCT00030823 do not have any overlapping inclusion or exclusion criteria.,"[""Inclusion Criteria:"", ""  Previous participation in study 971-ONC-0028-080."", ""Exclusion Criteria:"", ""  Subjects who had not previously participated in study 971-ONC-0028-080.""]",Entailment
More than 2% of patients in NCT00129376 experienced a clinically significant inflammation of the back of the throat.,"[""Adverse Events 1:"", ""  Acute Pharyngitis * 1/63 (1.59%)""]",Contradiction
"compared to cohort 1 of NCT00475670, other than sudden death, there are more cases of every observed adverse event in cohort 2. ","[""Adverse Events 1:"", ""  Total: 0/3 (0.00%)"", ""  Febrile Neutropenia * 0/3 (0.00%)"", ""  Neutropenia * 0/3 (0.00%)"", ""  Sudden Death * 0/3 (0.00%)"", ""  Bacterial Infection * 0/3 (0.00%)"", ""  Bronchitis * 0/3 (0.00%)"", ""  Sepsis * 0/3 (0.00%)"", ""  Lymphoedema * 0/3 (0.00%)"", ""Adverse Events 2:"", ""  Total: 6/41 (14.63%)"", ""  Febrile Neutropenia * 1/41 (2.44%)"", ""  Neutropenia * 1/41 (2.44%)"", ""  Sudden Death * 1/41 (2.44%)"", ""  Bacterial Infection * 1/41 (2.44%)"", ""  Bronchitis * 1/41 (2.44%)"", ""  Sepsis * 1/41 (2.44%)"", ""  Lymphoedema * 1/41 (2.44%)""]",Contradiction
"Although there is a much higher percentage of patients with Enterocolitis in NCT01498458 than in cohort 1 of NCT03176238, no robust comparisons can be made due to the significant differences in cohort sizes.","[""Adverse Events 1:"", ""  Total: 59/199 (29.65%)"", ""  Anaemia 7/199 (3.52%)"", ""  Thrombocytopenia 2/199 (1.01%)"", ""  Acute myocardial infarction 0/199 (0.00%)"", ""  Atrial fibrillation 1/199 (0.50%)"", ""  Cardiac arrest 1/199 (0.50%)"", ""  Cardiac failure 1/199 (0.50%)"", ""  Cardiopulmonary failure 1/199 (0.50%)"", ""  Left ventricular failure 1/199 (0.50%)"", ""  Supraventricular tachycardia 0/199 (0.00%)"", ""  Ventricular tachycardia 1/199 (0.50%)""]",Contradiction
"There were more patients with significantly elevated blood pressure in cohort 1 of NCT01332630, than in cohort 1 of NCT00121134.","[""Adverse Events 1:"", ""  Total: 6/21 (28.57%)"", ""  Hypertension 3/21 (14.29%)"", ""  Edema 3/21 (14.29%)"", ""  Nausea 2/21 (9.52%)"", ""  Fracture 1/21 (4.76%)"", ""  Dizziness 3/21 (14.29%)"", ""  Syncope 2/21 (9.52%)"", ""  Headache 2/21 (9.52%)"", ""  Dyspnea 2/21 (9.52%)"", ""  Hypoxia 3/21 (14.29%)""]",Entailment
NCT00423917 and NCT00082641 both report cases of confusion in all their patient cohorts.,"[""Adverse Events 1:"", ""  Confusion 1/33 (3.03%)""]",Contradiction
There were more cases of Anemia and vomiting in NCT01091454 than NCT00054275.,"[""Adverse Events 1:"", ""  Total: 29/48 (60.42%)"", ""  Anemia 4/48 (8.33%)"", ""  Febrile neutropenia 7/48 (14.58%)"", ""  Atrial fibrillation 1/48 (2.08%)"", ""  Pericardial effusion 1/48 (2.08%)"", ""  Sinus bradycardia 1/48 (2.08%)"", ""  Nausea 2/48 (4.17%)"", ""  Vomiting 2/48 (4.17%)"", ""  Death NOS 1/48 (2.08%)"", ""  Fatigue 3/48 (6.25%)"", ""  Allergic reaction 1/48 (2.08%)"", ""  Lung infection 1/48 (2.08%)"", ""  Mucosal infection 1/48 (2.08%)""]",Entailment
NCT00365365 and NCT00005908 only recorded one type of acute adverse event.,"[""Adverse Events 1:"", ""  Total: 23/78 (29.49%)"", ""  Febrile neutropenia * 4/78 (5.13%)"", ""  Neutropenia * 1/78 (1.28%)"", ""  Thrombocytopenia * 0/78 (0.00%)"", ""  Acute coronary syndrome * 1/78 (1.28%)"", ""  Cardiac failure congestive * 1/78 (1.28%)"", ""  Myocardial infarction * 1/78 (1.28%)"", ""  Cardiomyopathy * 0/78 (0.00%)"", ""  Abdominal pain * 1/78 (1.28%)"", ""  Diarrhoea * 1/78 (1.28%)"", ""  Upper gastrointestinal haemorrhage * 1/78 (1.28%)""]",Contradiction
"Less than 5% of cohort 1 of NCT01931163 had LACRIMAL DISORDER, 0% of NCT00274469 patients were recorded as having LACRIMAL DISORDER.","[""Adverse Events 1:"", ""  Total: 6/22 (27.27%)"", ""  Thrombocytopenia  1/22 (4.55%)"", ""  leucocytopenia  1/22 (4.55%)"", ""  neutropenia  1/22 (4.55%)"", ""  papilledema  1/22 (4.55%)"", ""  Nausea  1/22 (4.55%)"", ""  hyperglycemia  1/22 (4.55%)""]",Contradiction
Patients must be over the age of 18 and have a life expectancy over 6 months to participate in NCT00193050.,"[""Inclusion Criteria:"", ""  Female Patients >18 years of age"", ""Exclusion Criteria:"", ""  Life expectancy of < than 6 months""]",Entailment
NCT00618826 and NCT02040857 only record 4 of the same adverse events.,"[""Adverse Events 1:"", ""  Lymphopenia 1/14 (7.14%)"", ""  Diarrhea 1/14 (7.14%)"", ""  Fatigue (asthenia, lethargy, malaise) 2/14 (14.29%)"", ""  Hypertension 2/14 (14.29%)""]",Entailment
Cohort 1 of NCT01416389 had more cases of urinary infections and lumbar fractures than cohort 2.,"[""Adverse Events 1:"", ""  Urinary tract infection 1/26 (3.85%)"", ""  Lumbar vertebral fracture 1/26 (3.85%)"", ""Adverse Events 2:"", ""  Urinary tract infection 0/13 (0.00%)"", ""  Lumbar vertebral fracture 0/13 (0.00%)""]",Entailment
More patients in cohort 1 of NCT00068341 experienced death progressive disease  than in cohort 2.,"[""Adverse Events 1:"", ""  Total: 6/15 (40.00%)"", ""  diarrhea and dehydration * 0/15 (0.00%)"", ""  Severe Dehydration * 1/15 (6.67%)"", ""  hypokalemia * 1/15 (6.67%)"", ""  pain, swelling, mastectomy site cellulitis * 0/15 (0.00%)"", ""  death progressive disease * 0/15 (0.00%)"", ""  divetricular abscess * 0/15 (0.00%)"", ""  fever * 1/15 (6.67%)"", ""  febrile neutropenia * 3/15 (20.00%)"", ""  Neutropenia * 0/15 (0.00%)"", ""Adverse Events 2:"", ""  Total: 4/14 (28.57%)"", ""  diarrhea and dehydration * 0/14 (0.00%)"", ""  Severe Dehydration * 0/14 (0.00%)"", ""  hypokalemia * 0/14 (0.00%)"", ""  pain, swelling, mastectomy site cellulitis * 0/14 (0.00%)"", ""  death progressive disease * 1/14 (7.14%)"", ""  divetricular abscess * 0/14 (0.00%)"", ""  fever * 0/14 (0.00%)"", ""  febrile neutropenia * 2/14 (14.29%)"", ""  Neutropenia * 0/14 (0.00%)""]",Contradiction
"NCT01743560 and NCT02435680 use best Overall Response (OR) as their evaluation metrics, however they use significantly different time frames.","[""Outcome Measurement: "", ""  Progression Free Survival (PFS) as Per RECIST v1.1 (by Local Investigator Assessment)"", ""  PFS Results presented for all MCS110 treated patients (with and without day 8 dose), in line with phase 2 study design."", ""  Time frame: 4 years""]",Contradiction
A total of 3 patients in cohort 1 of NCT02115984 experience a Herpes related adverse event.,"[""Adverse Events 1:"", ""  Total: 57/57 (100.00%)"", ""  Dry eyes  13/33 (39.39%)"", ""  Heartburn  9/33 (27.27%)"", ""  Nausea after the CT (before day 7)  57/57 (100.00%)"", ""  Herpetic eruption  0/33 (0.00%)"", ""  Dry skin  15/33 (45.45%)"", ""  Alopecia  57/57 (100.00%)"", ""Adverse Events 2:"", ""  Total: 23/23 (100.00%)"", ""  Dry eyes  2/11 (18.18%)"", ""  Heartburn  2/11 (18.18%)"", ""  Nausea after the CT (before day 7)  23/23 (100.00%)"", ""  Herpetic eruption  3/11 (27.27%)"", ""  Dry skin  9/11 (81.82%)"", ""  Alopecia  23/23 (100.00%)""]",Contradiction
Across both cohorts of NCT00284180 a total of two patients had low levels of oxygen in their body tissues.,"[""Adverse Events 1:"", ""  Total: 5/11 (45.45%)"", ""  Diabetes insipidus  [1]1/11 (9.09%)"", ""  Nausea 0/11 (0.00%)"", ""  Ileus 1/11 (9.09%)"", ""  Dehydration 1/11 (9.09%)"", ""  Vomiting 0/11 (0.00%)"", ""  Pain NOS  [2]2/11 (18.18%)"", ""  Pain - abdomen 0/11 (0.00%)"", ""  Fracture  [3]0/11 (0.00%)"", ""  Progressive Disease 1/11 (9.09%)"", ""  CNS Ischemia 1/11 (9.09%)"", ""  Respiratory Failure 0/11 (0.00%)"", ""  Hypoxia 1/11 (9.09%)"", ""Adverse Events 2:"", ""  Total: 8/21 (38.10%)"", ""  Diabetes insipidus  [1]0/21 (0.00%)"", ""  Nausea 1/21 (4.76%)"", ""  Ileus 0/21 (0.00%)"", ""  Dehydration 1/21 (4.76%)"", ""  Vomiting 1/21 (4.76%)"", ""  Pain NOS  [2]0/21 (0.00%)"", ""  Pain - abdomen 1/21 (4.76%)"", ""  Fracture  [3]1/21 (4.76%)"", ""  Progressive Disease 1/21 (4.76%)"", ""  CNS Ischemia 1/21 (4.76%)"", ""  Respiratory Failure 1/21 (4.76%)"", ""  Hypoxia 1/21 (4.76%)""]",Entailment
"Any women with stage 4 or Unresectable, locally recurrent cancer breast cancer are eligible for NCT00316199.","[""Inclusion Criteria:"", ""  Female patients of Chinese origin with histologically or cytologically proven diagnosis of breast cancer."", ""  Unresectable, locally recurrent breast cancer or stage IV disease.""]",Contradiction
NCT01808573 Patients receiving Neratinib Plus Capecitabine had a PFS  much longer than the study time frame of 38 months.,"[""Outcome Measurement: "", ""  Centrally Assessed Progression Free Survival"", ""  Progression Free Survival (PFS), Measured in Months, for Randomized Subjects of the Central Assessment. The time interval from the date of randomization until the first date on which recurrence, progression (per Response Evaluation Criteria in Solid Tumors Criteria (RECIST) v1.1), or death due to any cause, is documented. For subjects without recurrence, progression or death, it is censored at the last valid tumor assessment. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Here, the time to event was reported as the restricted mean survival time. The restricted mean survival time was defined as the area under the curve of the survival function up to 24 months."", ""  Time frame: From randomization date to recurrence, progression or death, assessed up to 38 months. The result is based on primary analysis data cut."", ""Results 1: "", ""  Arm/Group Title: Neratinib Plus Capecitabine"", ""  Arm/Group Description: neratinib 240 mg orally, once daily with food, continuously in 21 day cycles, and capecitabine 1500 mg/m^2 daily in 2 evenly divided doses, orally with water within 30 minutes after a meal, taken on days 1 to 14 of each 21 day cycle."", ""  Overall Number of Participants Analyzed: 307"", ""  Mean (95% Confidence Interval)"", ""  Unit of Measure: months  8.8        (7.8 to 9.8)"", ""Results 2: "", ""  Arm/Group Title: Lapatinib Plus Capecitabine"", ""  Arm/Group Description: lapatinib 1250 mg orally, once daily, continuously in 21 day cycles, and capecitabine 2000 mg/m^2 daily in 2 evenly divided doses, orally with water within 30 minutes after a meal, taken on days 1 to 14 of each 21 day cycle."", ""  Overall Number of Participants Analyzed: 314"", ""  Mean (95% Confidence Interval)"", ""  Unit of Measure: months  6.6        (5.9 to 7.4)""]",Contradiction
Neutropenia was the most common adverse event for patients in cohort 1 of NCT01427933.,"[""Adverse Events 1:"", ""  Total: 26/69 (37.68%)"", ""  Anaemia 2/69 (2.90%)"", ""  Febrile neutropenia 3/69 (4.35%)"", ""  Neutropenia 4/69 (5.80%)"", ""  Cardiac arrest 1/69 (1.45%)"", ""  Cardiac failure congestive 1/69 (1.45%)"", ""  Cardiac tamponade 1/69 (1.45%)"", ""  Pericardial effusion 1/69 (1.45%)"", ""  Abdominal pain 1/69 (1.45%)"", ""  Ascites 2/69 (2.90%)"", ""  Colitis 1/69 (1.45%)"", ""  Gastritis 1/69 (1.45%)"", ""  Gastritis erosive 1/69 (1.45%)""]",Entailment
Nausea and Death are two of the most common adverse events for patients in cohort 1 of NCT00951665,"[""Adverse Events 1:"", ""  Total: 7/26 (26.92%)"", ""  Febrile neutropenia 1/26 (3.85%)"", ""  Neutropenia 0/26 (0.00%)"", ""  Thrombocytopenia 0/26 (0.00%)"", ""  Cardiac failure congestive 0/26 (0.00%)"", ""  Extrasystoles 0/26 (0.00%)"", ""  Nausea 1/26 (3.85%)"", ""  Abdominal pain 0/26 (0.00%)"", ""  Constipation 0/26 (0.00%)"", ""  Gastrointestinal haemorrhage 0/26 (0.00%)"", ""  Death - unknown cause 1/26 (3.85%)"", ""  Thrombosis in device 0/26 (0.00%)""]",Entailment
NCT00110084 and NCT01961544 both reported cases of sepsis in their patients.,"[""Adverse Events 1:"", ""  Sepsis 1/50 (2.00%)""]",Entailment
"Patients must have AST, ALP and ALT < 1.5 ULN to participate in NCT02988986.","[""Inclusion Criteria:"", ""  Hepatic status: Serum total bilirubin  1 x upper limit of normal (ULN; in the case of known Gilbert's syndrome, a higher serum total bilirubin [< 1.5 x ULN] is allowed), aspartate aminotransferase and alanine aminotransferase  1.5 x ULN, and alkaline phosphatase  1.5 x ULN;""]",Entailment
"In the NCT00193063 patient cohort, 3 different types of infections are observed. ","[""Adverse Events 1:"", ""  Total: 14/41 (34.15%)"", ""  Cardiac ischemia/infarction 2/41 (4.88%)"", ""  Duodenal ulcer 1/41 (2.44%)"", ""  Vomiting 2/41 (4.88%)"", ""  Fever 2/41 (4.88%)"", ""  Death NOS 1/41 (2.44%)"", ""  Liver failure 1/41 (2.44%)"", ""  Infection - pneumonia 2/41 (4.88%)"", ""  Infection - port site 2/41 (4.88%)"", ""  Infection - urinary tract 1/41 (2.44%)"", ""  Disease progression 3/41 (7.32%)"", ""  Confusion 1/41 (2.44%)""]",Entailment
A 30% of patients in NCT02630693 suffered a life-threatening reaction to an infection.,"[""Adverse Events 1:"", ""  Total: 9/90 (10.00%)"", ""  Febrile neutropenia 2/90 (2.22%)"", ""  Ascites 0/90 (0.00%)"", ""  Nausea 0/90 (0.00%)"", ""  Vomiting 0/90 (0.00%)"", ""  Death NOS 1/90 (1.11%)"", ""  Fever 0/90 (0.00%)"", ""  Other general disorders, administration site conditions 0/90 (0.00%)"", ""  Other hepatobiliary disorders 1/90 (1.11%)"", ""  Lung infection 2/90 (2.22%)"", ""  Sepsis 2/90 (2.22%)"", ""  Spinal fracture 0/90 (0.00%)"", ""Adverse Events 2:"", ""  Total: 12/89 (13.48%)"", ""  Febrile neutropenia 0/89 (0.00%)"", ""  Ascites 1/89 (1.12%)"", ""  Nausea 1/89 (1.12%)"", ""  Vomiting 1/89 (1.12%)"", ""  Death NOS 2/89 (2.25%)"", ""  Fever 1/89 (1.12%)"", ""  Other general disorders, administration site conditions 1/89 (1.12%)"", ""  Other hepatobiliary disorders 0/89 (0.00%)"", ""  Lung infection 0/89 (0.00%)"", ""  Sepsis 1/89 (1.12%)"", ""  Spinal fracture 1/89 (1.12%)""]",Contradiction
"NCT00615901 recorded many more seizures than NCT00829166, despite having less than one tenth the number of patients in its total cohort.","[""Adverse Events 1:"", ""  Seizure 1/38 (2.63%)""]",Contradiction
"For all adverse event types in NCT01498458, at least one case was recorded.","[""Adverse Events 1:"", ""  Total: 6/8 (75.00%)"", ""  Thrombocytopenia 1/8 (12.50%)"", ""  Hypertension 1/8 (12.50%)"", ""  Hepatotoxicity 3/8 (37.50%)"", ""  Pancreatectomy * 1/8 (12.50%)""]",Entailment
Cohort 1 of NCT01269346 and Cohort 1 of NCT01597193  have the same total number of adverse events.,"[""Adverse Events 1:"", ""  Total: 15/52 (28.85%)""]",Contradiction
NCT03283553 and NCT01646346 do not use topical medications in their studies.,"[""INTERVENTION 1: "", ""  4D Conformal Image-Guided Partial Breast RT"", ""  This is a single arm trial designed to look at the results in women treated with partial breast irradiation twice daily for 5 days."", ""  4D Conformal Image-Guided Partial Breast RT: External beam partial breast radiation to target a portion of the breast twice a day for 5 days.""]",Entailment
Patients with prior chemotherapy for the treatment of stage 4 cancer are not eligible for either NCT00428922 or NCT00499083.,"[""Inclusion Criteria:"", ""  No prior chemotherapy in the metastatic setting.""]",Entailment
Female patients with Peripheral neuropathy >0 are excluded from NCT00829166.,"[""Exclusion Criteria:"", ""  Peripheral neuropathy of Grade >/= 3 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 3.0""]",Contradiction
"pre-menopausal patients are excluded from NCT02455453, but eligible for NCT00429572.","[""Inclusion Criteria:"", ""  Recurrent or residual metastatic breast carcinoma"", ""  Zubrod performance status less than 2"", ""  18-60 years old"", ""  Related donor human leukocyte antigen (HLA)-compatible for allogeneic transplantation or unrelated HLA-compatible donor."", ""  No major organ dysfunction or active infection"", ""Exclusion Criteria: None""]",Entailment
Candidates for NCT00058058 must have a life expectancy over 6 months.,"[""  Life expectancy"", ""  Not specified""]",Contradiction
"There less than 1% of either cohort of NCT01492101 was effect by Pancytopenia, but just over 5% of cohort 1 patients suffered from Coagulopathy.","[""Adverse Events 1:"", ""  Pancytopenia *2/425 (0.47%)"", ""  Coagulopathy *1/425 (0.24%)"", ""Adverse Events 2:"", ""  Pancytopenia *0/406 (0.00%)""]",Contradiction
NCT02502864 recorded the same number of occurences for every type of adverse event.,"[""Adverse Events 1:"", ""  Total: 3/9 (33.33%)"", ""  Fatigue * 1/9 (11.11%)"", ""  Non-cardiac chest pain * 1/9 (11.11%)"", ""  Sepsis * 1/9 (11.11%)"", ""  Urinary tract infection * 1/9 (11.11%)"", ""  Syncope * 1/9 (11.11%)"", ""  Anxiety * 1/9 (11.11%)"", ""  Thromboembolic event * 1/9 (11.11%)""]",Entailment
Patients must have an ECOG score below 3 to participate in NCT00254592.,"[""Inclusion Criteria:"", ""  Patients must have a performance status of 0-2 by Zubrod criteria""]",Entailment
Patients intracranial metastasis may be eligible for NCT00405938.,"[""Exclusion Criteria:"", ""  No metastatic disease to the Central Nervous System""]",Contradiction
"Females over the age of 18, whose last period was 2 years prior to randomisation are eligible for NCT01073865.","[""Inclusion Criteria:"", ""  Female 20 years and pre-menopausal.Pre-menopausal defined as 1) last menses within 1 year of randomisation, and 2) E2 10 pg/mL and FSH  30 mIU/mL within 4 weeks of randomisation.""]",Contradiction
"Candidates for NCT00952692 must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion.","[""Inclusion Criteria:"", ""  The following criteria are to be checked at the time of study entry. The patients may only be included in the study if ALL of the following statements are FULLFILLED:"", ""  The patient (male or female) is at least 18 years old at the time of signature of the informed consent form."", ""  Written informed consent has been obtained from the patient prior to the performance of any protocol-specific procedure."", ""  The patient is diagnosed with confirmed invasive breast cancer with stage IV disease."", ""  Note: If the metastatic disease is restricted to a solitary lesion, its neoplastic nature should be confirmed by cytology or histology."", ""  The patient has documented disease progression or relapse following at least one prior standard therapy with trastuzumab (alone or in combination with chemotherapy)."", ""  Patients with prior lapatinib use are eligible. Furthermore,"", ""  The administration of the chemotherapeutic agent(s) should have been stopped for at least 28 days by the time of the first ASCI administration."", ""  The administration of trastuzumab alone could be maintained after chemotherapy, but the last dose of trastuzumab should not have been given less than three weeks before the first ASCI administration."", ""  The patient will not be given trastuzumab during the trial."", ""  For metastatic patients whose disease is ER+ and/or PR+ the following criteria should be met:"", ""  Patients with visceral disease that requires chemotherapy (eg., patients with liver or lung metastases)."", ""  Rapidly progressing or life threatening disease, as determined by the investigator."", ""  Patients who received hormonal therapy and are no longer benefiting from this therapy."", ""  A tumor lesion from the patient biopsied before or during screening shows either:"", ""  Overexpression of the HER2 protein, as determined by immunohistochemistry (IHC, with result IHC 3+) or"", ""  Amplification of the HER2 gene as determined by FISH (at least 4 fold i.e. at least 8 copies)."", ""  Note: Overexpression/amplification measurements must be performed on a metastatic lesion in all cases where such a lesion is sufficiently easily accessible. If however such a biopsy is not possible, then these measurements can be performed on the primary tumor. Use of the primary tumor is to be documented and justified."", ""  Ten FFPE tissue sections of the tumor on which the HER2 overexpression/amplification has been done -if available-may be requested. These may be used to retrospectively carry out part of the translational research (i.e. analysis of EGF receptor activity and of the presence of immune effector cells, refer to Section 7)."", ""  The patient has at least one measurable lesion according to RECIST criteria."", ""  The patient has ECOG status of 0 or 1."", ""  The patient has adequate bone marrow reserve as indicated by:"", ""  White blood cell count >/= 3,000/mm3."", ""  Neutrophil count >/= 1,500/mm3."", ""  Platelet count >/= 100,000/mm3."", ""  Hemoglobin levels >/= 10.0 g/dl."", ""  The patient has adequate renal function as shown by the creatinine levels (i.e. within the normal range)."", ""  The patient has adequate hepatic function as shown by serum bilirubin levels i.e:"", ""  Serum bilirubin levels within the normal limits."", ""  Both AST and ALT levels <1.5 times the ULN. Note: However, for patients with liver metastasis, a serum bilirubin level <1.5 times the ULN and both AST and ALT levels <3 times the ULN will be accepted."", ""  The patient has a baseline Left Ventricular Ejection Fraction (LVEF) measured by MUGA scan equal to or greater than the LLN for the radiology facility."", ""  If the patient is female, she must be of non-childbearing potential, i.e. have a current tubal ligation, hysterectomy, ovariectomy or be post-menopausal, or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to treatment, have a negative pregnancy test and continue such precautions for two months after completion of the study treatment."", ""  Adequate contraception is defined as a contraceptive method with failure rate of less than 1% per year when used consistently and correctly (when applicable, as mentioned in the product label) for example abstinence, combined or progestogen oral contraceptives, injectable progestogen, implants of levonorgestrel, oestrogenic vaginal ring, percutaneous contraceptive patches or intrauterine device (IUD) or intrauterine system (IUS), vasectomy with documented azoospermia of the sole male partner or double barrier method (condom or occlusive cap plus spermicidal agent)."", ""  For azoospermia, \""documented\"" refers to the outcome of the investigator's/ designee's medical examination of the subject or review of the subject's medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject's medical records."", ""  Post-menopause: Menopause is the age associated with complete cessation of menstrual cycles, menses, and implies the loss of reproductive potential by ovarian failure. A practical definition accepts menopause after 1 year without menses with an appropriate clinical profile at the appropriate age e.g. > 45 years."", ""  Able to swallow and retain oral medication."", ""  In the view of the investigator, the patient can and will comply with the requirements of the protocol."", ""Exclusion Criteria:"", ""  The following criteria should be checked at the time of study entry. If any apply, the patient must not be included in the study:"", ""  The patient has received > 300 mg/m2 doxorubicin (cumulative dose) or > 600 mg/m2 epirubicin (cumulative dose)."", ""  The patient is receiving treatment with bisphosphonate UNLESS the biphosphonate treatment was initiated more than three weeks before the first ASCI administration. (See also section 5.3.2.)."", ""  The patient has received any investigational or non-registered product (drug or vaccine) other than the study treatment(s) within 30 days preceding the first dose of study treatment, or planned use during the study period."", ""  The patient is currently receiving amiodarone or has received amiodarone in the 6 months prior to screening."", ""  The patient requires concomitant treatment with systemic corticosteroids or any immunosuppressive agents. The use of prednisone, or equivalent, <0.5 mg/kg/day (absolute maximum 40 mg/day), or inhaled corticosteroids or topical steroids is permitted."", ""  The patient has a malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel."", ""  Patients with ulcerative colitis."", ""  The patient has known coronary artery disease, arrhythmia requiring treatment, clinically significant valvular disease, cardiomegaly on chest X-ray, ventricular hypertrophy (found by ECG) or previous myocardial infarction."", ""  The patient has any acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests."", ""  The patient has current active hepatic or biliary's disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment)."", ""  The patient presents with autoimmune disease (vitiligo and autoimmune thyroid disease is not an exclusion criterion)."", ""  The patient has a known family history of congenital or hereditary immunodeficiency."", ""  The patient has any uncontrolled bleeding disorder or coagulation disorder or thrombocytopenia or pro-thrombotic disorder."", ""  The patient has a history of anaphylaxis or severe allergic reaction to vaccines or unknown allergens."", ""  The patient has a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to Lapatinib. These include other anilinoquinazolines, such as gefitinib (Iressa), erlotinib (Tarceva), or other chemically related compounds or excipients."", ""  The patient is known to be positive for the Human Immunodeficiency Virus (HIV)."", ""  The patient has (or has had) previous or concomitant malignancies at other sites except effectively treated:"", ""  Non-melanoma skin cancers or carcinoma in situ of the cervix"", ""  Malignancy that has been in remission for > 2 years and is considered highly likely to have been cured."", ""  The patient has any psychiatric or addictive disorder that may compromise her ability to give informed consent, or to comply with the trial procedures."", ""  The patient has any other condition that in the opinion of the investigator might jeopardize the patient's safety or ability to comply with the requirements of the study."", ""  The patient is pregnant or lactating.""]",Contradiction
Patients with left-sided breast cancer and an ECOG of 3 are excluded from NCT00581256.,"[""Inclusion Criteria:"", ""  All patients must have left-sided breast cancer."", ""  Performance status should be 0-2 by ECOG criteria."", ""Exclusion Criteria:"", ""  Performance status > 2 by ECOG criteria""]",Entailment
"Patients in NCT01828021 and NCT01326481 did not have any of the same adverse events, except Supraventricular extrasystoles which was the most common event in both trials.","[""Adverse Events 1:"", ""  Total: 6/25 (24.00%)"", ""  Supraventricular extrasystoles 1/25 (4.00%)"", ""  Ventricular extrasystoles 1/25 (4.00%)"", ""  Ascites 2/25 (8.00%)"", ""  Diarrhea 1/25 (4.00%)"", ""  Nausea 1/25 (4.00%)"", ""  Pancreatitis 1/25 (4.00%)"", ""  Small intestinal obstruction 1/25 (4.00%)"", ""  Vomiting 1/25 (4.00%)"", ""  Bile duct obstruction 1/25 (4.00%)"", ""  Portal hypertension 1/25 (4.00%)""]",Contradiction
Patients with a palpable breast lesions and axillary lymph nodes are eligible for NCT00072293.,"[""  Palpable or nonpalpable breast lesion"", ""  No palpable axillary lymph node(s)""]",Contradiction
Nobody in cohort 1 of NCT00130533 suffered from Hyperbilirrubinemia.,"[""Adverse Events 1:"", ""  Hyperbilirrubinemia  [1]1/436 (0.23%)""]",Contradiction
Only one adverse event is observed in patients from cohort 1 of NCT00759785.,"[""Adverse Events 1:"", ""  Total: 1/25 (4.00%)"", ""  Diarrhoea 0/25 (0.00%)"", ""  Breast abscess 0/25 (0.00%)"", ""  Breast cellulitis 0/25 (0.00%)"", ""  Syncope 1/25 (4.00%)""]",Entailment
"In NCT00410813, Dasatinib, 70 mg, Twice Daily results in a better median PFS than Dasatinib, 100 mg, Daily.","[""Outcome Measurement: "", ""  Progression-free Survival"", ""  RECIST progression defined as 20% increase in the sum of longest diameters of target measurable lesions over the smallest sum observed, unequivocal progression of non-measurable disease, the appearance of any new lesion/site, death due to disease without prior documentation of progression and without symptomatic deterioration, development of one or more new bone lesions from baseline, or symptomatic deterioration related to disease progression. Time from date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause. Patients last known to be alive and progression-free are censored at last date of contact."", ""  Time frame: Up to 2 years"", ""Results 1: "", ""  Arm/Group Title: Dasatinib, 100 mg, Daily"", ""  Arm/Group Description: Dasatinib, 100 mg PO daily until progression of disease"", ""  Overall Number of Participants Analyzed: 41"", ""  Median (95% Confidence Interval)"", ""  Unit of Measure: weeks  10.3        (8.4 to 16.7)"", ""Results 2: "", ""  Arm/Group Title: Dasatinib, 70 mg, Twice Daily"", ""  Arm/Group Description: Dasatinib, 70 mg PO twice daily until progression of disease"", ""  Overall Number of Participants Analyzed: 38"", ""  Median (95% Confidence Interval)"", ""  Unit of Measure: weeks  15.3        (8.7 to 20.1)""]",Entailment
No more than 1% of either cohorts of NCT00274469 felt nauseous.,"[""Adverse Events 1:"", ""  NAUSEA 1/101 (0.99%)"", ""Adverse Events 2:"", ""  NAUSEA 0/103 (0.00%)""]",Entailment
"The Cohort of NCT00303108 which received D+C and Taxane Naïve, produced marginally better results than the other cohort.","[""Outcome Measurement: "", ""  Objective Response Rate (ORR)"", ""  Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Objective response (OR) = CR + PR."", ""  Time frame: From date of randomization until the date of first documented progression or date of intolerable toxicity, whichever came first, assessed up to 54 months."", ""Results 1: "", ""  Arm/Group Title: D+C and Taxane Naive"", ""  Arm/Group Description: Doxil, Carboplatin and Taxane naive"", ""  Overall Number of Participants Analyzed: 39"", ""  Measure Type: Number"", ""  Unit of Measure: percentage of participants  30.8        (17.0 to 47.6)"", ""Results 2: "", ""  Arm/Group Title: D+C and Taxane Pretreated"", ""  Arm/Group Description: Doxil, Carboplatin and Taxane pretreated"", ""  Overall Number of Participants Analyzed: 42"", ""  Measure Type: Number"", ""  Unit of Measure: percentage of participants  31.0        (17.6 to 47.1)""]",Contradiction
"There were more patients with hypotension in cohort 1 of NCT01332630, than in cohort 1 of NCT00121134.","[""Adverse Events 1:"", ""  Total: 6/21 (28.57%)"", ""  Hypertension 3/21 (14.29%)"", ""  Edema 3/21 (14.29%)"", ""  Nausea 2/21 (9.52%)"", ""  Fracture 1/21 (4.76%)"", ""  Dizziness 3/21 (14.29%)"", ""  Syncope 2/21 (9.52%)"", ""  Headache 2/21 (9.52%)"", ""  Dyspnea 2/21 (9.52%)"", ""  Hypoxia 3/21 (14.29%)""]",Contradiction
There were no cases of Leukopenia or Arrhythmia observed in patients participating in NCT00403130.,"[""Adverse Events 1:"", ""  Total: 18/26 (69.23%)"", ""  Thrombocytopenia * 4/26 (15.38%)"", ""  Neutropenia * 3/26 (11.54%)"", ""  Epitasis * 1/26 (3.85%)"", ""  Peripheral arterial ischemia * 1/26 (3.85%)"", ""  Thrombosis *  [1]1/26 (3.85%)"", ""  Weakness * 1/26 (3.85%)"", ""  Pain *  [2]2/26 (7.69%)"", ""  Febrile neutropenia * 1/26 (3.85%)"", ""  Aspartate Aminotransferase *  [3]1/26 (3.85%)"", ""  Syncope * 1/26 (3.85%)""]",Entailment
Patients with both type 1 and 2 Diabetes are not suitable for NCT00723398.,"[""Exclusion Criteria:"", ""  Diabetes mellitus""]",Entailment
"All 4 of the CHF cases in NCT00777049, were in cohort 1.","[""Adverse Events 1:"", ""  Cardiac failure congestive 1/32 (3.13%)"", ""Adverse Events 2:"", ""  Cardiac failure congestive 0/20 (0.00%)""]",Contradiction
"In NCT00190671 cohort 2 had more patients with Leukopenia than cohort 1, whereas in NCT00455533 cohort 1 had more than cohort 2. Cohort 1 of NCT00190671 had the highest proportion of patients with leukopenia.","[""Adverse Events 1:"", ""  Leukopenia 0/42 (0.00%)"", ""Adverse Events 2:"", ""  Leukopenia 2/61 (3.28%)""]",Contradiction
NCT01166763 recorded 4 life-threatening adverse events.,"[""Adverse Events 1:"", ""  Total: 3/30 (10.00%)"", ""  Cholecystitis *  [1]1/30 (3.33%)"", ""  Increase in diarrhea *  [2]1/30 (3.33%)"", ""  Flank pain *  [3]1/30 (3.33%)""]",Contradiction
One of the cohorts in NCT00003782 had more than 5% of patients experiencing side effects.,"[""Adverse Events 1:"", ""  Total: 66/1748 (3.78%)"", ""Adverse Events 2:"", ""  Total: 43/1748 (2.46%)""]",Contradiction
There were 10x more patients with Left ventricular systolic dysfunction in NCT01026142 than in NCT00846027.,"[""Adverse Events 1:"", ""  Left Ventricular Dysfunction 4/218 (1.83%)"", ""Adverse Events 2:"", ""  Left Ventricular Dysfunction 13/228 (5.70%)""]",Entailment
"A higher number of cohort 2 participants from NCT00828074 experienced fever, compared to cohort 1.","[""Adverse Events 1:"", ""  Fever * 2/41 (4.88%)"", ""Adverse Events 2:"", ""  Fever * 0/5 (0.00%)""]",Contradiction
"NCT01961544 reported a combined total of 3 cases of Ascites, Asthenia and Gastritis in cohort 1.","[""Adverse Events 1:"", ""  Ascites * 1/101 (0.99%)"", ""  Gastritis * 1/101 (0.99%)"", ""  Asthenia * 1/101 (0.99%)""]",Entailment
"1 patient in NCT01201265 was affected by Sepsis, and several were affected in NCT00932373.","[""Adverse Events 1:"", ""  Total: 17/40 (42.50%)"", ""  Anaemia 2/40 (5.00%)"", ""  Febrile Neutropenia 3/40 (7.50%)"", ""  Neutropenia 2/40 (5.00%)"", ""  Thrombocytopenia 5/40 (12.50%)"", ""  Pericardial Effusion 1/40 (2.50%)"", ""  Abdominal Pain Lower 1/40 (2.50%)"", ""  Disease Progression 6/40 (15.00%)"", ""  Fatigue 1/40 (2.50%)"", ""  Pyrexia 3/40 (7.50%)"", ""  Septic Shock 1/40 (2.50%)"", ""  Streptococcal Infection 1/40 (2.50%)""]",Contradiction
NCT00171314 recorded more total occurences of gastrointestinal adverse events than NCT02896855.,"[""Adverse Events 1:"", ""  Total: 23/120 (19.17%)"", ""  Febrile neutropenia 4/120 (3.33%)"", ""  Leukopenia 2/120 (1.67%)"", ""  Neutropenia 8/120 (6.67%)"", ""  Cardiac tamponade 0/120 (0.00%)"", ""  Ventricular arrhythmia 1/120 (0.83%)"", ""  Ascites 0/120 (0.00%)"", ""  Oesophagitis 0/120 (0.00%)"", ""  Large intestine polyp 0/120 (0.00%)"", ""  Death 1/120 (0.83%)"", ""  Liver injury 1/120 (0.83%)"", ""  Pneumonia 3/120 (2.50%)"", ""Adverse Events 2:"", ""  Total: 30/122 (24.59%)"", ""  Febrile neutropenia 3/122 (2.46%)"", ""  Leukopenia 3/122 (2.46%)"", ""  Neutropenia 9/122 (7.38%)"", ""  Cardiac tamponade 2/122 (1.64%)"", ""  Ventricular arrhythmia 0/122 (0.00%)"", ""  Ascites 1/122 (0.82%)"", ""  Oesophagitis 1/122 (0.82%)"", ""  Large intestine polyp 0/122 (0.00%)"", ""  Death 1/122 (0.82%)"", ""  Liver injury 0/122 (0.00%)"", ""  Pneumonia 5/122 (4.10%)""]",Contradiction
NCT03283553 has two cohorts.,"[""INTERVENTION 1: "", ""  Multicomponent Intervention"", ""  1.) A one-page paper-pencil agenda setting checklist completed immediately before a regularly scheduled medical oncology visit to elicit and align patient and companion perspectives regarding issues to discuss with the provider, and to stimulate discussion about the role of the companion in the visit, 2.) facilitated registration for the patient portal (for patient and family member, as desired by the patient), and 3.) education (as relevant) on access to doctor's electronic visit notes."", ""INTERVENTION 2: "", ""  Usual Care"", ""  Care as usual with the medical oncologist.""]",Entailment
"More patients in cohort 1 of NCT01276041 suffered from oedema in their limbs, compared to patients in cohort 2 of NCT00796978.","[""Adverse Events 1:"", ""  Total: 8/56 (14.29%)"", ""  Platelets * 1/56 (1.79%)"", ""  Heart failure * 1/56 (1.79%)"", ""  Left ventricular systolic dysfunction * 1/56 (1.79%)"", ""  Dehydration * 1/56 (1.79%)"", ""  Diarrhea * 1/56 (1.79%)"", ""  Infection with normal ANC or Grade 1 or 2 neutrophils - Bladder (urinary) * 1/56 (1.79%)"", ""  Sodium, serum-low (hyponatremia) * 1/56 (1.79%)"", ""  Fracture * 2/56 (3.57%)""]",Contradiction
"Patients with a positive FISH result are eligible for NCT00392392, but not for NCT00971737.","[""DISEASE CHARACTERISTICS:"", ""  Histologically confirmed adenocarcinoma of the breast"", ""  Does not overexpress HER-2/neu, defined as FISH negative or 0, 1+, or 2+ by IHC"", ""  Stage IV disease""]",Entailment
"The Median time from randomization to death due to any cause, was a month longer for patients in cohort 1 of NCT02555657, compared to those in cohort 2.","[""Outcome Measurement: "", ""  Overall Survival in Participants With Programmed Cell Death Ligand 1 (PD-L1) With Combined Positive Score (CPS) 10"", ""  Overall survival (OS) was defined as the time from randomization to death due to any cause."", ""  Time frame: Up to approximately 36 months (through Final Analysis database cutoff date of 11-April-2019)"", ""Results 1: "", ""  Arm/Group Title: Pembrolizumab"", ""  Arm/Group Description: Participants received pembrolizumab 200 mg IV every Q3W for up to 35 administrations (up to ~2 years)."", ""  Overall Number of Participants Analyzed: 96"", ""  Median (95% Confidence Interval)"", ""  Unit of Measure: Months  12.7        (9.9 to 16.3)"", ""Results 2: "", ""  Arm/Group Title: Chemotherapy"", ""  Arm/Group Description: Participants received capecitabine, eribulin, gemcitabine, or vinorelbine as single agent chemotherapy chosen by the treating physician (Treatment of Physician's Choice, TPC) in accordance with local regulations and guidelines."", ""  Overall Number of Participants Analyzed: 98"", ""  Median (95% Confidence Interval)"", ""  Unit of Measure: Months  11.6        (8.3 to 13.7)""]",Contradiction
"Patients whose breast tumour is 0.1 cm across or less are eligible for NCT02748213, but not NCT00290732.","[""  T1-3, any N disease"", ""  No inflammatory breast cancer or other T4 features""]",Contradiction
There is the same number of cases of Diplopia in NCT02049957 as anemia in NCT01506609.,"[""Adverse Events 1:"", ""  Total: 1/6 (16.67%)"", ""  Angina pectoris 0/6 (0.00%)"", ""  Pericardial effusion 0/6 (0.00%)"", ""  Diplopia 0/6 (0.00%)"", ""  Abdominal pain 0/6 (0.00%)"", ""  Colitis 0/6 (0.00%)"", ""  Gastritis 0/6 (0.00%)"", ""  Nausea 0/6 (0.00%)"", ""  Vomiting 0/6 (0.00%)"", ""  Fatigue 0/6 (0.00%)"", ""  General physical health deterioration 0/6 (0.00%)"", ""  Generalised oedema 0/6 (0.00%)"", ""  Hepatic failure  [1]0/6 (0.00%)"", ""Adverse Events 2:"", ""  Total: 2/6 (33.33%)"", ""  Angina pectoris 0/6 (0.00%)"", ""  Pericardial effusion 0/6 (0.00%)"", ""  Diplopia 0/6 (0.00%)"", ""  Abdominal pain 0/6 (0.00%)"", ""  Colitis 0/6 (0.00%)"", ""  Gastritis 0/6 (0.00%)"", ""  Nausea 0/6 (0.00%)"", ""  Vomiting 0/6 (0.00%)"", ""  Fatigue 0/6 (0.00%)"", ""  General physical health deterioration 0/6 (0.00%)"", ""  Generalised oedema 0/6 (0.00%)"", ""  Hepatic failure  [1]0/6 (0.00%)""]",Entailment
A total of 89 patients in NCT02340221 had Supraventricular tachycardia.,"[""Adverse Events 1:"", ""  Total: 19/213 (8.92%)"", ""  Pancytopenia 0/213 (0.00%)"", ""  Anaemia 1/213 (0.47%)"", ""  Atrial fibrillation 0/213 (0.00%)"", ""  Cardiac failure congestive 0/213 (0.00%)"", ""  Myocardial infarction 0/213 (0.00%)"", ""  Supraventricular tachycardia 0/213 (0.00%)"", ""  Diarrhoea 0/213 (0.00%)"", ""  Colitis 0/213 (0.00%)"", ""  Vomiting 1/213 (0.47%)"", ""  Nausea 1/213 (0.47%)"", ""  Enterocolitis 0/213 (0.00%)"", ""Adverse Events 2:"", ""  Total: 133/416 (31.97%)"", ""  Pancytopenia 1/416 (0.24%)"", ""  Anaemia 0/416 (0.00%)"", ""  Atrial fibrillation 2/416 (0.48%)"", ""  Cardiac failure congestive 1/416 (0.24%)"", ""  Myocardial infarction 1/416 (0.24%)"", ""  Supraventricular tachycardia 1/416 (0.24%)"", ""  Diarrhoea 32/416 (7.69%)"", ""  Colitis 14/416 (3.37%)"", ""  Vomiting 4/416 (0.96%)"", ""  Nausea 3/416 (0.72%)"", ""  Enterocolitis 2/416 (0.48%)""]",Contradiction
A patient with a Histologically confirmed breast cancer would be accepted for NCT00209092 and NCT00631852.,"[""Inclusion Criteria:"", ""  Histologically or cytologically confirmed breast carcinoma.""]",Contradiction
Candidates for NCT02694029 are expected to be capable of holding their breath underwater for 30 seconds.,"[""Inclusion Criteria:"", ""  Women with diagnosis of breast malignancy"", ""  Women whom requires left chest wall post-mastectomy radiation with or without bolus"", ""  Age  18 years."", ""  Performance status ECOG </=3"", ""  Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately Ability to understand and the willingness to sign a written informed consent."", ""  Patient must be able to maintain a 30 second breath hold."", ""  Conventional chest wall radiation delivery dose of 50.4 Gy/ 28 fractions with or without a boost (boost will not be evaluated for endpoints)"", ""Exclusion Criteria:"", ""  Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements."", ""  Subjects must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.""]",Contradiction
Cases of Cardiomyopathy and  Leukopenia were only observed in cohort 1 of NCT00312208.,"[""Adverse Events 1:"", ""  Total: 331/1634 (20.26%)"", ""  Anemia 3/1634 (0.18%)"", ""  Coagulation disorders 1/1634 (0.06%)"", ""  Hemorrhage Vaginal 1/1634 (0.06%)"", ""  Leukopenia 18/1634 (1.10%)"", ""  Lymphadenopathy 0/1634 (0.00%)"", ""  Lymphedema 0/1634 (0.00%)"", ""  Pancytopenia 0/1634 (0.00%)"", ""  Thrombocytopenia 0/1634 (0.00%)"", ""  Arrhythmia 3/1634 (0.18%)"", ""  Arrhythmia Ventricular 0/1634 (0.00%)"", ""  Cardiomyopathy 1/1634 (0.06%)"", ""Adverse Events 2:"", ""  Total: 520/1635 (31.80%)"", ""  Anemia 5/1635 (0.31%)"", ""  Coagulation disorders 0/1635 (0.00%)"", ""  Hemorrhage Vaginal 0/1635 (0.00%)"", ""  Leukopenia 56/1635 (3.43%)"", ""  Lymphadenopathy 1/1635 (0.06%)"", ""  Lymphedema 2/1635 (0.12%)"", ""  Pancytopenia 1/1635 (0.06%)"", ""  Thrombocytopenia 1/1635 (0.06%)"", ""  Arrhythmia 3/1635 (0.18%)"", ""  Arrhythmia Ventricular 1/1635 (0.06%)"", ""  Cardiomyopathy 0/1635 (0.00%)""]",Contradiction
Female patients with Peripheral neuropathy grade 3 or 4 are excluded from NCT00829166.,"[""Exclusion Criteria:"", ""  Peripheral neuropathy of Grade >/= 3 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 3.0""]",Entailment
"Acute coronary syndrome was the most prevalent adverse event in NCT00670982, other than Thrombocytopenia .","[""Adverse Events 1:"", ""  Total: 9/29 (31.03%)"", ""  Neutropenia 5/29 (17.24%)"", ""  Cataracts 1/29 (3.45%)"", ""  Abdominal Pain 1/29 (3.45%)"", ""  Perforated Appendix 1/29 (3.45%)"", ""  Surgical Intervention 1/29 (3.45%)"", ""  Deep Vein Thrombosis 1/29 (3.45%)"", ""  Cerebrovascular Ischemia 1/29 (3.45%)""]",Contradiction
" To be eligible for both NCT00853996 and NCT00365417 patients must satisfy all the following conditions; alkaline phosphatase  < 2.5 x ULN, aspartate aminotransferase  <= 1.5 x ULN and Hemoglobin > 10 g/dL.","[""  The following criteria for evidence of adequate hepatic function must be met:"", ""  alkaline phosphatase must be less than 2.5 x ULN for the lab; and"", ""  aspartate aminotransferase (AST) must be less than/equal to 1.5 x ULN for the lab."", ""  Platelet count must be greater than/equal to 100,000/mm^3."", ""  Hemoglobin must be greater than/equal to 10 g/dL.""]",Contradiction
Most patients treated with Dasatinib and Letrozole in NCT00696072 had a Disease Free Interval (DFI) Greater Than 2 Years.,"[""Outcome Measurement: "", ""  Number of Participants With Clinical Benefit (CBR) and Number of Participants With CBR Having a Disease Free Interval (DFI) Greater Than 2 Years - Evaluable Population"", ""  CBR=participants with complete response (CR) + participants with partial response (PR) + participants with stable disease (SD) for a length of time greater than, equal to 6 months. CR= Disappearance of all target lesions. No new lesions. PR= At least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD. SD= Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) taking as reference the smallest sum LD since the treatment started. Physical examination,radiological assessment, and bone scans (if applicable) were used to assess outcome."", ""  Time frame: First dose of study drug to last dose plus 7 days, up to study completion (approximately 6 years)"", ""Results 1: "", ""  Arm/Group Title: Dasatinib Plus Letrozole"", ""  Arm/Group Description: Dasatinib + Letrozole: Tablets, Oral, once daily, up to 2 years"", ""  Dasatinib 100 mg + Letrozole 2.5 mg"", ""  Patients on letrozole plus dasatinib received both drugs until progressive disease (PD) or intolerable toxicity. If the intolerable toxicity was determined to be related to dasatinib, dasatinib was discontinued and the patient continued on single-agent letrozole. Although drugs were taken daily, cycle length was 28-days"", ""  Overall Number of Participants Analyzed: 56"", ""  Measure Type: Number"", ""  Unit of Measure: participants  CBR (CR+PR+SD): 40"", ""  CBR, DFI <= 2 Years: 20"", ""CBR, DFI > 2 Years: 20""]",Contradiction
There were no adverse event in NCT01007942 which affected more than 10% of a particular patient cohort.,"[""Adverse Events 1:"", ""  Febrile neutropenia 30/280 (10.71%)""]",Contradiction
All of the patients in cohort 1 of NCT00086957 experienced an adverse event.,"[""Adverse Events 1:"", ""  Total: 2/2 (100.00%)"", ""  Febrile neutropenia * 2/2 (100.00%)"", ""  Haemorrhage NOS * 0/2 (0.00%)"", ""  Abdominal pain * 0/2 (0.00%)"", ""  Diarrhea * 0/2 (0.00%)"", ""  Melaena * 0/2 (0.00%)"", ""  Mucositis oral * 0/2 (0.00%)"", ""  Nausea * 0/2 (0.00%)"", ""  Vomiting * 0/2 (0.00%)"", ""  Catheter related infection * 0/2 (0.00%)"", ""  Infection NOS * 0/2 (0.00%)"", ""  Leukopenia * 1/2 (50.00%)""]",Entailment
Patient who have undergone External beam radiation therapy and major surgery in the last two weeks are eligible for NCT00458237.,"[""Inclusion Criteria:"", ""  Patients may have received prior radiation therapy"", ""Exclusion Criteria:"", ""  Major surgery within 2 weeks before study entry""]",Contradiction
There was one patient in NCT01419197 who suffered from a significant decrease in the number of granulocytes in their blood.,"[""Adverse Events 2:"", ""  Granulocytopenia 1/184 (0.54%)""]",Contradiction
NCT01446159 only had a total of 6 patients in across both its cohorts.,"[""Adverse Events 1:"", ""  Total: 2/3 (66.67%)"", ""Adverse Events 2:"", ""  Total: 0/3 (0.00%)""]",Entailment
Every adverse event in NCT00544167 occurred once.,"[""Adverse Events 1:"", ""  Total: 7/45 (15.56%)"", ""  Febrile neutropenia 1/45 (2.22%)"", ""  Cardiac ischemia/infarction 1/45 (2.22%)"", ""  Ventricular arrhythmia - left ventricular systolic dysfunction 1/45 (2.22%)"", ""  Hemmorhage - GI 1/45 (2.22%)"", ""  Pancreatitis 1/45 (2.22%)"", ""  Infection - pneumonia 1/45 (2.22%)"", ""  Infection - Streptococcus 1/45 (2.22%)"", ""  Abcess of Bartholin's cyst 1/45 (2.22%)""]",Entailment
"A patient with Histologically confirmed estrogen receptor-negative, progesterone receptor-negative, and human epidermal growth factor 2 positive breast cancer, with no known Brain metastases and no prior history of cardiac dysfunction, could be eligible for both NCT00356148 and NCT02322814.","[""Inclusion Criteria:"", ""  Histologically confirmed estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and human epidermal growth factor 2 (HER2)-negative adenocarcinoma of the breast with measurable metastatic or locally advanced disease"", ""  History of autoimmune disease"", ""  Brain metastases (symptomatic or nonsymptomatic) that have not been treated previously, are progressive, or require any type of therapy (e.g., radiation, surgery, or steroids) to control symptoms from brain metastases within 30 days prior to first study treatment dose"", ""  History of clinically significant cardiac dysfunction""]",Contradiction
Patients must have either AST or ALT < 1.5 ULN to participate in NCT02988986.,"[""Inclusion Criteria:"", ""  Hepatic status: Serum total bilirubin  1 x upper limit of normal (ULN; in the case of known Gilbert's syndrome, a higher serum total bilirubin [< 1.5 x ULN] is allowed), aspartate aminotransferase and alanine aminotransferase  1.5 x ULN, and alkaline phosphatase  1.5 x ULN;""]",Contradiction
There is no age limit for either NCT00167414 or NCT00334802.,"[""Inclusion Criteria:"", ""  Histologically and/or cytologically confirmed breast cancer"", ""  Received adjuvant/neo-adjuvant chemotherapy for breast cancer with anthracycline regimen"", ""  To have at least one measurable region"", ""  Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1"", ""  To have adequate organ function (bone marrow, liver and renal function)"", ""Exclusion Criteria:"", ""  To have interstitial pneumonia or pulmonary fibrosis"", ""  To have inflammatory breast cancer"", ""  Within 28 days after the latest chemotherapy or radiotherapy, 14 days after the latest hormonal/immunotherapy or 7 days after surgery"", ""  To have brain metastases with symptoms"", ""  To have severe complication (cardiac infarction, infection, drug hypersensitivity or diabetes)""]",Entailment
There were several cases of Multi-Organ Failure in both cohort 1 of NCT00454805 and cohort 2 of NCT00499122.,"[""Adverse Events 1:"", ""  Total: 27/41 (65.85%)"", ""  Febrile Neutropenia 4/41 (9.76%)"", ""  Neutropenia 1/41 (2.44%)"", ""  Deep Vein Thrombosis 1/41 (2.44%)"", ""  Pulmonary embolism 1/41 (2.44%)"", ""  Femoral Artery occlusion 1/41 (2.44%)"", ""  Abdominal Pain 2/41 (4.88%)"", ""  Constipation 1/41 (2.44%)"", ""  Fatigue 2/41 (4.88%)"", ""  Headache 1/41 (2.44%)"", ""  Nausea 1/41 (2.44%)"", ""  Cellulitis 1/41 (2.44%)"", ""  Muscular Weakness 1/41 (2.44%)""]",Contradiction
Cohort 1 of NCT00490646 had 25% more patients experiencing adverse events than cohort 2.,"[""Adverse Events 1:"", ""  Total: 13/24 (54.17%)"", ""  FEBRILE NEUTROPENIA 5/24 (20.83%)"", ""  HAEMATOTOXICITY 0/24 (0.00%)"", ""  NEUTROPENIA 3/24 (12.50%)"", ""  LYMPHADENOPATHY 0/24 (0.00%)"", ""  PERICARDIAL EFFUSION 1/24 (4.17%)"", ""  ATRIAL FIBRILLATION 1/24 (4.17%)"", ""  APLASIA 0/24 (0.00%)"", ""  NAUSEA 0/24 (0.00%)"", ""  PYREXIA 1/24 (4.17%)"", ""  EXTRAVASATION 0/24 (0.00%)"", ""  CHOLECYSTITIS 1/24 (4.17%)"", ""  PATHOLOGICAL FRACTURE 1/24 (4.17%)"", ""Adverse Events 2:"", ""  Total: 6/24 (25.00%)"", ""  FEBRILE NEUTROPENIA 0/24 (0.00%)"", ""  HAEMATOTOXICITY 1/24 (4.17%)"", ""  NEUTROPENIA 0/24 (0.00%)"", ""  LYMPHADENOPATHY 1/24 (4.17%)"", ""  PERICARDIAL EFFUSION 0/24 (0.00%)"", ""  ATRIAL FIBRILLATION 0/24 (0.00%)"", ""  APLASIA 1/24 (4.17%)"", ""  NAUSEA 1/24 (4.17%)"", ""  PYREXIA 0/24 (0.00%)"", ""  EXTRAVASATION 1/24 (4.17%)"", ""  CHOLECYSTITIS 0/24 (0.00%)"", ""  PATHOLOGICAL FRACTURE 0/24 (0.00%)""]",Entailment
The only cases of Leukopenia in NCT00915018 occurred in cohort 1.,"[""Adverse Events 1:"", ""  Total: 67/240 (27.92%)"", ""  Anaemia 0/240 (0.00%)"", ""  Febrile neutropenia 1/240 (0.42%)"", ""  Leukopenia 2/240 (0.83%)"", ""  Neutropenia 1/240 (0.42%)"", ""  Thrombocytopenia 0/240 (0.00%)"", ""  Atrial fibrillation 0/240 (0.00%)"", ""  Cardiac failure congestive 2/240 (0.83%)"", ""  Cardiac tamponade 1/240 (0.42%)"", ""  Cardio-respiratory arrest 1/240 (0.42%)"", ""  Left ventricular dysfunction 0/240 (0.00%)"", ""Adverse Events 2:"", ""  Total: 56/234 (23.93%)"", ""  Anaemia 1/234 (0.43%)"", ""  Febrile neutropenia 0/234 (0.00%)"", ""  Leukopenia 0/234 (0.00%)"", ""  Neutropenia 0/234 (0.00%)"", ""  Thrombocytopenia 1/234 (0.43%)"", ""  Atrial fibrillation 1/234 (0.43%)"", ""  Cardiac failure congestive 0/234 (0.00%)"", ""  Cardiac tamponade 0/234 (0.00%)"", ""  Cardio-respiratory arrest 0/234 (0.00%)"", ""  Left ventricular dysfunction 1/234 (0.43%)""]",Entailment
Across all three cohorts of NCT00284180 a total of two patients had low levels of oxygen in their body tissues.,"[""Adverse Events 1:"", ""  Total: 5/11 (45.45%)"", ""  Diabetes insipidus  [1]1/11 (9.09%)"", ""  Nausea 0/11 (0.00%)"", ""  Ileus 1/11 (9.09%)"", ""  Dehydration 1/11 (9.09%)"", ""  Vomiting 0/11 (0.00%)"", ""  Pain NOS  [2]2/11 (18.18%)"", ""  Pain - abdomen 0/11 (0.00%)"", ""  Fracture  [3]0/11 (0.00%)"", ""  Progressive Disease 1/11 (9.09%)"", ""  CNS Ischemia 1/11 (9.09%)"", ""  Respiratory Failure 0/11 (0.00%)"", ""  Hypoxia 1/11 (9.09%)"", ""Adverse Events 2:"", ""  Total: 8/21 (38.10%)"", ""  Diabetes insipidus  [1]0/21 (0.00%)"", ""  Nausea 1/21 (4.76%)"", ""  Ileus 0/21 (0.00%)"", ""  Dehydration 1/21 (4.76%)"", ""  Vomiting 1/21 (4.76%)"", ""  Pain NOS  [2]0/21 (0.00%)"", ""  Pain - abdomen 1/21 (4.76%)"", ""  Fracture  [3]1/21 (4.76%)"", ""  Progressive Disease 1/21 (4.76%)"", ""  CNS Ischemia 1/21 (4.76%)"", ""  Respiratory Failure 1/21 (4.76%)"", ""  Hypoxia 1/21 (4.76%)""]",Contradiction
"Sam has recently received a liver transplant, he is not eligible for NCT00418028, but is eligible for NCT00293540.","[""Exclusion criteria:"", ""  Patients with organ transplants.""]",Entailment
"To be eligible for NCT01027416, patients must have an invasive carcinoma confirmed by core biopsy, and a -ive human chorionic gonadotropin urine test.","[""Inclusion Criteria:"", ""  Core biopsy should definitively demonstrate invasive carcinoma."", ""  Negative serum or urine beta-hCG pregnancy test at screening for patients of child-bearing potential (this is routinely done if the patient is premenopausal and having surgery)""]",Entailment
"NCT01015131 records instances of Rectal Hemorrhage within its patient cohort, whereas NCT00312208 records Vaginal hemorrhages.","[""Adverse Events 1:"", ""  Total: 8/44 (18.18%)"", ""  Febrile neutropenia4/44 (9.09%)"", ""  Rectal bleeding1/44 (2.27%)"", ""  Chest pain2/44 (4.55%)"", ""  Fever1/44 (2.27%)"", ""  Catheter site infection1/44 (2.27%)"", ""  Neutrophil count decreased1/44 (2.27%)"", ""  Dizziness1/44 (2.27%)""]",Entailment
"patients with Phosphoinositide 3-kinase inhibitor based treatments are eligible for NCT01790932, if this treatment ended over 5 years prior.","[""Exclusion Criteria:"", ""  Have received previous treatment with PI3K inhibitors""]",Contradiction
Patients must have a life expectancy over a year to participate in NCT03511378.,"[""Inclusion Criteria:"", ""  Patient who have estimated life expectancy of more than six months""]",Contradiction
"The Median time from randomization to death due to any cause was higher in cohort 1 of NCT02555657, compared to cohort 2.","[""Outcome Measurement: "", ""  Overall Survival in Participants With Programmed Cell Death Ligand 1 (PD-L1) With Combined Positive Score (CPS) 10"", ""  Overall survival (OS) was defined as the time from randomization to death due to any cause."", ""  Time frame: Up to approximately 36 months (through Final Analysis database cutoff date of 11-April-2019)"", ""Results 1: "", ""  Arm/Group Title: Pembrolizumab"", ""  Arm/Group Description: Participants received pembrolizumab 200 mg IV every Q3W for up to 35 administrations (up to ~2 years)."", ""  Overall Number of Participants Analyzed: 96"", ""  Median (95% Confidence Interval)"", ""  Unit of Measure: Months  12.7        (9.9 to 16.3)"", ""Results 2: "", ""  Arm/Group Title: Chemotherapy"", ""  Arm/Group Description: Participants received capecitabine, eribulin, gemcitabine, or vinorelbine as single agent chemotherapy chosen by the treating physician (Treatment of Physician's Choice, TPC) in accordance with local regulations and guidelines."", ""  Overall Number of Participants Analyzed: 98"", ""  Median (95% Confidence Interval)"", ""  Unit of Measure: Months  11.6        (8.3 to 13.7)""]",Entailment
"The total number of patients affected by adverse events in cohort 2 NCT00528567, is larger than the cohort size of NCT01196052.","[""Adverse Events 2:"", ""  Total: 250/1271 (19.67%)""]",Entailment
60% of Subjects in NCT00270894 were able to Complete at least 85% of the Planned Dose on Schedule.,"[""Outcome Measurement: "", ""  Percentage of Subjects Able to Complete > 85% of the Planned Dose on Schedule"", ""  Feasibility will be determined by evaluating the percentage of subjects able to complete the neoadjuvant portion of the study on time with > 85% of the protocol-specified dose."", ""  Time frame: From the start of treatment through the neoadjuvant treatment period (approximately 20 weeks)"", ""Results 1: "", ""  Arm/Group Title: Neoadjuvant Therapy"", ""  Arm/Group Description: Neoadjuvant therapy will consist of epirubicin (100 mg/m^2) + cyclophosphamide (600 mg/m^2) every 2 weeks for 4 cycles; followed by a 3-week break; followed by docetaxel (75 mg/m^2) every 2 weeks for 4 cycles + trastuzumab (6 mg/kg [loading dose] once then 4 mg/kg [maintenance dose]) every 2 weeks for 4 treatments."", ""  Overall Number of Participants Analyzed: 30"", ""  Measure Type: Number"", ""  Unit of Measure: percentage of participants  60""]",Entailment
"Less than 5% of cohort 1 of NCT01931163 had High blood sugar, 0% of NCT00274469 patients were recorded as having High blood sugar.","[""Adverse Events 1:"", ""  Total: 6/22 (27.27%)"", ""  Thrombocytopenia  1/22 (4.55%)"", ""  leucocytopenia  1/22 (4.55%)"", ""  neutropenia  1/22 (4.55%)"", ""  papilledema  1/22 (4.55%)"", ""  Nausea  1/22 (4.55%)"", ""  hyperglycemia  1/22 (4.55%)""]",Entailment
"NCT00878709 had a total of 3 patients experiencing pancreas related adverse events, NCT02447003 had 0.","[""Adverse Events 1:"", ""  Total: 103/1408 (7.32%)"", ""  Anaemia 1/1408 (0.07%)"", ""  Angina pectoris 1/1408 (0.07%)"", ""  Myocardial infarction 1/1408 (0.07%)"", ""  Atrial fibrillation 0/1408 (0.00%)"", ""  Sinus tachycardia 0/1408 (0.00%)"", ""  Tachycardia 0/1408 (0.00%)"", ""  Vertigo 0/1408 (0.00%)"", ""  Diarrhoea 22/1408 (1.56%)"", ""  Vomiting 12/1408 (0.85%)"", ""  Nausea 4/1408 (0.28%)"", ""  Abdominal pain 2/1408 (0.14%)"", ""  Pancreatitis 2/1408 (0.14%)"", ""Adverse Events 2:"", ""  Total: 85/1408 (6.04%)"", ""  Anaemia 1/1408 (0.07%)"", ""  Angina pectoris 0/1408 (0.00%)"", ""  Myocardial infarction 1/1408 (0.07%)"", ""  Atrial fibrillation 1/1408 (0.07%)"", ""  Sinus tachycardia 1/1408 (0.07%)"", ""  Tachycardia 1/1408 (0.07%)"", ""  Vertigo 1/1408 (0.07%)"", ""  Diarrhoea 1/1408 (0.07%)"", ""  Vomiting 1/1408 (0.07%)"", ""  Nausea 1/1408 (0.07%)"", ""  Abdominal pain 0/1408 (0.00%)"", ""  Pancreatitis 1/1408 (0.07%)""]",Entailment
"There were an equal number of cases of Febrile neutropenia, Leukopenia and Neutropenia across cohorts in NCT00426556.","[""Adverse Events 1:"", ""  Total: 3/6 (50.00%)"", ""  Febrile neutropenia 0/6 (0.00%)"", ""  Leukopenia 0/6 (0.00%)"", ""  Neutropenia 0/6 (0.00%)"", ""Adverse Events 2:"", ""  Total: 6/17 (35.29%)"", ""  Febrile neutropenia 0/17 (0.00%)"", ""  Leukopenia 0/17 (0.00%)"", ""  Neutropenia 0/17 (0.00%)""]",Entailment
Patients with a positive sentinel node biopsy must have surgery to remove lymph nodes from the armpit (underarm or axilla) or they will not be eligible for NCT00009945.,"[""Eligibility"", ""  Patients must have undergone either a total mastectomy or a lumpectomy with either an axillary dissection or sentinel node biopsy. If any sentinel node is histologically positive by H & E, or histologically suspicious on H & E and confirmed positive by immunohistochemistry (IHC), then the patient must have a completion axillary dissection.""]",Entailment
"postmenopausal women with T1-4N1-3M1 Early invasive breast cancer are eligible for NCT01176916, and Premenopausal women with T4-4N1-3M1 Early invasive breast cancerare eligible for NCT00186121.","[""Inclusion Criteria:"", ""  The patient must be postmenopausal woman.""]",Contradiction
"Patients with metallic vascular clips placed to prevent bleeding from conditions such as intracranial aneurysms, are elligible for NCT01823991.","[""Exclusion Criteria:"", ""  Known claustrophobia, presence of pacemaker and/or ferromagnetic material in their body that would prohibit MRI imaging""]",Contradiction
"Participants with HER2- primary breast tumors, confirmed by fluorescence in-situ hybridization are eligible for NCT00274768 and NCT00703326.","[""Inclusion Criteria:"", ""  Participant has histologically or cytologically confirmed adenocarcinoma of the breast that is now metastatic or locally-recurrent and inoperable with curative intent. Every effort should be made to make paraffin-embedded tissue or slides from the diagnostic biopsy or surgical specimen available for confirmation of diagnosis"", ""  Participants' primary and/or metastatic tumor is human epidermal growth factor receptor 2 (HER2)-negative by fluorescence in-situ hybridization (FISH) or chromogenic in-situ hybridization (CISH) or 0, 1+ overexpression by immunohistochemistry (IHC)""]",Entailment
NCT01234402 more than 6 different types of cardiac related adverse events.,"[""Adverse Events 1:"", ""  Acute myocardial infarction 0/52 (0.00%)"", ""  Atrial fibrillation 0/52 (0.00%)"", ""  Cardiac failure 1/52 (1.92%)"", ""  Cardiogenic shock 1/52 (1.92%)"", ""  Palpitations 0/52 (0.00%)"", ""  Pericardial effusion 0/52 (0.00%)"", ""  Right ventricular failure 1/52 (1.92%)"", ""Adverse Events 2:"", ""  Acute myocardial infarction 1/49 (2.04%)"", ""  Atrial fibrillation 1/49 (2.04%)"", ""  Cardiac failure 0/49 (0.00%)"", ""  Cardiogenic shock 0/49 (0.00%)"", ""  Palpitations 1/49 (2.04%)"", ""  Pericardial effusion 4/49 (8.16%)"", ""  Right ventricular failure 0/49 (0.00%)""]",Entailment
A 55 year old postmenopausal patient with sarcoidosis would be excluded from NCT00553410 due to her age.,"[""DISEASE CHARACTERISTICS:"", ""  Confirmed diagnosis of prior operable, noninflammatory breast cancer meeting the following criteria:"", ""  Steroid hormone receptor-positive tumors (estrogen receptor and/or progesterone receptor), determined by immunohistochemistry, after primary surgery and before commencement of prior endocrine therapy"", ""  Prior local treatment including surgery with or without radiotherapy for primary breast cancer with no known clinical residual loco-regional disease"", ""  Following primary surgery, eligible patients must have had evidence of lymph node involvement either in the axillary or internal mammary nodes, but not supraclavicular nodes"", ""  Clinically disease-free"", ""  Must have completed 4-6 years of prior adjuvant selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), or a sequential combination of both"", ""  When calculating 4-6 years, neoadjuvant endocrine therapy should not be included"", ""  No evidence of recurrent disease or distant metastatic disease"", ""  No prior bilateral breast cancer"", ""  PATIENT CHARACTERISTICS:"", ""  Female"", ""  Must be postmenopausal by any of the following criteria:"", ""  Patients of any age who have had a bilateral oophorectomy (including radiation castration AND amenorrheic for > 3 months)"", ""  Patients 56 years old or older with any evidence of ovarian function must have biochemical evidence of definite postmenopausal status (defined as estradiol, luteinizing hormone [LH], and follicle-stimulating hormone [FSH] in the postmenopausal range)"", ""  Patients 55 years old or younger must have biochemical evidence of definite postmenopausal status (defined as estradiol, LH, and FSH in the postmenopausal range)"", ""  Patients who have received prior luteinizing-hormone releasing-hormone (LHRH) analogues within the last year are eligible if they have definite evidence of postmenopausal status as defined above"", ""  Clinically adequate hepatic function"", ""  No bone fracture due to osteoporosis at any time during the 4-6 years of prior therapy"", ""  No prior or current malignancy except adequately treated basal cell or squamous cell carcinoma of the skin, in situ carcinoma of the cervix or bladder, or contra- or ipsilateral in situ breast carcinoma"", ""  No other nonmalignant systemic diseases (cardiovascular, renal, lung, etc.) that would prevent prolonged follow-up"", ""  No psychiatric, addictive, or any other disorder that compromises compliance with protocol requirements"", ""  PRIOR CONCURRENT THERAPY:"", ""  See Disease Characteristics"", ""  More than 12 months since prior and no other concurrent endocrine SERM/AI therapy"", ""  Any type of prior adjuvant therapy allowed including, but not limited to, any of the following:"", ""  Neoadjuvant chemotherapy"", ""  Neoadjuvant endocrine therapy"", ""  Adjuvant chemotherapy"", ""  Trastuzumab (Herceptin\u00ae)"", ""  Ovarian ablation"", ""  Gonadotropin releasing hormone analogues"", ""  Lapatinib ditosylate"", ""  No concurrent hormone-replacement therapy, bisphosphonates (except for treatment of bone loss), or any other investigational agent""]",Contradiction
The highest number of occurences for any adverse event in both NCT00083174 and NCT00190671 was 39.,"[""Adverse Events 1:"", ""  Total: 39/2240 (1.74%)"", ""  Supraven.arrhyth. Atrial fibrillation 1/2240 (0.04%)"", ""  Cardiac ischemia/infarction 2/2240 (0.09%)"", ""  Valvular heart disease 1/2240 (0.04%)"", ""  Cardiac General - Other 2/2240 (0.09%)"", ""  Endocrine - Other 1/2240 (0.04%)"", ""  Ocular - Other 1/2240 (0.04%)"", ""  Colitis 2/2240 (0.09%)"", ""  Diarrhea 1/2240 (0.04%)"", ""  Dysphagia 1/2240 (0.04%)"", ""  Gastritis 1/2240 (0.04%)""]",Contradiction
1 patient in NCT01201265 was affected by Sepsis.,"[""Adverse Events 1:"", ""  Total: 17/40 (42.50%)"", ""  Anaemia 2/40 (5.00%)"", ""  Febrile Neutropenia 3/40 (7.50%)"", ""  Neutropenia 2/40 (5.00%)"", ""  Thrombocytopenia 5/40 (12.50%)"", ""  Pericardial Effusion 1/40 (2.50%)"", ""  Abdominal Pain Lower 1/40 (2.50%)"", ""  Disease Progression 6/40 (15.00%)"", ""  Fatigue 1/40 (2.50%)"", ""  Pyrexia 3/40 (7.50%)"", ""  Septic Shock 1/40 (2.50%)"", ""  Streptococcal Infection 1/40 (2.50%)""]",Entailment
T4 N3 M0 adenocarcinoma of the breast are eligible for NCT00005957.,"[""DISEASE CHARACTERISTICS:"", ""  Histologically proven invasive carcinoma of the breast"", ""  No evidence of T4, N2-3, or M1 disease prior to surgery"", ""  Node positive or high-risk node negative""]",Contradiction
Patients suffering from vomiting are still eligible for both  NCT01931163 and NCT00676793.,"[""Inclusion Criteria:"", ""  Definitive biopsy demonstrating primary breast cancer"", ""  Residual breast cancer requiring additional surgical resection"", ""  Stage I, II or III disease"", ""  Patient has ability to give signed informed consent"", ""  Normal hepatic and renal function (creatinine<1.5, transaminases <1.5 times upper limit of normal)."", ""  ECOG Performance status of 0 or 1."", ""  Age  21 years and less than 75"", ""Exclusion Criteria:"", ""  Prior hormonal or surgical therapy for breast cancer"", ""  Abnormal liver function test"", ""  Liver or kidney problems that would interfere with metabolism of study drug"", ""  Any condition that would hamper informed consent or ability to comply with study protocol"", ""  Participation in another research study in the last three months"", ""  Known malignancy at any site other than breast"", ""  Recent consumption of green tea (5 or more cups per day, within one week prior to biopsy)"", ""  Allergy or intolerance to any component of green tea"", ""  Inability or refusal to comply with definitive surgical therapy""]",Contradiction
Several adverse events which occurred in NCT02149524 were not heart related.,"[""Adverse Events 1:"", ""  Total: 58/438 (13.24%)"", ""  Febrile neutropenia  13/438 (2.97%)"", ""  Neutropenia  5/438 (1.14%)"", ""  Anaemia  0/438 (0.00%)"", ""  Thrombocytopenia  0/438 (0.00%)"", ""  Haemolytic anaemia  1/438 (0.23%)"", ""  Leukopenia  1/438 (0.23%)"", ""  Cardiac failure congestive  0/438 (0.00%)"", ""  Supraventricular tachycardia  0/438 (0.00%)"", ""  Myocardial infarction  1/438 (0.23%)"", ""  Vertigo  0/438 (0.00%)"", ""Adverse Events 2:"", ""  Total: 56/437 (12.81%)"", ""  Febrile neutropenia  10/437 (2.29%)"", ""  Neutropenia  7/437 (1.60%)"", ""  Anaemia  2/437 (0.46%)"", ""  Thrombocytopenia  1/437 (0.23%)"", ""  Haemolytic anaemia  0/437 (0.00%)"", ""  Leukopenia  0/437 (0.00%)"", ""  Cardiac failure congestive  3/437 (0.69%)"", ""  Supraventricular tachycardia  1/437 (0.23%)"", ""  Myocardial infarction  0/437 (0.00%)"", ""  Vertigo  1/437 (0.23%)""]",Entailment
"Patients that are ambulatory and capable of all selfcare but unable to carry out any work activities, are excluded from NCT02878057.","[""Inclusion Criteria:"", ""  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.""]",Entailment
"NCT00623233 recorded 1 patient with a deficiency of platelets in the blood, whereas a total of 6 patients with a platelet deficiency where found in NCT01525589.","[""Adverse Events 1:"", ""  Total: 18/52 (34.62%)"", ""  Anaemia 2/52 (3.85%)"", ""  Febrile Neutropenia 1/52 (1.92%)"", ""  Haemolytic Uraemic Syndrome 1/52 (1.92%)"", ""  Leukopenia 1/52 (1.92%)"", ""  Neutropenia 1/52 (1.92%)"", ""  Thrombocytopenia 1/52 (1.92%)"", ""  Cardiac Failure Congestive 1/52 (1.92%)"", ""  Cardio-Respiratory Arrest 1/52 (1.92%)"", ""  Abdominal Pain 1/52 (1.92%)"", ""  Constipation 1/52 (1.92%)"", ""  Diarrhoea 1/52 (1.92%)""]",Entailment
"There are several coagulative adverse events recorded in NCT00333775, but not a single one in NCT00201864.","[""Adverse Events 1:"", ""  Total: 82/217 (37.79%)"", ""  Febrile neutropenia 21/217 (9.68%)"", ""  Neutropenia 4/217 (1.84%)"", ""  Leukopenia 0/217 (0.00%)"", ""  Anaemia 1/217 (0.46%)"", ""  Thrombocytopenia 0/217 (0.00%)"", ""  Atrial fibrillation 0/217 (0.00%)"", ""  Arrhythmia 1/217 (0.46%)"", ""  Arteriospasm coronary 0/217 (0.00%)"", ""  Atrioventricular block first degree 0/217 (0.00%)"", ""  Cardiac failure 0/217 (0.00%)"", ""Adverse Events 2:"", ""  Total: 106/252 (42.06%)"", ""  Febrile neutropenia 29/252 (11.51%)"", ""  Neutropenia 13/252 (5.16%)"", ""  Leukopenia 3/252 (1.19%)"", ""  Anaemia 0/252 (0.00%)"", ""  Thrombocytopenia 1/252 (0.40%)"", ""  Atrial fibrillation 1/252 (0.40%)"", ""  Arrhythmia 0/252 (0.00%)"", ""  Arteriospasm coronary 1/252 (0.40%)"", ""  Atrioventricular block first degree 1/252 (0.40%)"", ""  Cardiac failure 1/252 (0.40%)""]",Contradiction
"A patient with a cytologically confirmed breast cancer with a 5 millimeter greatest diameter on imaging would be accepted for NCT00209092, but not for NCT00631852.","[""Inclusion Criteria:"", ""  Histologically or cytologically confirmed breast carcinoma.""]",Entailment
 Patients with metastasis in four or more axillary lymph nodes are eligible for NCT00050167.,"[""Inclusion Criteria:"", ""  Patients with pN2a (metastasis in four to nine axillary lymph nodes) are eligible as are patients with pN3a (ten or more axillary lymph nodes). Patients with infraclavicular lymph node involvement are NOT eligible.""]",Entailment
Cases of Cardiomyopathy and Coagulation disorders were only observed in cohort 1 of NCT00312208.,"[""Adverse Events 1:"", ""  Total: 331/1634 (20.26%)"", ""  Anemia 3/1634 (0.18%)"", ""  Coagulation disorders 1/1634 (0.06%)"", ""  Hemorrhage Vaginal 1/1634 (0.06%)"", ""  Leukopenia 18/1634 (1.10%)"", ""  Lymphadenopathy 0/1634 (0.00%)"", ""  Lymphedema 0/1634 (0.00%)"", ""  Pancytopenia 0/1634 (0.00%)"", ""  Thrombocytopenia 0/1634 (0.00%)"", ""  Arrhythmia 3/1634 (0.18%)"", ""  Arrhythmia Ventricular 0/1634 (0.00%)"", ""  Cardiomyopathy 1/1634 (0.06%)"", ""Adverse Events 2:"", ""  Total: 520/1635 (31.80%)"", ""  Anemia 5/1635 (0.31%)"", ""  Coagulation disorders 0/1635 (0.00%)"", ""  Hemorrhage Vaginal 0/1635 (0.00%)"", ""  Leukopenia 56/1635 (3.43%)"", ""  Lymphadenopathy 1/1635 (0.06%)"", ""  Lymphedema 2/1635 (0.12%)"", ""  Pancytopenia 1/1635 (0.06%)"", ""  Thrombocytopenia 1/1635 (0.06%)"", ""  Arrhythmia 3/1635 (0.18%)"", ""  Arrhythmia Ventricular 1/1635 (0.06%)"", ""  Cardiomyopathy 0/1635 (0.00%)""]",Entailment
Patients with E2 outside the premenopausal range are ineligible for NCT00186121.,"[""  If tamoxifen administered within the past 3 months, plasma estradiol must be in the premenopausal range""]",Entailment
There were more cases of Pulmonary embolisms in NCT00323479 than NCT03078751.,"[""Adverse Events 1:"", ""  Total: 6/110 (5.45%)"", ""  Sudden death unexplained 1/110 (0.91%)"", ""  General body pain 1/110 (0.91%)"", ""  Lymphangitis 1/110 (0.91%)"", ""  Femur fracture 1/110 (0.91%)"", ""  Parathyroid adenoma 1/110 (0.91%)"", ""  Depression worsened 1/110 (0.91%)"", ""  Calculus urinary bladder 1/110 (0.91%)"", ""  Pneumopathy 1/110 (0.91%)""]",Contradiction
"Samantha has recently received a liver transplant, and is taking the combined oral contraceptive pill, she is not eligible for NCT00418028, but is eligible for NCT00293540.","[""Exclusion criteria:"", ""  Patients with organ transplants.""]",Contradiction
One patient in NCT01875367 suffered a cerebral infarction.,"[""Adverse Events 1:"", ""  Total: 2/81 (2.47%)"", ""  Heart failure 0/81 (0.00%)"", ""  Fever 1/81 (1.23%)"", ""  Cold 0/81 (0.00%)"", ""  Catheter related infection (Bacteriemia) 0/81 (0.00%)"", ""  Lack of strength in left leg 0/81 (0.00%)"", ""  Ostenecrosis produced by biphosphonates 0/81 (0.00%)"", ""  Gastric cancer 0/81 (0.00%)"", ""  Stroke 0/81 (0.00%)"", ""  Hematuria 1/81 (1.23%)"", ""  Nodule in left breast 0/81 (0.00%)"", ""Adverse Events 2:"", ""  Total: 10/85 (11.76%)"", ""  Heart failure 1/85 (1.18%)"", ""  Fever 0/85 (0.00%)"", ""  Cold 1/85 (1.18%)"", ""  Catheter related infection (Bacteriemia) 1/85 (1.18%)"", ""  Lack of strength in left leg 1/85 (1.18%)"", ""  Ostenecrosis produced by biphosphonates 1/85 (1.18%)"", ""  Gastric cancer 1/85 (1.18%)"", ""  Stroke 1/85 (1.18%)"", ""  Hematuria 0/85 (0.00%)"", ""  Nodule in left breast 1/85 (1.18%)""]",Entailment
The only types of adverse events recorded by both NCT00728949 and NCT02301988 is Diarrhoea and various pains .,"[""Adverse Events 1:"", ""  Total: 10/76 (13.16%)"", ""  Sickle cell anaemia with crisis 1/76 (1.32%)"", ""  Diarrhoea 1/76 (1.32%)"", ""  Pyrexia 1/76 (1.32%)"", ""  Chest pain 1/76 (1.32%)"", ""  Complication associated with device 1/76 (1.32%)"", ""  General physical health deterioration 0/76 (0.00%)"", ""  Device related infection 2/76 (2.63%)"", ""  Pneumonia 1/76 (1.32%)"", ""  Atypical pneumonia 1/76 (1.32%)"", ""  Dehydration 1/76 (1.32%)"", ""Adverse Events 2:"", ""  Total: 3/75 (4.00%)"", ""  Sickle cell anaemia with crisis 0/75 (0.00%)"", ""  Diarrhoea 0/75 (0.00%)"", ""  Pyrexia 1/75 (1.33%)"", ""  Chest pain 0/75 (0.00%)"", ""  Complication associated with device 0/75 (0.00%)"", ""  General physical health deterioration 1/75 (1.33%)"", ""  Device related infection 0/75 (0.00%)"", ""  Pneumonia 1/75 (1.33%)"", ""  Atypical pneumonia 0/75 (0.00%)"", ""  Dehydration 0/75 (0.00%)""]",Entailment
patients with Multi-focal breast cancer cannot be accepted for NCT00945061.,"[""Inclusion Criteria:"", ""  Unifocal breast cancer recurrence""]",Entailment
"Patients with cytologically confirmed, non metastatic, early stage invasive breast cancer with an Allred score of 1 are excluded from NCT00756717.","[""Inclusion Criteria:"", ""  Patients must have histologically or cytologically confirmed early stage, ER-positive (Allred score 3), invasive breast cancer that is not either locally advanced by criteria other than size or inflammatory, and is not metastatic. - Patients must be candidates for surgical removal of the tumor by lumpectomy or mastectomy.""]",Entailment
"Patients with tumors underexpressing HER2 are excluded from NCT00944047, but may be included in NCT00228943.","[""Inclusion Criteria:"", ""  HER-2/neu 1+ or 2+ by immunohistochemistry""]",Entailment
NCT00266110 and NCT00879086 have entirely different adverse event reports.,"[""Adverse Events 1:"", ""  Total: 2/17 (11.76%)"", ""  Nausea * 1/17 (5.88%)"", ""  Pain - Abdomen NOS * 1/17 (5.88%)"", ""  Constipation * 1/17 (5.88%)""]",Entailment
Heart-related adverse events were recorded in both NCT00093145 and NCT00703326.,"[""Adverse Events 1:"", ""  Supraventricular tachycardia 1/32 (3.13%)""]",Entailment
NCT00193206 records a total of 7 patients suffering from various infections.,"[""Adverse Events 1:"", ""  Total: 22/123 (17.89%)"", ""  Cardiac Ischemia/Infarction  [1]1/123 (0.81%)"", ""  Pain - Chest 2/123 (1.63%)"", ""  Dehydration 2/123 (1.63%)"", ""  Death  [2]1/123 (0.81%)"", ""  Weakness 1/123 (0.81%)"", ""  Pain - Liver 1/123 (0.81%)"", ""  Infection - Skin  [3]3/123 (2.44%)"", ""  Infection - Gastrointestinal  [4]1/123 (0.81%)"", ""  Infection - Vein  [5]2/123 (1.63%)"", ""  Infection - Pneumonia 1/123 (0.81%)""]",Entailment
Patients diagnosed with intradural tumors are excluded from NCT00405938.,"[""Exclusion Criteria:"", ""  No metastatic disease to the Central Nervous System""]",Entailment
Japanese participants with an ECOG <=1 are eligible for NCT01256567 and NCT01771666.,"[""Inclusion Criteria:"", ""  Eastern Cooperative Oncology Group (ECOG) or Karnofsky Performance Status 0,1,2.""]",Entailment
There were 4% more cases (1 more case) of Dyspnea than Dehydration in NCT01127763.,"[""  Dehydration 1/25 (4.00%)"", ""  Dyspnea (Shortness Of Breath) 2/25 (8.00%)""]",Entailment
"If Hannah has been taking ketoconazole to treat athlete's foot for 6 weeks, until today, she will be eligible for NCT00411788 next Tuesday.","[""Exclusion Criteria:"", ""  Use of any of these medications within 4 weeks; cyclosporine, diltiazen, ketoconazole, rifampin, fluconazole, delavirdine, nicardipine, pioglitazone, and sulfonamides, erythromycin, clarithromycin, itraconazole, erythromycin, metoclopramide, nevirapine, phenobarbital, phenytoin, indinavir, fosamprenavir, nefazadone, St Johns Wort.""]",Contradiction
Patients with a COPD diagnosis through spirometry are ineligible for NCT00328783.,"[""Inclusion Criteria:"", ""  Adequate pulmonary function""]",Entailment
Sufferers of Systemic lupus erythematosus are excluded from NCT00847171 but may still be eligible for NCT01764022.,"[""  No prior or currently active autoimmune disease* requiring management with systemic immunosuppression, including any of the following:"", ""  Systemic lupus erythematosus""]",Entailment
"In order to be eligible for both NCT03045653 and NCT00499083, patients must be female, over the age of 18, ECOG <2 and have Histologically confirmed HER2 negative breast cancer.","[""  HER2/neu-negative tumor by IHC"", ""  Female"", ""  ECOG performance status 0-1""]",Entailment
NCT01166763 only recorded three types of adverse events.,"[""Adverse Events 1:"", ""  Total: 3/30 (10.00%)"", ""  Cholecystitis *  [1]1/30 (3.33%)"", ""  Increase in diarrhea *  [2]1/30 (3.33%)"", ""  Flank pain *  [3]1/30 (3.33%)""]",Entailment
No less than 2 patients from either cohorts of NCT00274469 felt nauseous.,"[""Adverse Events 1:"", ""  NAUSEA 1/101 (0.99%)"", ""Adverse Events 2:"", ""  NAUSEA 0/103 (0.00%)""]",Contradiction
In total cohort 1 of NCT01439282 recorded more than 10 times the number of adverse events as cohort 2.,"[""Adverse Events 1:"", ""  Total: 14/67 (20.90%)"", ""Adverse Events 2:"", ""  Total: 1/10 (10.00%)""]",Entailment
There are no cases of Vertigo in NCT00546156 or NCT00546156.,"[""Adverse Events 1:"", ""  Total: 4/104 (3.85%)"", ""  Neutropenia 1/104 (0.96%)"", ""  Leukopenia 2/104 (1.92%)"", ""  paranasal sinus reaction 1/104 (0.96%)"", ""  cellulitis 1/104 (0.96%)""]",Entailment
10 of the patients in Cohort 1 of NCT00193037 suffered from Hypotension.,"[""Adverse Events 1:"", ""  Hypotension 0/50 (0.00%)""]",Contradiction
Patients with HER2 positive tumors are ineligible for NCT00741260.,"[""INCLUSION CRITERIA"", ""  erbB-2 gene amplified tumor (FISH or CISH) or erbB-2 overexpression (IHC 3+, or IHC2+ with FISH or CISH confirmation), based on local testing, or based on centralized FISH testing prior to day 1.""]",Contradiction
Japanese participants with an ECOG of 2 are eligible for NCT01256567 and NCT01771666.,"[""Inclusion Criteria:"", ""  Eastern Cooperative Oncology Group (ECOG) or Karnofsky Performance Status 0,1,2.""]",Contradiction
NCT00110084 and NCT01961544 both reported cases of Pseudomonal sepsis in their patients.,"[""Adverse Events 1:"", ""  Sepsis 1/50 (2.00%)""]",Contradiction
"Nursing patients are not eligible for NCT01313039 or NCT01031446, due to potential harm to the father from the study interventions.","[""  Patients who are pregnant or breast-feeding are excluded from the study due to potential harm to the fetus or nursing infant from the study therapy. Patients of reproductive potential must consent to use of contraception or abstinence to be eligible for the study.""]",Contradiction
NCT00693719 recorded less than 5 different Adverse Events .,"[""Adverse Events 1:"", ""  Total: 4/31 (12.90%)"", ""  Bleeding  1/31 (3.23%)"", ""  Pain  2/31 (6.45%)"", ""  Dehydration  1/31 (3.23%)"", ""  Dyspnea  1/31 (3.23%)""]",Entailment
None of the patients in cohort 1 of NCT00266799 had Acute coronary syndrome.,"[""Adverse Events 1:"", ""  Total: 30/98 (30.61%)"", ""  NEUTROPENIA 1/98 (1.02%)"", ""  ATRIAL FIBRILLATION 1/98 (1.02%)"", ""  CARDIAC FAILURE 1/98 (1.02%)"", ""  TACHYCARDIA 0/98 (0.00%)"", ""  ACUTE VESTIBULAR SYNDROME 1/98 (1.02%)"", ""  VERTIGO 0/98 (0.00%)"", ""  ABDOMINAL PAIN 0/98 (0.00%)"", ""  COLITIS 0/98 (0.00%)"", ""  DIARRHOEA 2/98 (2.04%)"", ""  FEMORAL HERNIA 0/98 (0.00%)"", ""  HAEMATEMESIS 0/98 (0.00%)"", ""  ILEUS 0/98 (0.00%)"", ""  NAUSEA 0/98 (0.00%)""]",Entailment
A patient who underwent T-cell transfer therapy in the past 2 weeks would be excluded from NCT01401062.,"[""  Must be 4 weeks since all of the following treatments (recovered from toxicity of prior treatment to Grade 1, excluding alopecia):"", ""  immunotherapy;""]",Entailment
Sarah has been experiencing epileptic seizures from a brain tumor. This excludes her from participating in NCT01031446.,"[""  No symptomatic brain metastases""]",Entailment
Neither of the cohorts in NCT00003782 had more than 5% of patients experiencing side effects.,"[""Adverse Events 1:"", ""  Total: 66/1748 (3.78%)"", ""Adverse Events 2:"", ""  Total: 43/1748 (2.46%)""]",Entailment
"Febrile neutropenia was in excess of 5 times more common in cohort 1 of NCT01007942, than in cohort 2.","[""Adverse Events 1:"", ""  Febrile neutropenia 30/280 (10.71%)"", ""Adverse Events 2:"", ""  Febrile neutropenia 4/282 (1.42%)""]",Entailment
More patients with a Low Platelet Count where found in NCT00623233 than in NCT01525589.,"[""Adverse Events 1:"", ""  Total: 18/52 (34.62%)"", ""  Anaemia 2/52 (3.85%)"", ""  Febrile Neutropenia 1/52 (1.92%)"", ""  Haemolytic Uraemic Syndrome 1/52 (1.92%)"", ""  Leukopenia 1/52 (1.92%)"", ""  Neutropenia 1/52 (1.92%)"", ""  Thrombocytopenia 1/52 (1.92%)"", ""  Cardiac Failure Congestive 1/52 (1.92%)"", ""  Cardio-Respiratory Arrest 1/52 (1.92%)"", ""  Abdominal Pain 1/52 (1.92%)"", ""  Constipation 1/52 (1.92%)"", ""  Diarrhoea 1/52 (1.92%)""]",Contradiction
"One case of hematolysis was recorded in NCT00265759, none in NCT00866905.","[""Adverse Events 1:"", ""  Total: 9/157 (5.73%)"", ""  Blood disorder 1/157 (0.64%)"", ""  Hemoglobin decreased 1/157 (0.64%)"", ""  Hemolysis 0/157 (0.00%)"", ""  Arrhythmia 0/157 (0.00%)"", ""  Cardiac disorder 0/157 (0.00%)"", ""  Myocardial ischemia 1/157 (0.64%)"", ""  Hearing impaired 0/157 (0.00%)"", ""  Tinnitus 0/157 (0.00%)"", ""  Cataract 0/157 (0.00%)"", ""  Diplopia 0/157 (0.00%)"", ""  Glaucoma 0/157 (0.00%)"", ""  Vision blurred 0/157 (0.00%)"", ""Adverse Events 2:"", ""  Total: 14/157 (8.92%)"", ""  Blood disorder 0/157 (0.00%)"", ""  Hemoglobin decreased 2/157 (1.27%)"", ""  Hemolysis 1/157 (0.64%)"", ""  Arrhythmia 0/157 (0.00%)"", ""  Cardiac disorder 0/157 (0.00%)"", ""  Myocardial ischemia 0/157 (0.00%)"", ""  Hearing impaired 2/157 (1.27%)"", ""  Tinnitus 1/157 (0.64%)"", ""  Cataract 1/157 (0.64%)"", ""  Diplopia 0/157 (0.00%)"", ""  Glaucoma 1/157 (0.64%)"", ""  Vision blurred 1/157 (0.64%)""]",Entailment
"In total there were more adverse events in cohort 1 of NCT00448279, than in cohort 2.","[""Adverse Events 1:"", ""  Total: 4/26 (15.38%)"", ""  Febrile neutropenia * 1/26 (3.85%)"", ""  Gastric volvulus * 20/26 (0.00%)"", ""  General Malaise * 21/26 (3.85%)"", ""  Hospitalisation for intrapleuric chemotherapy and thoracentesis * 21/26 (3.85%)"", ""  Acute renal failure * 21/26 (3.85%)"", ""Adverse Events 2:"", ""  Total: 1/28 (3.57%)"", ""  Febrile neutropenia * 0/28 (0.00%)"", ""  Gastric volvulus * 21/28 (3.57%)"", ""  General Malaise * 20/28 (0.00%)"", ""  Hospitalisation for intrapleuric chemotherapy and thoracentesis * 20/28 (0.00%)"", ""  Acute renal failure * 20/28 (0.00%)""]",Entailment
prior hormonal treatment(s) in the metastatic or adjuvant setting is not necessary for patients in NCT00896649.,"[""Inclusion criteria:"", ""  DISEASE CHARACTERISTICS:"", ""  Scheduled to undergo screening mammogram at one of the Boston Medical Center-affiliated primary care clinics and meets 1 of the following criteria:"", ""  Dense breast tissue"", ""  At high-risk for breast cancer"", ""  PATIENT CHARACTERISTICS:"", ""  Has 1 of the following racial or ethnic backgrounds based on the patient's country of birth or the mother and father's country of birth:"", ""  Hispanic"", ""  Haitian Creole"", ""  African American"", ""  Caucasian"", ""  PRIOR CONCURRENT THERAPY:"", ""  None specified"", ""Exclusion criteria:"", ""  No history of breast cancer, palpable breast mass, abnormal nipple discharge, or other focal complaints warranting diagnostic mammogram""]",Entailment
"Patients with stage I, II, III or IV triple negative breast cancer are not eliglbe for NCT00030823.","[""  Hormone receptor status:"", ""  Not specified""]",Contradiction
Patients with Clinical stage II (T2 N2) invasive mammary carcinoma are not eligible for NCT00633750.,"[""Inclusion Criteria:"", ""  Clinical stage I or II (T1 or T2, N0 or N1) invasive mammary carcinoma"", ""Exclusion Criteria:"", ""  Fixed axillary lymph node metastases (N2)""]",Entailment
Cohort 1 patients in NCT02513472 surivied almost twice as long as those in cohort 2.,"[""Outcome Measurement: "", ""  Objective Response Rate (ORR)"", ""  ORR was defined as percentage of participants with confirmed best overall response (BOR) of complete response (CR) or partial response (PR) using independent imaging review (IIR) based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. BOR of CR and PR was confirmed by a subsequent CR assessment and CR or PR assessment, respectively at least 4 weeks later. CR: disappearance of all measurable, non-measurable lesions and no unequivocal new lesions. Any pathological lymph nodes (target or non-target) had to be reduced in short axis to less than (<) 10 millimeter (mm). PR: at least a 30 percent (%) decrease in sum of diameters (SOD) of target lesions, taking as reference the baseline SOD and there are no unequivocal new lesions, and no progression of non-target disease. The 2-sided 95% confidence interval (CI) calculated by Clopper-Pearson method. As planned, data up to the primary completion date only were analyzed."", ""  Time frame: From date of first dose of study drug administration to date of first documentation of disease progression or death, whichever occurred first (up to 3 years 11 months)"", ""Results 1: "", ""  Arm/Group Title: Stratum 1: Eribulin Mesylate + Pembrolizumab"", ""  Arm/Group Description: Participants with mTNBC who were never treated with systemic anticancer therapy in the metastatic setting received eribulin mesylate 1.4 mg/m^2, intravenous infusion on Days 1 and 8 and pembrolizumab 200 mg, intravenous infusion on Day 1 in Treatment Cycle 1 (safety run-in, Phase 1b) and then continued in each 21-days Treatment Cycles in the presence of clinical benefit until confirmed disease progression, development of unacceptable toxicity, participant request, withdrawal of consent, or study termination by the sponsor in Phase 2 in the Stratum 1."", ""  Overall Number of Participants Analyzed: 66"", ""  Measure Type: Number"", ""  Unit of Measure: percentage of participant  25.8        (15.8 to 38.0)"", ""Results 2: "", ""  Arm/Group Title: Stratum 2: Eribulin Mesylate + Pembrolizumab"", ""  Arm/Group Description: Participants with mTNBC previously treated with 1 to 2 lines of systemic anticancer therapy in the metastatic setting received eribulin mesylate 1.4 mg/m^2, intravenous infusion on Days 1 and 8 and pembrolizumab 200 mg, intravenous infusion on Day 1 in Treatment Cycle 1 (safety run-in, Phase 1b) and then continued in each 21-days Treatment Cycles in the presence of clinical benefit until confirmed disease progression, development of unacceptable toxicity, participant request, withdrawal of consent, or study termination by the sponsor in Phase 2 in the Stratum 2."", ""  Overall Number of Participants Analyzed: 101"", ""  Measure Type: Number"", ""  Unit of Measure: percentage of participant  21.8        (14.2 to 31.1)""]",Contradiction
3/112 patients (2.68%) in NCT00509769 had Diabetes insipidus  ,"[""Adverse Events 1:"", ""  Total: 30/112 (26.79%)"", ""  Thrombocytopenia 1/112 (0.89%)"", ""  Dysphagia 1/112 (0.89%)"", ""  Haemorrhoidal haemorrhage 1/112 (0.89%)"", ""  Oesophageal stenosis 1/112 (0.89%)"", ""  Upper gastrointestinal haemorrhage 1/112 (0.89%)"", ""  Asthenia 1/112 (0.89%)"", ""  Disease progression 1/112 (0.89%)"", ""  Hepatotoxicity 1/112 (0.89%)"", ""  Cellulitis 3/112 (2.68%)"", ""  Pneumonia 2/112 (1.79%)"", ""  Osteomyelitis 1/112 (0.89%)""]",Contradiction
"Patients with Leukemia, Hepatitis or Cataracts cannot be included in NCT02600923.","[""Inclusion Criteria:"", ""  Adult women with proven diagnosis of advanced adenocarcinoma of the breast (locoregional recurrent or metastatic disease)."", ""  Women who are not of childbearing potential."", ""  ER-positive and/or Progesterone receptor (PgR)-positive tumor based on local laboratory results (test as per local practice)."", ""  HER2-negative breast cancer based on local laboratory results (test as per local practice or local guidelines)."", ""  Patients must be appropriate candidates for letrozole therapy."", ""  Eastern Cooperative Oncology Group (ECOG) performance status 0-2."", ""  Adequate bone marrow function."", ""  Adequate liver function"", ""  Adequate renal function."", ""Exclusion Criteria:"", ""  Known hypersensitivity to letrozole, or any of its excipients, or to any palbociclib excipients."", ""  Current use of food or drugs known to be potent inhibitors or inducers of CYP3A4 isoenzymes within 7 days prior to study entry."", ""  Prior treatment with any CDK inhibitor."", ""  Previous participation in a palbociclib clinical study."", ""  Participation in other studies involving investigational drug(s) within 2 weeks prior to study entry and/or during study participation."", ""  QTc >480 msec; history of QT syndrome, Brugada syndrome or known history of QTc prolongation, or Torsade de Pointes."", ""  High cardiovascular risk, including, but not limited to recent myocardial infarction, severe/unstable angina and severe cardiac dysrhythmias in the past 6 months prior to enrollment."", ""  Diagnosis of any second invasive malignancy within the last 3 years prior to enrollment. Note: patients with adequately treated basal cell or squamous cell skin cancer, a history of intraepithelial neoplasia or in situ disease (eg, carcinoma in situ of the cervix or melanoma in situ) may enter."", ""  Active uncontrolled or symptomatic brain metastases. Previously treated and clinically stable, brain metastases are permitted."", ""  Other severe acute or chronic medical or psychiatric conditions."", ""  Patients who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or patients who are Pfizer employees directly involved in the conduct of the study.""]",Contradiction
NCT00121134 requires participants to have undergone PTR.,"[""Inclusion Criteria:"", ""  Patients must have completed definitive resection of primary tumor with adequate excision of gross disease.""]",Entailment
"Ae-Cha is a 32 year old Korean woman with an inoperable breast cancer, she is ineligible for both NCT01299038 and NCT00248170.","[""Inclusion Criteria:"", ""  Recent primary surgery for breast cancer""]",Entailment
There were 80% more cases of embolisms in cohort 2 of NCT00129935 than cohort 1.,"[""Adverse Events 1:"", ""  Total: 111/669 (16.59%)"", ""  Leukocytes *  [1]1/669 (0.15%)"", ""  Hemoglobin *  [1]1/669 (0.15%)"", ""  Hemoglobin *  [2]0/669 (0.00%)"", ""  CNS cerebrovascular ischemia *  [1]0/669 (0.00%)"", ""  CNS cerebrovascular ischemia *  [3]0/669 (0.00%)"", ""  Heart Failure *  [1]3/669 (0.45%)"", ""  Thrombosis/embolism *  [1]1/669 (0.15%)"", ""  Thrombosis/embolism *  [3]0/669 (0.00%)"", ""Adverse Events 2:"", ""  Total: 138/715 (19.30%)"", ""  Leukocytes *  [1]0/715 (0.00%)"", ""  Hemoglobin *  [1]0/715 (0.00%)"", ""  Hemoglobin *  [2]1/715 (0.14%)"", ""  CNS cerebrovascular ischemia *  [1]1/715 (0.14%)"", ""  CNS cerebrovascular ischemia *  [3]1/715 (0.14%)"", ""  Heart Failure *  [1]1/715 (0.14%)"", ""  Thrombosis/embolism *  [1]3/715 (0.42%)"", ""  Thrombosis/embolism *  [3]2/715 (0.28%)""]",Contradiction
Patients with LVEF greater than or equal to 60% are eligible for NCT00976989.,"[""Inclusion Criteria:"", ""  baseline left ventricular ejection fraction (LVEF) >/=55%""]",Entailment
INR of 1.35 is enough for participation in NCT00915603 and NCT02511730.,"[""Inclusion Criteria:"", ""  International normalized ratio (INR) <=1.5 or prothrombin time (PT)/partial""]",Contradiction
Patients with AIDS are eligible for both NCT00458237 and NCT00880464.,"[""Exclusion Criteria:"", ""  Evidence of HIV infection""]",Contradiction
Cohort 2 of NCT00303108 produced marginally better results than cohort 1.,"[""Outcome Measurement: "", ""  Objective Response Rate (ORR)"", ""  Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Objective response (OR) = CR + PR."", ""  Time frame: From date of randomization until the date of first documented progression or date of intolerable toxicity, whichever came first, assessed up to 54 months."", ""Results 1: "", ""  Arm/Group Title: D+C and Taxane Naive"", ""  Arm/Group Description: Doxil, Carboplatin and Taxane naive"", ""  Overall Number of Participants Analyzed: 39"", ""  Measure Type: Number"", ""  Unit of Measure: percentage of participants  30.8        (17.0 to 47.6)"", ""Results 2: "", ""  Arm/Group Title: D+C and Taxane Pretreated"", ""  Arm/Group Description: Doxil, Carboplatin and Taxane pretreated"", ""  Overall Number of Participants Analyzed: 42"", ""  Measure Type: Number"", ""  Unit of Measure: percentage of participants  31.0        (17.6 to 47.1)""]",Entailment
HIV+ Patients are excluded from both NCT00458237 and NCT00880464.,"[""Exclusion Criteria:"", ""  Evidence of HIV infection""]",Entailment
Patients must have already participated in a specific clinical study to participate in NCT00971945 or NCT01027416.,"[""Inclusion Criteria:"", ""  Subjects who were confirmed to have a response after receiving at least two courses of weekly paclitaxel therapy and considered to need to continue the therapy by the investigator/subinvestigator among the patients with advanced or recurrent breast cancer who had met the selection criteria and participated in the preceding phase II clinical study""]",Contradiction
"If Hannah has been taking ketoconazole to treat athlete's foot for 6 weeks, until today, she will not be eligible for NCT00411788 for the next month.","[""Exclusion Criteria:"", ""  Use of any of these medications within 4 weeks; cyclosporine, diltiazen, ketoconazole, rifampin, fluconazole, delavirdine, nicardipine, pioglitazone, and sulfonamides, erythromycin, clarithromycin, itraconazole, erythromycin, metoclopramide, nevirapine, phenobarbital, phenytoin, indinavir, fosamprenavir, nefazadone, St Johns Wort.""]",Entailment
Patients needing active supportive care can participate in NCT00254592.,"[""Inclusion Criteria:"", ""  Patients must have a performance status of 0-2 by Zubrod criteria""]",Contradiction
Candidates with hyperparathyroidism are automatically excluded from NCT00656019.,"[""EXCLUSION CRITERIA:"", ""  History of parathyroid disease, hypercalcemia, or kidney stones.""]",Entailment
The overall most frequent adverse event in NCT00930930 was Dehydration.,"[""Adverse Events 1:"", ""  Total: 22/96 (22.92%)"", ""  Anemia 1/96 (1.04%)"", ""  lymphopenia 1/96 (1.04%)"", ""  cardiac ischemia/infarction 1/96 (1.04%)"", ""  sinus tachycardia 2/96 (2.08%)"", ""  Dehydration 5/96 (5.21%)"", ""  colitis 1/96 (1.04%)"", ""  diarrhea 5/96 (5.21%)"", ""  ileus 1/96 (1.04%)"", ""  nausea 2/96 (2.08%)"", ""  vomiting 1/96 (1.04%)"", ""  distal small bowel obstruction 1/96 (1.04%)"", ""  edema 1/96 (1.04%)"", ""  fatigue 2/96 (2.08%)"", ""Adverse Events 2:"", ""  Total: 6/49 (12.24%)"", ""  Anemia 0/49 (0.00%)"", ""  lymphopenia 0/49 (0.00%)"", ""  cardiac ischemia/infarction 0/49 (0.00%)"", ""  sinus tachycardia 0/49 (0.00%)"", ""  Dehydration 1/49 (2.04%)"", ""  colitis 0/49 (0.00%)"", ""  diarrhea 0/49 (0.00%)"", ""  ileus 0/49 (0.00%)"", ""  nausea 1/49 (2.04%)"", ""  vomiting 1/49 (2.04%)"", ""  distal small bowel obstruction 0/49 (0.00%)"", ""  edema 0/49 (0.00%)"", ""  fatigue 0/49 (0.00%)""]",Entailment
Intervention 2 of NCT01224678 resulted in a lower percentage in Mammographic Density than intervention 1.,"[""Outcome Measurement: "", ""  Percent Change (Between Baseline and Month 12) in Mammographic Density by the Boyd Method Compared Between Arms"", ""  To evaluate change in mammographic density using the Boyd method after one year of vitamin D supplementation compared to placebo in premenopausal women. The percent change in breast density will be reported here."", ""  Time frame: 12 months"", ""Results 1: "", ""  Arm/Group Title: Placebo"", ""  Arm/Group Description: Patients receive oral placebo once daily for 12 months."", ""  Overall Number of Participants Analyzed: 46"", ""  Mean (Standard Deviation)"", ""  Unit of Measure: percent change  -3.4         (7.1)"", ""Results 2: "", ""  Arm/Group Title: Vitamin D"", ""  Arm/Group Description: Patients receive oral vitamin D (2000 IU) once daily for 12 months."", ""  Overall Number of Participants Analyzed: 40"", ""  Mean (Standard Deviation)"", ""  Unit of Measure: percent change  -1.4         (11.9)""]",Entailment
"Some of the patients in NCT01565499 were recorded as having heart related adverse events, whereas many patients in NCT01234402 experienced several different breathing related issues.","[""Adverse Events 1:"", ""  Total: 6/81 (7.41%)"", ""  Colitis  [1]1/81 (1.23%)"", ""  Multiple Sclerosis Relapse 1/81 (1.23%)"", ""  Neurotoxicity  [2]2/81 (2.47%)"", ""  Community-acquired pneumonia 1/81 (1.23%)"", ""  Local Infection Reservoir Area 1/81 (1.23%)""]",Contradiction
Cohort 2 of NCT01764022 recorded 1 incident of thrombocytopenia.,"[""Adverse Events 2:"", ""  Anemia with trombocytopenia  1/110 (0.91%)""]",Entailment
Clinically anxious patients are not able to participate in NCT00228943.,"[""Exclusion Criteria:"", ""  Exclusion criteria are current depression, history of migraines or hepatitis, abnormal chemistry profile (e.g., sodium, potassium, glucose), or a positive urine drug screen for illegal substances.""]",Contradiction
"There were no depressed patients in either NCT00777101 or NCT00559845, however there was one suicide attempt in cohort 2 of NCT00559845.","[""Adverse Events 1:"", ""  Total: 31/116 (26.72%)"", ""  Neutropenia 1/116 (0.86%)"", ""  Thrombocytopenia 1/116 (0.86%)"", ""  Acute myocardial infarction 1/116 (0.86%)"", ""  Myocardial infarction 0/116 (0.00%)"", ""  Pericardial effusion 0/116 (0.00%)"", ""  Abdominal pain 3/116 (2.59%)"", ""  Ascites 1/116 (0.86%)"", ""  Diarrhoea 3/116 (2.59%)"", ""  Gingival bleeding 1/116 (0.86%)"", ""  Intestinal haemorrhage 1/116 (0.86%)"", ""  Nausea 2/116 (1.72%)"", ""Adverse Events 2:"", ""  Total: 24/115 (20.87%)"", ""  Neutropenia 1/115 (0.87%)"", ""  Thrombocytopenia 0/115 (0.00%)"", ""  Acute myocardial infarction 0/115 (0.00%)"", ""  Myocardial infarction 1/115 (0.87%)"", ""  Pericardial effusion 1/115 (0.87%)"", ""  Abdominal pain 0/115 (0.00%)"", ""  Ascites 0/115 (0.00%)"", ""  Diarrhoea 4/115 (3.48%)"", ""  Gingival bleeding 0/115 (0.00%)"", ""  Intestinal haemorrhage 0/115 (0.00%)"", ""  Nausea 3/115 (2.61%)""]",Contradiction
"NCT00191269 measured the Number of Participants With Disease Progression (PD) or Death, to evaluate the performance of its interventions.","[""Outcome Measurement: "", ""  Tumor Response"", ""  Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve (\""respond\""), stay the same (\""stable\""), or worsen (\""progression\"") during treatment."", ""  Time frame: baseline to measured progressive disease""]",Contradiction
Both cohorts of NCT00767520 reported the same number of patients vomiting during the trial.,"[""Adverse Events 1:"", ""  Vomiting 2/79 (2.53%)"", ""Adverse Events 2:"", ""  Vomiting 2/76 (2.63%)""]",Entailment
"Between the patients in NCT00382018 and NCT03012477, only 1.56% suffered from sepsis.","[""Adverse Events 1:"", ""  Total: 0/161 (0.00%)"", ""  Gastrointestinal-Other 0/161 (0.00%)"", ""  Dehydration 0/161 (0.00%)"", ""  Renal/Genitourinary-Other 0/161 (0.00%)"", ""Adverse Events 2:"", ""  Total: 1/64 (1.56%)"", ""  Gastrointestinal-Other 1/64 (1.56%)"", ""  Dehydration 1/64 (1.56%)"", ""  Renal/Genitourinary-Other 1/64 (1.56%)""]",Contradiction
More than 20% of  patients in cohort 1 of NCT01298193 experienced adverse events.,"[""Adverse Events 1:"", ""  Total: 31/185 (16.76%)""]",Contradiction
At least 1 patient in cohort 1 of NCT01120184 suffered from a coagulation disorder.,"[""Adverse Events 1:"", ""  Hypercoagulation * 21/353 (0.28%)""]",Entailment
"There were 5 more cases of THROMBOCYTOPENIA in cohort 2 of NCT00080301, than in cohort 1.","[""Adverse Events 1:"", ""  THROMBOCYTOPENIA 2/368 (0.54%)"", ""Adverse Events 2:"", ""  THROMBOCYTOPENIA 7/369 (1.90%)""]",Entailment
7 patients in cohort 1 of NCT00452673 suffered dose-limiting toxicities.,"[""Outcome Measurement: "", ""  Number of Participants With Dose Limiting Toxicities Per Dose Level - Safety Population"", ""  Safety was assessed from first dose of study drug through at least 30 days after the last dose, until resolution of drug-related toxicity or when toxicity was deemed irreversible, whichever was longer. An adverse event (AE) was considered a dose limiting toxicity (DLT) if it occurred in the first 21 days and was at least possibly related to study drugs and were: Clinically-evident toxicity of Grade >= 3, or of Grade 2 which required interruption of treatment for >= 7 days (consecutive or non-consecutive); non-hematologic abnormal laboratory value of Grade >= 3, or hematologic toxicity of Grade 4, which persisted 7 days; any grade toxicity which in the judgment of the investigator required a dose reduction or removal from further study therapy."", ""  Time frame: Day 1 to 30 days post last dose"", ""Results 1: "", ""  Arm/Group Title: 50 mg Dasatinib + 825 mg/m^2Capecitabine"", ""  Arm/Group Description: Dose Level 1: 50 milligram (mg) dasatinib oral tablet twice daily (BID) plus 825 mg per meter squared (m^2) capecitabine oral tablet BID. Participants were treated at each dose level (DL) for minimum of 21 days before accrual to the next DL. Rules for dose escalation: If 0 dose level toxicity (DLT) was observed in the first 3 participants in a cohort, the next higher cohort was opened to accrual. If 1 DLT was observed in the first 3 participants in a cohort, then 3 additional participants were studied. If 0 DLT was observed in those 3 (ie, 1 DLT in 6 subjects at the DL), the next higher cohort was opened for accrual. If >=2 DLT was observed in up to 6 subjects, then the maximum tolerated dose (MTD) was exceeded and the next lower DL was defined as the MTD. If 0 DLT was observed in 6 participants in a cohort and the next higher DL exceeded the MTD, then intermediate DLs would be studied. Once the MTD was determined, additional participants were enrolled into that dose group."", ""  Overall Number of Participants Analyzed: 7"", ""  Measure Type: Number"", ""  Unit of Measure: participants  1""]",Contradiction
More than 2 cases of Anaphylaxis occurred in either NCT01234337 or NCT00217672.,"[""Adverse Events 1:"", ""  Total: 80/260 (30.77%)"", ""  Anaemia * 2/260 (0.77%)"", ""  Febrile neutropenia * 0/260 (0.00%)"", ""  Neutropenia * 2/260 (0.77%)"", ""  Thrombocytopenia * 0/260 (0.00%)"", ""  Bundle branch block right * 0/260 (0.00%)"", ""  Pericardial effusion * 0/260 (0.00%)"", ""  Cardiopulmonary failure * 0/260 (0.00%)"", ""  Aplasia * 0/260 (0.00%)"", ""  Eye symptom * 1/260 (0.38%)"", ""  Abdominal discomfort * 0/260 (0.00%)"", ""Adverse Events 2:"", ""  Total: 71/267 (26.59%)"", ""  Anaemia * 2/267 (0.75%)"", ""  Febrile neutropenia * 1/267 (0.37%)"", ""  Neutropenia * 0/267 (0.00%)"", ""  Thrombocytopenia * 1/267 (0.37%)"", ""  Bundle branch block right * 1/267 (0.37%)"", ""  Pericardial effusion * 5/267 (1.87%)"", ""  Cardiopulmonary failure * 1/267 (0.37%)"", ""  Aplasia * 1/267 (0.37%)"", ""  Eye symptom * 0/267 (0.00%)"", ""  Abdominal discomfort * 1/267 (0.37%)""]",Contradiction
Patients with an FEV1 of 80% to 120% are ineligible for NCT00328783.,"[""Inclusion Criteria:"", ""  Adequate pulmonary function""]",Contradiction
The only adverse event recorded in NCT01033032 was one single case of pleural effusion.,"[""Adverse Events 1:"", ""  Total: 1/3 (33.33%)"", ""  FEBRILE NEUTROPENIA 0/3 (0.00%)"", ""  LYMPH NODE PAIN 0/3 (0.00%)"", ""  NEUTROPHIL COUNT DECREASED 0/3 (0.00%)"", ""  THROMBOCYTOPENIA 0/3 (0.00%)"", ""  CHEST PAIN 0/3 (0.00%)"", ""  DEHYDRATION 0/3 (0.00%)"", ""  PLEURAL EFFUSION 1/3 (33.33%)"", ""  PNEUMONITIS 0/3 (0.00%)"", ""  PULMONARY INFILTERATES 0/3 (0.00%)"", ""  ALOPECIA 0/3 (0.00%)""]",Entailment
on assessment 0 NCT00662025 Participants had a confirmed disappearance of all target and non-target lesions.,"[""Outcome Measurement: "", ""  Number of Participants With Objective Response Based on Data Review Committee's Assessment"", ""  Number of participants with objective response based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors version 1.0 (RECIST). CR is defined as disappearance of all target and non-target lesions. PR is defined as 30% decrease in sum of the longest dimensions (LDs) of the target lesions taking as reference the baseline sum LD according to RECIST. Confirmed responses are those that persist on repeat evaluation 4 weeks after initial documentation of response."", ""  Time frame: Day 1 of Cycle 2, every 6 weeks after Cycle 2, and at the end of Cycle 8."", ""Results 1: "", ""  Arm/Group Title: SUNITINIB+CAPECITABINE"", ""  Arm/Group Description: Sunitinib was administered orally from Day 1 at the starting dose of 37.5 mg/day on a continuous daily dosing schedule in 21-day cycles. Capecitabine was administered orally from Days 1 to 14 every 21 days at a starting dose of 2,000 mg/m^2/day. Participants were monitored for toxicity, and sunitinib and/or capecitabine dosing could be interrupted or reduced according to individual tolerance. Participants with progressive disease (PD) or intolerable toxicity were considered for discontinuation from the study."", ""  Overall Number of Participants Analyzed: 63"", ""  Measure Type: Number"", ""  Unit of Measure: participants  Total Number of Participants with CR+PR: 19"", ""  Complete Response (CR): 0"", ""  Partial Response (PR): 19""]",Contradiction
"the percentage of participants achieving complete response (CR) or partial response (PR) was 6x higher in the HER2-positive group in NCT02260531, than in the ER+ and/or PR+ group.","[""Outcome Measurement: "", ""  CNS Objective Response Rate (ORR)"", ""  The central nervous system (CNS) ORR was defined as the percentage of participants achieving complete response (CR) or partial response (PR) based on RECIST 1.1 criteria in the evaluation CNS lesions on treatment: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions."", ""  Time frame: Disease assessments occurred every 6 cycles. Patients with stable or responsive disease after completion of 6 cycles could reduce frequency of assessments to every 3 cycles. Response was evaluated up to 25 months."", ""Results 1: "", ""  Arm/Group Title: Cohort 1 - Cabozantinib, Trastuzumab for HER2+"", ""  Arm/Group Description: HER2-positive"", ""  Cabozantinib- orally administered daily per treatment cycle"", ""  Trastuzumab- IV administered once per cycle"", ""  MRI- Baseline, Cycle 2 Day 1, and every 2 cycles"", ""  Magnetic Resonance Angiography (MRA ), Baseline, Cycle 2 Day 1,"", ""  Cabozantinib: One, 60 mg tablet daily of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops."", ""  Trastuzumab: For HER2-Positive participants only. Administered by IV on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops."", ""  Overall Number of Participants Analyzed: 21"", ""  Measure Type: Number"", ""  Unit of Measure: percentage of participants  5        (.2 to 24)"", ""Results 2: "", ""  Arm/Group Title: Cohort 2 - Cabozantinib for ER+ and/or PR+"", ""  Arm/Group Description: Hormone receptor-positive (ER+ and/or PR+)"", ""  Cabozantinib- orally administered daily per treatment cycle"", ""  MRI- Baseline, Cycle 2 Day 1, and every 2 cycles"", ""  Magnetic Resonance Angiography (MRA ), Baseline, Cycle 2 Day 1,"", ""  Cabozantinib: One, 60 mg tablet daily of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops."", ""  Overall Number of Participants Analyzed: 7"", ""  Measure Type: Number"", ""  Unit of Measure: percentage of participants  14        (.4 to 58)""]",Contradiction
"Participants for NCT02222337 must be in pairs, a breast cancer survivor and a caregiver, both must either be fluent in english or spanish.","[""Inclusion Criteria:"", ""  Survivors: Latina, has been diagnosed with breast cancer, speaks English or Spanish, has a Caregiver who is willing to participate."", ""  Caregivers: a primary caregiver for a Latina breast cancer survivor, speak English or Spanish""]",Entailment
1/42 patients in cohort 1 of NCT01671319 fainted.,"[""Adverse Events 1:"", ""  Total: 4/42 (9.52%)"", ""  Perforation, GI 1/42 (2.38%)"", ""  Febrile neutropenia 1/42 (2.38%)"", ""  Syncope 1/42 (2.38%)"", ""  Rash/desquamation 1/42 (2.38%)""]",Entailment
Patients with Myocardial Infarction or Deep vein thrombosis within the last 3 months are excluded from NCT01326481.,"[""Exclusion Criteria:"", ""  Angina, MI, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, arterial embolism, pulmonary embolism, DVT, PTCA or CABG within the past 6 months""]",Entailment
Patients must have LVEF < 50% to be eligible for NCT01904903 and NCT01663727.,"[""  LVEF < 50% and  40% documented in echocardiogram done within the last 30 days""]",Contradiction
Patients cannot be excluded from NCT00836186 on the basis of race or ethnicity.,"[""INCLUSION CRITERIA:"", ""  Women of all races and ethnic groups are eligible for this trial""]",Entailment
Patients with E2 outside the premenopausal range are ineligible for NCT00186121.,"[""  If tamoxifen administered within the past 3 months, plasma estradiol must be in the premenopausal range""]",Contradiction
"There were no observed cases of Constipation, Diarrhoea, Nausea or Febrile neutropenia within patient cohorts 1 and 2 of NCT01111825.","[""Adverse Events 1:"", ""  Total: 3/8 (37.50%)"", ""  Anaemia 0/8 (0.00%)"", ""  Febrile neutropenia 0/8 (0.00%)"", ""  Polycythaemia 0/8 (0.00%)"", ""  Acute coronary syndrome 0/8 (0.00%)"", ""  Vertigo 0/8 (0.00%)"", ""  Eyelid oedema 1/8 (12.50%)"", ""  Constipation 0/8 (0.00%)"", ""  Diarrhoea 0/8 (0.00%)"", ""  Nausea 0/8 (0.00%)"", ""  Stomatitis 0/8 (0.00%)"", ""  Upper gastrointestinal haemorrhage 0/8 (0.00%)"", ""  Vomiting 0/8 (0.00%)"", ""  Chest pain 0/8 (0.00%)"", ""Adverse Events 2:"", ""  Total: 2/6 (33.33%)"", ""  Anaemia 0/6 (0.00%)"", ""  Febrile neutropenia 0/6 (0.00%)"", ""  Polycythaemia 0/6 (0.00%)"", ""  Acute coronary syndrome 0/6 (0.00%)"", ""  Vertigo 0/6 (0.00%)"", ""  Eyelid oedema 0/6 (0.00%)"", ""  Constipation 0/6 (0.00%)"", ""  Diarrhoea 0/6 (0.00%)"", ""  Nausea 0/6 (0.00%)"", ""  Stomatitis 0/6 (0.00%)"", ""  Upper gastrointestinal haemorrhage 0/6 (0.00%)"", ""  Vomiting 0/6 (0.00%)"", ""  Chest pain 1/6 (16.67%)""]",Entailment
"NCT00394082 recorded cases of Anaphylaxis and Spinal compression fracture, neither of these were observed in NCT01033032.","[""Adverse Events 1:"", ""  Total: 13/50 (26.00%)"", ""  Febrile neutropenia 3/50 (6.00%)"", ""  Neutropenia 1/50 (2.00%)"", ""  Pancreatitis 1/50 (2.00%)"", ""  Cholangitis 1/50 (2.00%)"", ""  Cholelithiasis 1/50 (2.00%)"", ""  Anaphylactic reaction  [1]1/50 (2.00%)"", ""  Pneumonia 1/50 (2.00%)"", ""  Pneumonitis chemical 1/50 (2.00%)"", ""  Spinal compression fracture 1/50 (2.00%)"", ""  Dehydration 1/50 (2.00%)"", ""  Electrolyte imbalance 1/50 (2.00%)""]",Entailment
"To be included in NCT00217399, patients must have at least 1 unidimensionally measurable lesion, there are no size boundaries for eligibility.","[""  Measurable disease, defined as >=1 unidimensionally measurable lesion, including >= 1 of the following:"", ""  Lesion >= 10 mm on CT scan (5 mm sections)"", ""  Lesion >= 20 mm on CT scan or MRI (10 mm sections)"", ""  Lesion >= 10 mm on physical exam""]",Contradiction
Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T3 N1 M0) are eligible for NCT01097642.,"[""Inclusion Criteria:"", ""  Patients with histologic confirmation of invasive breast carcinoma."", ""  Patients greater than or equal to 18 years."", ""  Patients should have T1N1-3M0 or T2-4 N0-3M0."", ""  Patients with bilateral breast cancer are eligible.""]",Entailment
Patients with HER2 negative BC are eligible for both NCT00593827 and NCT00478257.,"[""Inclusion Criteria:"", ""  Has MBC that is measurable by RECIST or has nonmeasurable disease with serum CA27.29 (or CA15.3)  50"", ""  Has Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer""]",Entailment
More than 18 participants in NCT01365845 had radiation dermatitis.,"[""  Radiation dermatitis 2 [1]4/18 (22.22%)""]",Contradiction
"There were no cases of Cellulitis, Nausea or Anaemia in NCT01926886.","[""Adverse Events 1:"", ""  Total: 8/101 (7.92%)"", ""  Vertigo * 1/101 (0.99%)"", ""  Infected lymphocele * 1/101 (0.99%)"", ""  Ejection fraction decreased * 5/101 (4.95%)"", ""  Lymphoedema * 1/101 (0.99%)""]",Entailment
"The most common adverse events in NCT00965523 where Infection and Stomatitis, affecting a total of 14 patients.","[""Adverse Events 1:"", ""  Total: 14/81 (17.28%)"", ""  Neutropenia1/81 (1.23%)"", ""  Cataract1/81 (1.23%)"", ""  Ascites1/81 (1.23%)"", ""  Gastritis Hemorrhagic1/81 (1.23%)"", ""  Nausea1/81 (1.23%)"", ""  Stomatitis2/81 (2.47%)"", ""  Malaise1/81 (1.23%)"", ""  Oedema1/81 (1.23%)"", ""  Pain1/81 (1.23%)"", ""  Pyrexia1/81 (1.23%)"", ""  Infection2/81 (2.47%)"", ""  Upper Limb Fracture1/81 (1.23%)"", ""  Dehydration1/81 (1.23%)"", ""  Hypercalcemia1/81 (1.23%)""]",Contradiction
Patients with a nonpalpable breast lesion and 0 palpable axillary lymph nodes are eligible for NCT00072293.,"[""  Palpable or nonpalpable breast lesion"", ""  No palpable axillary lymph node(s)""]",Entailment
Neutropenia affected the majority of patients in cohort 1 of NCT01427933.,"[""Adverse Events 1:"", ""  Neutropenia 4/69 (5.80%)""]",Contradiction
"postmenopausal women are eligible for NCT01176916, and Premenopausal women are eligible for NCT00186121.","[""Inclusion Criteria:"", ""  The patient must be postmenopausal woman.""]",Entailment
NCT00618826 and NCT02040857 only record 2 of the same adverse events.,"[""Adverse Events 1:"", ""  Lymphopenia 1/14 (7.14%)"", ""  Diarrhea 1/14 (7.14%)"", ""  Fatigue (asthenia, lethargy, malaise) 2/14 (14.29%)"", ""  Hypertension 2/14 (14.29%)""]",Contradiction
"Ae-Cha is a 32 year old Korean woman with an inoperable breast cancer, she is too old to participate in both NCT01299038 and NCT00248170.","[""Inclusion Criteria:"", ""  Recent primary surgery for breast cancer"", ""  Early stage breast cancer"", ""  Postmenopausal"", ""  Hormone receptor positive"", ""  Positive lymph node involvement"", ""Exclusion Criteria:"", ""  Metastatic disease"", ""  Presence of contralateral breast cancer including DCIS"", ""  Progression"", ""  Other protocol-defined inclusion/exclusion criteria may apply.""]",Contradiction
participants from both cohorts of NCT00706030 had a drastically lower CNS Objective Response Rate than those in NCT00171704.,"[""Outcome Measurement: "", ""  Overall Response Rate"", ""  Overall Response Rate (ORR), subjects with CR or PR by independent review in subjects with ErbB-2-positive breast cancer treated at the MTD of neratinib in combination with vinorelbine per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.0: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; and Non-PD for non-target lesions, and no new lesions."", ""  Time frame: From first dose date to progression or last tumor assessment, up to four years and six months.""]",Contradiction
Patients eligible for NCT02964234 and NCT00246090 must live in the USA.,"[""Inclusion Criteria:"", ""  Age 52-75 years old;"", ""  Identification as Latina/Hispanic/Chicana female;"", ""  Residence in Pilsen, Little Village, East Side or South Chicago;""]",Contradiction
Only Patients with metastasis in less than 9 infraclavicular lymph nodes are eligible for NCT00050167.,"[""Inclusion Criteria:"", ""  Patients with pN2a (metastasis in four to nine axillary lymph nodes) are eligible as are patients with pN3a (ten or more axillary lymph nodes). Patients with infraclavicular lymph node involvement are NOT eligible.""]",Contradiction
NCT00593827 and NCT02425891 both measure PFS of their patient cohorts and use the same time frame.,"[""Outcome Measurement: "", ""  Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) in All Randomized Participants"", ""  PFS was defined as the time from randomization to the occurrence of disease progression, as determined by investigators from tumor assessments per RECIST v1.1, or death from any cause, whichever occurred first."", ""  Time frame: Baseline up to approximately 34 months""]",Contradiction
"In contrast to NCT00768222, NCT02102490 did not record any cases of Skin lymphangitis, Bone marrow suppression or Allergic shock.","[""Adverse Events 1:"", ""  Total: 33/132 (25.00%)"", ""  Febrile neutropenia 1/132 (0.76%)"", ""  Haematotoxicity 1/132 (0.76%)"", ""  Neutropenia 1/132 (0.76%)"", ""  Sinus bradycardia 1/132 (0.76%)"", ""  Tachycardia 1/132 (0.76%)"", ""  Abdominal pain 2/132 (1.52%)"", ""  Abdominal pain upper 1/132 (0.76%)"", ""  Constipation 1/132 (0.76%)"", ""  Large intestinal obstruction 1/132 (0.76%)"", ""  Nausea 3/132 (2.27%)""]",Entailment
The majority of patients in NCT00811135 experienced at least one adverse event.,"[""Adverse Events 1:"", ""  Total: 20/88 (22.73%)""]",Contradiction
There were no cases of extravasation in either NCT02402764 or NCT00490646.,"[""Adverse Events 1:"", ""  Total: 3/10 (30.00%)"", ""  Sinus tachycardia * 1/10 (10.00%)"", ""  Blurred vision * 1/10 (10.00%)"", ""  Memory impairment * 1/10 (10.00%)"", ""  Dyspnea * 2/10 (20.00%)""]",Contradiction
All cancer stages are accepted for NCT03190083 and NCT01805089.,"[""Inclusion Criteria:"", ""  New diagnosis of breast cancer"", ""  New diagnosis if a previous breast cancer patient with negative surgical margins"", ""  Patients willing to sign a written informed consent form""]",Contradiction
"Helen had stage III ovarian cancer 7 years prior, but has been disease-free for 5 years., she is excluded from NCT00859651.","[""Exclusion Criteria:"", ""  Other prior malignancy. The following is allowed: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the participant is currently in complete remission, or any other cancer (including breast cancer) for which the participant has been disease-free for 5 years.""]",Contradiction
A 56 year old patient with a masectomy would not be eligible for NCT02165605,"[""Inclusion Criteria:"", ""  Female, age 18 or older"", ""  Intact breast (not surgically absent)""]",Entailment
Two different types of tachycardia occurred to patients in cohort 2 of NCT01565083.,"[""Adverse Events 2:"", ""  Supraventricular tachycardia * 1/107 (0.93%)"", ""  Tachycardia * 1/107 (0.93%)""]",Entailment
Patients with an ImmunoHistoChemistry test result of 3+ are excluded from NCT00675259 and NCT01875367.,"[""  Exclusion:"", ""  HER-2 neu overexpression either by IHC 3+ or FISH+""]",Contradiction
1/7 patients in cohort 1 of NCT00452673 suffered dose-limiting toxicities.,"[""Outcome Measurement: "", ""  Number of Participants With Dose Limiting Toxicities Per Dose Level - Safety Population"", ""  Safety was assessed from first dose of study drug through at least 30 days after the last dose, until resolution of drug-related toxicity or when toxicity was deemed irreversible, whichever was longer. An adverse event (AE) was considered a dose limiting toxicity (DLT) if it occurred in the first 21 days and was at least possibly related to study drugs and were: Clinically-evident toxicity of Grade >= 3, or of Grade 2 which required interruption of treatment for >= 7 days (consecutive or non-consecutive); non-hematologic abnormal laboratory value of Grade >= 3, or hematologic toxicity of Grade 4, which persisted 7 days; any grade toxicity which in the judgment of the investigator required a dose reduction or removal from further study therapy."", ""  Time frame: Day 1 to 30 days post last dose"", ""Results 1: "", ""  Arm/Group Title: 50 mg Dasatinib + 825 mg/m^2Capecitabine"", ""  Arm/Group Description: Dose Level 1: 50 milligram (mg) dasatinib oral tablet twice daily (BID) plus 825 mg per meter squared (m^2) capecitabine oral tablet BID. Participants were treated at each dose level (DL) for minimum of 21 days before accrual to the next DL. Rules for dose escalation: If 0 dose level toxicity (DLT) was observed in the first 3 participants in a cohort, the next higher cohort was opened to accrual. If 1 DLT was observed in the first 3 participants in a cohort, then 3 additional participants were studied. If 0 DLT was observed in those 3 (ie, 1 DLT in 6 subjects at the DL), the next higher cohort was opened for accrual. If >=2 DLT was observed in up to 6 subjects, then the maximum tolerated dose (MTD) was exceeded and the next lower DL was defined as the MTD. If 0 DLT was observed in 6 participants in a cohort and the next higher DL exceeded the MTD, then intermediate DLs would be studied. Once the MTD was determined, additional participants were enrolled into that dose group."", ""  Overall Number of Participants Analyzed: 7"", ""  Measure Type: Number"", ""  Unit of Measure: participants  1""]",Entailment
"Stephanie has been living with her boyfriend for 2 months, she is eligible for NCT02721147.","[""Inclusion Criteria:"", ""  Has a partner or spouse who is > 21"", ""  Lives with a romantic partner > 6 months""]",Contradiction
A patient who had a total bilateral mastectomy in the year prior to study entry would be excluded from both NCT01966471 and NCT00981812.,"[""Inclusion Criteria:"", ""  Known hormone receptor status of the primary tumor"", ""Adequately excised: participants must have undergone either breast-conserving surgery or mastectomy/nipple- or skin-sparing mastectomy""]",Entailment
Presence of Extracranial metastases is part of the exclusion critera for NCT00617539.,"[""DISEASE CHARACTERISTICS:"", ""  Histologically or cytologically confirmed breast cancer with radiographically confirmed metastases to the brain"", ""  Extracranial metastases allowed""]",Contradiction
"NCT00464646 records only gastrointestinal adverse events, whereas NCT00006110 doesn’t record any GI adverse events.","[""Adverse Events 1:"", ""  Total: 7/52 (13.46%)"", ""  Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infe * 0/52 (0.00%)"", ""  Atrial Fibrillation * 1/52 (1.92%)"", ""  Sepsis * 1/52 (1.92%)"", ""  Muscle weakness upper limb * 1/52 (1.92%)"", ""  Dizziness * 1/52 (1.92%)"", ""  Seizure * 1/52 (1.92%)"", ""  Nervous system disorders - Other, specify *  [1]1/52 (1.92%)"", ""Adverse Events 2:"", ""  Total: 1/30 (3.33%)"", ""  Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infe * 1/30 (3.33%)"", ""  Atrial Fibrillation * 0/30 (0.00%)"", ""  Sepsis * 0/30 (0.00%)"", ""  Muscle weakness upper limb * 0/30 (0.00%)"", ""  Dizziness * 0/30 (0.00%)"", ""  Seizure * 0/30 (0.00%)"", ""  Nervous system disorders - Other, specify *  [1]0/30 (0.00%)""]",Contradiction
Patients with HER2 positive breast tumors are eligible for NCT00372424 and NCT00041067.,"[""Inclusion Criteria:"", ""  Breast cancer with evidence of unresectable, locally recurrent, or metastatic disease."", ""  Tumors over-expressing Her-2"", ""  Candidate for treatment with docetaxel/trastuzumab""]",Entailment
A patient in cohort 2 of NCT00024102 received a Plasma transfusion.,"[""Adverse Events 2:"", ""  Total: 17/181 (9.39%)"", ""  Disseminated intravascular coagulation 0/181 (0.00%)"", ""  Febrile neutropenia 1/181 (0.55%)"", ""  Hemoglobin decreased 13/181 (7.18%)"", ""  Lymphatics 0/181 (0.00%)"", ""  Transfusion: pRBCs 1/181 (0.55%)"", ""  Arrhythmia supraventricular 1/181 (0.55%)"", ""  Cardiac disorder 0/181 (0.00%)"", ""  Edema 0/181 (0.00%)"", ""  Left ventricular failure 1/181 (0.55%)"", ""  Myocardial ischemia 0/181 (0.00%)""]",Contradiction
The majority of patients in NCT00811135 did not experience Left ventricular dysfunction.,"[""Adverse Events 1:"", ""  Total: 20/88 (22.73%)""]",Entailment
"Adequate Hematologic, Hepatic and renal function is not necessary for participating in NCT00478257.","[""Inclusion Criteria:"", ""  stage I-III breast cancer"", ""  adjuvant or neoadjuvant anthracycline-based chemotherapy"", ""Exclusion Criteria:"", ""  under age 18"", ""  pregnancy"", ""  metastatic or inoperable (including inflammatory) breast cancer"", ""  confounding underlying medical illnesses"", ""  history of mania"", ""  history of other axis-I psychiatric disorder"", ""  other physical or psychological impairments -""]",Entailment
"There were 0 cases of night blindness in NCT00066573, and 1 in NCT01091454.","[""Adverse Events 1:"", ""  Total: 19/3761 (0.51%)"", ""  Cardiac ischemia/infarction 3/3761 (0.08%)"", ""  Left ventricular systolic dysfunction 1/3761 (0.03%)"", ""  Restrictive cardiomyopathy 1/3761 (0.03%)"", ""  Supraven.arrhyth. Atrial flutter 1/3761 (0.03%)"", ""  Ventric.arrhyth. Trigeminy 1/3761 (0.03%)"", ""  Hypothyroidism 0/3761 (0.00%)"", ""  Blurred vision 1/3761 (0.03%)"", ""  Nyctalopia 0/3761 (0.00%)"", ""  Ocular - Other 1/3761 (0.03%)"", ""Adverse Events 2:"", ""  Total: 7/3759 (0.19%)"", ""  Cardiac ischemia/infarction 0/3759 (0.00%)"", ""  Left ventricular systolic dysfunction 0/3759 (0.00%)"", ""  Restrictive cardiomyopathy 0/3759 (0.00%)"", ""  Supraven.arrhyth. Atrial flutter 0/3759 (0.00%)"", ""  Ventric.arrhyth. Trigeminy 0/3759 (0.00%)"", ""  Hypothyroidism 1/3759 (0.03%)"", ""  Blurred vision 0/3759 (0.00%)"", ""  Nyctalopia 1/3759 (0.03%)"", ""  Ocular - Other 0/3759 (0.00%)""]",Contradiction
Mark complained he had a racing heart twice in the last month and he is therefore excluded from NCT02732119.,"[""Exclusion Criteria:"", ""  Clinically significant, uncontrolled heart disease and/or recent cardiac events.""]",Contradiction
"Patients with Class III obesity cannot be included in NCT02650193, but can be entered into NCT00656669, even if they have uncontrolled Hypertension.","[""Inclusion Criteria:"", ""  Body mass index (BMI) of 19 to 40 kg/m^2 , inclusive""]",Contradiction
57% of patients in cohort 1 of NCT00723125 had Pathological Complete Response Rates at Surgery.,"[""Outcome Measurement: "", ""  Pathological Complete Response Rates at Surgery"", ""  [Not Specified]"", ""  Time frame: at surgery approximately 5 months after initial treatment"", ""Results 1: "", ""  Arm/Group Title: Cohort 1"", ""  Arm/Group Description: Avastin 10 mg/kg IV over 90 minutes day -14 Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 Avastin 10 mg/kg IV over 30-60 minutes cycles 1-3 (omit dose with cycle 4) Doxorubicin 60 mg/m2* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles Definitive surgery Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks"", ""  Cohort 1 and Cohort 2: Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)"", ""  Overall Number of Participants Analyzed: 28"", ""  Measure Type: Number"", ""  Unit of Measure: participants  16""]",Entailment
"One patient in NCT00924352 had abnormally low levels of AST, ALT and ANC.","[""Adverse Events 1:"", ""  Total: 11/56 (19.64%)"", ""  Febrile Neutropenia * 3/56 (5.36%)"", ""  Neutropenia * 1/56 (1.79%)"", ""  Pancytopenia * 1/56 (1.79%)"", ""  Atrial Fibrillation * 1/56 (1.79%)"", ""  Coronary Artery Disease * 1/56 (1.79%)"", ""  Constipation * 1/56 (1.79%)"", ""  Chest Pain * 1/56 (1.79%)"", ""  Non-Cardiac Chest Pain * 1/56 (1.79%)"", ""  Edema due to Cardiac Disease * 1/56 (1.79%)"", ""  Cellulitis * 1/56 (1.79%)""]",Contradiction
Patients must be english to participate in NCT01042938.,"[""Inclusion Criteria:"", ""  Female with a diagnosis of, non-inflammatory breast adenocarcinoma and be referred for post-operative radiotherapy without concurrent chemotherapy."", ""  Participants must be at least 21 years of age."", ""  Participants must not be pregnant."", ""  Participants can be from any racial or ethnic origin."", ""  Breast adenocarcinoma could have been treated by either lumpectomy or mastectomy with or without adjuvant or neoadjuvant chemotherapy or hormonal treatment."", ""  Participants with in situ breast cancer are eligible."", ""  Participants who are prescribed concurrent hormone treatment with radiation treatment are eligible."", ""  Participants must be scheduled to receive five sessions of radiation therapy per week (1 session per day) for at least four weeks using standard (1.8-2.0 Gy per session)or Canadian (2.2-2.5 Gy per session)irradiation fractionation."", ""  A time period of three weeks must elapse after chemotherapy and surgery before beginning the study."", ""  The total dose prescribed to the whole breast should be 50 Gy or greater."", ""  Participants must be able to understand English and able to complete assessment forms (all assessment forms are in English)."", ""  Participants must be able to swallow medication."", ""  Topical skin agents, e.g., Aquaphor, Cetaphil, or other emollients, are allowed either PRN or prophylactically."", ""  Participant must give informed consent."", ""Exclusion Criteria:"", ""  Patients with bilateral breast cancer are not eligible."", ""  Patients who have had previous radiation therapy to the breast or chest are not eligible."", ""  Patients who are prescribed chemotherapy concurrently with radiation treatment are not eligible."", ""  Patients who will be receiving treatment with Herceptin (trastuzumab), anti-coagulants, or anti-human epidermal growth factor receptor (EGFR) drugs, e.g. Iressa (gefitinib), Erbitux (cetuximab, C225), concurrently with their radiation therapy are not eligible."", ""  Patients cannot have had breast reconstructions, implants, and/or expanders."", ""  Patients with known radiosensitivity syndromes (e.g., Ataxia-telangiectasia) are not eligible."", ""  Patients with collagen vascular disease, vasculitis, unhealed surgical sites, or breast infections are not eligible."", ""  Patients whose baseline blood tests meet the following criteria are not eligible: greater than or equal to Grade 2 change Hemoglobin (i.e., 25% decrease from baseline); greater than or equal to Grade 1 change in Platelets (i.e., less than 75,000/mm3); greater than or equal to Grade 2 change in PT and PTT(i.e., 1.5-2x upper level normal (ULN)); greater than or equal to Grade 1 change in AST, ALT (i.e., greater than 2.5x ULN); greater than or equal to Grade 1 change in Bilirubin (i.e., greater than 1.5x ULN); greater than or equal to Grade 1 change in Creatinine (i.e., greater than 2x ULN).""]",Contradiction
NCT00322348 and NCT00429572 use ECOG to evaluate potential candidates' performance status.,"[""  World Health Organization (WHO) performance status of 0, 1, or 2""]",Contradiction
"Patients with tumors overexpressing HER-2 are eligible for NCT00392392, but not for NCT00971737.","[""DISEASE CHARACTERISTICS:"", ""  Histologically confirmed adenocarcinoma of the breast"", ""  Does not overexpress HER-2/neu, defined as FISH negative or 0, 1+, or 2+ by IHC"", ""  Stage IV disease""]",Contradiction
"Anna is a 57 year old female with an ECOG of 0, diagnosed with a HER2-positive invasive adenocarcinoma of the breast, with ipsilateral nodes pN2. She is eligible for NCT00464646.","[""Inclusion Criteria:"", ""  Patients must be female."", ""  The patient must be greater than or equal to 18 years old."", ""  The patient's ECOG performance status must be 0 or 1."", ""  The tumor must be invasive adenocarcinoma of the breast on histologic examination."", ""  The breast cancer must be determined to be HER2-positive prior to study entry. Assays performed using FISH require gene amplification. Assays using IHC require a strongly positive (3+) staining score."", ""  By pathologic evaluation, ipsilateral nodes must be pN2 or pN3.""]",Entailment
Men are not eligible for NCT00605267.,"[""Inclusion Criteria:"", ""  Premenopausal, estrogen receptor positive women, aged 20 years and over, with operable and measurable breast cancer who have provided written informed consent"", ""Exclusion Criteria:"", ""  Medical history of chemotherapy or endocrine therapy for breast cancer, or with treatment history of radiotherapy. Unwillingness to stop taking any drug known to affect sex hormone status (including hormone replacement therapy (HRT).""]",Entailment
Cohort 1 and 2 of NCT00451555 recorded exactly the same number of each type of adverse events.,"[""Adverse Events 1:"", ""  Total: 17/94 (18.09%)"", ""  Anaemia 2/94 (2.13%)"", ""  Lymphadenopathy 0/94 (0.00%)"", ""  Angina pectoris 0/94 (0.00%)"", ""  Ischaemic cardiomyopathy 0/94 (0.00%)"", ""  Myocardial infarction 1/94 (1.06%)"", ""  Haemorrhoids 1/94 (1.06%)"", ""  Ileus 1/94 (1.06%)"", ""  Nausea 1/94 (1.06%)"", ""  Vomiting 1/94 (1.06%)"", ""  Asthenia 1/94 (1.06%)"", ""  Disease progression 0/94 (0.00%)"", ""  Oedema peripheral 1/94 (1.06%)"", ""Adverse Events 2:"", ""  Total: 9/39 (23.08%)"", ""  Anaemia 2/39 (5.13%)"", ""  Lymphadenopathy 0/39 (0.00%)"", ""  Angina pectoris 0/39 (0.00%)"", ""  Ischaemic cardiomyopathy 0/39 (0.00%)"", ""  Myocardial infarction 1/39 (2.56%)"", ""  Haemorrhoids 1/39 (2.56%)"", ""  Ileus 1/39 (2.56%)"", ""  Nausea 1/39 (2.56%)"", ""  Vomiting 1/39 (2.56%)"", ""  Asthenia 1/39 (2.56%)"", ""  Disease progression 0/39 (0.00%)"", ""  Oedema peripheral 1/39 (2.56%)""]",Entailment
Patients with LVEF equal to 53.5% are eligible for NCT00976989.,"[""Inclusion Criteria:"", ""  baseline left ventricular ejection fraction (LVEF) >/=55%""]",Contradiction
None of the adverse events which occurred in NCT02149524 were not GI related.,"[""Adverse Events 1:"", ""  Total: 58/438 (13.24%)"", ""  Febrile neutropenia  13/438 (2.97%)"", ""  Neutropenia  5/438 (1.14%)"", ""  Anaemia  0/438 (0.00%)"", ""  Thrombocytopenia  0/438 (0.00%)"", ""  Haemolytic anaemia  1/438 (0.23%)"", ""  Leukopenia  1/438 (0.23%)"", ""  Cardiac failure congestive  0/438 (0.00%)"", ""  Supraventricular tachycardia  0/438 (0.00%)"", ""  Myocardial infarction  1/438 (0.23%)"", ""  Vertigo  0/438 (0.00%)"", ""Adverse Events 2:"", ""  Total: 56/437 (12.81%)"", ""  Febrile neutropenia  10/437 (2.29%)"", ""  Neutropenia  7/437 (1.60%)"", ""  Anaemia  2/437 (0.46%)"", ""  Thrombocytopenia  1/437 (0.23%)"", ""  Haemolytic anaemia  0/437 (0.00%)"", ""  Leukopenia  0/437 (0.00%)"", ""  Cardiac failure congestive  3/437 (0.69%)"", ""  Supraventricular tachycardia  1/437 (0.23%)"", ""  Myocardial infarction  0/437 (0.00%)"", ""  Vertigo  1/437 (0.23%)""]",Contradiction
NCT00721630 and NCT00364611 recorded the same proportion of patients experiencing nausea.,"[""Adverse Events 1:"", ""  Nausea  1/23 (4.35%)""]",Contradiction
There were more cases of Anemia and Leukopenia in NCT01091454 than NCT00054275.,"[""Adverse Events 1:"", ""  Total: 29/48 (60.42%)"", ""  Anemia 4/48 (8.33%)"", ""  Febrile neutropenia 7/48 (14.58%)"", ""  Atrial fibrillation 1/48 (2.08%)"", ""  Pericardial effusion 1/48 (2.08%)"", ""  Sinus bradycardia 1/48 (2.08%)"", ""  Nausea 2/48 (4.17%)"", ""  Vomiting 2/48 (4.17%)"", ""  Death NOS 1/48 (2.08%)"", ""  Fatigue 3/48 (6.25%)"", ""  Allergic reaction 1/48 (2.08%)"", ""  Lung infection 1/48 (2.08%)"", ""  Mucosal infection 1/48 (2.08%)""]",Contradiction
Patients with undetermined  human epidermal growth factor receptor 2 expression cannot be accepted by either NCT02244580 or NCT01901146.,"[""Inclusion Criteria:"", ""  Estrogen receptor (ER), PgR and HER2 expression have been determined""]",Entailment
There was exactly the same proportion of anemic patinets in both cohorts of NCT00567190.,"[""Adverse Events 1:"", ""  Anaemia 3/396 (0.76%)"", ""Adverse Events 2:"", ""  Anaemia 3/408 (0.74%)""]",Contradiction
"Less than 5% of patients undergoing the intervention in NCT00107276 had adverse events, in comparison almost 10% patients in cohort 1 of NCT00232505  experienced an adverse event, and more than 30% of those in cohort 2 of NCT00232505 had adverse events.","[""Adverse Events 1:"", ""  Total: 4/95 (4.21%)""]",Entailment
Every single patient in NCT00203502 experienced at least 1 adverse event.,"[""Adverse Events 1:"", ""  Total: 39/39 (100.00%)""]",Entailment
The most common adverse event in cohort 1 of NCT00075764 is low Hemoglobin levels.,"[""Adverse Events 1:"", ""  Total: 21/337 (6.23%)"", ""  Blood/Bone Marrow-Other 0/337 (0.00%)"", ""  Febrile neutropenia 0/337 (0.00%)"", ""  Hemoglobin 2/337 (0.59%)"", ""  Atrioventricular block - 2nd degree Mobitz Type II 0/337 (0.00%)"", ""  Cardiac-ischemia/infarction 1/337 (0.30%)"", ""  Left ventricular diastolic dysfunction 0/337 (0.00%)"", ""  Left ventricular systolic dysfunction 1/337 (0.30%)"", ""  Restrictive cardiomyopathy 1/337 (0.30%)""]",Entailment
Hyperglycemia was the most common adverse event in cohort 1 of NCT00820872.,"[""Adverse Events 1:"", ""  Total: 10/30 (33.33%)"", ""  Hemoglobin decreased 2/30 (6.67%)"", ""  Abdominal pain 1/30 (3.33%)"", ""  Colitis 1/30 (3.33%)"", ""  Diarrhea 7/30 (23.33%)"", ""  Nausea 2/30 (6.67%)"", ""  Rectal hemorrhage 1/30 (3.33%)"", ""  Fatigue 1/30 (3.33%)"", ""  Skin infection 1/30 (3.33%)"", ""  Neutrophil count decreased 1/30 (3.33%)"", ""  Platelet count decreased 3/30 (10.00%)"", ""  Dehydration 1/30 (3.33%)""]",Contradiction
"The adverse events in NCT00503906 where all equally prevalent, whereas in NCT01142661, alcohol poisoning was reported as the most common event.","[""Adverse Events 1:"", ""  Total: 8/29 (27.59%)"", ""  Leukopenia  [1]1/29 (3.45%)"", ""  Thrombocytopenia  [1]1/29 (3.45%)"", ""  Abscess  [1]1/29 (3.45%)"", ""  Breast Abscess 1/29 (3.45%)"", ""  Fever/Sepsis  [1]1/29 (3.45%)"", ""  Neutropenic Fever  [2]1/29 (3.45%)"", ""  Peripheral Neuropathy  [1]1/29 (3.45%)"", ""  Seizure/Syncope  [1]1/29 (3.45%)"", ""  Hematuria  [1]1/29 (3.45%)"", ""  UTI  [1]1/29 (3.45%)"", ""  Shortness of breath  [1]1/29 (3.45%)""]",Contradiction
"Only people who have previously been diagnosed with cancer and have no signs of cancer after finishing treatment are eliglbe for NCT00981305, as long as they are over the age of 20.","[""Inclusion Criteria:"", ""  breast cancer survivors over 20 years-old""]",Entailment
All cancer stages are accepted for NCT03190083.,"[""Inclusion Criteria:"", ""  New diagnosis of breast cancer"", ""  New diagnosis if a previous breast cancer patient with negative surgical margins"", ""  Patients willing to sign a written informed consent form""]",Entailment
"1 patient, in cohort 1 of NCT02748213 was recorded as having an overactive thyroid gland.","[""Adverse Events 1:"", ""  Total: 52/112 (46.43%)"", ""  Febrile neutropenia * 16/112 (14.29%)"", ""  Neutropenia * 7/112 (6.25%)"", ""  Anaemia * 1/112 (0.89%)"", ""  Cardiac failure * 1/112 (0.89%)"", ""  Coronary artery disease * 1/112 (0.89%)"", ""  Left ventricular dysfunction * 1/112 (0.89%)"", ""  Pericardial effusion * 0/112 (0.00%)"", ""  Hyperthyroidism * 1/112 (0.89%)"", ""  Diarrhoea * 5/112 (4.46%)"", ""  Vomiting * 3/112 (2.68%)"", ""Adverse Events 2:"", ""  Total: 51/110 (46.36%)"", ""  Febrile neutropenia * 26/110 (23.64%)"", ""  Neutropenia * 7/110 (6.36%)"", ""  Anaemia * 1/110 (0.91%)"", ""  Cardiac failure * 0/110 (0.00%)"", ""  Coronary artery disease * 0/110 (0.00%)"", ""  Left ventricular dysfunction * 0/110 (0.00%)"", ""  Pericardial effusion * 1/110 (0.91%)"", ""  Hyperthyroidism * 0/110 (0.00%)"", ""  Diarrhoea * 0/110 (0.00%)"", ""  Vomiting * 1/110 (0.91%)""]",Entailment
Female patients with a womb cannot take part in either NCT00193180 or NCT00570323.,"[""Inclusion Criteria:"", ""  All subjects must be female."", ""  Postmenopausal status, defined as any one of the following criteria:"", ""  Documented history of bilateral oophorectomy."", ""  Age 60 years or more."", ""  Age 45 to 59 and satisfying one or more of the following criteria:"", ""  Amenorrhea for at least 12 months and intact uterus."", ""  Amenorrhea for less than 12 months and a follicle stimulating hormone (FSH) and estradiol concentration within postmenopausal range including: patients who have had a hysterectomy and patients who have received hormone replacement."", ""  Patients must have histologically confirmed invasive breast cancer with a primary tumor of 3 cm or more in greatest dimension as measured by clinical examination."", ""  Estrogen receptor and/or progesterone receptor positive disease."", ""  Patients must not have received any prior treatment for current or newly diagnosed breast cancer."", ""  Patients must have not received previous treatment with any of the study medications or similar drugs."", ""  No use of selective estrogen receptor modulators (SERM) such as raloxifene or similar agents in the past 2 years."", ""  WHO performance status of 0, 1, or 2."", ""  Adequate organ function defined as follows:"", ""  Adequate renal function, defined by a serum creatinine within 3 times the upper limits of normal."", ""  Adequate liver function, defined by total bilirubin, AST, ALT, and alkaline phosphatase within 3 times the upper limits of normal."", ""  Adequate bone marrow function, defined as a WBC greater than 3.0 ml, PLT greater than 75,000/ul, Hb greater than 9 gm/l."", ""  Willing to undergo breast core biopsies as required by the study protocol. - Ability to understand and sign a written informed consent for participation in the trial."", ""  Life expectancy of at least 1 year."", ""Exclusion Criteria:"", ""  Premenopausal status."", ""  Other coexisting malignancies with the exception of basal cell carcinoma or cervical cancer in situ."", ""  Patients with brain metastasis."", ""  WHO performance status of 3 or 4."", ""  Is judged by the investigator, uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, significant cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements."", ""  Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the clinical trial. - Concurrent treatment with estrogens or progestins. Patients must stop these drugs at least two weeks prior to study entry."", ""  Treatment with a non-approved or investigational drug within 30 days before Day 1 of study treatment."", ""  Platelet count less than 75,000."", ""  In the opinion of the investigator, bleeding diathesis or anticoagulation therapy that would preclude intramuscular injections."", ""  History of hypersensitivity to castor oil."", ""  Any evidence of clinically active interstitial lung disease (patients with chronic stable radiographic changes who are asymptomatic need not be excluded) - Patients with recurrent breast cancer."", ""  Patients with contralateral second primary breast cancers are eligible.""]",Contradiction
Candidates must have a life expectancy less than 12 weeks to particpate in NCT00580333 and NCT00934856.,"[""Exclusion Criteria:"", ""  Life expectancy of less than 12 weeks""]",Contradiction
"Less than 5% of patients undergoing the intervention in NCT00107276 had adverse events, in comparison almost 10% patients in cohort 1 of NCT00232505  experienced an adverse event, and less than a 1/3 of those in cohort 2 of NCT00232505 had adverse events.","[""Adverse Events 1:"", ""  Total: 4/95 (4.21%)""]",Contradiction
"Patients with any of the following conditions will be excluded from NCT00825734; grade 3 infection, unstable angina or a grade 4 hemorrhage within the last month.","[""  Exclusion Criteria"", ""  Uncontrolled intercurrent illness including (but not limited to)"", ""  ongoing or active infection >grade 2."", ""  Unstable angina (anginal symptoms at rest) or new onset angina"", ""  Pulmonary hemorrhage or bleeding event  grade 2 within"", ""  4 weeks of the first dose of study treatment, or any other"", ""  hemorrhage or bleeding event  grade 3 within 4 weeks of the"", ""  first dose of study treatment.""]",Entailment
NCT03283553 and NCT01646346 both use irradiation techniques in their studies.,"[""INTERVENTION 1: "", ""  4D Conformal Image-Guided Partial Breast RT"", ""  This is a single arm trial designed to look at the results in women treated with partial breast irradiation twice daily for 5 days."", ""  4D Conformal Image-Guided Partial Breast RT: External beam partial breast radiation to target a portion of the breast twice a day for 5 days.""]",Contradiction
"Patients must have eceptorsestrogen receptor (ER) -, progesterone receptor (PR) - and human epidermal growth factor receptor 2 (HER2) - non metastatic breast cancer, aswell as not having Dysphagia.","[""Inclusion Criteria:"", ""  recurrent or progressive locally advanced, or 'triple negative' metastatic breast cancer"", ""Exclusion Criteria:"", ""  Unable to take oral medication""]",Contradiction
At least one type of respiratory illness was observed in patients from both NCT02536339 and NCT00371345.,"[""Adverse Events 1:"", ""  Parainfluenzae virus infection 1/39 (2.56%)""]",Entailment
Males are not eligible for NCT00293540.,"[""Inclusion Criteria:"", ""  Estrogen receptor or progesterone receptor positive breast cancer"", ""  Premenopausal with regular menstrual cycles"", ""Exclusion Criteria:"", ""  Current oral contraceptives""]",Entailment
0 patients in NCT01276041 or NCT00688909 died.,"[""Adverse Events 1:"", ""  Total: 18/70 (25.71%)"", ""  Cardiac arrest  1/70 (1.43%)"", ""  Pericardial effusion  1/70 (1.43%)"", ""  Ear pain  1/70 (1.43%)"", ""  Blurred vision  1/70 (1.43%)"", ""  Eye disorders - Other, specify  2/70 (2.86%)"", ""  Abdominal Pain  5/70 (7.14%)"", ""  Colitis  1/70 (1.43%)"", ""  Diarrhea  2/70 (2.86%)"", ""  Nausea  2/70 (2.86%)"", ""  Death NOS  1/70 (1.43%)"", ""  Edema limbs  1/70 (1.43%)"", ""  Fatigue  3/70 (4.29%)""]",Contradiction
African American patients are eligible for both NCT02673918 and NCT01042938.,"[""Inclusion Criteria:"", ""  Diagnosis of breast cancer"", ""  Part 1 only: Surgery for breast cancer within the past eight weeks (mastectomy or lumpectomy with either sentinel or axillar dissection), including those women with a history of previous surgery for breast cancer, radiation therapy or chemotherapy"", ""  Part 2 only: Completion of surgery and radiation therapy for breast cancer within the past six weeks."", ""  Home access to internet from stationary computer, lab top or tablet"", ""  Ability to use internet"", ""  Ability to read and understand Danish"", ""Exclusion Criteria:"", ""  Surgery for breast cancer with immediate breast reconstruction"", ""  Diagnosis of primary lymphedema"", ""  Metastatic or inflammatory breast cancer"", ""  Planned use of chemotherapy within the next 6 weeks"", ""  Surgical complications: infection, drainage issues, seroma, hematoma"", ""  Severe physical, cognitive, or psychiatric illness causing inability to follow the study protocol: i.e. severe depression, anxiety, dementia, poor physical health with likely possibility of hospitalization within the next twelve weeks."", ""  Planned hospitalization or surgery within the next twelve weeks"", ""  Participation in another clinical trial with a rehabilitation or exercise intervention""]",Entailment
"The same number of cases of Neutropenia, Febrile neutropenia and Pancytopenia are observed in patients from cohort 1 of NCT01998906.","[""Adverse Events 1:"", ""  Febrile neutropenia * 7/115 (6.09%)"", ""  Neutropenia * 1/115 (0.87%)"", ""  Pancytopenia * 1/115 (0.87%)""]",Contradiction
There are no recorded cases of thrombocytopenia in NCT02015676.,"[""Adverse Events 1:"", ""  Total: 26/69 (37.68%)"", ""  Thrombophlebitis * 1/69 (1.45%)"", ""  Anaemia NOS * 1/69 (1.45%)"", ""  Acute febrile neutrophilic dermatosis * 1/69 (1.45%)"", ""  Cardiac failure NOS * 2/69 (2.90%)"", ""  Ejection fraction decreased * 1/69 (1.45%)"", ""  Intestinal obstruction NOS * 1/69 (1.45%)"", ""  Diarrhoea NOS * 2/69 (2.90%)"", ""  Febrile neutropenia * 12/69 (17.39%)"", ""  Mucosal inflammation NOS * 1/69 (1.45%)""]",Entailment
"Only two types of adverse events, Leukopenia and Anaemia, occurred in more than 1% of patient in cohort 1 of NCT00448591.","[""  Total: 672/2264 (29.68%)"", ""  Febrile neutropenia * 117/2264 (5.17%)"", ""  Neutropenia * 98/2264 (4.33%)"", ""  Febrile bone marrow aplasia * 14/2264 (0.62%)"", ""  Anaemia * 8/2264 (0.35%)"", ""  Leukopenia * 8/2264 (0.35%)"", ""  Thrombocytopenia * 6/2264 (0.27%)"", ""  Disseminated intravascular coagulation * 3/2264 (0.13%)"", ""  Agranulocytosis * 1/2264 (0.04%)"", ""  Bone marrow failure * 1/2264 (0.04%)""]",Contradiction
"In total there were 5x more adverse events in cohort 1 of NCT00448279, than in cohort 2.","[""Adverse Events 1:"", ""  Total: 4/26 (15.38%)"", ""  Febrile neutropenia * 1/26 (3.85%)"", ""  Gastric volvulus * 20/26 (0.00%)"", ""  General Malaise * 21/26 (3.85%)"", ""  Hospitalisation for intrapleuric chemotherapy and thoracentesis * 21/26 (3.85%)"", ""  Acute renal failure * 21/26 (3.85%)"", ""Adverse Events 2:"", ""  Total: 1/28 (3.57%)"", ""  Febrile neutropenia * 0/28 (0.00%)"", ""  Gastric volvulus * 21/28 (3.57%)"", ""  General Malaise * 20/28 (0.00%)"", ""  Hospitalisation for intrapleuric chemotherapy and thoracentesis * 20/28 (0.00%)"", ""  Acute renal failure * 20/28 (0.00%)""]",Contradiction
NCT01142661 does not accept patients with grade 1 alopecia.,"[""  Exclusion Criteria Subjects who meet any of the following criteria will be excluded from participation in the treatment protocol:"", ""  Existing anti-cancer therapy-related toxicities of Grade >/= 2, except that alopecia and Grade 2 neuropathy are acceptable.""]",Entailment
"Participants in NCT01196052 must be willing to undergo anthracycline-based chemotherapy, or have previously received either cyclophosphamide or epirubicin.","[""Inclusion Criteria:"", ""  Willingness to receive anthracycline-based chemotherapy or have received doxorubicin/cyclophosphamide (AC) OR 5-fluorouracil (FU)/epirubicin/ cyclophosphamide (FEC) in a similar dose and schedule as described in the protocol as part of neoadjuvant or adjuvant treatment.""]",Entailment
"In total, across both cohorts of NCT00934856, there was at least 2 fatigued patients.","[""Adverse Events 1:"", ""  Total: 2/6 (33.33%)"", ""  Febrile neutropenia * 1/6 (16.67%)"", ""  Neutropenia * 0/6 (0.00%)"", ""  Thrombocytopenia * 1/6 (16.67%)"", ""  Diarrhoea * 0/6 (0.00%)"", ""  Pyrexia * 0/6 (0.00%)"", ""  Thrombosis in device * 1/6 (16.67%)"", ""  Fatigue * 0/6 (0.00%)"", ""  Mucosal inflammation * 0/6 (0.00%)"", ""  Device deployment issue * 0/6 (0.00%)"", ""  Hepatocellular injury * 1/6 (16.67%)"", ""  Cholecystitis * 1/6 (16.67%)"", ""Adverse Events 2:"", ""  Total: 2/6 (33.33%)"", ""  Febrile neutropenia * 1/6 (16.67%)"", ""  Neutropenia * 1/6 (16.67%)"", ""  Thrombocytopenia * 0/6 (0.00%)"", ""  Diarrhoea * 0/6 (0.00%)"", ""  Pyrexia * 0/6 (0.00%)"", ""  Thrombosis in device * 1/6 (16.67%)"", ""  Fatigue * 0/6 (0.00%)"", ""  Mucosal inflammation * 0/6 (0.00%)"", ""  Device deployment issue * 0/6 (0.00%)"", ""  Hepatocellular injury * 0/6 (0.00%)"", ""  Cholecystitis * 0/6 (0.00%)""]",Contradiction
Participants in NCT01196052 must be willing to undergo cyclophosphamide-based chemotherapy.,"[""Inclusion Criteria:"", ""  Willingness to receive anthracycline-based chemotherapy or have received doxorubicin/cyclophosphamide (AC) OR 5-fluorouracil (FU)/epirubicin/ cyclophosphamide (FEC) in a similar dose and schedule as described in the protocol as part of neoadjuvant or adjuvant treatment.""]",Contradiction
The median TTP for patients in cohort one of NCT00534417 is NA.,"[""Outcome Measurement: "", ""  Time to Progression (TTP)"", ""  Time to progression is defined as the time from treatment start until objective tumor progression. Progression is defined per Response Evaluation Criteria in Solid Tumors (RECIST)v1.0 guidelines as a measurable increase in the smallest diameter of any target lesion, progression of existing non-target lesions, or the appearance of 1 or more new lesions. The median time to progression is the parameter used to describe TTP."", ""  Time frame: TTP was measured from day 1 of treatment until time of progression (assessed every 8 weeks), up to 29 months."", ""Results 1: "", ""  Arm/Group Title: Capecitabine and Fulvestrant"", ""  Arm/Group Description: Capecitabine will be given on a continuous basis at a total dose of 1500 mg, given as 1000 mg po AM and 500 mg po PM in patients of body weight < 80 kg, and at a total dose of 2000 mg given as 1000 mg po bid in patients with a body weight of   80 kg."", ""  Fulvestrant will be given at 500 mg on Day 1 followed by 250 mg on Days 15 and 29, then 250 mg every 28 days."", ""  Overall Number of Participants Analyzed: 41"", ""  Median (95% Confidence Interval)"", ""  Unit of Measure: Months  26.94  [1]    (7.26 to NA)""]",Contradiction
"A patient with stage 2B , pathologically confirmed PR positive breast cancer is elgible for both NCT02806544 and NCT00605267.","[""Inclusion Criteria:"", ""  Clinical locally advance breast cancer (Stage IIB or III)"", ""  Pathologically confirmed diagnosis of estrogen receptor (ER)-positive or progesterone receptor (PR)-positive breast cancer with ER or PR Allred Score > 4""]",Contradiction
Less than 1% of patients in NCT00866905 became depressed.,"[""Adverse Events 1:"", ""  DEPRESSION 1/168 (0.60%)""]",Entailment
Women who have undergone a breast enlargement procedure in the last 2 years are excluded from NCT00981812.,"[""Exclusion Criteria:"", ""  subject has breast implants""]",Entailment
"For some adverse event types in NCT01498458, there were no recorded cases.","[""Adverse Events 1:"", ""  Total: 6/8 (75.00%)"", ""  Thrombocytopenia 1/8 (12.50%)"", ""  Hypertension 1/8 (12.50%)"", ""  Hepatotoxicity 3/8 (37.50%)"", ""  Pancreatectomy * 1/8 (12.50%)""]",Contradiction
"Elizabeth has HER2 positive breast cancer, she is eligible for NCT00033514.","[""Inclusion Criteria:"", ""  Women aged > 18 years"", ""  Histologically documents metastatic breast cancer"", ""  HER2 positive using Fluorescence In Situ Hybridization (FISH)""]",Entailment
One patient in NCT01674062 was observed vomiting blood.,"[""  Haematemesis * 1/66 (1.52%)""]",Entailment
1/42 patients in cohort 2 of NCT01671319 fainted.,"[""Adverse Events 1:"", ""  Total: 4/42 (9.52%)"", ""  Perforation, GI 1/42 (2.38%)"", ""  Febrile neutropenia 1/42 (2.38%)"", ""  Syncope 1/42 (2.38%)"", ""  Rash/desquamation 1/42 (2.38%)""]",Contradiction
NCT00693719 recorded less than 3 different Adverse Events .,"[""Adverse Events 1:"", ""  Total: 4/31 (12.90%)"", ""  Bleeding  1/31 (3.23%)"", ""  Pain  2/31 (6.45%)"", ""  Dehydration  1/31 (3.23%)"", ""  Dyspnea  1/31 (3.23%)""]",Contradiction
Cohort 1 of NCT03078751 reported one case of AML.,"[""Adverse Events 1:"", ""  Total: 4/26 (15.38%)"", ""  Disseminated intravascular coagulation 1/26 (3.85%)"", ""  Cardiac failure congestive 1/26 (3.85%)"", ""  Breast cellulitis 1/26 (3.85%)"", ""  Cellulitis 1/26 (3.85%)"", ""  Acute myeloid leukaemia 1/26 (3.85%)"", ""  Seizure 0/26 (0.00%)"", ""  Pulmonary embolism 1/26 (3.85%)""]",Entailment
Patients with radiologically confirmed bone metatases are excluded from both NCT00428922 and NCT00630032.,"[""Exclusion criteria:"", ""  Clinically or radiologically detectable metastases (M0)""]",Contradiction
"There were more cases of Febrile neutropenia than eukopenia observed in NCT00091442, but less cases of Febrile neutropenia than Neutropenia.","[""Adverse Events 1:"", ""  Neutropenia 14/373 (3.75%)"", ""  Febrile neutropenia 10/373 (2.68%)"", ""  Leukopenia 1/373 (0.27%)""]",Entailment
A patient in NCT00206427 had a fungal infection of the mouth.,"[""Adverse Events 1:"", ""  Total: 3/49 (6.12%)"", ""  Neutrophils/ANC *1/49 (2.04%)"", ""  Leukocytes *1/49 (2.04%)"", ""  Hypocalcemia *1/49 (2.04%)"", ""  Febrile neutropenia *1/49 (2.04%)"", ""  Left Ventricular Systolic Dysfunction *1/49 (2.04%)"", ""  Constipation *1/49 (2.04%)"", ""  Mucositis-oral *1/49 (2.04%)"", ""  Infection-oral thrush *1/49 (2.04%)"", ""  rash *1/49 (2.04%)""]",Entailment
Patients with ER-positive tumours are eligible for NCT00721409 but not for NCT02413320.,"[""Inclusion Criteria:"", ""  Inoperable estrogen receptor positive and HER2 negative breast cancer.""]",Entailment
Patients that are fully active and able to carry on all pre-disease performance without restriction are excluded from NCT02878057.,"[""Inclusion Criteria:"", ""  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.""]",Contradiction
Less than half of patients in cohorts 1 and 2 in NCT00454532 experienced adverse events.,"[""Adverse Events 1:"", ""  Total: 5/11 (45.45%)"", ""  Hemorrhage, GI-abdomen NOS 21/11 (9.09%)"", ""  Pain-liver 21/11 (9.09%)"", ""  Infection-ulcer 20/11 (0.00%)"", ""  Hemoglobin 20/11 (0.00%)"", ""  Hypoglycemia 20/11 (0.00%)"", ""  Pain-rib cage due to vomiting 20/11 (0.00%)"", ""  Obstruction-gu ureter 1/11 (9.09%)"", ""  Hemorrhage gu-bladder 21/11 (9.09%)"", ""  Pain-breast 21/11 (9.09%)"", ""  Pleural effusion 22/11 (18.18%)"", ""Adverse Events 2:"", ""  Total: 0/6 (0.00%)""]",Entailment
"Women who have undergone a breast enlargement procedure, and have since had the implants removed, are excluded from NCT00981812.","[""Inclusion Criteria:"", ""  female"", ""  subject is 25-100 years of age"", ""  subjects has at least one breast imaging finding on mammography and/or ultrasound which is assessed as highly suggestive of malignancy and recommended to biopsy"", ""  subject is able to provide informed consent"", ""Exclusion Criteria:"", ""  subject is pregnant"", ""  subject is actively lactating or discontinued breastfeeding less than 2 months ago"", ""  subject has breast implants"", ""  subject is scheduled for sentinel node procedure using radioactive Tc-99m within 24 hours of the PEM study"", ""  subject has contraindications for core biopsy and other invasive procedures"", ""  subject has Type I diabetes mellitus or poorly controlled Type II diabetes mellitus"", ""  subject has had surgery or radiation therapy on the study breast or has had chemotherapy within the past 12 months"", ""  subject has not fasted for 4-6 hours prior to the procedure and/or have a fasting blood glucose level greater than 140 mg/dl on day of PEM imaging""]",Contradiction
Less patients in cohort 2 of NCT00912340 had an unusual amount of fluid around the lungs than in cohort 1.,"[""Adverse Events 1:"", ""  Pleural effusion *0/24 (0.00%)"", ""Adverse Events 2:"", ""  Pleural effusion *2/30 (6.67%)""]",Contradiction
"Patients that have previously been trated with bevacizumab are not eligible for NCT00479674, unless they have also received carboplatin 2 weeks prior to study entry.","[""Exclusion Criteria:"", ""  Prior treatment with Abraxane\u00ae, carboplatin or bevacizumab, or any taxane for metastatic breast cancer;""]",Contradiction
More patients in NCT00127205 suffer from dysfunctions with ventricular contractions than ventricular relaxations.,"[""Adverse Events 2:"", ""  Left ventricular diastolic dysfunction 3/2186 (0.14%)"", ""  Left ventricular systolic dysfunction 1/2186 (0.05%)""]",Entailment
NCT01142661 accepts patients with grade  3 neuropathy.,"[""  Exclusion Criteria Subjects who meet any of the following criteria will be excluded from participation in the treatment protocol:"", ""  Existing anti-cancer therapy-related toxicities of Grade >/= 2, except that alopecia and Grade 2 neuropathy are acceptable.""]",Contradiction
Patients do not need to have a known hormone receptor status to participate in NCT00167414.,"[""Inclusion Criteria:"", ""  Age: no limit"", ""  Karnofsky performance status (KPS)  70"", ""  No more than 5 metastatic sites involving one or more different organs (liver, lung or bone)."", ""  The size of the lesion must be such that it can be safely treated to sterilizing radiation doses according to the rules in the protocol."", ""  Previously treated lesions are not eligible unless the prescribed dose can be safely delivered."", ""  Concurrent therapy is allowed and recommended. The chemotherapy protocol type and schedule are at the discretion of the medical oncologist."", ""  Informed consent must be obtained."", ""  Pregnancy test must be negative for women of child bearing potential"", ""Exclusion Criteria:"", ""  Inability of patient to be followed longitudinally as specified by protocol."", ""  Technical inability to achieve required dose based on safe dose constraints required for radiosurgery."", ""  Women who are pregnant or nursing."", ""  Failure to meet requirements in Inclusion Criteria"", ""  Contraindications to radiation.""]",Entailment
There was no adverse event in cohort 2 of NCT00320710 which occurred in more than 0.5% of patients.,"[""Adverse Events 2:"", ""  Anaemia 3/202 (1.49%)"", ""  Febrile neutropenia 2/202 (0.99%)"", ""  Leukocytosis 0/202 (0.00%)"", ""  Leukopenia 0/202 (0.00%)"", ""  Neutropenia 0/202 (0.00%)"", ""  Pancytopenia 1/202 (0.50%)"", ""  Atrial fibrillation 1/202 (0.50%)"", ""  Cardiac failure congestive 1/202 (0.50%)"", ""  Palpitations 1/202 (0.50%)"", ""  Pericardial effusion 1/202 (0.50%)"", ""  Supraventricular tachycardia 1/202 (0.50%)""]",Contradiction
"Only Black women are eligible for NCT02692755, as long as they do not have uncontrolled or symptomatic brain metastases.","[""Inclusion Criteria:"", ""  Self-identified Black, African or African American women of  18 years of age with proven diagnosis of advanced adenocarcinoma of the breast (locoregionally recurrent or metastatic disease)"", ""Exclusion Criteria:"", ""  Current use of food or drugs known to be potent inhibitors or inducers of CYP3A4"", ""  Active uncontrolled or symptomatic brain metastases. Previously treated and clinically stable, as per Investigator's judgment, brain metastases are permitted.""]",Entailment
Patients prescribed with bisoprolol or labetalol to treat CHF are eligible for NCT00821886.,"[""Exclusion Criteria:"", ""  current use of medications (e.g., digitalis, beta-blockers, calcium channel-blockers) that alter cardiac conduction, if these medications are administered for the management of cardiac arrhythmia, angina, or CHF. If these medications are administered for other reasons (e.g., hypertension), the patient may be eligible.""]",Contradiction
Between both of the patient cohorts of NCT02132949 and NCT01111825 there was only a single patient with a deficiency of granulocytes in the blood.,"[""Adverse Events 1:"", ""  Total: 56/199 (28.14%)"", ""  AGRANULOCYTOSIS 1/199 (0.50%)"", ""  ANAEMIA 1/199 (0.50%)"", ""  BONE MARROW FAILURE 1/199 (0.50%)"", ""  FEBRILE NEUTROPENIA 11/199 (5.53%)"", ""  LEUKOPENIA 1/199 (0.50%)"", ""  NEUTROPENIA 1/199 (0.50%)"", ""  PANCYTOPENIA 1/199 (0.50%)"", ""  ACUTE MYOCARDIAL INFARCTION 1/199 (0.50%)"", ""  ATRIAL FLUTTER 1/199 (0.50%)"", ""  ATRIAL THROMBOSIS 0/199 (0.00%)"", ""  CARDIAC FAILURE 3/199 (1.51%)"", ""Adverse Events 2:"", ""  Total: 66/198 (33.33%)"", ""  AGRANULOCYTOSIS 0/198 (0.00%)"", ""  ANAEMIA 0/198 (0.00%)"", ""  BONE MARROW FAILURE 0/198 (0.00%)"", ""  FEBRILE NEUTROPENIA 27/198 (13.64%)"", ""  LEUKOPENIA 0/198 (0.00%)"", ""  NEUTROPENIA 2/198 (1.01%)"", ""  PANCYTOPENIA 1/198 (0.51%)"", ""  ACUTE MYOCARDIAL INFARCTION 0/198 (0.00%)"", ""  ATRIAL FLUTTER 0/198 (0.00%)"", ""  ATRIAL THROMBOSIS 1/198 (0.51%)"", ""  CARDIAC FAILURE 4/198 (2.02%)""]",Entailment
"Patients with prior radiotherapy for the treatment of stage 4 cancer over 5 years ago, are not eligible for either NCT00428922 or NCT00499083.","[""Inclusion Criteria:"", ""  Histologically confirmed breast cancer with evidence of metastatic disease"", ""  HER2 3+ or FISH (fluorescent in situ hybridization)+"", ""  Age  18 years"", ""  No prior trastuzumab, except as given in the adjuvant or neoadjuvant setting."", ""  No prior chemotherapy in the metastatic setting."", ""Exclusion Criteria:"", ""  CNS (central nervous system) metastases"", ""  Prior radiation therapy within the last 4 weeks"", ""  Pregnant (positive pregnancy test) or lactating women"", ""  Major surgical procedure, open biopsy, non-healing wounds, or significant traumatic injury within 28 days prior to starting study or anticipation of need for major surgical procedure during the study"", ""  Minor surgical procedures such as fine needle aspirations or core biopsies within 7 days prior to start of study.""]",Contradiction
"A 56 year old patient with a masectomy would not be eligible for NCT02165605, due to her age.","[""Inclusion Criteria:"", ""  Female, age 18 or older"", ""  Intact breast (not surgically absent)""]",Contradiction
"In NCT02924883, all cases of  Enteritis, Vertigo and Cardiac failure occurred in cohort 2.","[""Adverse Events 1:"", ""  Total: 52/133 (39.10%)"", ""  Thrombocytopenia 2/133 (1.50%)"", ""  Anaemia 1/133 (0.75%)"", ""  Disseminated intravascular coagulation 0/133 (0.00%)"", ""  Atrial thrombosis 1/133 (0.75%)"", ""  Cardiac failure 0/133 (0.00%)"", ""  Vertigo 0/133 (0.00%)"", ""  Vomiting 3/133 (2.26%)"", ""  Nausea 1/133 (0.75%)"", ""  Colitis 1/133 (0.75%)"", ""  Constipation 1/133 (0.75%)"", ""  Enteritis 0/133 (0.00%)"", ""  Abdominal pain 0/133 (0.00%)"", ""Adverse Events 2:"", ""  Total: 16/67 (23.88%)"", ""  Thrombocytopenia 0/67 (0.00%)"", ""  Anaemia 0/67 (0.00%)"", ""  Disseminated intravascular coagulation 1/67 (1.49%)"", ""  Atrial thrombosis 0/67 (0.00%)"", ""  Cardiac failure 1/67 (1.49%)"", ""  Vertigo 1/67 (1.49%)"", ""  Vomiting 0/67 (0.00%)"", ""  Nausea 1/67 (1.49%)"", ""  Colitis 0/67 (0.00%)"", ""  Constipation 0/67 (0.00%)"", ""  Enteritis 1/67 (1.49%)"", ""  Abdominal pain 2/67 (2.99%)""]",Entailment
"Participants of NCT00579826 cannot be currently receiving for treatment rheumatoid arthritis, experiencing poorly controlled migraines, receiving hormone replacement therapy or have any prior history of invasive breast cancer in the last 3 years.","[""Inclusion Criteria:"", ""  On a stable dose of hormone replacement therapy"", ""Exclusion Criteria:"", ""  Prior history of invasive breast cancer or other invasive cancer within five years from date of study entry."", ""  Receiving treatment for rheumatoid arthritis or fibromyalgia"", ""  Current history of poorly controlled migraines or perimenopausal symptoms""]",Contradiction
"NCT00259090 studies the impact of Fulvestrant, Docetaxel on Oestrogen Receptor H-score.","[""  Percentage Change From Baseline to Time of Surgery in Oestrogen Receptor (ER) H-score: Antitumour Effects of Fulvestrant, Anastrozole and a Combination of Both as Measured by the ER H-score.""]",Contradiction
"The adverse events in NCT00503906 where all equally prevalent, whereas in NCT01142661, progression of disease was reported as the most common event.","[""Adverse Events 1:"", ""  Total: 8/29 (27.59%)"", ""  Leukopenia  [1]1/29 (3.45%)"", ""  Thrombocytopenia  [1]1/29 (3.45%)"", ""  Abscess  [1]1/29 (3.45%)"", ""  Breast Abscess 1/29 (3.45%)"", ""  Fever/Sepsis  [1]1/29 (3.45%)"", ""  Neutropenic Fever  [2]1/29 (3.45%)"", ""  Peripheral Neuropathy  [1]1/29 (3.45%)"", ""  Seizure/Syncope  [1]1/29 (3.45%)"", ""  Hematuria  [1]1/29 (3.45%)"", ""  UTI  [1]1/29 (3.45%)"", ""  Shortness of breath  [1]1/29 (3.45%)""]",Entailment
"Candidates for NCT00952692 must have adequate renal and hepatic function, and must not be currently receiving amiodarone or have received amiodarone in the 6 months","[""Inclusion Criteria:"", ""  The patient has adequate renal function as shown by the creatinine levels (i.e. within the normal range)."", ""  The patient has adequate hepatic function as shown by serum bilirubin levels i.e:"", ""Exclusion Criteria:"", ""  The patient is currently receiving amiodarone or has received amiodarone in the 6 months prior to screening.""]",Entailment
There were more allergic reactions observed in cohort 1 of NCT01940497 than cohort 2.,"[""Adverse Events 1:"", ""  Total: 5/95 (5.26%)"", ""  Febrile neutropenia 0/95 (0.00%)"", ""  Neutropenia 0/95 (0.00%)"", ""  Atrial fibrillation 0/95 (0.00%)"", ""  Pleuropericarditis 0/95 (0.00%)"", ""  Vomiting 0/95 (0.00%)"", ""  Pryexia 0/95 (0.00%)"", ""  Anaphylactic shock 1/95 (1.05%)"", ""  Gastroenteritis 0/95 (0.00%)"", ""  Fibula fracture 1/95 (1.05%)"", ""  Tibia fracture 1/95 (1.05%)"", ""  Intervertebral disc protrusion 0/95 (0.00%)"", ""Adverse Events 2:"", ""  Total: 3/20 (15.00%)"", ""  Febrile neutropenia 0/20 (0.00%)"", ""  Neutropenia 0/20 (0.00%)"", ""  Atrial fibrillation 1/20 (5.00%)"", ""  Pleuropericarditis 1/20 (5.00%)"", ""  Vomiting 0/20 (0.00%)"", ""  Pryexia 0/20 (0.00%)"", ""  Anaphylactic shock 0/20 (0.00%)"", ""  Gastroenteritis 1/20 (5.00%)"", ""  Fibula fracture 0/20 (0.00%)"", ""  Tibia fracture 0/20 (0.00%)""]",Entailment
Gastrointestinal haemorrhage was more common in patients from cohort 2 of NCT00951665. than cohort 1 of NCT00471276 .,"[""Adverse Events 1:"", ""  Total: 13/83 (15.66%)"", ""  Cardiac failure congestive 1/83 (1.20%)"", ""  Hypothyroidism 1/83 (1.20%)"", ""  Nausea 2/83 (2.41%)"", ""  Vomiting 2/83 (2.41%)"", ""  Diarrhea 1/83 (1.20%)"", ""  Gastrointestinal Haemorrhage 1/83 (1.20%)"", ""  Asthenia 1/83 (1.20%)"", ""  Hyperbilirubinaemia 1/83 (1.20%)"", ""  Anal abscess 1/83 (1.20%)"", ""  Dehydration 3/83 (3.61%)"", ""  Decreased appetite 1/83 (1.20%)""]",Contradiction
Patients with Cervical carcinoma in situ are excluded from NCT02005549.,"[""Inclusion Criteria:"", ""  no prior or current neoplasm except for non-melanoma skin cancer, or in situ cancer of the cervix;""]",Contradiction
NCT00087152 recorded less patients with nausea than NCT00203502.,"[""Adverse Events 1:"", ""  Nausea 1/20 (5.00%)""]",Entailment
Patients with Grade III peripheral neuropathy or above are eliminated from participation in NCT00932373.,"[""Exclusion Criteria:"", ""  Grade  2 peripheral neuropathy""]",Entailment
"Patients must have ductal carcinoma, that can be felt by touch to be eligible for NCT02550210.","[""Inclusion Criteria:"", ""  Histologic diagnosis of palpable invasive breast cancer or ductal carcinoma in situ""]",Contradiction
"One patient in NCT02187744 suffered from sepsis, due to the presence of an implanted device.","[""Adverse Events 1:"", ""  Device related sepsis 1/113 (0.88%)""]",Entailment
"the percentage of participants achieving complete response (CR) or partial response (PR) was much lower in the HER2-positive group in NCT02260531,than in the ER+ and/or PR+ group.","[""Outcome Measurement: "", ""  CNS Objective Response Rate (ORR)"", ""  The central nervous system (CNS) ORR was defined as the percentage of participants achieving complete response (CR) or partial response (PR) based on RECIST 1.1 criteria in the evaluation CNS lesions on treatment: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions."", ""  Time frame: Disease assessments occurred every 6 cycles. Patients with stable or responsive disease after completion of 6 cycles could reduce frequency of assessments to every 3 cycles. Response was evaluated up to 25 months."", ""Results 1: "", ""  Arm/Group Title: Cohort 1 - Cabozantinib, Trastuzumab for HER2+"", ""  Arm/Group Description: HER2-positive"", ""  Cabozantinib- orally administered daily per treatment cycle"", ""  Trastuzumab- IV administered once per cycle"", ""  MRI- Baseline, Cycle 2 Day 1, and every 2 cycles"", ""  Magnetic Resonance Angiography (MRA ), Baseline, Cycle 2 Day 1,"", ""  Cabozantinib: One, 60 mg tablet daily of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops."", ""  Trastuzumab: For HER2-Positive participants only. Administered by IV on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops."", ""  Overall Number of Participants Analyzed: 21"", ""  Measure Type: Number"", ""  Unit of Measure: percentage of participants  5        (.2 to 24)"", ""Results 2: "", ""  Arm/Group Title: Cohort 2 - Cabozantinib for ER+ and/or PR+"", ""  Arm/Group Description: Hormone receptor-positive (ER+ and/or PR+)"", ""  Cabozantinib- orally administered daily per treatment cycle"", ""  MRI- Baseline, Cycle 2 Day 1, and every 2 cycles"", ""  Magnetic Resonance Angiography (MRA ), Baseline, Cycle 2 Day 1,"", ""  Cabozantinib: One, 60 mg tablet daily of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops."", ""  Overall Number of Participants Analyzed: 7"", ""  Measure Type: Number"", ""  Unit of Measure: percentage of participants  14        (.4 to 58)""]",Entailment
Patients with an ECOG score between 3-5 are eligible for NCT00295867.,"[""Inclusion Criteria"", ""  Women > 18 years of age with histologically or cytologically confirmed stage I, II or III breast cancer."", ""  If adjuvant chemotherapy is recommended, it must be completed before study start."", ""  Bone marrow aspirate positive by IC/FC assay"", ""  a. Definition of positive: > 4 MM/ml b. Timing of bone marrow aspiration to determine study eligibility: i. If patient is to receive either no adjuvant therapy or hormonal therapy alone, the aspiration may be performed at diagnosis as part of the large MM study at University of California, San Francisco, or following diagnosis if the patient received initial surgery elsewhere. This is also true for patients who have surgery following neoadjuvant therapy for breast cancer."", ""  ii. If the patient is to receive adjuvant chemotherapy, the aspiration will be performed at least three weeks after chemotherapy has been completed."", ""  Adequate renal function as defined by:"", ""  a. Creatinine must be < upper limit of normal"", ""  Normal liver function tests including total bilirubin, alkaline phosphatase, and aspartate aminotransferase (AST) / serum glutamic-oxaloacetic transaminase (SGOT)"", ""  Ability to understand and sign informed consent."", ""  Concomitant hormonal therapy is allowed"", ""  Concomitant radiation therapy is allowed"", ""  Patients who have had surgery following neoadjuvant chemotherapy or hormonal therapy are eligible to participate in this trial"", ""  Exclusion Criteria"", ""  History of allergy to bisphosphonates. Acute phase reactions occur in up to 24% of patients and disappear with subsequent dosing. An acute phase reaction does not qualify as an allergic reaction."", ""  History of renal insufficiency. Renal insufficiency is defined by a serum creatinine greater than the upper limit of normal or a creatinine clearance < 50 mL/min due to any underlying cause."", ""  Karnofsky Performance status < 90%."", ""  Any significant medical condition that might interfere with treatment."", ""  Women participating in this study are not allowed to receive other bisphosphonate therapy during the study period, either oral or intravenous."", ""  Patients who are pregnant""]",Contradiction
"NCT01237327 and NCT00030823 do not have any overlapping inclusion criteria, apart from the mimimum age limit of 18.","[""Inclusion Criteria:"", ""  Previous participation in study 971-ONC-0028-080."", ""Exclusion Criteria:"", ""  Subjects who had not previously participated in study 971-ONC-0028-080.""]",Contradiction
" To be eligible for both NCT00853996 and NCT00365417 patients must satisfy all the following conditions; alkaline phosphatase  < 2 x ULN, aspartate aminotransferase  <= 1.5 x ULN and Hemoglobin > 10 g/dL.","[""  The following criteria for evidence of adequate hepatic function must be met:"", ""  alkaline phosphatase must be less than 2.5 x ULN for the lab; and"", ""  aspartate aminotransferase (AST) must be less than/equal to 1.5 x ULN for the lab."", ""  Platelet count must be greater than/equal to 100,000/mm^3."", ""  Hemoglobin must be greater than/equal to 10 g/dL.""]",Entailment
"A total of 2/93 patients in NCT00444587 were observed with either Leukopenia, Cardiopulmonary failure or Diarrhoea.","[""  Leukopenia 2/93 (2.15%)"", ""  Cardiopulmonary failure 2/93 (2.15%)"", ""  Diarrhoea 3/93 (3.23%)""]",Contradiction
Patients with invasive breast cancer with a diameter of less than 4 cm are included in NCT02321527.,"[""  Ipsilateral biopsy-proven invasive breast cancer <5 cm in maximal dimension by Ultrasound or Mammography.""]",Entailment
The only type of adverse event recorded by both NCT00728949 and NCT02301988 is Diarrhoea and Abdominal pain.,"[""Adverse Events 1:"", ""  Total: 10/76 (13.16%)"", ""  Sickle cell anaemia with crisis 1/76 (1.32%)"", ""  Diarrhoea 1/76 (1.32%)"", ""  Pyrexia 1/76 (1.32%)"", ""  Chest pain 1/76 (1.32%)"", ""  Complication associated with device 1/76 (1.32%)"", ""  General physical health deterioration 0/76 (0.00%)"", ""  Device related infection 2/76 (2.63%)"", ""  Pneumonia 1/76 (1.32%)"", ""  Atypical pneumonia 1/76 (1.32%)"", ""  Dehydration 1/76 (1.32%)"", ""Adverse Events 2:"", ""  Total: 3/75 (4.00%)"", ""  Sickle cell anaemia with crisis 0/75 (0.00%)"", ""  Diarrhoea 0/75 (0.00%)"", ""  Pyrexia 1/75 (1.33%)"", ""  Chest pain 0/75 (0.00%)"", ""  Complication associated with device 0/75 (0.00%)"", ""  General physical health deterioration 1/75 (1.33%)"", ""  Device related infection 0/75 (0.00%)"", ""  Pneumonia 1/75 (1.33%)"", ""  Atypical pneumonia 0/75 (0.00%)"", ""  Dehydration 0/75 (0.00%)""]",Contradiction
In total NCT00375427 recorded only 1 more case of Mucosal inflammation than NCT01008150.,"[""Adverse Events 1:"", ""  Total: 7/42 (16.67%)"", ""  Febrile neutropenia 1/42 (2.38%)"", ""  Left venrticular dysfunction 1/42 (2.38%)"", ""  Cardiac valve disease 1/42 (2.38%)"", ""  Diarrhoea 0/42 (0.00%)"", ""  Abdominal pain 1/42 (2.38%)"", ""  Colitis 0/42 (0.00%)"", ""  Nausea 0/42 (0.00%)"", ""  Vomiting 0/42 (0.00%)"", ""  Pyrexia 0/42 (0.00%)"", ""  Influenza like illness 1/42 (2.38%)"", ""  Oedema peripheral 1/42 (2.38%)"", ""  Fatigue 0/42 (0.00%)"", ""Adverse Events 2:"", ""  Total: 7/42 (16.67%)"", ""  Febrile neutropenia 0/42 (0.00%)"", ""  Left venrticular dysfunction 1/42 (2.38%)"", ""  Cardiac valve disease 0/42 (0.00%)"", ""  Diarrhoea 0/42 (0.00%)"", ""  Abdominal pain 0/42 (0.00%)"", ""  Colitis 0/42 (0.00%)"", ""  Nausea 0/42 (0.00%)"", ""  Vomiting 0/42 (0.00%)"", ""  Pyrexia 2/42 (4.76%)"", ""  Influenza like illness 0/42 (0.00%)"", ""  Oedema peripheral 0/42 (0.00%)"", ""  Fatigue 0/42 (0.00%)""]",Entailment
"A higher percentage of cohort 1 of NCT00828074 showed signs of fever, compared to cohort 2.","[""Adverse Events 1:"", ""  Fever * 2/41 (4.88%)"", ""Adverse Events 2:"", ""  Fever * 0/5 (0.00%)""]",Entailment
Patients suffering from Ulcerative colitis are excluded from NCT00876395.,"[""Exclusion Criteria:"", ""  Impairment of gastrointestinal (GI) function or GI disease or active ulceration of the upper gastrointestinal tract.""]",Entailment
"histologically confirmed extensive intraductal component of primary breast carcinoma would result in exclusion from NCT01581619, but not from NCT01008150.","[""Exclusion Criteria:"", ""  No histologic evidence of EIC""]",Entailment
Patients with No QT prolongation are excluded from NCT00482391.,"[""  No QT prolongation (> 500 ms)""]",Contradiction
"WOCBP that refuse to use contraception are excluded from NCT00045032, but may be eligible for NCT00416572 if they are a UK resident.","[""  Women of childbearing potential or less than 1 year post-menopause unwilling to use adequate contraceptive measures""]",Contradiction
NCT03283553 and NCT03283553 have a different number of cohorts.,"[""INTERVENTION 1: "", ""  Multicomponent Intervention"", ""  1.) A one-page paper-pencil agenda setting checklist completed immediately before a regularly scheduled medical oncology visit to elicit and align patient and companion perspectives regarding issues to discuss with the provider, and to stimulate discussion about the role of the companion in the visit, 2.) facilitated registration for the patient portal (for patient and family member, as desired by the patient), and 3.) education (as relevant) on access to doctor's electronic visit notes."", ""INTERVENTION 2: "", ""  Usual Care"", ""  Care as usual with the medical oncologist.""]",Contradiction
Cohort 2 of NCT00633464 reported worse results than cohort 1.,"[""Outcome Measurement: "", ""  Percentage of Participants With Objective Response (OR; Using Response Evaluation Criteria in Solid Tumors [RECIST])"", ""  The participant had an OR if her best overall response (BOR) during the study was either a complete response (CR) or a partial response (PR) according to the RECIST as determined by the investigator. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (LD) of all target lesions. Confidence interval (CI) was Computed using Clopper-Pearson method."", ""  Time frame: Assessed every 6 weeks for first 12 months from randomization thereafter every 3 months until disease progression (maximum participant objective response of 18.3 weeks)"", ""Results 1: "", ""  Arm/Group Title: Ixabepilone 40 mg/m^2"", ""  Arm/Group Description: ixabepilone 40 mg/m^2 every 3 weeks"", ""  Overall Number of Participants Analyzed: 40"", ""  Measure Type: Number"", ""  Unit of Measure: percentage of participants  30.0        (16.6 to 46.5)"", ""Results 2: "", ""  Arm/Group Title: Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2"", ""  Arm/Group Description: cetuximab 400 mg/m^2 loading dose then 250 mg/m^2 weekly + ixabepilone 40 mg/m^2 every 3 weeks"", ""  Overall Number of Participants Analyzed: 39"", ""  Measure Type: Number"", ""  Unit of Measure: percentage of participants  35.9        (21.2 to 52.8)""]",Contradiction
Patients that have previously been trated with bevacizumab are not eligible for NCT00479674.,"[""Exclusion Criteria:"", ""  Prior treatment with Abraxane\u00ae, carboplatin or bevacizumab, or any taxane for metastatic breast cancer;""]",Entailment
"Anna is a 57 year old female with an ECOG of 0, diagnosed with an invasive adenocarcinoma of the breast, IHC results were 1+. She is eligible for NCT00464646.","[""Inclusion Criteria:"", ""  Patients must be female."", ""  The patient must be greater than or equal to 18 years old."", ""  The patient's ECOG performance status must be 0 or 1."", ""  The tumor must be invasive adenocarcinoma of the breast on histologic examination."", ""  The breast cancer must be determined to be HER2-positive prior to study entry. Assays performed using FISH require gene amplification. Assays using IHC require a strongly positive (3+) staining score."", ""  By pathologic evaluation, ipsilateral nodes must be pN2 or pN3.""]",Contradiction
Across all cohorts of NCT00365599 and NCT01856543 there was only a single recorded case of Myocarditis and Thrombosis.,"[""Adverse Events 1:"", ""  Total: 3/73 (4.11%)"", ""  Chest Pain - cardiac  1/73 (1.37%)"", ""  Myocarditis  1/73 (1.37%)"", ""  Pericarditis  1/73 (1.37%)"", ""  Ventricular tachycardia  1/73 (1.37%)"", ""  Skin infection  0/73 (0.00%)"", ""  Dermatitis radiation  0/73 (0.00%)"", ""  Dyspnea  1/73 (1.37%)"", ""Adverse Events 2:"", ""  Total: 3/70 (4.29%)"", ""  Chest Pain - cardiac  0/70 (0.00%)"", ""  Myocarditis  0/70 (0.00%)"", ""  Pericarditis  0/70 (0.00%)"", ""  Ventricular tachycardia  0/70 (0.00%)"", ""  Skin infection  2/70 (2.86%)"", ""  Dermatitis radiation  1/70 (1.43%)"", ""  Dyspnea  0/70 (0.00%)""]",Contradiction
A patient in NCT01705691 suffered from Kidney stones.,"[""Adverse Events 2:"", ""  Nephrolithiasis 1/30 (3.33%)""]",Entailment
"Participants for NCT02222337 must be in pairs, a breast cancer survivor and a caregiver, both must be ethnically Hispanic.","[""Inclusion Criteria:"", ""  Survivors: Latina, has been diagnosed with breast cancer, speaks English or Spanish, has a Caregiver who is willing to participate."", ""  Caregivers: a primary caregiver for a Latina breast cancer survivor, speak English or Spanish""]",Contradiction
Any patient can enter into NCT04396665 as long as they are willing to provide Informed consent and are capable of using the internet.,"[""Inclusion Criteria:"", ""  Informed consent signed"", ""  Capability to use internet"", ""Exclusion Criteria:"", ""  Breast cancer diagnosis duting the intervention""]",Entailment
"By week 48 of NCT01743560 the majority of patients had Stable Disease, none of them had complete or partial response.","[""Outcome Measurement: "", ""  Best Overall Response of Everolimus and Exemestane Treatment in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer"", ""  The best Overall Response (OR) for each patient is determined from the sequence of investigator overall lesion responses according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1.). To be assigned a best OR of Complete Responese (CR) at least two determinations of CR at least 4 weeks apart before progression are required. To be assigned a best OR of Partial Response (PR) at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) are required.The Overall Response Rate (ORR) was defined as the proportion of patients with a best OR of confirmed CR or PR by week 48."", ""  Time frame: At 48 weeks"", ""Results 1: "", ""  Arm/Group Title: Everolimus and Exemestane"", ""  Arm/Group Description: Postmenopausal women diagnosed with oestrogen receptor positive locally advanced or metastatic breast cancer will receive everolimus at a dose of 10mg daily p.o. and exemestane 25mg daily p.o."", ""  Overall Number of Participants Analyzed: 49"", ""  Measure Type: Number"", ""  Unit of Measure: participants  Patients with measurable disease at baseline: 39"", ""  Patients with non-measurable disease at baseline: 10"", ""  Best at WK 48 - Complete Response (CR): 0"", ""  Best at WK 48 - Partial Response (PR): 7"", ""  Best at WK 48 - Stable Disease (SD): 18"", ""  Best at WK 48 - Progressive Disease (PD): 15"", ""Unknown: 1"", ""Missing: 8""]",Contradiction
Patients with prior chemotherapy are excluded from NCT00193206 and NCT02511730.,"[""Inclusion Criteria:"", ""  Female subjects participating in FMSU004A protocol with known clinical status"", ""Exclusion Criteria:"", ""  Subjects with unknown clinical status not participating in FMSU004A protocol.""]",Contradiction
Patients with irrational fear of confined spaces are not elligible for NCT01823991.,"[""Exclusion Criteria:"", ""  Known claustrophobia, presence of pacemaker and/or ferromagnetic material in their body that would prohibit MRI imaging""]",Entailment
There was twice as many Cardiac adverse events as cases of Dyspnea in cohort 1 of NCT01273896.,"[""Adverse Events 1:"", ""  Cardiac General, other1/22 (4.55%)"", ""  Dyspnea (shortness of breath)2/22 (9.09%)""]",Contradiction
NCT01840163 and NCT02005549 do not exclude patients with non-melanoma skin cancer.,"[""Inclusion Criteria:"", ""  Stage 1-2 invasive breast cancer diagnosis,"", ""  DCIS"", ""  Ability to read English"", ""Exclusion Criteria:"", ""Male""]",Entailment
There was one GU and three GI adverse events recorded in NCT00290758.,"[""Adverse Events 1:"", ""  Total: 6/62 (9.68%)"", ""  Musculoskeletal * 1/62 (1.61%)"", ""  Mood Alteration: Depression * 1/62 (1.61%)"", ""  renal - Other * 1/62 (1.61%)"", ""  Obstruction, GU: Uterus * 1/62 (1.61%)"", ""  Sexual * 0/62 (0.00%)"", ""  Pulmonary/Upper Respiratory: Dyspnea * 1/62 (1.61%)"", ""  Ulceration * 1/62 (1.61%)"", ""Adverse Events 2:"", ""  Total: 1/64 (1.56%)"", ""  Musculoskeletal * 0/64 (0.00%)"", ""  Mood Alteration: Depression * 0/64 (0.00%)"", ""  renal - Other * 0/64 (0.00%)"", ""  Obstruction, GU: Uterus * 0/64 (0.00%)"", ""  Sexual * 1/64 (1.56%)"", ""  Pulmonary/Upper Respiratory: Dyspnea * 0/64 (0.00%)"", ""  Ulceration * 0/64 (0.00%)""]",Contradiction
The majority of patients in NCT00182793 experienced an adverse event.,"[""Adverse Events 1:"", ""  Total: 24/32 (75.00%)""]",Entailment
Patients must have already participated in a specific clinical study to participate in NCT00971945.,"[""Inclusion Criteria:"", ""  Subjects who were confirmed to have a response after receiving at least two courses of weekly paclitaxel therapy and considered to need to continue the therapy by the investigator/subinvestigator among the patients with advanced or recurrent breast cancer who had met the selection criteria and participated in the preceding phase II clinical study""]",Entailment
All of the adverse event cases in NCT00074152 occurred in patients from cohort 2.,"[""Adverse Events 1:"", ""  Total: 0/77 (0.00%)"", ""  Neutropenia  [1]0/77 (0.00%)"", ""  Left ventricular dysfunction 0/77 (0.00%)"", ""  Cardiac ischemia 0/77 (0.00%)"", ""  Gastrointestinal pain 0/77 (0.00%)"", ""  Colitis 0/77 (0.00%)"", ""  Febrile neutropenia 0/77 (0.00%)"", ""  Pulmonary/upper respiratory infection 0/77 (0.00%)"", ""  Diverticulitis 0/77 (0.00%)"", ""  Motor neuropathy 0/77 (0.00%)"", ""  Endometrial mucosa thinkening 0/77 (0.00%)"", ""Adverse Events 2:"", ""  Total: 12/85 (14.12%)"", ""  Neutropenia  [1]1/85 (1.18%)"", ""  Left ventricular dysfunction 1/85 (1.18%)"", ""  Cardiac ischemia 2/85 (2.35%)"", ""  Gastrointestinal pain 1/85 (1.18%)"", ""  Colitis 1/85 (1.18%)"", ""  Febrile neutropenia 3/85 (3.53%)"", ""  Pulmonary/upper respiratory infection 1/85 (1.18%)"", ""  Diverticulitis 1/85 (1.18%)"", ""  Motor neuropathy 1/85 (1.18%)"", ""  Endometrial mucosa thinkening 1/85 (1.18%)""]",Entailment
There was less than a 5% difference in the Percentage of Participants With Objective Response in the GTx-024 9 mg and GTx-024 18 mg group in NCT02463032.,"[""Outcome Measurement: "", ""  Clinical Benefit Rate, in Centrally Confirmed Androgen Receptor (AR)+ Subjects"", ""  To estimate the clinical benefit rate (defined as complete response, partial response, or stable disease) according to RECIST 1.1, in subjects with estrogen receptor positive/androgen receptor positive (ER+/AR+) BC who have centrally confirmed AR+ status. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR; Clinical Benefit Rate (CBR)= CR + PR + SD."", ""  Time frame: 24 weeks"", ""Results 1: "", ""  Arm/Group Title: GTx-024 9 mg"", ""  Arm/Group Description: Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 9 mg"", ""  GTx-024: To determine whether either or both doses result in an acceptable clinical benefit rate."", ""  Overall Number of Participants Analyzed: 50"", ""  Measure Type: Number"", ""  Unit of Measure: participants  16"", ""Results 2: "", ""  Arm/Group Title: GTx-024 18 mg"", ""  Arm/Group Description: Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 18 mg"", ""  GTx-024: To determine whether either or both doses result in an acceptable clinical benefit rate."", ""  Overall Number of Participants Analyzed: 52"", ""  Measure Type: Number"", ""  Unit of Measure: participants  15""]",Contradiction
"A patient was treated with Pertuzumab for 6 months, and this treatment was discontinued 2 months prior to study entry and the patient has fully recovered from the entailing side effects, hence this patient is eligible for NCT02027376.","[""Exclusion Criteria:"", ""  Patients who have received biologic therapy (e.g. antibodies)  4 weeks prior to starting study drug or who have not recovered from the side effects of such therapy.""]",Entailment
"Patients with HER2 + breast cancer are eligible for both NCT02419807 and NCT00777101. However, only patients with stage 1-2 breast cancer are eligible for NCT02419807, and patients with stage 3-4 are eligilbe for NCT00777101. ","[""Inclusion Criteria:"", ""  Participants with a confirmed diagnosis of clinical stage 1 or 2 breast cancer""]",Entailment
NCT01989676 only records cardiovasuclar adverse events.,"[""Adverse Events 1:"", ""  Total: 67/349 (19.20%)"", ""  Anaemia * 3/349 (0.86%)"", ""  Leukopenia * 1/349 (0.29%)"", ""  Neutropenia * 3/349 (0.86%)"", ""  Thrombocytopenia * 1/349 (0.29%)"", ""  Atrial fibrillation * 2/349 (0.57%)"", ""  Cardiac arrest * 1/349 (0.29%)"", ""  Cardiac failure * 0/349 (0.00%)"", ""  Cardiac failure acute * 0/349 (0.00%)"", ""  Cardio-respiratory arrest * 2/349 (0.57%)"", ""  Cardiovascular insufficiency * 0/349 (0.00%)""]",Entailment
"Patients in NCT01830933 do not receive any extra medication for the study, whereas in NCT01224678 they are given an oral medication.","[""INTERVENTION 1: "", ""  Usual Care"", ""  Usual Care is the comparison Clinic Patients, where there is no change in their standard or usual care."", ""INTERVENTION 2: "", ""  BreastCARE Intervention"", ""  Intervention Clinic Patients: The participants will answer questions on the tablet-PC to calculate their breast cancer risk."", ""  Intervention Patient Report. Once the patient completes the BreastCare Computer survey, the program will immediately generate a personal feedback report containing information about her risk factors and recommendations to reduce her risk. This report will be printed and given to the patients before she meets with her doctor."", ""  BreastCARE : The physician will receive a physician report that contains information similar to the patient report.""]",Entailment
Participants with T2 N1 M0 breast carcinoma are eligible for NCT03004534.,"[""  Tumor must be confined to either the breast or to the breast and ipsilateral axilla (Note: patinets with multifocal/multicentric tumors are eligible). Patient must have (according to TNM 7th edition rules):"", ""  T1 with T 1.0cm, T2 or T3 by at least one radiographic or clinical measurement"", ""  Either clinically positive (N1 only) or clinically negative axillary nodes (N0)"", ""  M0""]",Entailment
There are no cases of Febrile neutropenia in NCT00929240.,"[""Adverse Events 1:"", ""  Total: 78/284 (27.46%)"", ""  Febrile neutropenia * 28/284 (9.86%)"", ""  Neutropenia * 217/284 (5.99%)"", ""  Leukopenia * 23/284 (1.06%)"", ""  Anaemia * 22/284 (0.70%)"", ""  Thrombocytopenia * 20/284 (0.00%)"", ""  Myocardial infarction * 20/284 (0.00%)"", ""  Arrhythmia * 21/284 (0.35%)"", ""  Atrial fibrillation * 1/284 (0.35%)"", ""  Coronary artery disease * 20/284 (0.00%)"", ""  Left ventricular dysfunction * 21/284 (0.35%)"", ""Adverse Events 2:"", ""  Total: 7/92 (7.61%)"", ""  Febrile neutropenia * 0/92 (0.00%)"", ""  Neutropenia * 20/92 (0.00%)"", ""  Leukopenia * 20/92 (0.00%)"", ""  Anaemia * 20/92 (0.00%)"", ""  Thrombocytopenia * 20/92 (0.00%)"", ""  Myocardial infarction * 20/92 (0.00%)"", ""  Arrhythmia * 20/92 (0.00%)"", ""  Atrial fibrillation * 0/92 (0.00%)"", ""  Coronary artery disease * 20/92 (0.00%)"", ""  Left ventricular dysfunction * 20/92 (0.00%)""]",Contradiction
"Paula recently had fell down a flight of stairs and fractured her hip, she is excluded from NCT00494481.","[""Inclusion Criteria:"", ""  Females with histological/cytological confirmation of breast cancer."", ""  Subjects with a measurable lesion or bone lesions"", ""Exclusion Criteria:"", ""  Previous radiotherapy within 6 weeks"", ""  Significant cardiac events, arrhythmias or other cardiac conditions""]",Contradiction
Patients with HER2 negative MBC are eligible for both NCT00593827 and NCT00478257.,"[""Inclusion Criteria:"", ""  Has MBC that is measurable by RECIST or has nonmeasurable disease with serum CA27.29 (or CA15.3)  50"", ""  Has Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer""]",Contradiction
NCT00423917 and NCT00082641 both report cases of confusion in their patient cohorts.,"[""Adverse Events 1:"", ""  Confusion 1/33 (3.03%)""]",Entailment
No cases of Metastasis to the CNS were recorded in NCT02001974.,"[""Adverse Events 1:"", ""  Total: 2/4 (50.00%)"", ""  Abdominal pain 0/4 (0.00%)"", ""  Disease progression 0/4 (0.00%)"", ""  Dehydration 2/4 (50.00%)"", ""  Hyponatraemia 1/4 (25.00%)"", ""  Metastasis to central nervous system 1/4 (25.00%)"", ""  Oesophageal adenocarcinoma 0/4 (0.00%)"", ""  Intracranial hypotension 0/4 (0.00%)"", ""  Pneumothorax 0/4 (0.00%)"", ""  Dyspnoea 0/4 (0.00%)"", ""  Hypoxia 0/4 (0.00%)"", ""Adverse Events 2:"", ""  Total: 1/3 (33.33%)"", ""  Abdominal pain 0/3 (0.00%)"", ""  Disease progression 0/3 (0.00%)"", ""  Dehydration 0/3 (0.00%)"", ""  Hyponatraemia 0/3 (0.00%)"", ""  Metastasis to central nervous system 0/3 (0.00%)"", ""  Oesophageal adenocarcinoma 0/3 (0.00%)"", ""  Intracranial hypotension 0/3 (0.00%)"", ""  Pneumothorax 1/3 (33.33%)"", ""  Dyspnoea 0/3 (0.00%)"", ""  Hypoxia 0/3 (0.00%)""]",Contradiction
"Patients must have a confirmed pregnancy by positive Hcg test, if they are to take part in NCT01004744.","[""  Postmenopausal status defined as cessation of menses for >1 year or FSH > 20 mIU/mL (within the past month)""]",Contradiction
Cohort 1 of NCT00246090 0.0015% less total adverse events than cohort 2 of NCT00266799.,"[""Adverse Events 1:"", ""  Total: 88/291 (30.24%)""]",Contradiction
A 55 year old postmenopausal patient with sarcoidosis would be excluded from NCT00553410 as it would prevent prevent prolonged follow-up.,"[""DISEASE CHARACTERISTICS:"", ""  Confirmed diagnosis of prior operable, noninflammatory breast cancer meeting the following criteria:"", ""  Steroid hormone receptor-positive tumors (estrogen receptor and/or progesterone receptor), determined by immunohistochemistry, after primary surgery and before commencement of prior endocrine therapy"", ""  Prior local treatment including surgery with or without radiotherapy for primary breast cancer with no known clinical residual loco-regional disease"", ""  Following primary surgery, eligible patients must have had evidence of lymph node involvement either in the axillary or internal mammary nodes, but not supraclavicular nodes"", ""  Clinically disease-free"", ""  Must have completed 4-6 years of prior adjuvant selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), or a sequential combination of both"", ""  When calculating 4-6 years, neoadjuvant endocrine therapy should not be included"", ""  No evidence of recurrent disease or distant metastatic disease"", ""  No prior bilateral breast cancer"", ""  PATIENT CHARACTERISTICS:"", ""  Female"", ""  Must be postmenopausal by any of the following criteria:"", ""  Patients of any age who have had a bilateral oophorectomy (including radiation castration AND amenorrheic for > 3 months)"", ""  Patients 56 years old or older with any evidence of ovarian function must have biochemical evidence of definite postmenopausal status (defined as estradiol, luteinizing hormone [LH], and follicle-stimulating hormone [FSH] in the postmenopausal range)"", ""  Patients 55 years old or younger must have biochemical evidence of definite postmenopausal status (defined as estradiol, LH, and FSH in the postmenopausal range)"", ""  Patients who have received prior luteinizing-hormone releasing-hormone (LHRH) analogues within the last year are eligible if they have definite evidence of postmenopausal status as defined above"", ""  Clinically adequate hepatic function"", ""  No bone fracture due to osteoporosis at any time during the 4-6 years of prior therapy"", ""  No prior or current malignancy except adequately treated basal cell or squamous cell carcinoma of the skin, in situ carcinoma of the cervix or bladder, or contra- or ipsilateral in situ breast carcinoma"", ""  No other nonmalignant systemic diseases (cardiovascular, renal, lung, etc.) that would prevent prolonged follow-up"", ""  No psychiatric, addictive, or any other disorder that compromises compliance with protocol requirements"", ""  PRIOR CONCURRENT THERAPY:"", ""  See Disease Characteristics"", ""  More than 12 months since prior and no other concurrent endocrine SERM/AI therapy"", ""  Any type of prior adjuvant therapy allowed including, but not limited to, any of the following:"", ""  Neoadjuvant chemotherapy"", ""  Neoadjuvant endocrine therapy"", ""  Adjuvant chemotherapy"", ""  Trastuzumab (Herceptin\u00ae)"", ""  Ovarian ablation"", ""  Gonadotropin releasing hormone analogues"", ""  Lapatinib ditosylate"", ""  No concurrent hormone-replacement therapy, bisphosphonates (except for treatment of bone loss), or any other investigational agent""]",Entailment
"The minimum number of days from start of study treatment to first documentation of objective tumor progression or death due to cancer for any patient in NCT00076024, was 191.","[""Outcome Measurement: "", ""  Time to Tumor Progression (TTP)"", ""  Time in days from start of study treatment to first documentation of objective tumor progression or death due to cancer, whichever comes first. TTP was calculated as first event date minus the date of first dose of study medication plus 1. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD])."", ""  Time frame: Phase 2 double-blind baseline until tumor progression or death or discontinuation from study treatment, assessed every 9 weeks up to 129 weeks"", ""Results 1: "", ""  Arm/Group Title: Axitinib + Docetaxel (Phase 2, Double-blind)"", ""  Arm/Group Description: Axitinib (AG-013736) 5 mg tablet orally BID starting from Day 1 of Cycle 1, in cycles of 3 weeks. Docetaxel 80 mg/m^2 1 hr IV infusion on Day 1 of each cycle, in cycles of 3 weeks. Treatment was continued until disease progression, intolerable toxicity, or for 2 cycles after complete response."", ""  Overall Number of Participants Analyzed: 112"", ""  Median (95% Confidence Interval)"", ""  Unit of Measure: days  247        (208 to 265)"", ""Results 2: "", ""  Arm/Group Title: Docetaxel + Placebo (Phase 2, Double-blind)"", ""  Arm/Group Description: Placebo matched to axitinib (AG-013736) tablet orally BID starting from Day 1 of Cycle 1, in cycles of 3 weeks. Docetaxel 80 mg/m^2 1 hr IV infusion on Day 1 of each cycle, in cycles of 3 weeks. Treatment was continued until disease progression, intolerable toxicity, or for 2 cycles after complete response. Participants with disease progression after consent were continued to open-label phase."", ""  Overall Number of Participants Analyzed: 55"", ""  Median (95% Confidence Interval)"", ""  Unit of Measure: days  215        (191 to 247)""]",Entailment
One patient in NCT01674062 was observed suffering from Enteritis.,"[""Adverse Events 1:"", ""  Total: 12/66 (18.18%)"", ""  Palpitations * 1/66 (1.52%)"", ""  Haematemesis * 1/66 (1.52%)"", ""  Performance status decreased * 1/66 (1.52%)"", ""  Hepatic failure * 1/66 (1.52%)"", ""  Cellulitis * 1/66 (1.52%)"", ""  Device related infection * 1/66 (1.52%)"", ""  Pneumonia * 1/66 (1.52%)"", ""  Pneumonia pneumococcal * 1/66 (1.52%)"", ""  Femur fracture * 0/66 (0.00%)"", ""  Hypokalaemia * 1/66 (1.52%)"", ""  Back pain * 2/66 (3.03%)""]",Contradiction
1 patient in NCT00509769 had toxic hepatitis.,"[""Adverse Events 1:"", ""  Hepatotoxicity 1/112 (0.89%)""]",Entailment
less than 1% of either cohort of NCT01492101 was effect by either Pancytopenia or Coagulopathy.,"[""Adverse Events 1:"", ""  Pancytopenia *2/425 (0.47%)"", ""  Coagulopathy *1/425 (0.24%)"", ""Adverse Events 2:"", ""  Pancytopenia *0/406 (0.00%)"", ""  Coagulopathy *0/406 (0.00%)""]",Entailment
Only patients with HER2 positive breast carcinoma are eligible for NCT00232479.,"[""Inclusion Criteria:"", ""  HER-2 overexpressing breast cancer""]",Entailment
"Throughout NCT01644890, one patient developed issues with their vision.","[""Adverse Events 1:"", ""  Total: 34/214 (15.89%)"", ""  Leukocytosis 0/214 (0.00%)"", ""  Atrial fibrillation 0/214 (0.00%)"", ""  Cardiac failure congestive 0/214 (0.00%)"", ""  Pericardial effusion 1/214 (0.47%)"", ""  Cataract 0/214 (0.00%)"", ""  Macular fibrosis 0/214 (0.00%)"", ""  Constipation 2/214 (0.93%)"", ""  Diarrhoea 2/214 (0.93%)"", ""  Enterocolitis 0/214 (0.00%)"", ""  Ileus 1/214 (0.47%)"", ""  Nausea 3/214 (1.40%)"", ""Adverse Events 2:"", ""  Total: 27/213 (12.68%)"", ""  Leukocytosis 1/213 (0.47%)"", ""  Atrial fibrillation 1/213 (0.47%)"", ""  Cardiac failure congestive 1/213 (0.47%)"", ""  Pericardial effusion 0/213 (0.00%)"", ""  Cataract 1/213 (0.47%)"", ""  Macular fibrosis 1/213 (0.47%)"", ""  Constipation 1/213 (0.47%)"", ""  Diarrhoea 1/213 (0.47%)"", ""  Enterocolitis 1/213 (0.47%)"", ""  Ileus 0/213 (0.00%)"", ""  Nausea 0/213 (0.00%)""]",Entailment
"None of the patients in cohort 1 of NCT00063570 had a platlet deficiency, and none of the patients in cohort 2 had Pyrexia.","[""Adverse Events 1:"", ""  Total: 17"", ""  Anaemia 2/52 (3.85%)"", ""  Febrile neutropenia 4/52 (7.69%)"", ""  Pancytopenia 1/52 (1.92%)"", ""  Thrombocytopenia 0/52 (0.00%)"", ""  Abdominal pain 1/52 (1.92%)"", ""  Constipation 1/52 (1.92%)"", ""  Pyrexia 2/52 (3.85%)"", ""  Hepatic failure 1/52 (1.92%)"", ""  Hyperbilirubinaemia 1/52 (1.92%)"", ""  Device related infection 1/52 (1.92%)"", ""  Pneumonia 2/52 (3.85%)"", ""  Sepsis 1/52 (1.92%)"", ""Adverse Events 2:"", ""  Total: 7"", ""  Anaemia 0/21 (0.00%)"", ""  Febrile neutropenia 1/21 (4.76%)"", ""  Pancytopenia 0/21 (0.00%)"", ""  Thrombocytopenia 1/21 (4.76%)"", ""  Abdominal pain 0/21 (0.00%)"", ""  Constipation 0/21 (0.00%)"", ""  Pyrexia 1/21 (4.76%)"", ""  Hepatic failure 0/21 (0.00%)"", ""  Hyperbilirubinaemia 0/21 (0.00%)"", ""  Device related infection 0/21 (0.00%)"", ""  Pneumonia 0/21 (0.00%)"", ""  Sepsis 0/21 (0.00%)""]",Contradiction
Patients with a Karnofsky status of 94% are eligible for NCT00295867.,"[""  Exclusion Criteria"", ""  Karnofsky Performance status < 90%.""]",Entailment
In total there were 32 cases of Febrile neutropenia in NCT00391092.,"[""Adverse Events 1:"", ""  Febrile neutropenia * 14/206 (6.80%)"", ""Adverse Events 2:"", ""  Febrile neutropenia * 18/215 (8.37%)""]",Entailment
The highest number of occurences for any adverse event in both NCT00083174 and NCT00190671 was 2.,"[""Adverse Events 1:"", ""  Total: 39/2240 (1.74%)"", ""  Supraven.arrhyth. Atrial fibrillation 1/2240 (0.04%)"", ""  Cardiac ischemia/infarction 2/2240 (0.09%)"", ""  Valvular heart disease 1/2240 (0.04%)"", ""  Cardiac General - Other 2/2240 (0.09%)"", ""  Endocrine - Other 1/2240 (0.04%)"", ""  Ocular - Other 1/2240 (0.04%)"", ""  Colitis 2/2240 (0.09%)"", ""  Diarrhea 1/2240 (0.04%)"", ""  Dysphagia 1/2240 (0.04%)"", ""  Gastritis 1/2240 (0.04%)""]",Entailment
"Patients who received over 5 years of anastrozole therapy, completed 2 years prior, are eligible for NCT00754845.","[""  Must have received 4\u00bd - 6 years of aromatase inhibitor therapy (e.g., letrozole, anastrozole, or exemestane), either as initial therapy or after prior tamoxifen citrate, including treatment received as part of clinical trial CAN-NCIC-MA17"", ""  Completed aromatase inhibitor therapy  2 years ago""]",Entailment
All of the adverse events recorded in NCT00432172 occurred in patients from cohort 1.,"[""Adverse Events 1:"", ""  Total: 5/45 (11.11%)"", ""  Neutrophils/granulocytes (ANC/AGC) *  [1]0/45 (0.00%)"", ""  Neutrophils/granulocytes (ANC/AGC) *  [2]0/45 (0.00%)"", ""  Diabetes decompensation * 0/45 (0.00%)"", ""  Diarrhea *  [2]0/45 (0.00%)"", ""  Mucositis/stomatitis and Vomiting *  [3]0/45 (0.00%)"", ""  Pancreatitis *  [4]1/45 (2.22%)"", ""  Febrile neutropenia *  [2]3/45 (6.67%)"", ""Adverse Events 2:"", ""  Total: 0/46 (0.00%)"", ""  Neutrophils/granulocytes (ANC/AGC) *  [1]0/46 (0.00%)"", ""  Neutrophils/granulocytes (ANC/AGC) *  [2]0/46 (0.00%)"", ""  Diabetes decompensation * 0/46 (0.00%)"", ""  Diarrhea *  [2]0/46 (0.00%)"", ""  Mucositis/stomatitis and Vomiting *  [3]0/46 (0.00%)"", ""  Pancreatitis *  [4]0/46 (0.00%)"", ""  Febrile neutropenia *  [2]0/46 (0.00%)"", ""  Infection pulmonary/ Upper airway NOS *  [5]0/46 (0.00%)""]",Entailment
There were no MRSA infections in either NCT01201265 or NCT00493649.,"[""Adverse Events 1:"", ""  Total: 51/486 (10.49%)"", ""  ANEMIA 1/486 (0.21%)"", ""  NEUTROPENIA 4/486 (0.82%)"", ""  FIBRILLATION ATRIAL 1/486 (0.21%)"", ""  ABDOMINAL PAIN 2/486 (0.41%)"", ""  BLOATING 1/486 (0.21%)"", ""  BOWEL PERFORATION 1/486 (0.21%)"", ""  COLITIS 1/486 (0.21%)"", ""  DEHYDRATION 5/486 (1.03%)"", ""  DIARRHEA 5/486 (1.03%)"", ""  GASTRIC INFLAMMATION 1/486 (0.21%)"", ""  NAUSEA 3/486 (0.62%)"", ""  NAUSEA AND VOMITING 1/486 (0.21%)""]",Entailment
NCT00468585 did not record any skin infections in their patients.,"[""Adverse Events 1:"", ""  Total: 2/4 (50.00%)"", ""  Atrial fibrillation 0/4 (0.00%)"", ""  Dehydration 1/4 (25.00%)"", ""  Fatigue (asthenia, lethargy, malaise) 1/4 (25.00%)"", ""  Pain - Back 1/4 (25.00%)"", ""  Urinary tract infection 0/4 (0.00%)"", ""  Dyspnea (shortness of breath) 0/4 (0.00%)"", ""  Pericardial effusion 0/4 (0.00%)"", ""  Thrombosis 0/4 (0.00%)"", ""  Skin infection 0/4 (0.00%)"", ""  Rash: hand-foot skin reaction 0/4 (0.00%)"", ""Adverse Events 2:"", ""  Total: 0/3 (0.00%)"", ""  Atrial fibrillation 0/3 (0.00%)"", ""  Dehydration 0/3 (0.00%)"", ""  Fatigue (asthenia, lethargy, malaise) 0/3 (0.00%)"", ""  Pain - Back 0/3 (0.00%)"", ""  Urinary tract infection 0/3 (0.00%)"", ""  Dyspnea (shortness of breath) 0/3 (0.00%)"", ""  Pericardial effusion 0/3 (0.00%)"", ""  Thrombosis 0/3 (0.00%)"", ""  Skin infection 0/3 (0.00%)"", ""  Rash: hand-foot skin reaction 0/3 (0.00%)""]",Entailment
"INR equal to or above 1.5 is mandatory for participation in NCT00915603, it is not necessary for NCT02511730.","[""Inclusion Criteria:"", ""  International normalized ratio (INR) <=1.5 or prothrombin time (PT)/partial""]",Entailment
Cohort 1 of NCT00856492 recorded no deaths and no cases of Enterocolitis infectious.,"[""Adverse Events 1:"", ""  Total: 22/96 (22.92%)"", ""  Anemia  1/96 (1.04%)"", ""  Febrile neutropenia  4/96 (4.17%)"", ""  Heart failure  1/96 (1.04%)"", ""  Abdominal pain  1/96 (1.04%)"", ""  Dysphagia  1/96 (1.04%)"", ""  Mucositis oral  1/96 (1.04%)"", ""  Nausea  1/96 (1.04%)"", ""  Vomiting  2/96 (2.08%)"", ""  Death NOS  0/96 (0.00%)"", ""  Pain  1/96 (1.04%)"", ""  Catheter related infection  1/96 (1.04%)"", ""  Enterocolitis infectious  0/96 (0.00%)""]",Entailment
"Agatha had her 53rd birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. Agatha is of white british origin. she is eligible for NCT00089479 but not NCT02964234, due to her age.","[""Inclusion Criteria:"", ""  female patients 18-70 years of age;"", ""  adenocarcinoma of the breast;"", ""  previous invasive breast cancer if diagnosed >5 years before entering study;"", ""  no evidence of metastatic disease."", ""Exclusion Criteria:"", ""  history of severe hypersensitivity reaction to Taxotere;"", ""  previous treatment with anthracycline, anthracenedione (mitoxantrone), or taxane;"", ""  treatment with fluoropyrimidine (5-fluorouracil) within the last 5 years.""]",Contradiction
The total number of patients affected by adverse events in cohort 2 NCT00528567 is more than 1000.,"[""Adverse Events 2:"", ""  Total: 250/1271 (19.67%)""]",Contradiction
There was over 10 more cases of adverse events in cohort 2 than in cohort 1 of NCT01560416.,"[""Adverse Events 1:"", ""  Total: 2/15 (13.33%)"", ""Adverse Events 2:"", ""  Total: 11/35 (31.43%)""]",Contradiction
Patients with a positive sentinel node biopsy must have surgery to remove lymph nodes from the groin or they will not be eligible for NCT00009945.,"[""Eligibility"", ""  Patients must have undergone either a total mastectomy or a lumpectomy with either an axillary dissection or sentinel node biopsy. If any sentinel node is histologically positive by H & E, or histologically suspicious on H & E and confirmed positive by immunohistochemistry (IHC), then the patient must have a completion axillary dissection.""]",Contradiction
NCT00193206 records a total of 7 different types of infections.,"[""Adverse Events 1:"", ""  Total: 22/123 (17.89%)"", ""  Cardiac Ischemia/Infarction  [1]1/123 (0.81%)"", ""  Pain - Chest 2/123 (1.63%)"", ""  Dehydration 2/123 (1.63%)"", ""  Death  [2]1/123 (0.81%)"", ""  Weakness 1/123 (0.81%)"", ""  Pain - Liver 1/123 (0.81%)"", ""  Infection - Skin  [3]3/123 (2.44%)"", ""  Infection - Gastrointestinal  [4]1/123 (0.81%)"", ""  Infection - Vein  [5]2/123 (1.63%)"", ""  Infection - Pneumonia 1/123 (0.81%)""]",Contradiction
There were several patients who contracted Pneumonia in NCT00717405.,"[""Adverse Events 1:"", ""  Total: 20/52 (38.46%)"", ""  Febrile bone marrow aplasia * 5/52 (9.62%)"", ""  Febrile neutropenia * 6/52 (11.54%)"", ""  Leukopenia * 6/52 (11.54%)"", ""  Atrial tachycardia * 1/52 (1.92%)"", ""  Vomiting * 1/52 (1.92%)"", ""  Tooth loss * 1/52 (1.92%)"", ""  Hyperthermia * 1/52 (1.92%)"", ""  Malaise * 1/52 (1.92%)"", ""  Pyrexia * 1/52 (1.92%)"", ""  Impaired healing * 3/52 (5.77%)"", ""  Inflammation * 1/52 (1.92%)""]",Contradiction
"Candidates for NCT00090857 must have a bone density scan 1 month prior to study entry, if the results from this are more than 2 standard deviations below normal, they must be excluded.","[""  Bone density scan within 2 standard deviations from normal within the past 30 days"", ""  Bone density scan  2 standard deviations below normal allowed if approved by the study physician""]",Contradiction
patients with Multicentric breast cancer can be accepted for NCT00945061.,"[""Inclusion Criteria:"", ""  Unifocal breast cancer recurrence""]",Contradiction
Every adverse event in NCT00544167 occurred more than 8 times.,"[""Adverse Events 1:"", ""  Total: 7/45 (15.56%)"", ""  Febrile neutropenia 1/45 (2.22%)"", ""  Cardiac ischemia/infarction 1/45 (2.22%)"", ""  Ventricular arrhythmia - left ventricular systolic dysfunction 1/45 (2.22%)"", ""  Hemmorhage - GI 1/45 (2.22%)"", ""  Pancreatitis 1/45 (2.22%)"", ""  Infection - pneumonia 1/45 (2.22%)"", ""  Infection - Streptococcus 1/45 (2.22%)"", ""  Abcess of Bartholin's cyst 1/45 (2.22%)""]",Contradiction
1 patient in cohort 1 of NCT00871858 was diagnosed with a Clear cell renal cell carcinoma.,"[""Adverse Events 1:"", ""  Total: 2/60 (3.33%)"", ""  Bronchial infection 0/60 (0.00%)"", ""  Ankle fracture 1/60 (1.67%)"", ""  Clear cell kidney cancer 0/60 (0.00%)"", ""  Programmed peritoneal dialysis 1/60 (1.67%)"", ""  Endometrial atrophy 0/60 (0.00%)"", ""Adverse Events 2:"", ""  Total: 3/58 (5.17%)"", ""  Bronchial infection 1/58 (1.72%)"", ""  Ankle fracture 0/58 (0.00%)"", ""  Clear cell kidney cancer 1/58 (1.72%)"", ""  Programmed peritoneal dialysis 0/58 (0.00%)"", ""  Endometrial atrophy 1/58 (1.72%)""]",Contradiction
Patients must have LVEF < 50% to be eligible for NCT01904903.,"[""  LVEF < 50% and  40% documented in echocardiogram done within the last 30 days""]",Entailment
There over 20% difference in the Percentage of Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) between the 2 cohorts of NCT00370552.,"[""Outcome Measurement: "", ""  Percentage of Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) While On-study"", ""  CR=Disappearance of all clinical and radiologic evidence of target lesions; PR=At least 30% reduction in the sum of the longest diameter of all target lesions."", ""  Time frame: Baseline visit and then every 8 weeks to 12 months, then every 3 months until disease progression"", ""Results 1: "", ""  Arm/Group Title: Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg"", ""  Arm/Group Description: Ixabepilone,16 mg/m^2, administered as a 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity. Bevacizumab, 10 mg/kg, administered after ixabepilone as IV infusion every 2 weeks. Bevacizumab to be infused over 90 minutes for the first dose, and if well tolerated for 60 minutes, for the second dose. Then if still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity."", ""  Overall Number of Participants Analyzed: 46"", ""  Measure Type: Number"", ""  Unit of Measure: Percentage of participants  47.8        (32.9 to 63.1)"", ""Results 2: "", ""  Arm/Group Title: Ixabepilone, 40 mg/m^2 + Bevacizumab, 15 mg/kg"", ""  Arm/Group Description: Ixabepilone, 40 mg/m^2, administered as a 3-hour IV infusion on Day 1 of a 21-day cycle until disease progression or unacceptable toxicity After Cycle 4, dose reduction to 32 mg/m^2 implemented for all subsequent cycles. Bevacizumab, 15 mg/kg, administered after ixabepilone as IV infusion every 3 weeks. Bevacizumab to be infused over 90 minutes for the first dose, and if well tolerated for 60 minutes, for the second dose. Then if still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity."", ""  Overall Number of Participants Analyzed: 45"", ""  Measure Type: Number"", ""  Unit of Measure: Percentage of participants  71.1        (55.7 to 83.6)""]",Entailment
"Patients with Platelet count over 100,000/mm³, ANC <  1,700/mm³ and Hemoglobin between 4 to 5 grams per deciliter are eligible for NCT00662129.","[""  PATIENT CHARACTERISTICS:"", ""  ANC  1,500/mm\u00b3"", ""  Platelet count  100,000/mm\u00b3"", ""  Hemoglobin  9.0 g/dL""]",Contradiction
"One patient in NCT00924352 had abnormally low red blood cells, white blood cells, and platelets.","[""  Pancytopenia * 1/56 (1.79%)""]",Entailment
Patients must have Human epidermal growth factor receptor 2 (HER2) overexpressive tumors to participate in NCT00167414.,"[""Inclusion Criteria:"", ""  Age: no limit"", ""  Karnofsky performance status (KPS)  70"", ""  No more than 5 metastatic sites involving one or more different organs (liver, lung or bone)."", ""  The size of the lesion must be such that it can be safely treated to sterilizing radiation doses according to the rules in the protocol."", ""  Previously treated lesions are not eligible unless the prescribed dose can be safely delivered."", ""  Concurrent therapy is allowed and recommended. The chemotherapy protocol type and schedule are at the discretion of the medical oncologist."", ""  Informed consent must be obtained."", ""  Pregnancy test must be negative for women of child bearing potential"", ""Exclusion Criteria:"", ""  Inability of patient to be followed longitudinally as specified by protocol."", ""  Technical inability to achieve required dose based on safe dose constraints required for radiosurgery."", ""  Women who are pregnant or nursing."", ""  Failure to meet requirements in Inclusion Criteria"", ""  Contraindications to radiation.""]",Contradiction
"Patients with T1N2M0, T2N1M0, T3N1M1 and TxN1M0 tumors are eliglbe for NCT01127373.","[""Inclusion Criteria:"", ""  Pathologic confirmation of metastatic disease in at least one regional lymph node. Regional lymph nodes are defined as the ipsilateral axillary lymph nodes, ipsilateral supraclavicular lymph nodes, and ipsilateral internal mammary lymph nodes. Thus, any T stage is allowed as long as the N stage is 1 and M stage is 0.""]",Contradiction
Candidates for NCT02694029 are expected to be capable of holding their breath for half a minute.,"[""Inclusion Criteria:"", ""  Patient must be able to maintain a 30 second breath hold.""]",Entailment
"Patients with BUN < 20 mg/dL,  Platelet count: <90,000/mm3, Leukocyte count of 5,000/mm3 to 8,000/mm3 may be eligible for both NCT00438100 and NCT00662025.","[""Inclusion Criteria:"", ""  Biopsy-diagnosed breast cancer with metastasis in multiple organs"", ""  Performance Status (World Health Organization :WHO) 0-2"", ""  Functions below are maintained in major organs:"", ""  Leukocyte count: 4,000/mm3 to 12,000/mm3"", ""  Neutrophil count: >2,000/mm3 or more"", ""  Platelet count: <100,000/mm3 or more"", ""  Hemoglobin: >9.5 g/dL"", ""  Total bilirubin: >1.5 mg/dL"", ""  AST(GOT): within twice a normal upper value in an institution"", ""  AST(GPT): within twice a normal upper value in an institution"", ""  BUN: < 25 mg/dL"", ""  Creatinine: within a normal upper value in the institution"", ""  24 hours creatinine clearance: >50 mL/min (using the Cockcroft-Gault formula)"", ""  Women's Ccr = Body weight x (140-Age)/(72 x Serum creatinine) x 0.85""]",Entailment
"NCT00615901 recorded more seizures than NCT00829166, despite having less than one tenth the number of patients in its total cohort.","[""Adverse Events 1:"", ""  Seizure 1/38 (2.63%)""]",Entailment
"The most common adverse event in both cohorts of NCT00003830 was Anaphylaxis, which affected more than 10 patients in total.","[""Adverse Events 1:"", ""  Total: 9/2788 (0.32%)"", ""  Anaphylaxis 5/2788 (0.18%)"", ""  Infections and infestations - Other, specify 2/2788 (0.07%)"", ""  Nervous system disorders - Other, specify 0/2788 (0.00%)"", ""  Respiratory, thoracic and mediastinal disorders - Other, specify 1/2788 (0.04%)"", ""  Thromboembolic event 1/2788 (0.04%)"", ""Adverse Events 2:"", ""  Total: 8/2800 (0.29%)"", ""  Anaphylaxis 5/2800 (0.18%)"", ""  Infections and infestations - Other, specify 0/2800 (0.00%)"", ""  Nervous system disorders - Other, specify 1/2800 (0.04%)"", ""  Respiratory, thoracic and mediastinal disorders - Other, specify 1/2800 (0.04%)"", ""  Thromboembolic event 2/2800 (0.07%)""]",Contradiction
Patients in NCT00191451 experienced a variety of Oesophageal and cardiac adverse events.,"[""Adverse Events 1:"", ""  Total: 10/50 (20.00%)"", ""  Anaemia 0/50 (0.00%)"", ""  Febrile neutropenia 0/50 (0.00%)"", ""  Neutropenia 0/50 (0.00%)"", ""  Thrombocytopenia 0/50 (0.00%)"", ""  Diastolic dysfunction 0/50 (0.00%)"", ""  Tachycardia 0/50 (0.00%)"", ""  Intestinal obstruction 0/50 (0.00%)"", ""  Nausea 1/50 (2.00%)"", ""  Oesophageal spasm 0/50 (0.00%)"", ""  Oesophagitis 0/50 (0.00%)"", ""  Retching 0/50 (0.00%)"", ""Adverse Events 2:"", ""  Total: 11/48 (22.92%)"", ""  Anaemia 4/48 (8.33%)"", ""  Febrile neutropenia 0/48 (0.00%)"", ""  Neutropenia 2/48 (4.17%)"", ""  Thrombocytopenia 2/48 (4.17%)"", ""  Diastolic dysfunction 1/48 (2.08%)"", ""  Tachycardia 1/48 (2.08%)"", ""  Intestinal obstruction 0/48 (0.00%)"", ""  Nausea 0/48 (0.00%)"", ""  Oesophageal spasm 1/48 (2.08%)"", ""  Oesophagitis 0/48 (0.00%)"", ""  Retching 1/48 (2.08%)""]",Entailment
"Patients with Leukemia, Hepatitis or Polycystic Kidney Disease cannot be included in NCT02600923.","[""Inclusion Criteria:"", ""  Adequate bone marrow function."", ""  Adequate liver function"", ""  Adequate renal function.""]",Entailment
Patients with incurable and  unresectable Locally Advanced Breast Cancer are eligible for NCT01702571.,"[""Inclusion Criteria:"", ""  Documented progression of incurable, unresectable, LABC, or mBC, defined by the investigator: progression must occur during or after most recent treatment for LABC/mBC or within 6 months of completing adjuvant therapy""]",Entailment
All patients in the Letrozole group of NCT00171704 had a decreased Bone Mineral Density of the Lumbar Spine after 3 years.,"[""Outcome Measurement: "", ""  Percent Change From Baseline of Bone Mineral Density of the Lumbar Spine (L2-l4)"", ""  Lumbar spine (L2-L4) BMD measurements by dual energy X-ray absorptiometry (DXA) were performed after surgery and within 2 weeks prior to randomization and repeated every 6 months for the first 2 years and annually thereafter until 5 years after enrollment. The primary scanning site was the lumbar spine (L2 to L4) and the secondary scanning site was the total hip. All DXA scans were evaluated by a central reader."", ""  Time frame: Baseline, 24 months"", ""Results 1: "", ""  Arm/Group Title: Letrozole"", ""  Arm/Group Description: 2.5 mg once daily (q.d.)orally for 5 years"", ""  Overall Number of Participants Analyzed: 63"", ""  Median (Full Range)"", ""  Unit of Measure: Percent Change  -4.63        (-14.21 to 4.32)"", ""Results 2: "", ""  Arm/Group Title: Tam-Let"", ""  Arm/Group Description: 20 mg Tamoxifen once daily (q.d.) orally for 2 years followed by Letrozole 2.5 mg q.d. orally for 3 years."", ""  Overall Number of Participants Analyzed: 68"", ""  Median (Full Range)"", ""  Unit of Measure: Percent Change  0.37        (-6.98 to 15.21)""]",Contradiction
NCT00243503 and NCT00448279 observed a different number of adverse events in their patients.,"[""Adverse Events 1:"", ""  Total: 25/60 (41.67%)"", ""  Anaemia * 1/60 (1.67%)"", ""  Febrile neutropenia * 2/60 (3.33%)"", ""  Idiopathic thrombocytopenic purpura * 1/60 (1.67%)"", ""  Thrombocytopenia * 3/60 (5.00%)"", ""  Cardiac failure * 1/60 (1.67%)"", ""  Cardiac failure acute * 1/60 (1.67%)"", ""  Cardiogenic shock * 1/60 (1.67%)"", ""  Left ventricular dysfunction * 1/60 (1.67%)"", ""  Anal fistula * 1/60 (1.67%)""]",Entailment
"Candidates for NCT00090857 must have a bone density scan 1 month prior to study entry, if the results from this are more than 2 standard deviations below normal, the study physician can still decide to let them participate.","[""  Bone density scan within 2 standard deviations from normal within the past 30 days"", ""  Bone density scan  2 standard deviations below normal allowed if approved by the study physician""]",Entailment
"Heart-related adverse events were recorded in NCT00703326, but not  NCT00093145.","[""Adverse Events 1:"", ""  Supraventricular tachycardia 1/32 (3.13%)""]",Contradiction
ECOG > 1 and a life expectancy over 12 weeks are necessary to participate in NCT01597193.,"[""Inclusion Criteria:"", ""  Eastern Cooperative Oncology Group performance (ECOG) status of 0 or 1;"", ""  Estimated life expectancy of at least 3 months""]",Contradiction
"There were no patients with paranasal sinus reactions, or Left ventricular dysfunction in NCT00545688.","[""Adverse Events 1:"", ""  Total: 21/107 (19.63%)"", ""  Febrile neutropenia * 10/107 (9.35%)"", ""  Neutropenia * 1/107 (0.93%)"", ""  Left ventricular dysfunction * 0/107 (0.00%)"", ""  Angina pectoris * 0/107 (0.00%)"", ""  Cardiac failure congestive * 0/107 (0.00%)"", ""  Diarrhoea * 2/107 (1.87%)"", ""  Abdominal strangulated hernia * 0/107 (0.00%)"", ""  Duodenal ulcer haemorrhage * 0/107 (0.00%)"", ""  Pyrexia * 1/107 (0.93%)"", ""Adverse Events 2:"", ""  Total: 22/107 (20.56%)"", ""  Febrile neutropenia * 8/107 (7.48%)"", ""  Neutropenia * 6/107 (5.61%)"", ""  Left ventricular dysfunction * 3/107 (2.80%)"", ""  Angina pectoris * 1/107 (0.93%)"", ""  Cardiac failure congestive * 0/107 (0.00%)"", ""  Diarrhoea * 0/107 (0.00%)"", ""  Abdominal strangulated hernia * 1/107 (0.93%)"", ""  Duodenal ulcer haemorrhage * 0/107 (0.00%)"", ""  Pyrexia * 1/107 (0.93%)""]",Contradiction
A total of 32 patients in NCT02340221 had Diarrhoea.,"[""Adverse Events 1:"", ""  Total: 19/213 (8.92%)"", ""  Pancytopenia 0/213 (0.00%)"", ""  Anaemia 1/213 (0.47%)"", ""  Atrial fibrillation 0/213 (0.00%)"", ""  Cardiac failure congestive 0/213 (0.00%)"", ""  Myocardial infarction 0/213 (0.00%)"", ""  Supraventricular tachycardia 0/213 (0.00%)"", ""  Diarrhoea 0/213 (0.00%)"", ""  Colitis 0/213 (0.00%)"", ""  Vomiting 1/213 (0.47%)"", ""  Nausea 1/213 (0.47%)"", ""  Enterocolitis 0/213 (0.00%)"", ""Adverse Events 2:"", ""  Total: 133/416 (31.97%)"", ""  Pancytopenia 1/416 (0.24%)"", ""  Anaemia 0/416 (0.00%)"", ""  Atrial fibrillation 2/416 (0.48%)"", ""  Cardiac failure congestive 1/416 (0.24%)"", ""  Myocardial infarction 1/416 (0.24%)"", ""  Supraventricular tachycardia 1/416 (0.24%)"", ""  Diarrhoea 32/416 (7.69%)"", ""  Colitis 14/416 (3.37%)"", ""  Vomiting 4/416 (0.96%)"", ""  Nausea 3/416 (0.72%)"", ""  Enterocolitis 2/416 (0.48%)""]",Entailment
"Less than half of patients in cohorts 1 in NCT00454532 experienced adverse events, but more than 45% of patients cohort 2 did experience adverse events.","[""Adverse Events 1:"", ""  Total: 5/11 (45.45%)"", ""  Hemorrhage, GI-abdomen NOS 21/11 (9.09%)"", ""  Pain-liver 21/11 (9.09%)"", ""  Infection-ulcer 20/11 (0.00%)"", ""  Hemoglobin 20/11 (0.00%)"", ""  Hypoglycemia 20/11 (0.00%)"", ""  Pain-rib cage due to vomiting 20/11 (0.00%)"", ""  Obstruction-gu ureter 1/11 (9.09%)"", ""  Hemorrhage gu-bladder 21/11 (9.09%)"", ""  Pain-breast 21/11 (9.09%)"", ""  Pleural effusion 22/11 (18.18%)"", ""Adverse Events 2:"", ""  Total: 0/6 (0.00%)""]",Contradiction
"Participants of NCT00317603 must be older than 18, have histologically confirmed stage 4 breast cancer, ECOG<2 and a life expectancy exceeding 6 months.","[""Inclusion Criteria:"", ""  Histologically confirmed Stage IV breast cancer"", ""  ECOG performance status 0 or 1"", ""  Estimated life expectancy of greater than or equal to 6 months"", ""  18 years of age or older""]",Entailment
NCT01446159 only had a total of 66 patients in across both its cohorts.,"[""Adverse Events 1:"", ""  Total: 2/3 (66.67%)"", ""Adverse Events 2:"", ""  Total: 0/3 (0.00%)""]",Contradiction
"There were no cases of Oesophageal spasming, Diastolic dysfunction or thrombosis observed in NCT00201851.","[""Adverse Events 1:"", ""  Total: 0/244 (0.00%)"", ""  Pregnancy *0/244 (0.00%)"", ""  Endocervical cancer *0/244 (0.00%)"", ""  Nosocomial pneumonia *0/244 (0.00%)"", ""  Venous thrombosis *0/244 (0.00%)"", ""Adverse Events 2:"", ""  Total: 5/255 (1.96%)"", ""  Pregnancy *1/255 (0.39%)"", ""  Endocervical cancer *1/255 (0.39%)"", ""  Nosocomial pneumonia *2/255 (0.78%)"", ""  Venous thrombosis *1/255 (0.39%)""]",Contradiction
"There are several cardiac adverse events recorded in NCT00333775, but not a single one in NCT00201864.","[""Adverse Events 1:"", ""  Total: 82/217 (37.79%)"", ""  Febrile neutropenia 21/217 (9.68%)"", ""  Neutropenia 4/217 (1.84%)"", ""  Leukopenia 0/217 (0.00%)"", ""  Anaemia 1/217 (0.46%)"", ""  Thrombocytopenia 0/217 (0.00%)"", ""  Atrial fibrillation 0/217 (0.00%)"", ""  Arrhythmia 1/217 (0.46%)"", ""  Arteriospasm coronary 0/217 (0.00%)"", ""  Atrioventricular block first degree 0/217 (0.00%)"", ""  Cardiac failure 0/217 (0.00%)"", ""Adverse Events 2:"", ""  Total: 106/252 (42.06%)"", ""  Febrile neutropenia 29/252 (11.51%)"", ""  Neutropenia 13/252 (5.16%)"", ""  Leukopenia 3/252 (1.19%)"", ""  Anaemia 0/252 (0.00%)"", ""  Thrombocytopenia 1/252 (0.40%)"", ""  Atrial fibrillation 1/252 (0.40%)"", ""  Arrhythmia 0/252 (0.00%)"", ""  Arteriospasm coronary 1/252 (0.40%)"", ""  Atrioventricular block first degree 1/252 (0.40%)"", ""  Cardiac failure 1/252 (0.40%)""]",Entailment
"Patients with permanent sensory loss, interfering with daily activities are excluded from NCT00129389 and NCT00304096.","[""Exclusion Criteria:"", ""  Pre-existing grade >=2 motor or sensorial neurotoxicity by the National Cancer Institute Common Toxicity Criteria (NCICTC) v-2.0.""]",Contradiction
Patients in both NCT00688909 and NCT00129376 suffered from Pulmonary embolisms.,"[""Adverse Events 1:"", ""  Total: 5/261 (1.92%)"", ""  Cholecystitis chronic 1/261 (0.38%)"", ""  Post procedural bile leak 1/261 (0.38%)"", ""  Spinal column stenosis 1/261 (0.38%)"", ""  Depression 1/261 (0.38%)"", ""  Mania 1/261 (0.38%)"", ""  Pulmonary embolism 1/261 (0.38%)""]",Contradiction
"Patients with severe malabsorption disorders are ineligible for NCT01730729, unless they are able to receive intravenous (IV) alimentation.","[""  Patients with any of the following conditions or complications are NOT eligible for participation:"", ""  Require intravenous (IV) alimentation"", ""  Malabsorption syndrome""]",Contradiction
Patients cannot be excluded from NCT00836186 on the basis of gender or ethnicity.,"[""INCLUSION CRITERIA:"", ""  Women of all races and ethnic groups are eligible for this trial""]",Contradiction
"Patients with a platelet count of 50,0000 x 109/l are not eligible for NCT02429427","[""Inclusion Criteria:"", ""  Pre-treatment haematology and biochemistry values within acceptable local limits: Haemoglobin, white blood cell greater or equal to 3.0 x 109/l or absolute neutrophil count greater or equal to 1.51 x 109/l, Platelets greater or equal to 100 x 109/l, Serum bilirubin less than 1.5 x upper normal limit , Alkaline phosphatase less or equal to 1.5 x upper normal limit , Serum creatinine less than 1.5 x upper normal limit""]",Contradiction
"Potential participants will be considered regardless of the hormone receptivity of their breast cancer, except if they are overexpressing ERBB2.","[""  Will not exclude participants based on hormone receptivity, one exception is that we will exclude HER2 positive BCS""]",Entailment
Only patients which have been assigned as female at birth are eligible for NCT00129935 and NCT03136367.,"[""Inclusion Criteria:"", ""  Assigned female at birth;"", ""Exclusion Criteria:"", ""  Transgender men and women;""]",Entailment
"Abnormal LVEF, Pregnancy or lactating automatically eliminates patients from participating in NCT00404066, unless treated with herbal medicines.","[""  All herbal (alternative) medicines are prohibited."", ""  EXCLUSION CRITERIA"", ""  Congestive heart failure, abnormal left ventricular ejection fraction (LVEF), angina pectoris, uncontrolled cardiac arrhythmias, or other significant heart disease, or who have had a myocardial infarction within the past year."", ""  Pregnant or lactating""]",Contradiction
Patients with invasive breast cancer with a diameter of more than 70mm are included in NCT02321527.,"[""  Ipsilateral biopsy-proven invasive breast cancer <5 cm in maximal dimension by Ultrasound or Mammography.""]",Contradiction
NCT00365365 only recorded one type of acute adverse event.,"[""Adverse Events 1:"", ""  Total: 23/78 (29.49%)"", ""  Febrile neutropenia * 4/78 (5.13%)"", ""  Neutropenia * 1/78 (1.28%)"", ""  Thrombocytopenia * 0/78 (0.00%)"", ""  Acute coronary syndrome * 1/78 (1.28%)"", ""  Cardiac failure congestive * 1/78 (1.28%)"", ""  Myocardial infarction * 1/78 (1.28%)"", ""  Cardiomyopathy * 0/78 (0.00%)"", ""  Abdominal pain * 1/78 (1.28%)"", ""  Diarrhoea * 1/78 (1.28%)"", ""  Upper gastrointestinal haemorrhage * 1/78 (1.28%)""]",Entailment
"Males are not eligible for NCT00293540, because they do not produce oestrogen.","[""Inclusion Criteria:"", ""  Estrogen receptor or progesterone receptor positive breast cancer"", ""  Premenopausal with regular menstrual cycles"", ""Exclusion Criteria:"", ""  Current oral contraceptives""]",Contradiction
"Paula recently had a heart attack, she is excluded from NCT00494481.","[""Exclusion Criteria:"", ""  Previous radiotherapy within 6 weeks"", ""  Significant cardiac events, arrhythmias or other cardiac conditions""]",Entailment
Patients with Breast cancers that have estrogen receptors are included in NCT00635050.,"[""Inclusion Criteria:"", ""  Patients with node-negative, ER or PR-positive tumors 4 cm in size whose tumors are low risk (defined as a score of 0-17) on an Oncotype DX profile are not eligible.""]",Contradiction
The Median Overall Survival for cohort 1 patients was 44 days longer than for patients in cohort 2 of NCT00337103.,"[""Outcome Measurement: "", ""  Overall Survival (OS)"", ""  OS was measured from the date of randomization until the date of death from any cause, or the last date the participant was known to be alive. Participants who were lost to follow-up or who were alive at the date of data cutoff were censored. The censoring rules for OS were as follows: 1) if the participant was still alive at data cutoff, the date of data cutoff was considered the end date, and 2) if the participant was lost to follow-up before data cutoff, the date they were last known to be alive was considered the end date. Participants who survived past the end of the study were counted as in the full study period. If death occurred after data cutoff, the end date was to be censored at the time of data cutoff."", ""  Time frame: From date of randomization until date of death from any cause, assessed up to data cutoff date of 12 Mar 2012, or up to approximately 6 years"", ""Results 1: "", ""  Arm/Group Title: Eribulin Mesylate 1.4 mg/m^2"", ""  Arm/Group Description: Eribulin mesylate 1.4 mg/m^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days."", ""  Overall Number of Participants Analyzed: 554"", ""  Median (95% Confidence Interval)"", ""  Unit of Measure: days  484        (462 to 536)"", ""Results 2: "", ""  Arm/Group Title: Capecitabine 2.5 g/m^2/Day"", ""  Arm/Group Description: Capecitabine : Capecitabine 2.5 g/m^2/day administered orally twice daily in two equal doses on Days 1 to 14 every 21 days."", ""  Overall Number of Participants Analyzed: 548"", ""  Median (95% Confidence Interval)"", ""  Unit of Measure: days  440        (400 to 487)""]",Entailment
Joe has a known history of Hepatitis. However as he is over the age of 18 is still eligible for NCT01299038.,"[""Inclusion Criteria:"", ""  Metastatic adenocarcinoma of the breast (Stage IV)"", ""  Actively receiving endocrine therapy for at least 6 weeks (with or without HER2 therapy)"", ""  Minimum age 18 years"", ""  ECOG Performance status of 0, 1 or 2"", ""  Normal organ and marrow function as defined in the protocol"", ""Exclusion Criteria:"", ""  Participants may not be receiving any other study agents"", ""  Actively receiving chemotherapy (exclusive of hormonal or HER2 therapy ) within last 5 weeks"", ""  Any statin therapy within the last 3 weeks"", ""  Asian decent (including Filipino, Chinese, Japanese, Korean, Vietnamese or Asian-Indian origin)"", ""  Concomitant use of the following drugs: cyclosporine, fibrates, niacin, gemfibrozil, ketaconazole, spironolactone, cimetidine, warfarin, erythromycin, or protease inhibitors"", ""  Conditions predisposing to renal failure secondary to rhabdomyolysis"", ""  Recent history of heavy alcohol use as judged by the treating physician"", ""  Known to be pregnant (testing not required) or nursing"", ""  History of rhabdomyolysis on statin therapy"", ""  Known history of Hepatitis C or active hepatitis B infection (baseline testing not required)"", ""  Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, hepatitis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements""]",Contradiction
There were more cases of Cardiac failure than Pericardial effusion recorded in cohort 1.,"[""Adverse Events 1:"", ""  Total: 30/98 (30.61%)"", ""  Coagulopathy 1/98 (1.02%)"", ""  Febrile neutropenia 7/98 (7.14%)"", ""  Pancytopenia 2/98 (2.04%)"", ""  Cardiac failure 0/98 (0.00%)"", ""  Cardiac failure congestive 0/98 (0.00%)"", ""  Pericardial effusion 0/98 (0.00%)"", ""  Appendicitis perforated 1/98 (1.02%)"", ""  Colitis 1/98 (1.02%)"", ""  Ileus 1/98 (1.02%)"", ""  Abdominal pain upper 1/98 (1.02%)"", ""  Gastrointestinal haemorrhage 0/98 (0.00%)""]",Contradiction
1 patient in NCT00871858 was diagnosed with a Clear cell renal cell carcinoma.,"[""Adverse Events 1:"", ""  Total: 2/60 (3.33%)"", ""  Bronchial infection 0/60 (0.00%)"", ""  Ankle fracture 1/60 (1.67%)"", ""  Clear cell kidney cancer 0/60 (0.00%)"", ""  Programmed peritoneal dialysis 1/60 (1.67%)"", ""  Endometrial atrophy 0/60 (0.00%)"", ""Adverse Events 2:"", ""  Total: 3/58 (5.17%)"", ""  Bronchial infection 1/58 (1.72%)"", ""  Ankle fracture 0/58 (0.00%)"", ""  Clear cell kidney cancer 1/58 (1.72%)"", ""  Programmed peritoneal dialysis 0/58 (0.00%)"", ""  Endometrial atrophy 1/58 (1.72%)""]",Entailment
There were 7 more cases of Anaemia and 1 more case of Disseminated intravascular coagulation in cohort 1 of NCT00863655 compared to cohort 2.,"[""Adverse Events 1:"", ""  Total: 158/482 (32.78%)"", ""  Anaemia 7/482 (1.45%)"", ""  Disseminated intravascular coagulation 1/482 (0.21%)"", ""Adverse Events 2:"", ""  Total: 37/238 (15.55%)"", ""  Anaemia 2/238 (0.84%)"", ""  Disseminated intravascular coagulation 0/238 (0.00%)""]",Contradiction
A significantly higher proportion of patients in NCT00965523 suffured from infection compared to NCT01463007.,"[""Adverse Events 1:"", ""  Total: 1/41 (2.44%)"", ""  Infection  1/41 (2.44%)"", ""  Creatinine  1/41 (2.44%)"", ""  Hypokalemia  1/41 (2.44%)"", ""  Bicarbonate  1/41 (2.44%)"", ""  SGOT  1/41 (2.44%)"", ""  Alkaline Phosphatase value  1/41 (2.44%)"", ""  Hyperbilirubineamia  1/41 (2.44%)"", ""  Hypoalbuminemia  1/41 (2.44%)"", ""  Leukocytes  1/41 (2.44%)"", ""  Hemoglobin  1/41 (2.44%)"", ""  Neutrophils  1/41 (2.44%)"", ""  INR  1/41 (2.44%)"", ""  PTT  1/41 (2.44%)""]",Contradiction
"Throughout NCT01644890, one patient in cohort 1 developed issues with their vision.","[""Adverse Events 1:"", ""  Total: 34/214 (15.89%)"", ""  Leukocytosis 0/214 (0.00%)"", ""  Atrial fibrillation 0/214 (0.00%)"", ""  Cardiac failure congestive 0/214 (0.00%)"", ""  Pericardial effusion 1/214 (0.47%)"", ""  Cataract 0/214 (0.00%)"", ""  Macular fibrosis 0/214 (0.00%)"", ""  Constipation 2/214 (0.93%)"", ""  Diarrhoea 2/214 (0.93%)"", ""  Enterocolitis 0/214 (0.00%)"", ""  Ileus 1/214 (0.47%)"", ""  Nausea 3/214 (1.40%)"", ""Adverse Events 2:"", ""  Total: 27/213 (12.68%)"", ""  Leukocytosis 1/213 (0.47%)"", ""  Atrial fibrillation 1/213 (0.47%)"", ""  Cardiac failure congestive 1/213 (0.47%)"", ""  Pericardial effusion 0/213 (0.00%)"", ""  Cataract 1/213 (0.47%)"", ""  Macular fibrosis 1/213 (0.47%)"", ""  Constipation 1/213 (0.47%)"", ""  Diarrhoea 1/213 (0.47%)"", ""  Enterocolitis 1/213 (0.47%)"", ""  Ileus 0/213 (0.00%)"", ""  Nausea 0/213 (0.00%)""]",Contradiction
Less than a quarter of participants in NCT01365845 had radiation dermatitis.,"[""  Radiation dermatitis 2 [1]4/18 (22.22%)""]",Entailment
Patients with cancer in situ of the cervix are eligible for NCT00903162 and NCT01674062.,"[""Exclusion Criteria:"", ""  History of cancer other than breast cancer within 5 years excluding basal/squamous cell skin carcinoma in situ of the cervix""]",Entailment
Only 6 patients in cohort 1 of NCT00357110 had Varicose Veins.,"[""Adverse Events 1:"", ""  Varicose Vein 1/6 (16.67%)""]",Contradiction
NCT00593827 and NCT02425891 both measure PFS of their patient cohorts.,"[""Outcome Measurement: "", ""  Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) in All Randomized Participants"", ""  PFS was defined as the time from randomization to the occurrence of disease progression, as determined by investigators from tumor assessments per RECIST v1.1, or death from any cause, whichever occurred first."", ""  Time frame: Baseline up to approximately 34 months""]",Entailment
"NCT00645333 records several immune system related adverse events in its patients, whereas NCT00006110 does not.","[""  Autoimmune disorder *1/30 (3.33%)"", ""  Immune system disorder *1/30 (3.33%)""]",Entailment
NCT00322348 and NCT00429572 use different metrics to evaluate potential candidates' performance status.,"[""  World Health Organization (WHO) performance status of 0, 1, or 2""]",Entailment
There are no cases of agranulocytosis in NCT01419197.,"[""Adverse Events 1:"", ""  Granulocytopenia 0/403 (0.00%)""]",Entailment
"Patients with severe malabsorption disorders are ineligible for NCT01730729, even if they are able to receive intravenous (IV) alimentation.","[""  Patients with any of the following conditions or complications are NOT eligible for participation:"", ""  Require intravenous (IV) alimentation"", ""  Malabsorption syndrome""]",Entailment
"More than half of patients in NCT02445586 experienced adverse events, and 100% of patients in NCT02115984 did not experience an adverse event.","[""Adverse Events 1:"", ""  Total: 31/52 (59.62%)"", ""  Febrile neutropenia 2/52 (3.85%)"", ""  Left ventricular dysfunction 2/52 (3.85%)"", ""  Sinus tachycardia 1/52 (1.92%)"", ""  Congenital arterial malformation 1/52 (1.92%)"", ""  Diarrhoea 5/52 (9.62%)"", ""  Salivary hypersecretion 1/52 (1.92%)"", ""  Enteritis 1/52 (1.92%)"", ""  Abdominal pain 1/52 (1.92%)"", ""  Vomiting 1/52 (1.92%)"", ""  Stomatitis 1/52 (1.92%)"", ""  Haematemesis 1/52 (1.92%)""]",Contradiction
NCT00320541 recorded more cardiac related adverse events than NCT01629615.,"[""Adverse Events 1:"", ""  Total: 17/50 (34.00%)"", ""  Fatigue  4/50 (8.00%)"", ""  Papulopustular rash  1/50 (2.00%)"", ""  Alanine aminotransferase increased  5/50 (10.00%)"", ""  Aspartate aminotransferase increased  4/50 (8.00%)"", ""  Alkalosis  1/50 (2.00%)"", ""  Anorexia  1/50 (2.00%)"", ""  Hyperglycemia  2/50 (4.00%)"", ""  Nervous system disorders - Other  1/50 (2.00%)"", ""  Dry skin  1/50 (2.00%)"", ""  Rash acneiform  1/50 (2.00%)""]",Entailment
"sepsis, due to the presence of an implanted device was a common adverse event in NCT02187744","[""Adverse Events 1:"", ""  Device related sepsis 1/113 (0.88%)""]",Contradiction
A patient in NCT00206427 had a vaginal fungal infection.,"[""Adverse Events 1:"", ""  Total: 3/49 (6.12%)"", ""  Neutrophils/ANC *1/49 (2.04%)"", ""  Leukocytes *1/49 (2.04%)"", ""  Hypocalcemia *1/49 (2.04%)"", ""  Febrile neutropenia *1/49 (2.04%)"", ""  Left Ventricular Systolic Dysfunction *1/49 (2.04%)"", ""  Constipation *1/49 (2.04%)"", ""  Mucositis-oral *1/49 (2.04%)"", ""  Infection-oral thrush *1/49 (2.04%)"", ""  rash *1/49 (2.04%)""]",Contradiction
"19.57% of patients in NCT00093808 developed an eating disorder, there were no cases of this happening in NCT01310231.","[""Adverse Events 1:"", ""  Total: 3/22 (13.64%)"", ""  ascites with hyponatraemia 0/22 (0.00%)"", ""  febrile neutropenia with respiratory infection 1/22 (4.55%)"", ""  urosepsis 1/22 (4.55%)"", ""  febrile neutropenia with urinary tract infection 0/22 (0.00%)"", ""  dyspnoea 1/22 (4.55%)"", ""  hypoxia 0/22 (0.00%)"", ""  thromboembolism 0/22 (0.00%)"", ""Adverse Events 2:"", ""  Total: 4/17 (23.53%)"", ""  ascites with hyponatraemia 1/17 (5.88%)"", ""  febrile neutropenia with respiratory infection 0/17 (0.00%)"", ""  urosepsis 0/17 (0.00%)"", ""  febrile neutropenia with urinary tract infection 1/17 (5.88%)"", ""  dyspnoea 0/17 (0.00%)"", ""  hypoxia 1/17 (5.88%)"", ""  thromboembolism 1/17 (5.88%)""]",Contradiction
"A 75 year old female patient, with an ECOG of 3 and an estimated life expectancy of more than a year would be eligible for NCT00388726.","[""Inclusion Criteria:"", ""  Age >= 18 years."", ""  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2."", ""  Life expectancy of >= 3 months.""]",Contradiction
In total NCT00375427 recorded only 3 more cases of Pyrexia than NCT01008150.,"[""Adverse Events 1:"", ""  Total: 7/42 (16.67%)"", ""  Febrile neutropenia 1/42 (2.38%)"", ""  Left venrticular dysfunction 1/42 (2.38%)"", ""  Cardiac valve disease 1/42 (2.38%)"", ""  Diarrhoea 0/42 (0.00%)"", ""  Abdominal pain 1/42 (2.38%)"", ""  Colitis 0/42 (0.00%)"", ""  Nausea 0/42 (0.00%)"", ""  Vomiting 0/42 (0.00%)"", ""  Pyrexia 0/42 (0.00%)"", ""  Influenza like illness 1/42 (2.38%)"", ""  Oedema peripheral 1/42 (2.38%)"", ""  Fatigue 0/42 (0.00%)"", ""Adverse Events 2:"", ""  Total: 7/42 (16.67%)"", ""  Febrile neutropenia 0/42 (0.00%)"", ""  Left venrticular dysfunction 1/42 (2.38%)"", ""  Cardiac valve disease 0/42 (0.00%)"", ""  Diarrhoea 0/42 (0.00%)"", ""  Abdominal pain 0/42 (0.00%)"", ""  Colitis 0/42 (0.00%)"", ""  Nausea 0/42 (0.00%)"", ""  Vomiting 0/42 (0.00%)"", ""  Pyrexia 2/42 (4.76%)"", ""  Influenza like illness 0/42 (0.00%)"", ""  Oedema peripheral 0/42 (0.00%)"", ""  Fatigue 0/42 (0.00%)""]",Contradiction
"To be included in NCT00217399, patients must have at least 1 unidimensionally measurable lesion, and must meet some specific size conditions.","[""  Measurable disease, defined as >=1 unidimensionally measurable lesion, including >= 1 of the following:"", ""  Lesion >= 10 mm on CT scan (5 mm sections)"", ""  Lesion >= 20 mm on CT scan or MRI (10 mm sections)"", ""  Lesion >= 10 mm on physical exam""]",Entailment
The difference in cohort size between cohort 2 of NCT00917735 and cohort 2 of NCT02447003 makes it impossible to make meaningful comparisons.,"[""Adverse Events 2:"", ""  Total: 0/1 (0.00%)"", ""  Anaemia 0/1 (0.00%)"", ""  Febrile neutropenia 0/1 (0.00%)"", ""  Cardiac tamponade 0/1 (0.00%)"", ""  Myocarditis 0/1 (0.00%)"", ""  Pericardial effusion 0/1 (0.00%)"", ""  Pericarditis 0/1 (0.00%)"", ""  Colitis 0/1 (0.00%)"", ""  Constipation 0/1 (0.00%)"", ""  Diarrhoea 0/1 (0.00%)"", ""  Gastroenteritis eosinophilic 0/1 (0.00%)"", ""  Intestinal obstruction 0/1 (0.00%)"", ""  Nausea 0/1 (0.00%)""]",Entailment
There were no cases of cardiac tamponade in NCT00574587 or NCT00777049.,"[""Adverse Events 1:"", ""  Total: 0/3 (0.00%)"", ""  cardiac tamponade 0/3 (0.00%)"", ""  congestive heart failure 0/3 (0.00%)"", ""  pulmonary emobolism 0/3 (0.00%)"", ""Adverse Events 2:"", ""  Total: 2/23 (8.70%)"", ""  cardiac tamponade 0/23 (0.00%)"", ""  congestive heart failure 1/23 (4.35%)"", ""  pulmonary emobolism 1/23 (4.35%)""]",Entailment
Patients in NCT00201851 and those in NCT00679341 did not share any of the same adverse events.,"[""Adverse Events 1:"", ""  Total: 14/69 (20.29%)"", ""  Febrile neutropenia  0/69 (0.00%)"", ""  Anaemia  0/69 (0.00%)"", ""  Atrial fibrillation  1/69 (1.45%)"", ""  Cardiopulmonary failure  0/69 (0.00%)"", ""  Supraventricular extrasystoles  1/69 (1.45%)"", ""  Abdominal pain  1/69 (1.45%)"", ""  Intestinal obstruction  0/69 (0.00%)"", ""  Vomiting  1/69 (1.45%)"", ""  Chills  1/69 (1.45%)"", ""  Oedema peripheral  0/69 (0.00%)"", ""  Pyrexia  1/69 (1.45%)"", ""Adverse Events 2:"", ""  Total: 17/66 (25.76%)"", ""  Febrile neutropenia  6/66 (9.09%)"", ""  Anaemia  1/66 (1.52%)"", ""  Atrial fibrillation  1/66 (1.52%)"", ""  Cardiopulmonary failure  1/66 (1.52%)"", ""  Supraventricular extrasystoles  0/66 (0.00%)"", ""  Abdominal pain  0/66 (0.00%)"", ""  Intestinal obstruction  1/66 (1.52%)"", ""  Vomiting  0/66 (0.00%)"", ""  Chills  0/66 (0.00%)"", ""  Oedema peripheral  1/66 (1.52%)"", ""  Pyrexia  0/66 (0.00%)""]",Entailment
Gastrointestinal haemorrhage was more common in patients from cohort 1 of NCT00471276 than cohort 1 of NCT00951665.,"[""Adverse Events 1:"", ""  Total: 13/83 (15.66%)"", ""  Cardiac failure congestive 1/83 (1.20%)"", ""  Hypothyroidism 1/83 (1.20%)"", ""  Nausea 2/83 (2.41%)"", ""  Vomiting 2/83 (2.41%)"", ""  Diarrhea 1/83 (1.20%)"", ""  Gastrointestinal Haemorrhage 1/83 (1.20%)"", ""  Asthenia 1/83 (1.20%)"", ""  Hyperbilirubinaemia 1/83 (1.20%)"", ""  Anal abscess 1/83 (1.20%)"", ""  Dehydration 3/83 (3.61%)"", ""  Decreased appetite 1/83 (1.20%)""]",Entailment
One patient in cohort 2 of NCT00917735 died in a motorcycle crash.,"[""Adverse Events 2:"", ""  Total: 8/537 (1.49%)"", ""  Hypertension 1/537 (0.19%)"", ""  Acoustic Neuroma 0/537 (0.00%)"", ""  Diarrhea 1/537 (0.19%)"", ""  Colitis 0/537 (0.00%)"", ""  Elevated ALT or AST enzyme 0/537 (0.00%)"", ""  Diagnosis of Uterine Cancer 2/537 (0.37%)"", ""  Motorcycle accident 1/537 (0.19%)"", ""  Fall 1/537 (0.19%)"", ""  Surgery 2/537 (0.37%)""]",Contradiction
"One patient in NCT03012477 experienced a thromboembolic event, a condition associated with a high degree of morbidity and mortality. However, the most common adverse event was Diarrhea.","[""Adverse Events 1:"", ""  Total: 13/34 (38.24%)"", ""  Anemia 3/34 (8.82%)"", ""  Diarrhea 7/34 (20.59%)"", ""  Nausea 2/34 (5.88%)"", ""  Sepsis 1/34 (2.94%)"", ""  Urinary tract infection 1/34 (2.94%)"", ""  Alkaline phosphatase increased 1/34 (2.94%)"", ""  Neutrophil count decreased 2/34 (5.88%)"", ""  Dehydration 1/34 (2.94%)"", ""  Headache 1/34 (2.94%)"", ""  Thromboembolic event 1/34 (2.94%)""]",Entailment
More than a quarter of patients in cohort 1 of NCT02574455 experienced an adverse event.,"[""Adverse Events 1:"", ""  Total: 69/258 (26.74%)""]",Entailment
"There was 1 case of night blindness in NCT00066573, and 0 in NCT01091454.","[""Adverse Events 1:"", ""  Total: 19/3761 (0.51%)"", ""  Cardiac ischemia/infarction 3/3761 (0.08%)"", ""  Left ventricular systolic dysfunction 1/3761 (0.03%)"", ""  Restrictive cardiomyopathy 1/3761 (0.03%)"", ""  Supraven.arrhyth. Atrial flutter 1/3761 (0.03%)"", ""  Ventric.arrhyth. Trigeminy 1/3761 (0.03%)"", ""  Hypothyroidism 0/3761 (0.00%)"", ""  Blurred vision 1/3761 (0.03%)"", ""  Nyctalopia 0/3761 (0.00%)"", ""  Ocular - Other 1/3761 (0.03%)"", ""Adverse Events 2:"", ""  Total: 7/3759 (0.19%)"", ""  Cardiac ischemia/infarction 0/3759 (0.00%)"", ""  Left ventricular systolic dysfunction 0/3759 (0.00%)"", ""  Restrictive cardiomyopathy 0/3759 (0.00%)"", ""  Supraven.arrhyth. Atrial flutter 0/3759 (0.00%)"", ""  Ventric.arrhyth. Trigeminy 0/3759 (0.00%)"", ""  Hypothyroidism 1/3759 (0.03%)"", ""  Blurred vision 0/3759 (0.00%)"", ""  Nyctalopia 1/3759 (0.03%)"", ""  Ocular - Other 0/3759 (0.00%)""]",Entailment
Patients currently prescribed laxatives are not excluded from NCT01351376.,"[""Exclusion Criteria:"", ""  medication(s) known to affect body fluid balance""]",Contradiction
"In NCT00410813, Dasatinib, 70 mg, Twice Daily results in a better median PFS than Dasatinib, 100 mg, Daily. The opposite was true in NCT00617539.","[""Outcome Measurement: "", ""  Progression-free Survival"", ""  RECIST progression defined as 20% increase in the sum of longest diameters of target measurable lesions over the smallest sum observed, unequivocal progression of non-measurable disease, the appearance of any new lesion/site, death due to disease without prior documentation of progression and without symptomatic deterioration, development of one or more new bone lesions from baseline, or symptomatic deterioration related to disease progression. Time from date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause. Patients last known to be alive and progression-free are censored at last date of contact."", ""  Time frame: Up to 2 years"", ""Results 1: "", ""  Arm/Group Title: Dasatinib, 100 mg, Daily"", ""  Arm/Group Description: Dasatinib, 100 mg PO daily until progression of disease"", ""  Overall Number of Participants Analyzed: 41"", ""  Median (95% Confidence Interval)"", ""  Unit of Measure: weeks  10.3        (8.4 to 16.7)"", ""Results 2: "", ""  Arm/Group Title: Dasatinib, 70 mg, Twice Daily"", ""  Arm/Group Description: Dasatinib, 70 mg PO twice daily until progression of disease"", ""  Overall Number of Participants Analyzed: 38"", ""  Median (95% Confidence Interval)"", ""  Unit of Measure: weeks  15.3        (8.7 to 20.1)""]",Contradiction
There were no patients with paranasal sinus reactions in NCT00545688.,"[""Adverse Events 1:"", ""  Total: 21/107 (19.63%)"", ""  Febrile neutropenia * 10/107 (9.35%)"", ""  Neutropenia * 1/107 (0.93%)"", ""  Left ventricular dysfunction * 0/107 (0.00%)"", ""  Angina pectoris * 0/107 (0.00%)"", ""  Cardiac failure congestive * 0/107 (0.00%)"", ""  Diarrhoea * 2/107 (1.87%)"", ""  Abdominal strangulated hernia * 0/107 (0.00%)"", ""  Duodenal ulcer haemorrhage * 0/107 (0.00%)"", ""  Pyrexia * 1/107 (0.93%)"", ""Adverse Events 2:"", ""  Total: 22/107 (20.56%)"", ""  Febrile neutropenia * 8/107 (7.48%)"", ""  Neutropenia * 6/107 (5.61%)"", ""  Left ventricular dysfunction * 3/107 (2.80%)"", ""  Angina pectoris * 1/107 (0.93%)"", ""  Cardiac failure congestive * 0/107 (0.00%)"", ""  Diarrhoea * 0/107 (0.00%)"", ""  Abdominal strangulated hernia * 1/107 (0.93%)"", ""  Duodenal ulcer haemorrhage * 0/107 (0.00%)"", ""  Pyrexia * 1/107 (0.93%)""]",Entailment
NCT00281697 does not record any pain related adverse events.,"[""Adverse Events 1:"", ""  Total: 112/458 (24.45%)"", ""  Febrile neutropenia 8/458 (1.75%)"", ""  Neutropenia 6/458 (1.31%)"", ""  Anaemia 3/458 (0.66%)"", ""  Thrombocytopenia 3/458 (0.66%)"", ""  Pancytopenia 2/458 (0.44%)"", ""  Myocardial infarction 0/458 (0.00%)"", ""  Pericardial effusion 0/458 (0.00%)"", ""  Tachycardia 0/458 (0.00%)"", ""  Acute myocardial infarction 1/458 (0.22%)"", ""  Atrial fibrillation 0/458 (0.00%)"", ""Adverse Events 2:"", ""  Total: 39/221 (17.65%)"", ""  Febrile neutropenia 5/221 (2.26%)"", ""  Neutropenia 1/221 (0.45%)"", ""  Anaemia 2/221 (0.90%)"", ""  Thrombocytopenia 0/221 (0.00%)"", ""  Pancytopenia 0/221 (0.00%)"", ""  Myocardial infarction 2/221 (0.90%)"", ""  Pericardial effusion 2/221 (0.90%)"", ""  Tachycardia 2/221 (0.90%)"", ""  Acute myocardial infarction 0/221 (0.00%)"", ""  Atrial fibrillation 1/221 (0.45%)""]",Entailment
The only adverse event recorded in NCT01033032 was one single case of spinal fracture.,"[""Adverse Events 1:"", ""  Total: 1/3 (33.33%)"", ""  FEBRILE NEUTROPENIA 0/3 (0.00%)"", ""  LYMPH NODE PAIN 0/3 (0.00%)"", ""  NEUTROPHIL COUNT DECREASED 0/3 (0.00%)"", ""  THROMBOCYTOPENIA 0/3 (0.00%)"", ""  CHEST PAIN 0/3 (0.00%)"", ""  DEHYDRATION 0/3 (0.00%)"", ""  PLEURAL EFFUSION 1/3 (33.33%)"", ""  PNEUMONITIS 0/3 (0.00%)"", ""  PULMONARY INFILTERATES 0/3 (0.00%)"", ""  ALOPECIA 0/3 (0.00%)""]",Contradiction
"NCT01466972 recorded one patient with congestive Cardiac failure, NCT01446159 recorded more.","[""Adverse Events 1:"", ""  Heart Failure 1/30 (3.33%)""]",Contradiction
All of the adverse events recorded in NCT00432172 were cardiac related.,"[""Adverse Events 1:"", ""  Total: 5/45 (11.11%)"", ""  Neutrophils/granulocytes (ANC/AGC) *  [1]0/45 (0.00%)"", ""  Neutrophils/granulocytes (ANC/AGC) *  [2]0/45 (0.00%)"", ""  Diabetes decompensation * 0/45 (0.00%)"", ""  Diarrhea *  [2]0/45 (0.00%)"", ""  Mucositis/stomatitis and Vomiting *  [3]0/45 (0.00%)"", ""  Pancreatitis *  [4]1/45 (2.22%)"", ""  Febrile neutropenia *  [2]3/45 (6.67%)"", ""Adverse Events 2:"", ""  Total: 0/46 (0.00%)"", ""  Neutrophils/granulocytes (ANC/AGC) *  [1]0/46 (0.00%)"", ""  Neutrophils/granulocytes (ANC/AGC) *  [2]0/46 (0.00%)"", ""  Diabetes decompensation * 0/46 (0.00%)"", ""  Diarrhea *  [2]0/46 (0.00%)"", ""  Mucositis/stomatitis and Vomiting *  [3]0/46 (0.00%)"", ""  Pancreatitis *  [4]0/46 (0.00%)"", ""  Febrile neutropenia *  [2]0/46 (0.00%)"", ""  Infection pulmonary/ Upper airway NOS *  [5]0/46 (0.00%)""]",Contradiction
"At least 1 patient in cohort 1 of NCT01120184 suffered from a Hemophilia, a rare coagulation disorder.","[""Adverse Events 1:"", ""  Total: 81/353 (22.95%)"", ""  Febrile neutropenia * 13/353 (3.68%)"", ""  Anaemia * 21/353 (0.28%)"", ""  Neutropenia * 25/353 (1.42%)"", ""  Thrombocytopenia * 20/353 (0.00%)"", ""  Hypercoagulation * 21/353 (0.28%)"", ""  Leukopenia * 21/353 (0.28%)"", ""  Atrial fibrillation * 1/353 (0.28%)"", ""  Cardiac failure * 0/353 (0.00%)"", ""  Cardiac failure congestive * 0/353 (0.00%)"", ""  Myocardial infarction * 1/353 (0.28%)""]",Contradiction
Twice as many patients in cohort 1 of NCT02273973 suffered from Erysipelas than Bacterial diarrhoea.,"[""Adverse Events 1:"", ""  Erysipelas 2/167 (1.20%)"", ""  Bacterial diarrhoea 1/167 (0.60%)""]",Entailment
In NCT00454805 there were more cases of Intestinal Obstruction in cohort 1 than in cohort 2.,"[""Adverse Events 1:"", ""  Small Intestinal Obstruction 1/31 (3.23%)"", ""Adverse Events 2:"", ""  Small Intestinal Obstruction 0/31 (0.00%)""]",Contradiction
There was only one patient cohort in NCT00005908.,"[""Adverse Events 1:"", ""  Total: 29/30 (96.67%)"", ""  Febrile neutropenia  [1]3/30 (10.00%)"", ""  Lymphatics 1/30 (3.33%)"", ""  Diarrhea (without colostomy) 5/30 (16.67%)"", ""  Abdominal pain or cramping 2/30 (6.67%)"", ""  Colitis 1/30 (3.33%)"", ""  Dehydration 1/30 (3.33%)"", ""  Nausea 1/30 (3.33%)"", ""  Stomatitis/pharyngitis (oral/pharyngeal/mucositis) 1/30 (3.33%)"", ""  Vomiting 1/30 (3.33%)"", ""Adverse Events 2:""]",Entailment
None of the patients in NCT00191815 or NCT01301729 committed suicide.,"[""Adverse Events 1:"", ""  Total: 6"", ""  Atrial fibrillation 1/67 (1.49%)"", ""  Ventricular fibrillation 1/67 (1.49%)"", ""  Gastrointestinal perforation 1/67 (1.49%)"", ""  Periproctitis 1/67 (1.49%)"", ""  General physical health deterioration 1/67 (1.49%)"", ""  Escherichia sepsis 1/67 (1.49%)"", ""  Pneumonia 1/67 (1.49%)"", ""  Tumour pain 1/67 (1.49%)"", ""  Renal failure acute 1/67 (1.49%)"", ""  Pleurisy 1/67 (1.49%)""]",Contradiction
Cohort 1 and 2 of NCT00148668 recorded the same number of patients with Febrile Neutropenia.,"[""Adverse Events 1:"", ""  Total: 5/41 (12.20%)"", ""  Neutropenia  4/41 (9.76%)"", ""  Febrile Neutropenia  0/41 (0.00%)"", ""  SGPT (ALT)  1/41 (2.44%)"", ""Adverse Events 2:"", ""  Total: 5/40 (12.50%)"", ""  Neutropenia  4/40 (10.00%)"", ""  Febrile Neutropenia  1/40 (2.50%)"", ""  SGPT (ALT)  0/40 (0.00%)""]",Contradiction
In NCT00191789 there was 1 case of jaundice.,"[""Adverse Events 1:"", ""  Jaundice 1/65 (1.54%)""]",Entailment
Over 9 patients in NCT01421472 suffered from adverse events associated with a low number of white blood cells present in the bloodstream.,"[""Adverse Events 1:"", ""  Febrile Neutropenia * 5/67 (7.46%)""]",Contradiction
Only patients capable of understanding english are eligible for NCT01042938.,"[""Inclusion Criteria:"", ""  Participants must be able to understand English and able to complete assessment forms (all assessment forms are in English).""]",Entailment
Cohort 1 of NCT01572727 recorded more optical adversse events than cohort 2.,"[""Adverse Events 1:"", ""  Total: 61/202 (30.20%)"", ""  FEBRILE NEUTROPENIA 1/202 (0.50%)"", ""  LEUKOPENIA 0/202 (0.00%)"", ""  NEUTROPENIA 2/202 (0.99%)"", ""  CARDIAC FAILURE CONGESTIVE 0/202 (0.00%)"", ""  CARDIO-RESPIRATORY ARREST 1/202 (0.50%)"", ""  PERICARDIAL EFFUSION 1/202 (0.50%)"", ""  CATARACT 1/202 (0.50%)"", ""  OPTIC NEUROPATHY 0/202 (0.00%)"", ""  ABDOMINAL PAIN 0/202 (0.00%)"", ""  CONSTIPATION 0/202 (0.00%)"", ""  DIARRHOEA 5/202 (2.48%)"", ""Adverse Events 2:"", ""  Total: 42/201 (20.90%)"", ""  FEBRILE NEUTROPENIA 0/201 (0.00%)"", ""  LEUKOPENIA 1/201 (0.50%)"", ""  NEUTROPENIA 0/201 (0.00%)"", ""  CARDIAC FAILURE CONGESTIVE 1/201 (0.50%)"", ""  CARDIO-RESPIRATORY ARREST 0/201 (0.00%)"", ""  PERICARDIAL EFFUSION 0/201 (0.00%)"", ""  CATARACT 1/201 (0.50%)"", ""  OPTIC NEUROPATHY 1/201 (0.50%)"", ""  ABDOMINAL PAIN 1/201 (0.50%)"", ""  CONSTIPATION 1/201 (0.50%)"", ""  DIARRHOEA 3/201 (1.49%)""]",Contradiction
In cohort 2 and 3 of NCT00191789 there was only case 1 of jaundice.,"[""Adverse Events 1:"", ""  Total: 17/65 (26.15%)"", ""  Febrile neutropenia 3/65 (4.62%)"", ""  Neutropenia 2/65 (3.08%)"", ""  Pancytopenia 1/65 (1.54%)"", ""  Thrombocytopenia 1/65 (1.54%)"", ""  Cardiac arrest 2/65 (3.08%)"", ""  Myocardial infarction 1/65 (1.54%)"", ""  Diarrhoea 5/65 (7.69%)"", ""  Stomatitis 1/65 (1.54%)"", ""  Vomiting 2/65 (3.08%)"", ""  Fatigue 1/65 (1.54%)"", ""  Jaundice 1/65 (1.54%)"", ""  Neutropenic infection 2/65 (3.08%)""]",Contradiction
"Sharone had a hip replacement 3 weeks prior, she is not elgible for NCT03045653.","[""Exclusion Criteria:"", ""  Major surgery (excluding placement of vascular access) within 4 weeks before study treatment Evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, or active infection including hepatitis B, hepatitis C and HIV With the exception of alopecia, any unresolved toxicities from previous therapy greater than CTCAE grade 1 before study treatment Elevated ALP in absence of bone metastasis Evidence of dementia, altered mental status or any psychiatric condition that would prohibit understanding or rendering of informed consent Participation in another study with investigational product during last 30 days Inability or unwillingness to comply with study procedures, including inability to take regular oral medication""]",Entailment
There was over 10% more cases of adverse events in cohort 2 than in cohort 1 of NCT01560416.,"[""Adverse Events 1:"", ""  Total: 2/15 (13.33%)"", ""Adverse Events 2:"", ""  Total: 11/35 (31.43%)""]",Entailment
"NCT00127933 recorded at least one patient with an infection, whereas in NCT00191789 none where observed.","[""  Catheter site cellulitis 1/122 (0.82%)"", ""  Catheter site cellulitis 0/34 (0.00%)""]",Contradiction
"Patients with HER2 positive breast tumors are eligible for NCT00372424, but excluded from NCT00041067.","[""Inclusion Criteria:"", ""  Breast cancer with evidence of unresectable, locally recurrent, or metastatic disease."", ""  Tumors over-expressing Her-2"", ""  Candidate for treatment with docetaxel/trastuzumab""]",Contradiction
Patients with clinically significant grade 3 PVD are eligible for NCT00364611.,"[""  Presence of any non-healing wound, fracture, or ulcer, or the presence of clinically significant (>/= Grade 2) peripheral vascular disease""]",Contradiction
Only White and Asian patients are eligible for both NCT02673918 and NCT01042938.,"[""Inclusion Criteria:"", ""  Diagnosis of breast cancer"", ""  Part 1 only: Surgery for breast cancer within the past eight weeks (mastectomy or lumpectomy with either sentinel or axillar dissection), including those women with a history of previous surgery for breast cancer, radiation therapy or chemotherapy"", ""  Part 2 only: Completion of surgery and radiation therapy for breast cancer within the past six weeks."", ""  Home access to internet from stationary computer, lab top or tablet"", ""  Ability to use internet"", ""  Ability to read and understand Danish"", ""Exclusion Criteria:"", ""  Surgery for breast cancer with immediate breast reconstruction"", ""  Diagnosis of primary lymphedema"", ""  Metastatic or inflammatory breast cancer"", ""  Planned use of chemotherapy within the next 6 weeks"", ""  Surgical complications: infection, drainage issues, seroma, hematoma"", ""  Severe physical, cognitive, or psychiatric illness causing inability to follow the study protocol: i.e. severe depression, anxiety, dementia, poor physical health with likely possibility of hospitalization within the next twelve weeks."", ""  Planned hospitalization or surgery within the next twelve weeks"", ""  Participation in another clinical trial with a rehabilitation or exercise intervention""]",Contradiction
NCT00281697 does not record any cardiac related adverse events.,"[""Adverse Events 1:"", ""  Total: 112/458 (24.45%)"", ""  Febrile neutropenia 8/458 (1.75%)"", ""  Neutropenia 6/458 (1.31%)"", ""  Anaemia 3/458 (0.66%)"", ""  Thrombocytopenia 3/458 (0.66%)"", ""  Pancytopenia 2/458 (0.44%)"", ""  Myocardial infarction 0/458 (0.00%)"", ""  Pericardial effusion 0/458 (0.00%)"", ""  Tachycardia 0/458 (0.00%)"", ""  Acute myocardial infarction 1/458 (0.22%)"", ""  Atrial fibrillation 0/458 (0.00%)"", ""Adverse Events 2:"", ""  Total: 39/221 (17.65%)"", ""  Febrile neutropenia 5/221 (2.26%)"", ""  Neutropenia 1/221 (0.45%)"", ""  Anaemia 2/221 (0.90%)"", ""  Thrombocytopenia 0/221 (0.00%)"", ""  Pancytopenia 0/221 (0.00%)"", ""  Myocardial infarction 2/221 (0.90%)"", ""  Pericardial effusion 2/221 (0.90%)"", ""  Tachycardia 2/221 (0.90%)"", ""  Acute myocardial infarction 0/221 (0.00%)"", ""  Atrial fibrillation 1/221 (0.45%)""]",Contradiction
There were no cases of Myocardial ischaemia in NCT00574587 or NCT00777049.,"[""Adverse Events 1:"", ""  Total: 0/3 (0.00%)"", ""  cardiac tamponade 0/3 (0.00%)"", ""  congestive heart failure 0/3 (0.00%)"", ""  pulmonary emobolism 0/3 (0.00%)"", ""Adverse Events 2:"", ""  Total: 2/23 (8.70%)"", ""  cardiac tamponade 0/23 (0.00%)"", ""  congestive heart failure 1/23 (4.35%)"", ""  pulmonary emobolism 1/23 (4.35%)""]",Contradiction
Less than 0.25% of patients in cohort 1 of NCT00130533 suffered from Hyperbilirrubinemia.,"[""Adverse Events 1:"", ""  Hyperbilirrubinemia  [1]1/436 (0.23%)""]",Entailment
There was 1 MRSA infection in cohort 1 of NCT01201265 and 4 in cohort 2 of NCT00493649.,"[""Adverse Events 1:"", ""  Total: 51/486 (10.49%)"", ""  ANEMIA 1/486 (0.21%)"", ""  NEUTROPENIA 4/486 (0.82%)"", ""  FIBRILLATION ATRIAL 1/486 (0.21%)"", ""  ABDOMINAL PAIN 2/486 (0.41%)"", ""  BLOATING 1/486 (0.21%)"", ""  BOWEL PERFORATION 1/486 (0.21%)"", ""  COLITIS 1/486 (0.21%)"", ""  DEHYDRATION 5/486 (1.03%)"", ""  DIARRHEA 5/486 (1.03%)"", ""  GASTRIC INFLAMMATION 1/486 (0.21%)"", ""  NAUSEA 3/486 (0.62%)"", ""  NAUSEA AND VOMITING 1/486 (0.21%)""]",Contradiction
A patient in cohort 2 of NCT00024102 received a Packed red blood cell transfusion.,"[""Adverse Events 2:"", ""  Transfusion: pRBCs 1/181 (0.55%)""]",Entailment
There were at least 15 patients with Dysphagia or Fever between the NCT01596751 and NCT00193050 patient cohorts.,"[""  Dysphagia 0/5 (0.00%)"", ""  Fever 0/5 (0.00%)""]",Contradiction
Cohort 1 of NCT00493636 had a longer PFS than cohort 2. However the patient with the longest PFS was in cohort 2.,"[""Outcome Measurement: "", ""  Progression Free Survival"", ""  [Not Specified]"", ""  Time frame: From the date of randomization to date of first documented disease progression (i.e., the date on which a radiologic procedure or clinical evaluation was performed) or the date of death due to any cause, if before progression, assessed up to 39 months."", ""Results 1: "", ""  Arm/Group Title: A (Sorafenib + Gemcitabine or Capecitabine)"", ""  Arm/Group Description: Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours); Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle; Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine)"", ""  Gemcitabine: Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle"", ""  Sorafenib: Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours)"", ""  Capecitabine: Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine)."", ""  Overall Number of Participants Analyzed: 81"", ""  Median (95% Confidence Interval)"", ""  Unit of Measure: Days  103        (83 to 128)"", ""Results 2: "", ""  Arm/Group Title: B (Placebo + Gemcitabine or Capecitabine)"", ""  Arm/Group Description: Placebo will be administered ( 2 tablets ) orally twice daily (approximately every 12 hours); Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle; Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine)"", ""  Gemcitabine: Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle"", ""  Placebo: Placebo will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours)"", ""  Capecitabine: Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine)."", ""  Overall Number of Participants Analyzed: 79"", ""  Median (95% Confidence Interval)"", ""  Unit of Measure: Days  81        (48 to 95)""]",Contradiction
A female patient over the age of 18 suffering from chronic viral hepatitis would be eligible for NCT00193180.,"[""Inclusion Criteria:"", ""  Age 18 years or older"", ""Exclusion Criteria:"", ""  Known chronic liver disease""]",Contradiction
None of the adverse events recorded for NCT00846027 occurred less than twice.,"[""Adverse Events 1:"", ""  Total: 21/82 (25.61%)"", ""  Neutrophils count decreased 1/82 (1.22%)"", ""  Cardiac ischemia/infarction 1/82 (1.22%)"", ""  Left ventricular systolic dysfunction 1/82 (1.22%)"", ""  Hypertension 1/82 (1.22%)"", ""  Supraventricular and nodal arrhythmia 1/82 (1.22%)"", ""  Anorexia 1/82 (1.22%)"", ""  Gastrointestinal perforation 1/82 (1.22%)"", ""  Vomiting 1/82 (1.22%)"", ""  Dehydration 1/82 (1.22%)"", ""  Diarrhoea 1/82 (1.22%)""]",Contradiction
NCT01989676 only records GI adverse events.,"[""Adverse Events 1:"", ""  Total: 67/349 (19.20%)"", ""  Anaemia * 3/349 (0.86%)"", ""  Leukopenia * 1/349 (0.29%)"", ""  Neutropenia * 3/349 (0.86%)"", ""  Thrombocytopenia * 1/349 (0.29%)"", ""  Atrial fibrillation * 2/349 (0.57%)"", ""  Cardiac arrest * 1/349 (0.29%)"", ""  Cardiac failure * 0/349 (0.00%)"", ""  Cardiac failure acute * 0/349 (0.00%)"", ""  Cardio-respiratory arrest * 2/349 (0.57%)"", ""  Cardiovascular insufficiency * 0/349 (0.00%)""]",Contradiction
"Any patients with histologically confirmed stage 4 adenocarcinoma HER2/neu immunohistochemistry 3+, ECOG performance status <2 and a Negative HCG pregnancy test are eligible for NCT01827163.","[""Exclusion Criteria:"", ""  Patients with stage IV breast cancer or undergoing chemotherapy, radiation therapy, immunotherapy, or biotherapy for current breast cancer.""]",Contradiction
"Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for NCT00089479 but not NCT02964234.","[""Inclusion Criteria:"", ""  female patients 18-70 years of age;""]",Entailment
Cohort 1 of NCT01416389 had more cases of Hepatic encephalopathy and Pneumonia than cohort 2.,"[""Adverse Events 1:"", ""  Total: 5/26 (19.23%)"", ""  Febrile neutropenia 1/26 (3.85%)"", ""  Abdominal pain 0/26 (0.00%)"", ""  Constipation 0/26 (0.00%)"", ""  Nausea 1/26 (3.85%)"", ""  Pancreatitis 1/26 (3.85%)"", ""  Vomiting 2/26 (7.69%)"", ""  Pain 0/26 (0.00%)"", ""  Pneumonia 0/26 (0.00%)"", ""  Urinary tract infection 1/26 (3.85%)"", ""  Lumbar vertebral fracture 1/26 (3.85%)"", ""  Ammonia increased 1/26 (3.85%)"", ""  Hepatic encephalopathy 1/26 (3.85%)"", ""Adverse Events 2:"", ""  Total: 4/13 (30.77%)"", ""  Febrile neutropenia 1/13 (7.69%)"", ""  Abdominal pain 1/13 (7.69%)"", ""  Constipation 1/13 (7.69%)"", ""  Nausea 0/13 (0.00%)"", ""  Pancreatitis 0/13 (0.00%)"", ""  Vomiting 0/13 (0.00%)"", ""  Pain 1/13 (7.69%)"", ""  Pneumonia 1/13 (7.69%)"", ""  Urinary tract infection 0/13 (0.00%)"", ""  Lumbar vertebral fracture 0/13 (0.00%)"", ""  Ammonia increased 0/13 (0.00%)"", ""  Hepatic encephalopathy 0/13 (0.00%)""]",Contradiction
There was one genitourinary adverse events recorded in NCT00290758.,"[""Adverse Events 1:"", ""  Total: 6/62 (9.68%)"", ""  Musculoskeletal * 1/62 (1.61%)"", ""  Mood Alteration: Depression * 1/62 (1.61%)"", ""  renal - Other * 1/62 (1.61%)"", ""  Obstruction, GU: Uterus * 1/62 (1.61%)"", ""  Sexual * 0/62 (0.00%)"", ""  Pulmonary/Upper Respiratory: Dyspnea * 1/62 (1.61%)"", ""  Ulceration * 1/62 (1.61%)"", ""Adverse Events 2:"", ""  Total: 1/64 (1.56%)"", ""  Musculoskeletal * 0/64 (0.00%)"", ""  Mood Alteration: Depression * 0/64 (0.00%)"", ""  renal - Other * 0/64 (0.00%)"", ""  Obstruction, GU: Uterus * 0/64 (0.00%)"", ""  Sexual * 1/64 (1.56%)"", ""  Pulmonary/Upper Respiratory: Dyspnea * 0/64 (0.00%)"", ""  Ulceration * 0/64 (0.00%)""]",Entailment
1 patient in NCT00546104 suffered from a blood clot blocking their trachea.,"[""Adverse Events 1:"", ""  Total: 10/31 (32.26%)"", ""  Edema, limb 1/31 (3.23%)"", ""  Thrombosis1/31 (3.23%)"", ""  diarrhea1/31 (3.23%)"", ""  Pain 2/31 (6.45%)"", ""  Pain, back1/31 (3.23%)"", ""  Pain, extrimity limb 1/31 (3.23%)"", ""  Syncope 1/31 (3.23%)"", ""  Pain, chest/thorax1/31 (3.23%)"", ""  hyponatremia 1/31 (3.23%)"", ""  fever1/31 (3.23%)"", ""  AST 1/31 (3.23%)"", ""  infection1/31 (3.23%)"", ""  Anorexia 1/31 (3.23%)"", ""  Dyspnea 2/31 (6.45%)""]",Contradiction
Certain drinks are banned for patients undertaking NCT00895414.,"[""Inclusion Criteria:"", ""  Agrees not to consume grapefruit juice while on the study""]",Entailment
"The most common adverse event in NCT01256567 was Febrile neutropenia (14.29%), whereas in NCT01926886 it was a decrease in Ejection fraction (4.95%).","[""Adverse Events 1:"", ""  Total: 7/7 (100.00%)"", ""  Febrile neutropenia 3/7 (42.86%)"", ""  Cardiac failure 1/7 (14.29%)"", ""  Neutrophil count decreased 1/7 (14.29%)"", ""  Muscular weakness 1/7 (14.29%)"", ""  Epistaxis 1/7 (14.29%)"", ""  Interstitial lung disease 1/7 (14.29%)"", ""  Pleural effusion 2/7 (28.57%)""]",Contradiction
There was a dental adverse event in NCT00717405.,"[""Adverse Events 1:"", ""  Total: 20/52 (38.46%)"", ""  Febrile bone marrow aplasia * 5/52 (9.62%)"", ""  Febrile neutropenia * 6/52 (11.54%)"", ""  Leukopenia * 6/52 (11.54%)"", ""  Atrial tachycardia * 1/52 (1.92%)"", ""  Vomiting * 1/52 (1.92%)"", ""  Tooth loss * 1/52 (1.92%)"", ""  Hyperthermia * 1/52 (1.92%)"", ""  Malaise * 1/52 (1.92%)"", ""  Pyrexia * 1/52 (1.92%)"", ""  Impaired healing * 3/52 (5.77%)"", ""  Inflammation * 1/52 (1.92%)""]",Entailment
Mark suffered Refractory ventricular fibrillation twice in the last month he is therefore excluded from NCT02732119.,"[""Exclusion Criteria:"", ""  Clinically significant, uncontrolled heart disease and/or recent cardiac events.""]",Entailment
Cohort 2 of NCT00320541 recorded three times as many cases of Leukopenia as cohort 1.,"[""Adverse Events 1:"", ""  Leukopenia 1/94 (1.06%)"", ""Adverse Events 2:"", ""  Leukopenia 3/93 (3.23%)""]",Entailment
"There were 4 different adverse events, for which 0 cases were recorded in cohort 1.","[""Adverse Events 1:"", ""  Total: 30/98 (30.61%)"", ""  Coagulopathy 1/98 (1.02%)"", ""  Febrile neutropenia 7/98 (7.14%)"", ""  Pancytopenia 2/98 (2.04%)"", ""  Cardiac failure 0/98 (0.00%)"", ""  Cardiac failure congestive 0/98 (0.00%)"", ""  Pericardial effusion 0/98 (0.00%)"", ""  Appendicitis perforated 1/98 (1.02%)"", ""  Colitis 1/98 (1.02%)"", ""  Ileus 1/98 (1.02%)"", ""  Abdominal pain upper 1/98 (1.02%)"", ""  Gastrointestinal haemorrhage 0/98 (0.00%)""]",Entailment
Patients with a platelet count of 50 x 109/l are not eligible for NCT02429427,"[""Inclusion Criteria:"", ""  Pre-treatment haematology and biochemistry values within acceptable local limits: Haemoglobin, white blood cell greater or equal to 3.0 x 109/l or absolute neutrophil count greater or equal to 1.51 x 109/l, Platelets greater or equal to 100 x 109/l, Serum bilirubin less than 1.5 x upper normal limit , Alkaline phosphatase less or equal to 1.5 x upper normal limit , Serum creatinine less than 1.5 x upper normal limit""]",Entailment
"Patients with T1N1M0, T2N1M0, T3N1M0 and TxN1M0 tumors are eliglbe for NCT01127373.","[""Inclusion Criteria:"", ""  Pathologic confirmation of metastatic disease in at least one regional lymph node. Regional lymph nodes are defined as the ipsilateral axillary lymph nodes, ipsilateral supraclavicular lymph nodes, and ipsilateral internal mammary lymph nodes. Thus, any T stage is allowed as long as the N stage is 1 and M stage is 0.""]",Entailment
"A 75 year old female patient, with an ECOG of 1 and an estimated life expectancy of more than a year would be eligible for NCT00388726.","[""Inclusion Criteria:"", ""  Age >= 18 years."", ""  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2."", ""  Life expectancy of >= 3 months.""]",Entailment
"A patient who underwent T-cell transfer therapy in the past 6 months prior, and has fully recovered from the associated toxicities, would be excluded from NCT01401062.","[""  Must be 4 weeks since all of the following treatments (recovered from toxicity of prior treatment to Grade 1, excluding alopecia):"", ""  immunotherapy;""]",Contradiction
More than 1/3 patients in cohort 1 of NCT02574455 experienced an adverse event.,"[""Adverse Events 1:"", ""  Total: 69/258 (26.74%)""]",Contradiction
"A patient has recently had an oophorectomy,they are excluded from NCT02010021.","[""Exclusion Criteria:"", ""  Prior endocrine therapy for any histologically confirmed cancer is not allowed. Prior endocrine therapy that was administered  5 years ago for the prevention of breast cancer in patients with no history of breast cancer is allowed.""]",Contradiction
"Women with rheumatoid arthritis that does not require systemic corticosteroids for treatement, are eligible for NCT00399529.","[""  No prior or currently active autoimmune disease requiring management with systemic immunosuppression. This includes inflammatory bowel disease, systemic vasculitis, scleroderma, psoriasis, multiple sclerosis, hemolytic anemia or immune-mediated thrombocytopenia, rheumatoid arthritis, systemic lupus erythematosus, Sjogren's syndrome, sarcoidosis, or other rheumatologic disease. Asthma or chronic obstructive pulmonary disease that does not require daily systemic corticosteroids is acceptable.""]",Contradiction
Prior use of Anthracycline drugs for anticancer therapy is prohibted for patients in NCT00149214.,"[""Exclusion Criteria:"", ""  Prior anthracyclines as part of prior anticancer therapy.""]",Entailment
Urosepsis was the most common adverse event in NCT01216176.,"[""Adverse Events 1:"", ""  Total: 3/12 (25.00%)"", ""  Atrial fibrillation 0/12 (0.00%)"", ""  Cardiac ischemia/infarction  [1]0/12 (0.00%)"", ""  Congestive Heart Failure  [2]0/12 (0.00%)"", ""  Diverticulitis 0/12 (0.00%)"", ""  Cholecystitis 0/12 (0.00%)"", ""  Hyperbilirubinemia 0/12 (0.00%)"", ""  Urosepsis 2/12 (16.67%)"", ""  Brain hemorrhage complicating CNS metastasis 1/12 (8.33%)"", ""  Rash  [3]0/12 (0.00%)""]",Entailment
"A patient was treated with Pertuzumab for 6 months, and this treatment was discontinued less than 1 month prior to study entry and the patient has not fully recovered from the entailing side effects, hence this patient is eligible for NCT02027376.","[""Exclusion Criteria:"", ""  Patients who have received biologic therapy (e.g. antibodies)  4 weeks prior to starting study drug or who have not recovered from the side effects of such therapy.""]",Contradiction
"Participants of NCT00317603 must be older than 18, have histologically confirmed stage 3 or above breast cancer, ECOG<2 and a life expectancy exceeding 6 months.","[""Inclusion Criteria:"", ""  Histologically confirmed Stage IV breast cancer"", ""  ECOG performance status 0 or 1"", ""  Estimated life expectancy of greater than or equal to 6 months"", ""  18 years of age or older""]",Contradiction
"Female Patients recently prescribed Rapamycin are not eligible for NCT03096847, but may be eligible for NCT01840163 unless they have a stage 1 to 2 Ductal carcinoma in situ and can speak english.","[""  Exclusion Criteria"", ""  Patient who received any CDK4/6 inhibitor or any mTOR inhibitor.""]",Contradiction
The Ixabepilone 40 mg/m^2 group in NCT00633464 reported worse results than the Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 group.,"[""Outcome Measurement: "", ""  Percentage of Participants With Objective Response (OR; Using Response Evaluation Criteria in Solid Tumors [RECIST])"", ""  The participant had an OR if her best overall response (BOR) during the study was either a complete response (CR) or a partial response (PR) according to the RECIST as determined by the investigator. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (LD) of all target lesions. Confidence interval (CI) was Computed using Clopper-Pearson method."", ""  Time frame: Assessed every 6 weeks for first 12 months from randomization thereafter every 3 months until disease progression (maximum participant objective response of 18.3 weeks)"", ""Results 1: "", ""  Arm/Group Title: Ixabepilone 40 mg/m^2"", ""  Arm/Group Description: ixabepilone 40 mg/m^2 every 3 weeks"", ""  Overall Number of Participants Analyzed: 40"", ""  Measure Type: Number"", ""  Unit of Measure: percentage of participants  30.0        (16.6 to 46.5)"", ""Results 2: "", ""  Arm/Group Title: Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2"", ""  Arm/Group Description: cetuximab 400 mg/m^2 loading dose then 250 mg/m^2 weekly + ixabepilone 40 mg/m^2 every 3 weeks"", ""  Overall Number of Participants Analyzed: 39"", ""  Measure Type: Number"", ""  Unit of Measure: percentage of participants  35.9        (21.2 to 52.8)""]",Entailment
There was the same number of anemic patinets in both cohorts of NCT00567190.,"[""Adverse Events 1:"", ""  Anaemia 3/396 (0.76%)"", ""Adverse Events 2:"", ""  Anaemia 3/408 (0.74%)""]",Entailment
"NCT00464646 records several gastrointestinal adverse events, whereas NCT00006110 doesn’t record any GI adverse events.","[""Adverse Events 1:"", ""  Total: 7/52 (13.46%)"", ""  Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infe * 0/52 (0.00%)"", ""  Atrial Fibrillation * 1/52 (1.92%)"", ""  Sepsis * 1/52 (1.92%)"", ""  Muscle weakness upper limb * 1/52 (1.92%)"", ""  Dizziness * 1/52 (1.92%)"", ""  Seizure * 1/52 (1.92%)"", ""  Nervous system disorders - Other, specify *  [1]1/52 (1.92%)"", ""Adverse Events 2:"", ""  Total: 1/30 (3.33%)"", ""  Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infe * 1/30 (3.33%)"", ""  Atrial Fibrillation * 0/30 (0.00%)"", ""  Sepsis * 0/30 (0.00%)"", ""  Muscle weakness upper limb * 0/30 (0.00%)"", ""  Dizziness * 0/30 (0.00%)"", ""  Seizure * 0/30 (0.00%)"", ""  Nervous system disorders - Other, specify *  [1]0/30 (0.00%)""]",Entailment
People who inherit harmful variants of the BReast CAncer gene 1 or 2 are eligible for NCT01525589.,"[""Inclusion Criteria:"", ""  Known deleterious germline mutation of BRCA1/2 (Patients in Cohorts A and A1)""]",Entailment
Cohort 1 and 2 of NCT00148668 recorded the same number of patients with Neutropenia.,"[""Adverse Events 1:"", ""  Total: 5/41 (12.20%)"", ""  Neutropenia  4/41 (9.76%)"", ""  Febrile Neutropenia  0/41 (0.00%)"", ""  SGPT (ALT)  1/41 (2.44%)"", ""Adverse Events 2:"", ""  Total: 5/40 (12.50%)"", ""  Neutropenia  4/40 (10.00%)"", ""  Febrile Neutropenia  1/40 (2.50%)"", ""  SGPT (ALT)  0/40 (0.00%)""]",Entailment
There were significantly more cases of ventricular tachycardia than Supraventricular tachycardia in cohort 2 of NCT01565083.,"[""Adverse Events 2:"", ""  Supraventricular tachycardia * 1/107 (0.93%)"", ""  Tachycardia * 1/107 (0.93%)""]",Contradiction
NCT00399529 and NCT00754325 both accept patients with progesterone receptors(PgR+) adenocarcinoma of the breast.,"[""Inclusion Criteria:"", ""  Histologically confirmed hormone receptor positive (HR+) [(estrogen receptor (ER+) and/or progesterone receptors(PgR+)] breast cancer according to immunohistochemistry (IHC)""]",Contradiction
"There were more than 3 cases of Febrile neutropenia, Leukopenia and Neutropenia across all cohorts in NCT00426556.","[""Adverse Events 1:"", ""  Total: 3/6 (50.00%)"", ""  Febrile neutropenia 0/6 (0.00%)"", ""  Leukopenia 0/6 (0.00%)"", ""  Neutropenia 0/6 (0.00%)"", ""Adverse Events 2:"", ""  Total: 6/17 (35.29%)"", ""  Febrile neutropenia 0/17 (0.00%)"", ""  Leukopenia 0/17 (0.00%)"", ""  Neutropenia 0/17 (0.00%)""]",Contradiction
"Women classified as low-risk of developing breast cancer within the next 5 years by the Gail model , and no Family history consistent with hereditary breast cancer, are eligible for NCT00853996.","[""Inclusion Criteria:"", ""  Gail risk >= 1.7% and/or relative risk >= 3 times that for 5-year age group"", ""  Family history consistent with hereditary breast cancer, as indicated by 1 of the following criteria:""]",Contradiction
"Female patients over the age of 60, with Histologically confirmed breast cancer and advanced Alzheimer's disease are ineligible for both NCT00297596 and NCT00908791.","[""Inclusion Criteria:"", ""  A serious uncontrolled medical disorder or active infection which would impair their ability to receive study treatment will be excluded. Significant cardiac disease, including uncontrolled high blood pressure, unstable angina, and congestive heart failure, myocardial infarction within the previous 3 months or serious cardiac arrhythmias will be excluded. Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol will be excluded.""]",Entailment
NCT00243503 and NCT00448279 did not observe any of the same adverse events in their patients.,"[""Adverse Events 1:"", ""  Total: 25/60 (41.67%)"", ""  Febrile neutropenia * 2/60 (3.33%)""]",Contradiction
There is no maximum or minimum age defined for participation in NCT01663727 or NCT00072293.,"[""Inclusion Criteria:"", ""  Histologically or cytologically confirmed, HER2-negative adenocarcinoma of the breast, with measurable or non-measurable locally recurrent or metastatic disease. Locally recurrent disease must not be amenable to resection with curative intent."", ""  ECOG performance status of 0 or 1"", ""  For women of childbearing potential, use of an acceptable and effective method of non-hormonal contraception"", ""  For patients who have received recent radiotherapy, recovery prior to randomization from any significant acute toxicity, and radiation treatments have to be completed more than 3 weeks from randomization"", ""Exclusion Criteria:"", ""  Disease-Specific Exclusions:"", ""  HER2-positive status"", ""  Prior chemotherapy for locally recurrent or metastatic disease"", ""  Prior hormonal therapy < 2 weeks prior to randomization"", ""  Prior adjuvant or neo-adjuvant chemotherapy is allowed, provided its conclusion has been for at least 12 months prior to randomization"", ""  Investigational therapy within 28 days of randomization"", ""  General Medical Exclusions:"", ""  Life expectancy of < 12 weeks"", ""  Inadequate organ function"", ""  Uncontrolled serious medical or psychiatric illness"", ""  Active infection requiring intravenous (IV) antibiotics at screening"", ""  Pregnancy or lactation"", ""  History of other malignancies within 5 years prior to screening, except for tumors with a negligible risk for metastasis or death""]",Entailment
"There is one case of Cardiopulmonary failure in cohort 2 of NCT00274456, but none in cohort 1 of NCT00570921.","[""Adverse Events 1:"", ""  Total: 5/33 (15.15%)"", ""  Left Ventricular Thrombus * 1/33 (3.03%)"", ""  Nausea * 1/33 (3.03%)"", ""  Acute Cholecystitis * 1/33 (3.03%)"", ""  Renal Failure * 1/33 (3.03%)"", ""  Pneumonia * 1/33 (3.03%)""]",Entailment
Patients participating in NCT01325207 and NCT02429427 experienced a variety of cardiac problems. ,"[""  Pericardial effusion  [1]0/3 (0.00%)""]",Entailment
"Patients wanting to take part in NCT00721630 must be at a specific location, this is not necessary for NCT00256243.","[""Eligibility Criteria:"", ""  Patients must be women with a histologically confirmed diagnosis of locally advanced or inflammatory breast carcinoma. Histologic confirmation shall be by either core needle biopsy or incisional biopsy. Punch biopsy is allowed if invasive breast cancer is documented."", ""  Patients must meet one of the criteria defined below (indicate one):"", ""  a .Selected Stage IIB (T3, N0, M0) or IIIA (T3, N1-2, M0) disease judged primarily unresectable by an experienced breast surgeon; or otherwise deemed appropriate candidates for neoadjuvant treatment."", ""  b. Stage IIIB (T4, Any N, M0) or (Any T, N3, M0) disease."", ""  Physical examination, chest x-ray and any x-rays or scans needed for tumor assessment must be performed within 90 days prior to registration."", ""  Patients with the clinical diagnosis of congestive heart failure or angina pectoris are NOT eligible. Patients with hypertension or age > 60 years must have a Multiple Gated Acquisition (MUGA) or echocardiogram scan performed within 90 days prior to registration (indicate not applicable (NA) if no MUGA required) and Left Ventricular Ejection Fraction (LVEF) % must be greater than the institutional lower limit of normal."", ""  Patients must have a serum creatinine and bilirubin  the institutional upper limit of normal, and an Serum glutamic oxaloacetic transaminase (SGOT) or Serum glutamic pyruvic transaminase (SGPT)  2x the institutional upper limit of normal. These tests must have been performed within 90 days prior to registration."", ""  Patients must have an Absolute neutrophil count (ANC) of  1,500/\u03bcl and a platelet count of  100,000/\u03bcl. These tests must have been performed within 90 days prior to registration."", ""  Patients must have a performance status of 0-2 by Zubrod criteria"", ""  Pregnant or nursing women may not participate due to the possibility of fetal harm or of harm to nursing infants from this treatment regimen. Women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method. A urine pregnancy test is required for women of childbearing potential."", ""  All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.""]",Entailment
"Between the patients in NCT00382018 and NCT03012477, only a single one suffered from sepsis.","[""Adverse Events 1:"", ""  Total: 0/161 (0.00%)"", ""  Gastrointestinal-Other 0/161 (0.00%)"", ""  Dehydration 0/161 (0.00%)"", ""  Renal/Genitourinary-Other 0/161 (0.00%)"", ""Adverse Events 2:"", ""  Total: 1/64 (1.56%)"", ""  Gastrointestinal-Other 1/64 (1.56%)"", ""  Dehydration 1/64 (1.56%)"", ""  Renal/Genitourinary-Other 1/64 (1.56%)""]",Entailment
"Black men with and ECOG <=2, with ANC >1.5 x 10^9/L, PLT >100 x 10^9/L and no prior history of blood clots are eligible for NCT00365599 but excluded from NCT01771666","[""Inclusion Criteria:"", ""  Patients must have Eastern Cooperative Oncology Group (ECOG) performance status 0-2."", ""  Patients must have acceptable organ function, as defined by the following laboratory parameters: white blood count (WBC) >3.0 x 10^9/L; absolute neutrophil count (ANC) >1.5 x 10^9/L; hemoglobin (Hgb) >10.0g/dL; platelets (PLT) >100 x 10^9/L, Bilirubin < 2.0 mg/dl, aspartate aminotransferase/alanine aminotransferase (AST/ALT) < 2.5 X upper limit of normal (ULN), Creatinine <1.8 mg/dl (Creatinine clearance >60 ml/min)."", ""  Both men and women of all races and ethnic groups are eligible for this trial."", ""  Patient with a history of blood clots are not eligible.""]",Entailment
"2 of the patients in NCT02069093 were either symptomatic, but able to swallow a modified diet; symptomatic and unable to aliment or hydrate orally or had symptoms associated with life-threatening consequences.","[""Outcome Measurement: "", ""  Number of Participants With Stomatitis Grade  2"", ""  The incidence of grade  2 stomatitis was reported. Grade 1 = minimal symptoms, normal diet; grade 2 = symptomatic, but able to swallow a modified diet; grade 3 = symptomatic and unable to aliment or hydrate orally; and grade 4 = symptoms associated with life-threatening consequences."", ""  Time frame: 56 days"", ""Results 1: "", ""  Arm/Group Title: Dexamethasone Based Mouthwash"", ""  Arm/Group Description: Participants swished and spat 10mL of 0.5mg/5mL dexamethasone steroid mouthwash (investigational treatment) 4 times daily (qid) orally for 2 minutes each for 8 weeks. Participants remained without food or drink (NPO) for one hour after administration of the mouthwash. Also, participants received everolimus 10 mg and exemstane 25 mg (study treatments) according to local regulations."", ""  Overall Number of Participants Analyzed: 86"", ""  Measure Type: Number"", ""  Unit of Measure: Participants  Stomatitis grade >=2: Yes: 2"", ""  Stomatitis grade >=2: No: 83"", ""  Stomatitis grade >=2: Not evaluable: 1""]",Entailment
Patients with hemophilia are excluded from NCT00631852.,"[""Exclusion Criteria:"", ""  active bleeding or a pathological condition that carries a high risk of bleeding""]",Entailment
"Patients with aromatase inhibitor associated musculoskeletal symptoms, such as Grade 1 or above musculoskeletal pain or grade 0 sensory neuropathy, are eligible for NCT01028352.","[""Inclusion Criteria:"", ""  AI-associated musculoskeletal symptoms, defined as:"", ""  Grade 1 or higher musculoskeletal pain that developed or worsened (6 or 7 on CGICS) during AI therapy or"", ""  Grade 1 or higher sensory neuropathy that developed or worsened (6 or 7 on CGICS) during AI therapy;""]",Contradiction
None of the 3 patients in cohort 1 of NCT00875979 experienced any adverse events.,"[""Adverse Events 1:"", ""  Total: 0/3 (0.00%)"", ""  Pericardial effusion 0/3 (0.00%)"", ""  Tachycardia 0/3 (0.00%)"", ""  Nausea 0/3 (0.00%)"", ""  Vomiting 0/3 (0.00%)"", ""  Abdominal pain 0/3 (0.00%)"", ""  Colitis 0/3 (0.00%)"", ""  Diarrhoea 0/3 (0.00%)"", ""  Gastritis 0/3 (0.00%)"", ""  Ileus 0/3 (0.00%)"", ""  Fatigue 0/3 (0.00%)"", ""  Pyrexia 0/3 (0.00%)"", ""  Pain 0/3 (0.00%)"", ""  Hepatic cirrhosis 0/3 (0.00%)"", ""  Cellulitis 0/3 (0.00%)""]",Entailment
"Patients with tumors that are HER2 negative, PR and ER positive are eligible for NCT02455453.","[""Inclusion Criteria:"", ""  Patient must have any one of the following types of breast cancer (primary or metastatic): ER+/PgR+/HER2- or ER+/PgR-/HER2-.""]",Entailment
"Skin infections were more common in patients in cohort 2 of NCT00828074, than in cohort 1 of NCT00810797.","[""Adverse Events 1:"", ""  Skin infection * 1/36 (2.78%)""]",Contradiction
NCT02366130 reported more than 10 times the number of patients experiencing adverse events as NCT01262027 .,"[""Adverse Events 1:"", ""  Total: 28/36 (77.78%)"", ""  Lymphocytopenia 210/36 (27.78%)"", ""  Neutropenia 29/36 (25.00%)"", ""  Anemia 26/36 (16.67%)"", ""  Thrombocytopenia 24/36 (11.11%)"", ""  Hyperglycemia 27/36 (19.44%)"", ""  Nausea 213/36 (36.11%)"", ""  Diarrhea 211/36 (30.56%)"", ""  Fatigue 215/36 (41.67%)"", ""  Flu-like symptoms 26/36 (16.67%)"", ""  Hot Flashes 25/36 (13.89%)"", ""  AST/ALT elevation 211/36 (30.56%)"", ""  Arthralgia 24/36 (11.11%)""]",Contradiction
Sarah has been experiencing epileptic seizures from a brain tumor. This will not prevent her from participating in NCT01031446.,"[""  No symptomatic brain metastases""]",Contradiction
Cohort 1 of NCT01269346 and Cohort 1 of NCT01597193 both have less than 30% occurrence of adverse events.,"[""Adverse Events 1:"", ""  Total: 15/52 (28.85%)""]",Entailment
Patients must have an infiltrating breast carcinoma to participate in NCT00127933 or NCT00201760.,"[""Eligibility Criteria:"", ""  Must have invasive metastatic breast cancer""]",Entailment
"Patients with stage I, II, III or IV breast cancer may be eliglbe for NCT00030823.","[""  Stage I, II, or III previously treated with adjuvant chemotherapy and clinically free of identifiable disease, but have rising CA 15-3 or CEA levels"", ""  Stage IV that is free of all known disease after eradication by surgery, radiotherapy, or chemotherapy"", ""  Stage IV that is stable on hormonal therapy""]",Entailment
Patients with ICDs may be eligible for NCT02635737.,"[""Exclusion Criteria:"", ""  Patients with a Pacemaker or implanted device;""]",Contradiction
"A female with Hemoglobin > 10.0 g/dl, Absolute neutrophil count 1,733/mm3, platelet count = 100,000/µl and total bilirubin < 1.2 x ULN are eligilbe for NCT00101400.","[""  Hemoglobin > 9.0 g/dl"", ""  Absolute neutrophil count (ANC) > 1,500/mm3"", ""  Platelet count = 100,000/\u00b5l"", ""  Total bilirubin =1.5 x the upper limit of normal.""]",Contradiction
"None of the patients in NCT00191815 committed suicide, however there was one such case in NCT01301729.","[""Adverse Events 1:"", ""  Total: 6"", ""  Atrial fibrillation 1/67 (1.49%)"", ""  Ventricular fibrillation 1/67 (1.49%)"", ""  Gastrointestinal perforation 1/67 (1.49%)"", ""  Periproctitis 1/67 (1.49%)"", ""  General physical health deterioration 1/67 (1.49%)"", ""  Escherichia sepsis 1/67 (1.49%)"", ""  Pneumonia 1/67 (1.49%)"", ""  Tumour pain 1/67 (1.49%)"", ""  Renal failure acute 1/67 (1.49%)"", ""  Pleurisy 1/67 (1.49%)""]",Entailment
One patient in NCT02291913 suffered from an inflammation of the liver.,"[""Adverse Events 1:"", ""  Total: 15/48 (31.25%)"", ""  Anemia * 1/48 (2.08%)"", ""  Cardiac failure congestive * 1/48 (2.08%)"", ""  Constipation * 2/48 (4.17%)"", ""  Esophagitis * 1/48 (2.08%)"", ""  Gastrointestinal hemorrhage * 1/48 (2.08%)"", ""  Non-Cardiac chest pain * 1/48 (2.08%)"", ""  Pain * 1/48 (2.08%)"", ""  Cholecystitis * 1/48 (2.08%)"", ""  Diverticulitis * 1/48 (2.08%)"", ""  Cellulitis * 1/48 (2.08%)"", ""  Gastroenteritis * 1/48 (2.08%)""]",Contradiction
A patient who had a Joint injection in the last month would not be eligible for NCT01094184.,"[""Inclusion Criteria:"", ""  Histologically confirmed triple-negative (estrogen, progesterone, and HER-2 receptor negative) adenocarcinoma of the breast in pre- or post-menopausal women with measurable or non-measurable metastatic disease"", ""  Participant who in the Investigator's opinion requires combination therapy for their disease"", ""  Life expectancy of greater than or equal to (>/=)12 weeks"", ""Exclusion Criteria:"", ""  Previous chemotherapy for metastatic breast cancer"", ""  Participants currently undergoing radiation therapy for the treatment of metastatic disease (apart from the relief of metastatic bone pain)"", ""  Major surgery or significant traumatic injury within 28 days prior to enrollment or anticipation of the need for major surgery during study treatment""]",Contradiction
"Female Patients recently prescribed Rapamycin are not eligible for NCT03096847, but may be eligible for NCT01840163 as long as they have a stage 1 to 2 Ductal carcinoma in situ and can speak english.","[""  Exclusion Criteria"", ""  Patient who received any CDK4/6 inhibitor or any mTOR inhibitor.""]",Entailment
"Patients must be older than 18, female, have one or more target lesions and more than 2 regiments of chemotherapy to participate in NCT00077857.","[""Inclusion Criteria:"", ""  women >=18 years of age;"", ""  >=1 target lesion;"", ""  >=2 regimens of chemotherapy for advanced/metastatic disease.""]",Entailment
Both NCT01015131 and NCT00312208 record instances of Rectal Hemorrhage within their patient cohorts.,"[""Adverse Events 1:"", ""  Total: 8/44 (18.18%)"", ""  Febrile neutropenia4/44 (9.09%)"", ""  Rectal bleeding1/44 (2.27%)"", ""  Chest pain2/44 (4.55%)"", ""  Fever1/44 (2.27%)"", ""  Catheter site infection1/44 (2.27%)"", ""  Neutrophil count decreased1/44 (2.27%)"", ""  Dizziness1/44 (2.27%)""]",Contradiction
Only 1 respiratory adverse event was recorded across the duration of both NCT02129556 and NCT01301729.,"[""Adverse Events 1:"", ""  Total: 5/32 (15.63%)"", ""  Leukopenia 1/32 (3.13%)"", ""  Neutropenia 1/32 (3.13%)"", ""  Cataract 1/32 (3.13%)"", ""  Infection 1/32 (3.13%)"", ""  Upper respiratory tract infection 1/32 (3.13%)"", ""  Completed suicide 1/32 (3.13%)""]",Entailment
"Completely disabled patients below the age of 20, totally confined to bed or chair and unable to carry on any selfcare are eligible for NCT00568022 but excluded from NCT01120184.","[""Inclusion Criteria:"", ""  Women  20 years"", ""  Histologically or cytologically confirmed diagnosis of adenocarcinoma originating in the breast"", ""Exclusion Criteria:"", ""  Number of prior chemotherapy lines of treatment in the metastatic setting 3""]",Contradiction
"Abnormal LVEF, Pregnancy or lactating automatically eliminates patients from participating in NCT00404066.","[""  EXCLUSION CRITERIA"", ""  Congestive heart failure, abnormal left ventricular ejection fraction (LVEF), angina pectoris, uncontrolled cardiac arrhythmias, or other significant heart disease, or who have had a myocardial infarction within the past year."", ""  Pregnant or lactating""]",Entailment
Any patient can enter into NCT04396665 or NCT00493636; as long as they are willing to provide Informed consent and are capable of using the internet.,"[""Inclusion Criteria:"", ""  Informed consent signed"", ""  Capability to use internet"", ""Exclusion Criteria:"", ""  Breast cancer diagnosis duting the intervention""]",Contradiction
"Rachel is 19 years old and has skin ulcerations and allergic reactions to triclosan, she cannot take part in NCT00768222.","[""Inclusion Criteria:"", ""  18 years of age or older with written informed consent"", ""Exclusion Criteria:"", ""  Has inflammatory cancers or skin ulceration"", ""  Has known allergy or intolerance to triclosan""]",Entailment
NCT00217672 had a higher occurrence rate of fistula enterovesical than NCT00110084.,"[""Adverse Events 1:"", ""  fistula enterovesical 1/74 (1.35%)""]",Entailment
Patients participating in NCT01325207 and NCT02429427 experienced serious eye disorders.,"[""Adverse Events 1:"", ""  Total: 1/3 (33.33%)"", ""  Pericardial effusion  [1]0/3 (0.00%)"", ""  Abdominal muscle wall hemorrhage  [2]0/3 (0.00%)"", ""  Dehydration  [3]0/3 (0.00%)"", ""  Gastroenteritis 0/3 (0.00%)"", ""  Dehydration 0/3 (0.00%)"", ""  Vomiting  [4]0/3 (0.00%)"", ""  Colonic perforation  [5]0/3 (0.00%)"", ""  Abdominal pain 0/3 (0.00%)"", ""  Chemical meningitis 0/3 (0.00%)"", ""  Lung infection 0/3 (0.00%)"", ""  Wound infection 0/3 (0.00%)"", ""Adverse Events 2:"", ""  Total: 2/3 (66.67%)"", ""  Pericardial effusion  [1]0/3 (0.00%)"", ""  Abdominal muscle wall hemorrhage  [2]0/3 (0.00%)"", ""  Dehydration  [3]0/3 (0.00%)"", ""  Gastroenteritis 0/3 (0.00%)"", ""  Dehydration 0/3 (0.00%)"", ""  Vomiting  [4]0/3 (0.00%)"", ""  Colonic perforation  [5]0/3 (0.00%)"", ""  Abdominal pain 0/3 (0.00%)"", ""  Chemical meningitis 0/3 (0.00%)"", ""  Lung infection 0/3 (0.00%)"", ""  Wound infection 1/3 (33.33%)""]",Contradiction
A patient who had an oophorectomy in the last month would not be eligible for NCT01094184.,"[""Exclusion Criteria:"", ""  Major surgery or significant traumatic injury within 28 days prior to enrollment or anticipation of the need for major surgery during study treatment""]",Entailment
"More than half of patients in NCT02445586 experienced adverse events, and there was not a single patient in either cohort of NCT02115984 that did not experience an adverse event.","[""Adverse Events 1:"", ""  Total: 31/52 (59.62%)"", ""  Febrile neutropenia 2/52 (3.85%)"", ""  Left ventricular dysfunction 2/52 (3.85%)"", ""  Sinus tachycardia 1/52 (1.92%)"", ""  Congenital arterial malformation 1/52 (1.92%)"", ""  Diarrhoea 5/52 (9.62%)"", ""  Salivary hypersecretion 1/52 (1.92%)"", ""  Enteritis 1/52 (1.92%)"", ""  Abdominal pain 1/52 (1.92%)"", ""  Vomiting 1/52 (1.92%)"", ""  Stomatitis 1/52 (1.92%)"", ""  Haematemesis 1/52 (1.92%)""]",Entailment
"Patients who completed a trastuzumab regiment, to treat the current breast cancer  > 2 weeks before study entry are eligible for NCT00297596 but excluded from NCT00580333.","[""Inclusion Criteria:"", ""  Patients may have received one prior trastuzumab/chemotherapy containing regimen or prior single agent trastuzumab."", ""  All prior chemotherapy, trastuzumab and radiation therapy should be completed > 2 weeks before enrollment.""]",Entailment
Prior exposure to doxatel is obligatory for patients in NCT01908101.,"[""Inclusion Criteria:"", ""  Ability to provide written informed consent"", ""  Prior exposure to taxane in the adjuvant, neoadjuvant or metastatic setting""]",Contradiction
All genders are eligible for NCT02040857.,"[""  Men and both pre- and postmenopausal women are eligible.""]",Entailment
"None of the patients in NCT01250379 had Thrombocytopenia, congestive Cardiac failure, Pancytopenia, Acute coronary syndrome or Atrial fibrillation.","[""Adverse Events 1:"", ""  Thrombocytopenia * 0/238 (0.00%)"", ""  Pancytopenia * 0/238 (0.00%)"", ""  Acute coronary syndrome * 0/238 (0.00%)"", ""  Atrial fibrillation * 0/238 (0.00%)"", ""  Cardiac failure congestive * 0/238 (0.00%)""]",Entailment
Black women cannot take part in NCT00896649 or NCT00097721.,"[""Inclusion Criteria:"", ""  Female patients with histologically or cytologically confirmed carcinoma of the breast"", ""  Patients with advanced/metastatic disease that is not amenable to curative therapy (either surgery or radiation therapy)"", ""  Patients must have measurable disease by the RECIST criteria, defined as at least one lesion that can be accurately measured in at least one diameter (at least 10 mm in longest diameter (LD) by spiral computer tomography (CT) scan, or at least 20 mm by standard techniques; If the only measurable lesion is a lymph node, it must measure at least 20 mm in LD. If a single lesion is identified as the target lesion, a cytological or histological confirmation of breast carcinoma is required."", ""  Patients must have had prior treatment with an anthracycline and a taxane (either sequential or in combination) and may have had prior treatment with other agents as well."", ""  Patients must have progressed within six months of the last dose of chemotherapy, or experienced disease progression while receiving chemotherapy for advanced/metastatic disease."", ""  Resolution of all chemotherapy or radiation-related toxicities to less than grade 1 severity"", ""  Age  18 years"", ""  Eastern Cooperative Oncology Group (ECOG) Performance Status (APPENDIX 4) of 0 or 1"", ""  Life expectancy of  3 months"", ""  Adequate renal function as evidenced by serum creatinine  1.5 mg/dL or calculated creatinine clearance  50 mL/minute (min) per the Cockcroft and Gault formula"", ""  Adequate bone marrow function as evidenced by absolute neutrophil count (ANC)  1.5 x 10^9/L, hemoglobin  10.0 g/dL (a hemoglobin <10.0 g/dL would be acceptable if it can be corrected by growth factor or transfusion), and platelet count  100 x 10^9/L"", ""  Adequate liver function as evidenced by bilirubin  1.5 mg/dL and alkaline phosphatase, alanine transaminase (ALT), and aspartate transaminase (AST)  3 times the upper limits of normal (ULN) (in the case of liver metastases  5 x ULN)"", ""  Patients willing and able to complete the FACT-B questionnaire, Analgesic Diary, Pain VAS, and the tumor-related symptomatic assessment"", ""  Patients willing and able to comply with the study protocol for the duration of the study"", ""  A sample from the diagnostic biopsy (paraffin block) must be available"", ""  Written informed consent prior to any study-specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice"", ""Exclusion Criteria:"", ""  Patients who have received chemotherapy, radiation, hormonal therapy, or Herceptin within 2 weeks of E7389 treatment start"", ""  Radiation therapy encompassing > 10% of marrow"", ""  Failure to recover from any chemotherapy related or other therapy related toxicity at study entry that is deemed to be clinically significant by the study investigator"", ""  Prior treatment with Mitomycin C or nitrosoureas"", ""  Prior high dose chemotherapy with hematopoietic stem cell rescue in the past two years"", ""  Pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring active treatment, including the use of oxygen"", ""  Active symptomatic brain metastasis; Patients with central Nervous System (CNS) metastasis are considered eligible if they have completed local therapy and discontinued from corticosteroids for at least two weeks before starting treatment with E7389"", ""  Patients with meningeal carcinomatosis"", ""  Patients who require therapeutic anti-coagulant therapy with Warfarin or related compounds; Mini dose warfarin for catheter related thrombosis prophylaxis is permitted"", ""  Women who are pregnant or breast-feeding; Women of childbearing potential with either a positive pregnancy test at Screening or no pregnancy test. Women of childbearing potential unless (1) surgically sterile or (2) using adequate measures of contraception in the opinion of the Investigator. Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential."", ""  Severe /uncontrolled intercurrent illness/infection"", ""  Significant cardiovascular impairment (history of congestive heart failure > NYHA grade II, unstable angina or myocardial infarction within the past six months, or serious cardiac arrhythmia)"", ""  Patients with organ allografts"", ""  Patients with known positive HIV status"", ""  Patients who have had a prior malignancy, other than carcinoma in situ of the cervix, or non-melanoma skin cancer, unless the prior malignancy was diagnosed and definitively treated  5 years previously with no subsequent evidence of recurrence"", ""  Patients with pre-existing neuropathy > Grade 1"", ""  Patients with a hypersensitivity to halichondrin B and/or halichondrin B chemical derivative"", ""  Patients who participated in a prior E7389 clinical trial"", ""  Patients with other significant disease or disorders that, in the Investigator's opinion, would exclude the patient from the study""]",Contradiction
Patients with implantable cardioverter defibrillators are excluded from NCT02635737.,"[""Exclusion Criteria:"", ""  Patients with a Pacemaker or implanted device;""]",Entailment
The maximum Progression Free Survival for patients in cohort 1 NCT01997333 was 1 year.,"[""Outcome Measurement: "", ""  Progression Free Survival (PFS)"", ""  PFS is defined as the time from randomization to the earlier of disease progression or death due to any cause. Disease progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or progression in a non-target lesion, or the appearance of new lesions. The primary analysis of PFS was based on PFS events determined retrospectively by the central independent review committee, blinded to treatment assignment and investigator assessments according to RECIST 1.1 criteria."", ""  Time frame: Evaluated every 6 - 9 weeks following treatment initiation"", ""Results 1: "", ""  Arm/Group Title: Capecitabine"", ""  Arm/Group Description: Capecitabine administered on Days 1 through 14 of each 21 day cycle until disease progression, discontinuation due to toxicity, withdrawal of consent, or end of study."", ""  Overall Number of Participants Analyzed: 109"", ""  Median (95% Confidence Interval)"", ""  Unit of Measure: months  2.8        (1.6 to 3.2)""]",Contradiction
"Patients with tumors that are HER2 +, PR and ER -, are eligible for NCT02455453.","[""Inclusion Criteria:"", ""  Patient must have any one of the following types of breast cancer (primary or metastatic): ER+/PgR+/HER2- or ER+/PgR-/HER2-.""]",Contradiction
"Skin infections were more common in patients in cohort 1 of NCT00828074, than in cohort 1 of NCT00810797.","[""Adverse Events 1:"", ""  Skin infection * 1/36 (2.78%)""]",Entailment
"NCT00127933 recorded one patient with a catheter-related complication, whereas in NCT00191789 none where observed.","[""  Catheter site cellulitis 1/122 (0.82%)"", ""  Catheter site cellulitis 0/34 (0.00%)""]",Entailment
"Only people who have previously been diagnosed with cancer and are currently receiving ongoing treatment for their primary tumor are eliglbe for NCT00981305, as long as they are over the age of 20.","[""Inclusion Criteria:"", ""  breast cancer survivors over 20 years-old""]",Contradiction
Prior exposure to taxane is obligatory for patients in NCT01908101.,"[""Inclusion Criteria:"", ""  Ability to provide written informed consent"", ""  Prior exposure to taxane in the adjuvant, neoadjuvant or metastatic setting""]",Entailment
Both cohorts of NCT00767520 reported the same precentage of patients vomiting during the trial.,"[""Adverse Events 1:"", ""  Vomiting 2/79 (2.53%)"", ""Adverse Events 2:"", ""  Vomiting 2/76 (2.63%)""]",Contradiction
Patients with wounds that havent healed within five to eight weeks are ineligible for NCT00364611.,"[""  Presence of any non-healing wound, fracture, or ulcer, or the presence of clinically significant (>/= Grade 2) peripheral vascular disease""]",Entailment
None of the adverse events recorded for NCT00846027 occurred more than once.,"[""Adverse Events 1:"", ""  Total: 21/82 (25.61%)"", ""  Neutrophils count decreased 1/82 (1.22%)"", ""  Cardiac ischemia/infarction 1/82 (1.22%)"", ""  Left ventricular systolic dysfunction 1/82 (1.22%)"", ""  Hypertension 1/82 (1.22%)"", ""  Supraventricular and nodal arrhythmia 1/82 (1.22%)"", ""  Anorexia 1/82 (1.22%)"", ""  Gastrointestinal perforation 1/82 (1.22%)"", ""  Vomiting 1/82 (1.22%)"", ""  Dehydration 1/82 (1.22%)"", ""  Diarrhoea 1/82 (1.22%)""]",Entailment
Only 2 of the adverse event cases in NCT00074152 occurred in patients from cohort 1.,"[""Adverse Events 1:"", ""  Total: 0/77 (0.00%)"", ""  Neutropenia  [1]0/77 (0.00%)"", ""  Left ventricular dysfunction 0/77 (0.00%)"", ""  Cardiac ischemia 0/77 (0.00%)"", ""  Gastrointestinal pain 0/77 (0.00%)"", ""  Colitis 0/77 (0.00%)"", ""  Febrile neutropenia 0/77 (0.00%)"", ""  Pulmonary/upper respiratory infection 0/77 (0.00%)"", ""  Diverticulitis 0/77 (0.00%)"", ""  Motor neuropathy 0/77 (0.00%)"", ""  Endometrial mucosa thinkening 0/77 (0.00%)"", ""Adverse Events 2:"", ""  Total: 12/85 (14.12%)"", ""  Neutropenia  [1]1/85 (1.18%)"", ""  Left ventricular dysfunction 1/85 (1.18%)"", ""  Cardiac ischemia 2/85 (2.35%)"", ""  Gastrointestinal pain 1/85 (1.18%)"", ""  Colitis 1/85 (1.18%)"", ""  Febrile neutropenia 3/85 (3.53%)"", ""  Pulmonary/upper respiratory infection 1/85 (1.18%)"", ""  Diverticulitis 1/85 (1.18%)"", ""  Motor neuropathy 1/85 (1.18%)"", ""  Endometrial mucosa thinkening 1/85 (1.18%)""]",Contradiction
There was less than a 5% difference in the results from the 9 mg and 18 mg group in NCT02463032.,"[""Outcome Measurement: "", ""  Clinical Benefit Rate, in Centrally Confirmed Androgen Receptor (AR)+ Subjects"", ""  To estimate the clinical benefit rate (defined as complete response, partial response, or stable disease) according to RECIST 1.1, in subjects with estrogen receptor positive/androgen receptor positive (ER+/AR+) BC who have centrally confirmed AR+ status. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR; Clinical Benefit Rate (CBR)= CR + PR + SD."", ""  Time frame: 24 weeks"", ""Results 1: "", ""  Arm/Group Title: GTx-024 9 mg"", ""  Arm/Group Description: Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 9 mg"", ""  GTx-024: To determine whether either or both doses result in an acceptable clinical benefit rate."", ""  Overall Number of Participants Analyzed: 50"", ""  Measure Type: Number"", ""  Unit of Measure: participants  16"", ""Results 2: "", ""  Arm/Group Title: GTx-024 18 mg"", ""  Arm/Group Description: Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 18 mg"", ""  GTx-024: To determine whether either or both doses result in an acceptable clinical benefit rate."", ""  Overall Number of Participants Analyzed: 52"", ""  Measure Type: Number"", ""  Unit of Measure: participants  15""]",Entailment
Patients with Lactiferous duct carcinomas are eligible for NCT01805089.,"[""Inclusion Criteria:"", ""  History of ductal carcinoma in situ, lobular carcinoma in situ or stages 1-3 breast cancer""]",Entailment
NCT00266110 had a much higher rate of adverse events than NCT00879086.,"[""Adverse Events 1:"", ""  Total: 2/17 (11.76%)"", ""  Nausea * 1/17 (5.88%)"", ""  Pain - Abdomen NOS * 1/17 (5.88%)"", ""  Constipation * 1/17 (5.88%)""]",Contradiction
NCT00388726 had a lower total number of patients experiencing adverse events compared to NCT00617942.,"[""Adverse Events 1:"", ""  Total: 7/37 (18.92%)""]",Contradiction
A minimum bodyweight of 50kg is required to participate in either NCT00304096 or NCT00876395.,"[""  Body weight > 110 lbs (without clothes)""]",Contradiction
"Patients whose breast cancer has spread into both the skin and the chest wall are eligible for NCT02748213, but not NCT00290732.","[""  T1-3, any N disease"", ""  No inflammatory breast cancer or other T4 features""]",Entailment
Cohort 2 of NCT00320541 recorded 10% more cases of Leukopenia than cohort 1.,"[""Adverse Events 1:"", ""  Leukopenia 1/94 (1.06%)"", ""Adverse Events 2:"", ""  Leukopenia 3/93 (3.23%)""]",Contradiction
"By week 48 of NCT01743560 none of the patients had Complete Response, 7 had partial response and 15 had progressive disease.","[""Outcome Measurement: "", ""  Best Overall Response of Everolimus and Exemestane Treatment in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer"", ""  The best Overall Response (OR) for each patient is determined from the sequence of investigator overall lesion responses according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1.). To be assigned a best OR of Complete Responese (CR) at least two determinations of CR at least 4 weeks apart before progression are required. To be assigned a best OR of Partial Response (PR) at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) are required.The Overall Response Rate (ORR) was defined as the proportion of patients with a best OR of confirmed CR or PR by week 48."", ""  Time frame: At 48 weeks"", ""Results 1: "", ""  Arm/Group Title: Everolimus and Exemestane"", ""  Arm/Group Description: Postmenopausal women diagnosed with oestrogen receptor positive locally advanced or metastatic breast cancer will receive everolimus at a dose of 10mg daily p.o. and exemestane 25mg daily p.o."", ""  Overall Number of Participants Analyzed: 49"", ""  Measure Type: Number"", ""  Unit of Measure: participants  Patients with measurable disease at baseline: 39"", ""  Patients with non-measurable disease at baseline: 10"", ""  Best at WK 48 - Complete Response (CR): 0"", ""  Best at WK 48 - Partial Response (PR): 7"", ""  Best at WK 48 - Stable Disease (SD): 18"", ""  Best at WK 48 - Progressive Disease (PD): 15"", ""Unknown: 1"", ""Missing: 8""]",Entailment
Patients in NCT00688909 and NCT00129376 did not suffer from any of the same adverse events.,"[""Adverse Events 1:"", ""  Total: 5/261 (1.92%)"", ""  Cholecystitis chronic 1/261 (0.38%)"", ""  Post procedural bile leak 1/261 (0.38%)"", ""  Spinal column stenosis 1/261 (0.38%)"", ""  Depression 1/261 (0.38%)"", ""  Mania 1/261 (0.38%)"", ""  Pulmonary embolism 1/261 (0.38%)""]",Entailment
"A higher percent of patients in cohort 1 of NCT02924883 experienced adverse events, than in cohort 1 of NCT00559754.","[""Adverse Events 1:"", ""  Total: 13/72 (18.06%)""]",Entailment
"NCT00878709 had a total of 3 patients experiencing Pancreatic Cancer, NCT02447003 had 0.","[""Adverse Events 1:"", ""  Total: 103/1408 (7.32%)"", ""  Anaemia 1/1408 (0.07%)"", ""  Angina pectoris 1/1408 (0.07%)"", ""  Myocardial infarction 1/1408 (0.07%)"", ""  Atrial fibrillation 0/1408 (0.00%)"", ""  Sinus tachycardia 0/1408 (0.00%)"", ""  Tachycardia 0/1408 (0.00%)"", ""  Vertigo 0/1408 (0.00%)"", ""  Diarrhoea 22/1408 (1.56%)"", ""  Vomiting 12/1408 (0.85%)"", ""  Nausea 4/1408 (0.28%)"", ""  Abdominal pain 2/1408 (0.14%)"", ""  Pancreatitis 2/1408 (0.14%)"", ""Adverse Events 2:"", ""  Total: 85/1408 (6.04%)"", ""  Anaemia 1/1408 (0.07%)"", ""  Angina pectoris 0/1408 (0.00%)"", ""  Myocardial infarction 1/1408 (0.07%)"", ""  Atrial fibrillation 1/1408 (0.07%)"", ""  Sinus tachycardia 1/1408 (0.07%)"", ""  Tachycardia 1/1408 (0.07%)"", ""  Vertigo 1/1408 (0.07%)"", ""  Diarrhoea 1/1408 (0.07%)"", ""  Vomiting 1/1408 (0.07%)"", ""  Nausea 1/1408 (0.07%)"", ""  Abdominal pain 0/1408 (0.00%)"", ""  Pancreatitis 1/1408 (0.07%)""]",Contradiction
"NCT00696072 uses Clinical Benefit (CBR) as outcome measurement, which is different from Proportion of Participants With a Pathologic Complete Response Rate which is used for NCT01855828.","[""Outcome Measurement: "", ""  Proportion of Participants With a Pathologic Complete Response Rate"", ""  To estimate the pathologic complete response rate (pCR) when pertuzumab is added to weekly trastuzumab/paclitaxel followed by trastuzumab/5-fluorouracil, epirubicin and cyclophosphamide neoadjuvant chemotherapy in HER2-positive breast cancer. This study will assess pCR rates separately in ER+ and ER- cancers. Pathologic complete response is defined as no evidence of viable invasive tumor cells at the primary tumor site and axillary lymph nodes in the surgical specimen. Residual Disease (RD) is defined as: Any invasive cancer in the breast or axillary lymph nodes in the surgical specimen."", ""  Time frame: 20 weeks""]",Entailment
"NCT00392392 records two different types of pain in its adverse events, in the abdomen and chest area, NCT00503906 does not record any types of pain in its participants. ","[""Adverse Events 1:"", ""  Pain - Abdomen 1/29 (3.45%)"", ""  Pain - Chest 1/29 (3.45%)""]",Entailment
Patients that are not willing to sign and give written informed consent for participation of NCT00121836 will still be included.,"[""Inclusion Criteria:"", ""  Women >=18 years of age"", ""  HER2-negative metastatic breast cancer"", ""  Previous adjuvant chemotherapy or hormonal treatment"", ""  >=1 measurable target lesion"", ""Exclusion Criteria:"", ""  Previous treatment with chemotherapy, an anti-angiogenic agent, or a biologic therapy for advanced or metastatic cancer"", ""  Radiation therapy within 4 weeks of study treatment start or insufficient recovery from the effects of prior radiation therapy"", ""  Central nervous system metastases"", ""  Other malignancy within last 5 years, except cured basal cell carcinoma of skin and carcinoma in situ of uterine cervix"", ""  Serious concurrent infection""]",Contradiction
"None of the patients in NCT01565499 were recorded as having heart related adverse events, whereas many patients in NCT01234402 experienced several different heart related issues.","[""Adverse Events 1:"", ""  Total: 6/81 (7.41%)"", ""  Colitis  [1]1/81 (1.23%)"", ""  Multiple Sclerosis Relapse 1/81 (1.23%)"", ""  Neurotoxicity  [2]2/81 (2.47%)"", ""  Community-acquired pneumonia 1/81 (1.23%)"", ""  Local Infection Reservoir Area 1/81 (1.23%)""]",Entailment
Candidates for NCT00058058 do not need to meet a specific life expectancy criteria.,"[""  Life expectancy"", ""  Not specified""]",Entailment
Most patients in the Letrozole group of NCT00171704 had a decreased Bone Mineral Density of the Lumbar Spine after 24 months.,"[""Outcome Measurement: "", ""  Percent Change From Baseline of Bone Mineral Density of the Lumbar Spine (L2-l4)"", ""  Lumbar spine (L2-L4) BMD measurements by dual energy X-ray absorptiometry (DXA) were performed after surgery and within 2 weeks prior to randomization and repeated every 6 months for the first 2 years and annually thereafter until 5 years after enrollment. The primary scanning site was the lumbar spine (L2 to L4) and the secondary scanning site was the total hip. All DXA scans were evaluated by a central reader."", ""  Time frame: Baseline, 24 months"", ""Results 1: "", ""  Arm/Group Title: Letrozole"", ""  Arm/Group Description: 2.5 mg once daily (q.d.)orally for 5 years"", ""  Overall Number of Participants Analyzed: 63"", ""  Median (Full Range)"", ""  Unit of Measure: Percent Change  -4.63        (-14.21 to 4.32)"", ""Results 2: "", ""  Arm/Group Title: Tam-Let"", ""  Arm/Group Description: 20 mg Tamoxifen once daily (q.d.) orally for 2 years followed by Letrozole 2.5 mg q.d. orally for 3 years."", ""  Overall Number of Participants Analyzed: 68"", ""  Median (Full Range)"", ""  Unit of Measure: Percent Change  0.37        (-6.98 to 15.21)""]",Entailment
There were 5 more cases of Anaemia and 1 more case of Disseminated intravascular coagulation in cohort 1 of NCT00863655 compared to cohort 2.,"[""Adverse Events 1:"", ""  Total: 158/482 (32.78%)"", ""  Anaemia 7/482 (1.45%)"", ""  Disseminated intravascular coagulation 1/482 (0.21%)"", ""Adverse Events 2:"", ""  Total: 37/238 (15.55%)"", ""  Anaemia 2/238 (0.84%)"", ""  Disseminated intravascular coagulation 0/238 (0.00%)""]",Entailment
"Patients with dysphagia cannot participate in NCT01931163, but may be eligible for NCT00676793.","[""Inclusion Criteria:"", ""  Definitive biopsy demonstrating primary breast cancer"", ""  Residual breast cancer requiring additional surgical resection"", ""  Stage I, II or III disease"", ""  Patient has ability to give signed informed consent"", ""  Normal hepatic and renal function (creatinine<1.5, transaminases <1.5 times upper limit of normal)."", ""  ECOG Performance status of 0 or 1."", ""  Age  21 years and less than 75"", ""Exclusion Criteria:"", ""  Prior hormonal or surgical therapy for breast cancer"", ""  Abnormal liver function test"", ""  Liver or kidney problems that would interfere with metabolism of study drug"", ""  Any condition that would hamper informed consent or ability to comply with study protocol"", ""  Participation in another research study in the last three months"", ""  Known malignancy at any site other than breast"", ""  Recent consumption of green tea (5 or more cups per day, within one week prior to biopsy)"", ""  Allergy or intolerance to any component of green tea"", ""  Inability or refusal to comply with definitive surgical therapy""]",Entailment
"There were no cases of Leukopenia, Epitasis or Arrhythmia observed in patients participating in NCT00403130.","[""Adverse Events 1:"", ""  Total: 18/26 (69.23%)"", ""  Thrombocytopenia * 4/26 (15.38%)"", ""  Neutropenia * 3/26 (11.54%)"", ""  Epitasis * 1/26 (3.85%)"", ""  Peripheral arterial ischemia * 1/26 (3.85%)"", ""  Thrombosis *  [1]1/26 (3.85%)"", ""  Weakness * 1/26 (3.85%)"", ""  Pain *  [2]2/26 (7.69%)"", ""  Febrile neutropenia * 1/26 (3.85%)"", ""  Aspartate Aminotransferase *  [3]1/26 (3.85%)"", ""  Syncope * 1/26 (3.85%)""]",Contradiction
"Patients must be older than 18, female, have three or more target lesions and more than 1 regiment of chemotherapy to participate in NCT00077857.","[""Inclusion Criteria:"", ""  women >=18 years of age;"", ""  >=1 target lesion;"", ""  >=2 regimens of chemotherapy for advanced/metastatic disease.""]",Contradiction
There were 4 more cases of Dyspnea than Dehydration in NCT01127763.,"[""  Dehydration 1/25 (4.00%)"", ""  Dyspnea (Shortness Of Breath) 2/25 (8.00%)""]",Contradiction
NCT00721630 and NCT00256243 are both taking place at the Memorial Sloan Kettering Cancer Center.,"[""Eligibility Criteria:"", ""  Patients must be women with a histologically confirmed diagnosis of locally advanced or inflammatory breast carcinoma. Histologic confirmation shall be by either core needle biopsy or incisional biopsy. Punch biopsy is allowed if invasive breast cancer is documented."", ""  Patients must meet one of the criteria defined below (indicate one):"", ""  a .Selected Stage IIB (T3, N0, M0) or IIIA (T3, N1-2, M0) disease judged primarily unresectable by an experienced breast surgeon; or otherwise deemed appropriate candidates for neoadjuvant treatment."", ""  b. Stage IIIB (T4, Any N, M0) or (Any T, N3, M0) disease."", ""  Physical examination, chest x-ray and any x-rays or scans needed for tumor assessment must be performed within 90 days prior to registration."", ""  Patients with the clinical diagnosis of congestive heart failure or angina pectoris are NOT eligible. Patients with hypertension or age > 60 years must have a Multiple Gated Acquisition (MUGA) or echocardiogram scan performed within 90 days prior to registration (indicate not applicable (NA) if no MUGA required) and Left Ventricular Ejection Fraction (LVEF) % must be greater than the institutional lower limit of normal."", ""  Patients must have a serum creatinine and bilirubin  the institutional upper limit of normal, and an Serum glutamic oxaloacetic transaminase (SGOT) or Serum glutamic pyruvic transaminase (SGPT)  2x the institutional upper limit of normal. These tests must have been performed within 90 days prior to registration."", ""  Patients must have an Absolute neutrophil count (ANC) of  1,500/\u03bcl and a platelet count of  100,000/\u03bcl. These tests must have been performed within 90 days prior to registration."", ""  Patients must have a performance status of 0-2 by Zubrod criteria"", ""  Pregnant or nursing women may not participate due to the possibility of fetal harm or of harm to nursing infants from this treatment regimen. Women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method. A urine pregnancy test is required for women of childbearing potential."", ""  All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.""]",Contradiction
Patients with at most stage 3 cancer are eligible for NCT00654836 and NCT00274768.,"[""  Evidence of metastatic involvement (stage IV disease)""]",Contradiction
"Patients with cytologically confirmed, metastatic, early stage invasive breast cancer with an Allred score of 3 are eligible for NCT00756717.","[""Inclusion Criteria:"", ""  Patients must have histologically or cytologically confirmed early stage, ER-positive (Allred score 3), invasive breast cancer that is not either locally advanced by criteria other than size or inflammatory, and is not metastatic. - Patients must be candidates for surgical removal of the tumor by lumpectomy or mastectomy.""]",Contradiction
Only men and postmenopausal women are eligible for NCT02040857.,"[""  Men and both pre- and postmenopausal women are eligible.""]",Contradiction
There were 6 adverse event categories for cohort 1 of NCT00728949 which recorded at least one case.,"[""Adverse Events 1:"", ""  Total: 16/56 (28.57%)"", ""  Pancytopenia 0/56 (0.00%)"", ""  Pericarditis 0/56 (0.00%)"", ""  Abdominal pain 1/56 (1.79%)"", ""  Anal fissure 1/56 (1.79%)"", ""  Ascites 1/56 (1.79%)"", ""  Constipation 0/56 (0.00%)"", ""  Diarrhoea 1/56 (1.79%)"", ""  Nausea 0/56 (0.00%)"", ""  Oesophageal pain 0/56 (0.00%)"", ""  Vomiting 0/56 (0.00%)"", ""  Disease progression 2/56 (3.57%)"", ""  Infusion related reaction 1/56 (1.79%)"", ""  Pain 0/56 (0.00%)""]",Entailment
Cohort 2 of NCT01764022 recorded multiple incidents of thrombocytopenia.,"[""Adverse Events 2:"", ""  Anemia with trombocytopenia  1/110 (0.91%)""]",Contradiction
Patients with metastatic HER-2 positive adenocarcinoma of the breast can never be eligible for NCT00654836.,"[""DISEASE CHARACTERISTICS:"", ""  Histologically or cytologically confirmed primary adenocarcinoma of the breast"", ""  Locally recurrent or metastatic disease"", ""  Must have HER-2-negative breast cancer or, if HER-2-positive, must be unable to receive trastuzumab (Herceptin\u00ae) or have previously received trastuzumab in the past"", ""  No known CNS disease""]",Contradiction
T2 N1 M0 adenocarcinoma of the breast are eligible for NCT00005957.,"[""DISEASE CHARACTERISTICS:"", ""  Histologically proven invasive carcinoma of the breast"", ""  No evidence of T4, N2-3, or M1 disease prior to surgery"", ""  Node positive or high-risk node negative""]",Entailment
"NCT00394082 recorded cases of pleural effusion and Spinal compression fracture, neither of these were observed in NCT01033032.","[""Adverse Events 1:"", ""  Total: 13/50 (26.00%)"", ""  Febrile neutropenia 3/50 (6.00%)"", ""  Neutropenia 1/50 (2.00%)"", ""  Pancreatitis 1/50 (2.00%)"", ""  Cholangitis 1/50 (2.00%)"", ""  Cholelithiasis 1/50 (2.00%)"", ""  Anaphylactic reaction  [1]1/50 (2.00%)"", ""  Pneumonia 1/50 (2.00%)"", ""  Pneumonitis chemical 1/50 (2.00%)"", ""  Spinal compression fracture 1/50 (2.00%)"", ""  Dehydration 1/50 (2.00%)"", ""  Electrolyte imbalance 1/50 (2.00%)""]",Contradiction
Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T1 N1 M1) are eligible for NCT01097642.,"[""Inclusion Criteria:"", ""  Patients with histologic confirmation of invasive breast carcinoma."", ""  Patients greater than or equal to 18 years."", ""  Patients should have T1N1-3M0 or T2-4 N0-3M0."", ""  Patients with bilateral breast cancer are eligible.""]",Contradiction
NCT00244933 monitors the occurrence of anemia in its adverse events.,"[""Adverse Events 1:"", ""  Total: 5/19 (26.32%)"", ""  Pain 3/19 (15.79%)"", ""  White blood cells (WBC) 5/19 (26.32%)"", ""  Hemoglobin (Hgb) 1/19 (5.26%)"", ""  Absolute neutrophil count (ANC) 5/19 (26.32%)"", ""  Platelets 3/19 (15.79%)"", ""  Elevated Aspartate Aminotransferase (AST) 1/19 (5.26%)"", ""  Elevated Alanine Aminotransferase (ALT) 1/19 (5.26%)"", ""  Dyspnea 3/19 (15.79%)""]",Contradiction
Only 1 type of infection recorded across the duration of both NCT02129556 and NCT01301729.,"[""Adverse Events 1:"", ""  Total: 5/32 (15.63%)"", ""  Leukopenia 1/32 (3.13%)"", ""  Neutropenia 1/32 (3.13%)"", ""  Cataract 1/32 (3.13%)"", ""  Infection 1/32 (3.13%)"", ""  Upper respiratory tract infection 1/32 (3.13%)"", ""  Completed suicide 1/32 (3.13%)""]",Contradiction
"NCT00950300 recorded a multitude of patients with chest pain, whereas NCT00615901 observed only one patient with abdominal pain.","[""Adverse Events 1:"", ""  Angina pectoris * 1/298 (0.34%)""]",Contradiction
More than 15 patients in cohort 1 of NCT01298193 experienced adverse events.,"[""Adverse Events 1:"", ""  Total: 31/185 (16.76%)""]",Entailment
"The most common adverse event in both cohorts of NCT00003830 was Anaphylaxis, which affected less than 1% of patients.","[""Adverse Events 1:"", ""  Total: 9/2788 (0.32%)"", ""  Anaphylaxis 5/2788 (0.18%)"", ""  Infections and infestations - Other, specify 2/2788 (0.07%)"", ""  Nervous system disorders - Other, specify 0/2788 (0.00%)"", ""  Respiratory, thoracic and mediastinal disorders - Other, specify 1/2788 (0.04%)"", ""  Thromboembolic event 1/2788 (0.04%)"", ""Adverse Events 2:"", ""  Total: 8/2800 (0.29%)"", ""  Anaphylaxis 5/2800 (0.18%)"", ""  Infections and infestations - Other, specify 0/2800 (0.00%)"", ""  Nervous system disorders - Other, specify 1/2800 (0.04%)"", ""  Respiratory, thoracic and mediastinal disorders - Other, specify 1/2800 (0.04%)"", ""  Thromboembolic event 2/2800 (0.07%)""]",Entailment
"There were no cases of Cellulitis, Vertigo or Anaemia in NCT01926886.","[""Adverse Events 1:"", ""  Total: 8/101 (7.92%)"", ""  Vertigo * 1/101 (0.99%)"", ""  Infected lymphocele * 1/101 (0.99%)"", ""  Ejection fraction decreased * 5/101 (4.95%)"", ""  Lymphoedema * 1/101 (0.99%)""]",Contradiction
NCT00171314 recorded more total occurences of cardiac adverse events than NCT02896855.,"[""Adverse Events 1:"", ""  Total: 23/120 (19.17%)"", ""  Febrile neutropenia 4/120 (3.33%)"", ""  Leukopenia 2/120 (1.67%)"", ""  Neutropenia 8/120 (6.67%)"", ""  Cardiac tamponade 0/120 (0.00%)"", ""  Ventricular arrhythmia 1/120 (0.83%)"", ""  Ascites 0/120 (0.00%)"", ""  Oesophagitis 0/120 (0.00%)"", ""  Large intestine polyp 0/120 (0.00%)"", ""  Death 1/120 (0.83%)"", ""  Liver injury 1/120 (0.83%)"", ""  Pneumonia 3/120 (2.50%)"", ""Adverse Events 2:"", ""  Total: 30/122 (24.59%)"", ""  Febrile neutropenia 3/122 (2.46%)"", ""  Leukopenia 3/122 (2.46%)"", ""  Neutropenia 9/122 (7.38%)"", ""  Cardiac tamponade 2/122 (1.64%)"", ""  Ventricular arrhythmia 0/122 (0.00%)"", ""  Ascites 1/122 (0.82%)"", ""  Oesophagitis 1/122 (0.82%)"", ""  Large intestine polyp 0/122 (0.00%)"", ""  Death 1/122 (0.82%)"", ""  Liver injury 0/122 (0.00%)"", ""  Pneumonia 5/122 (4.10%)""]",Entailment
Orange juice is banned for patients undertaking NCT00895414.,"[""Inclusion Criteria:"", ""  Agrees not to consume grapefruit juice while on the study""]",Contradiction
Women of any age can participate in NCT01783444 or NCT03136367.,"[""Key Inclusion Criteria:"", ""  - Women with locally advanced, recurrent, or metastatic breast cancer along with confirmation of estrogen-receptor positive (ER+). Measurable disease defined as at least one lesion  10 mm by CT or MRI that can be accurately measured in at least one dimension (CT scan slice thickness  5 mm) OR  Bone lesions: lytic or mixed (lytic + blastic) in the absence of measurable disease as defined above."", ""  Key Exclusion Criteria:"", ""  - Patients who received more than one chemotherapy line. Patients with only non-measurable lesions other than lytic or mixed (lytic and blastic) bone metastasis.Previous treatment with exemestane, mTOR inhibitors, PI3K inhibitors or AKT inhibitors.""]",Contradiction
Patients with stage 3 Cervical carcinoma are excluded from NCT02005549.,"[""Inclusion Criteria:"", ""  no prior or current neoplasm except for non-melanoma skin cancer, or in situ cancer of the cervix;""]",Entailment
"Patients with incurable and unresectable Breast Cancer are eligible for NCT01702571, unless it is metastatic.","[""Inclusion Criteria:"", ""  Documented progression of incurable, unresectable, LABC, or mBC, defined by the investigator: progression must occur during or after most recent treatment for LABC/mBC or within 6 months of completing adjuvant therapy""]",Contradiction
Females aged between 18-25 with Bone lesions or Leptomeningeal disease cannot be included in either NCT00662129 or NCT03097653.,"[""Inclusion Criteria:"", ""  Women aged 45-69, according to the target age of the screening centres involved;"", ""  New invited women in mammography screening programme."", ""Exclusion Criteria:"", ""None""]",Entailment
"Patients must have a confirmed Postmenopausal status, defined as a lack of menses for over a year, if they are to take part in NCT01004744.","[""  Postmenopausal status defined as cessation of menses for >1 year or FSH > 20 mIU/mL (within the past month)""]",Entailment
"Patients who received over 5 years of anastrozole therapy, completed under a year ago, are eligible for NCT00754845.","[""  Must have received 4\u00bd - 6 years of aromatase inhibitor therapy (e.g., letrozole, anastrozole, or exemestane), either as initial therapy or after prior tamoxifen citrate, including treatment received as part of clinical trial CAN-NCIC-MA17"", ""  Completed aromatase inhibitor therapy  2 years ago""]",Contradiction
"Patients with ER positive, PR positive or HER2 positive stage 4 tumors may be eligible for NCT01273896 or NCT00041067.","[""DISEASE CHARACTERISTICS:"", ""  Histologically confirmed stage IV breast cancer""]",Contradiction
There were no pain related adverse events observed in NCT00179309.,"[""Adverse Events 1:"", ""  Total: 3/25 (12.00%)"", ""  Anemia 0/25 (0.00%)"", ""  Sinus tachycardia 0/25 (0.00%)"", ""  Pericardial effusion 1/25 (4.00%)"", ""  Gastrointestinal disorders - Other, specify -stomatitis) 0/25 (0.00%)"", ""  Vomiting 1/25 (4.00%)"", ""  Fever 0/25 (0.00%)"", ""  Injection site reaction 1/25 (4.00%)"", ""  Catheter related infection 0/25 (0.00%)"", ""  Activated partial thromboplastin time prolonged 0/25 (0.00%)"", ""Adverse Events 2:"", ""  Total: 2/23 (8.70%)"", ""  Anemia 1/23 (4.35%)"", ""  Sinus tachycardia 1/23 (4.35%)"", ""  Pericardial effusion 0/23 (0.00%)"", ""  Gastrointestinal disorders - Other, specify -stomatitis) 1/23 (4.35%)"", ""  Vomiting 0/23 (0.00%)"", ""  Fever 1/23 (4.35%)"", ""  Injection site reaction 1/23 (4.35%)"", ""  Catheter related infection 1/23 (4.35%)"", ""  Activated partial thromboplastin time prolonged 1/23 (4.35%)""]",Entailment
The majority of patients in NCT00182793 and NCT00509769 experienced an adverse event.,"[""Adverse Events 1:"", ""  Total: 24/32 (75.00%)""]",Contradiction
There was 16.67% more cases of hemorrhaging in NCT02139358 than in NCT02574455.,"[""Adverse Events 1:"", ""  Total: 7/15 (46.67%)"", ""  Cardiac arrest * 1/15 (6.67%)"", ""  Chest pain - cardiac * 1/15 (6.67%)"", ""  Diarrhea * 1/15 (6.67%)"", ""  Duodenal hemorrhage * 1/15 (6.67%)"", ""  Fatigue * 1/15 (6.67%)"", ""  Fever * 1/15 (6.67%)"", ""  Sudden death NOS * 1/15 (6.67%)"", ""  Sepsis * 1/15 (6.67%)"", ""  Skin infection * 1/15 (6.67%)"", ""  Neutrophil count decreased * 1/15 (6.67%)"", ""  Platelet count decreased * 1/15 (6.67%)""]",Contradiction
3/4 patients in NCT00398567 did not suffer any adverse events.,"[""Adverse Events 1:"", ""  Total: 1/4 (25.00%)""]",Entailment
Most NCT00004888 participants suffered Grade 3 or above Cardiotoxicity Events After Cycle 8 of the study.,"[""Outcome Measurement: "", ""  Grades of Cardiotoxicity Events in the Subset of Patients Reporting a Cardiotoxicity Event"", ""  This table summarizes the cardiotoxicity events of different grades. Grade 1 is a decline of left ventricular ejection fraction(LVEF) >=10% but <20% of baseline value. Grade 2 is LVEF below LLN (50%) or decline of LVEF >=20% of baseline value. Grade 3 is congestive heart failure responsive to treatment. Please note that only a subset of patients reported cardiotoxic events so the totals will not add up to the total number of participants."", ""  Time frame: Baseline, after cycle 4 (~84 days), after cycle 8 (~168 days), and 30 or more days after last cycle of induction therapy"", ""Results 1: "", ""  Arm/Group Title: Arm I: Doxorubicin and Taxotere"", ""  Arm/Group Description: Patients received PLD 30 mg/m^2 IV followed by docetaxel 60 mg/m^2 IV, one hour after PLD completion, every 3 weeks for a total of 8 cycles. Dexamthasone 8 mg orally twice a day was administered the day before, the day of, and the day following docetaxel. The maximum allowed cumulative dose of PLD was 240 mg/m^2. Pyridoxine 200 mg PO daily started on Day 1 of Cycle 1 and continued daily while the patient was on PLD."", ""  Overall Number of Participants Analyzed: 16"", ""  Measure Type: Number"", ""  Unit of Measure: participants  Grade 1 After Cycle 4 (approx. 84 days): 2"", ""  Grade 1 After Cycle 8 (approx. 168 days): 4"", ""  Grade 1 After 30 days or more after last cycle: 1"", ""  Grade 2 After Cycle 4 (approx 84 days): 3"", ""  Grade 2 After Cycle 8 (approx 168 days): 4"", ""  Grade 2 After 30 days or more after last cycle: 1"", ""  Grade 3 After Cycle 4 (approx 84 days): 1"", ""  Grade 3 After Cycle 8 (approx 168 days): 0"", ""  Grade 3 After 30 days or more after last cycle: 0""]",Contradiction
There were 2 cases of severe back pain observed in NCT00179309.,"[""Adverse Events 1:"", ""  Total: 3/25 (12.00%)"", ""  Anemia 0/25 (0.00%)"", ""  Sinus tachycardia 0/25 (0.00%)"", ""  Pericardial effusion 1/25 (4.00%)"", ""  Gastrointestinal disorders - Other, specify -stomatitis) 0/25 (0.00%)"", ""  Vomiting 1/25 (4.00%)"", ""  Fever 0/25 (0.00%)"", ""  Injection site reaction 1/25 (4.00%)"", ""  Catheter related infection 0/25 (0.00%)"", ""  Activated partial thromboplastin time prolonged 0/25 (0.00%)"", ""Adverse Events 2:"", ""  Total: 2/23 (8.70%)"", ""  Anemia 1/23 (4.35%)"", ""  Sinus tachycardia 1/23 (4.35%)"", ""  Pericardial effusion 0/23 (0.00%)"", ""  Gastrointestinal disorders - Other, specify -stomatitis) 1/23 (4.35%)"", ""  Vomiting 0/23 (0.00%)"", ""  Fever 1/23 (4.35%)"", ""  Injection site reaction 1/23 (4.35%)"", ""  Catheter related infection 1/23 (4.35%)"", ""  Activated partial thromboplastin time prolonged 1/23 (4.35%)""]",Contradiction
Cohort 1 of NCT01610284 had more than 50x the number of patients as cohort 1 of NCT00887575.,"[""Adverse Events 1:"", ""  Total: 3/41 (7.32%)""]",Contradiction
Patients diagnosed with osteonecrosis are eligible for NCT00375427 but excluded from NCT00579826.,"[""Inclusion criteria:"", ""  Female patients  18 years of age."", ""  Written informed consent given."", ""  Histologically confirmed Stage IV breast cancer with at least one bone metastasis radiologically confirmed."", ""  Previous treatment with zoledronic acid every 3-4 weeks, for 9-12 infusions over no more than 15 months."", ""  Eastern Cooperative Oncology Group (ECOG) performance status 2 ."", ""  Life expectancy  1 year."", ""Exclusion criteria:"", ""  More than 3 months since last infusion of Zoledronic Acid (Zometa\u00ae)."", ""  Treatments with other bisphosphonate than Zoledronic Acid (Zometa\u00ae) at any time prior to study entry."", ""  Serum creatinine > 3 mg/dL (265 \u03bcmol/L) or calculated (Cockcroft-Gault formula) creatinine clearance (CLCr) < 30 mL/min CrCl = ({[140-age (years)] x weight(kg)}/ [72 x serum creatinine (mg/dL)])x 0.85"", ""  Corrected (adjusted for serum albumin) serum calcium < 8 mg/dl (2 mmol/L) or > 12 mg/dL ( 3.0 mmol/L)."", ""  Current active dental problem including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a recurrent or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures."", ""  Recent (within 6 weeks) or planned dental or jaw surgery (e.g. extraction, implants)."", ""  Pregnant patients (with a positive pregnancy test prior to study entry) or lactating patients. Women of childbearing potential not using effective methods of birth control (e.g. abstinence, oral contraceptives or implants, IUD, vaginal diaphragm or sponge, or condom with spermicide)."", ""  History of non-compliance to medical regimens or potential unreliable behavior."", ""  Known sensitivity to study drug(s) or class of study drug(s)."", ""  Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study"", ""  Use of any other investigational agent in the last 30 days.""]",Contradiction
"The minimum period of time from start of study treatment to first documentation of objective tumor progression or death due to cancer for any patient in NCT00076024, was just over a year.","[""Outcome Measurement: "", ""  Time to Tumor Progression (TTP)"", ""  Time in days from start of study treatment to first documentation of objective tumor progression or death due to cancer, whichever comes first. TTP was calculated as first event date minus the date of first dose of study medication plus 1. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD])."", ""  Time frame: Phase 2 double-blind baseline until tumor progression or death or discontinuation from study treatment, assessed every 9 weeks up to 129 weeks"", ""Results 1: "", ""  Arm/Group Title: Axitinib + Docetaxel (Phase 2, Double-blind)"", ""  Arm/Group Description: Axitinib (AG-013736) 5 mg tablet orally BID starting from Day 1 of Cycle 1, in cycles of 3 weeks. Docetaxel 80 mg/m^2 1 hr IV infusion on Day 1 of each cycle, in cycles of 3 weeks. Treatment was continued until disease progression, intolerable toxicity, or for 2 cycles after complete response."", ""  Overall Number of Participants Analyzed: 112"", ""  Median (95% Confidence Interval)"", ""  Unit of Measure: days  247        (208 to 265)"", ""Results 2: "", ""  Arm/Group Title: Docetaxel + Placebo (Phase 2, Double-blind)"", ""  Arm/Group Description: Placebo matched to axitinib (AG-013736) tablet orally BID starting from Day 1 of Cycle 1, in cycles of 3 weeks. Docetaxel 80 mg/m^2 1 hr IV infusion on Day 1 of each cycle, in cycles of 3 weeks. Treatment was continued until disease progression, intolerable toxicity, or for 2 cycles after complete response. Participants with disease progression after consent were continued to open-label phase."", ""  Overall Number of Participants Analyzed: 55"", ""  Median (95% Confidence Interval)"", ""  Unit of Measure: days  215        (191 to 247)""]",Contradiction
"Candidates must have a life expectancy exceeding 3 months to particpate in NCT00580333, there is no mimimum life expectancy define for NCT00934856.","[""Exclusion Criteria:"", ""  Life expectancy of less than 12 weeks""]",Entailment
"There are more cases of Intestinal perforation, Chest pain, death, Erysipelas and Pneumonia in NCT00811135 than in NCT00483223","[""Adverse Events 1:"", ""  Total: 8/86 (9.30%)"", ""  Hypersensitivity reaction to Cisplatin 1/86 (1.16%)"", ""  Infection with normal ANC 4/86 (4.65%)"", ""  Neutrophil Count 1/86 (1.16%)"", ""  Hyperglycemia 1/86 (1.16%)"", ""  Hypertension 1/86 (1.16%)""]",Entailment
NCT00191269 did not use PFS to evaluate the performance of its interventions.,"[""Outcome Measurement: "", ""  Tumor Response"", ""  Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve (\""respond\""), stay the same (\""stable\""), or worsen (\""progression\"") during treatment."", ""  Time frame: baseline to measured progressive disease""]",Entailment
"More patients in NCT01276041 suffered from oedema in their limbs, compared to patients in NCT00796978.","[""Adverse Events 1:"", ""  Total: 8/56 (14.29%)"", ""  Platelets * 1/56 (1.79%)"", ""  Heart failure * 1/56 (1.79%)"", ""  Left ventricular systolic dysfunction * 1/56 (1.79%)"", ""  Dehydration * 1/56 (1.79%)"", ""  Diarrhea * 1/56 (1.79%)"", ""  Infection with normal ANC or Grade 1 or 2 neutrophils - Bladder (urinary) * 1/56 (1.79%)"", ""  Sodium, serum-low (hyponatremia) * 1/56 (1.79%)"", ""  Fracture * 2/56 (3.57%)""]",Entailment
All patients in NCT01011946 must have a bilateral breast mammography prior to study entry.,"[""Inclusion Criteria:"", ""  Women 18-75 years old with newly diagnosed breast cancer who are considered candidates for breast conserving surgery (i.e. lumpectomy)."", ""Exclusion Criteria:"", ""  Children (<18 years old)"", ""  Pregnant or Lactating women"", ""  Diabetic patients (Type I or II)"", ""  Patients who are scheduled for a sentinel node procedure using radioactive Tc-99m within 24 hours of PEM"", ""  Patients who have NOT undergone a standard of care bilateral breast MRI at UC.""]",Contradiction
ECOG < 2 and a life expectancy over 12 weeks are necessary to participate in NCT01597193.,"[""Inclusion Criteria:"", ""  Eastern Cooperative Oncology Group performance (ECOG) status of 0 or 1;"", ""  Estimated life expectancy of at least 3 months""]",Entailment
A 56 year old patient presenting occasional memory loss would be excluded from both NCT01216176 and NCT03624972.,"[""Exclusion Criteria:"", ""  Overt cognitive dysfunction or psychiatric disturbance or severe mental illness (e.g., dementia, suicidal behavior, or psychosis), as observed or judged by the researcher or referring source.""]",Contradiction
"Emily has an Inoperable breast cancer, she is eligible for both NCT01644890 and NCT00996632.","[""Inclusion Criteria:"", ""  Inoperable breast cancer""]",Entailment
NCT00617942 had a lower total percentage of patients experiencing adverse events compared to NCT00388726.,"[""Adverse Events 1:"", ""  Total: 7/37 (18.92%)""]",Entailment
NCT00127205 and NCT01740323 accept patients in the same age range.,"[""Inclusion Criteria:"", ""  Female breast cancer patients over the age of 18 will be recruited for this study. Patients enrolled in the study will meet standard criteria for whole breast XRT.""]",Entailment
More NCT00004888 participants suffered Grade 1 Cardiotoxicity Events After Cycle 8 than Grade 3 events.,"[""Outcome Measurement: "", ""  Grades of Cardiotoxicity Events in the Subset of Patients Reporting a Cardiotoxicity Event"", ""  This table summarizes the cardiotoxicity events of different grades. Grade 1 is a decline of left ventricular ejection fraction(LVEF) >=10% but <20% of baseline value. Grade 2 is LVEF below LLN (50%) or decline of LVEF >=20% of baseline value. Grade 3 is congestive heart failure responsive to treatment. Please note that only a subset of patients reported cardiotoxic events so the totals will not add up to the total number of participants."", ""  Time frame: Baseline, after cycle 4 (~84 days), after cycle 8 (~168 days), and 30 or more days after last cycle of induction therapy"", ""Results 1: "", ""  Arm/Group Title: Arm I: Doxorubicin and Taxotere"", ""  Arm/Group Description: Patients received PLD 30 mg/m^2 IV followed by docetaxel 60 mg/m^2 IV, one hour after PLD completion, every 3 weeks for a total of 8 cycles. Dexamthasone 8 mg orally twice a day was administered the day before, the day of, and the day following docetaxel. The maximum allowed cumulative dose of PLD was 240 mg/m^2. Pyridoxine 200 mg PO daily started on Day 1 of Cycle 1 and continued daily while the patient was on PLD."", ""  Overall Number of Participants Analyzed: 16"", ""  Measure Type: Number"", ""  Unit of Measure: participants  Grade 1 After Cycle 4 (approx. 84 days): 2"", ""  Grade 1 After Cycle 8 (approx. 168 days): 4"", ""  Grade 1 After 30 days or more after last cycle: 1"", ""  Grade 2 After Cycle 4 (approx 84 days): 3"", ""  Grade 2 After Cycle 8 (approx 168 days): 4"", ""  Grade 2 After 30 days or more after last cycle: 1"", ""  Grade 3 After Cycle 4 (approx 84 days): 1"", ""  Grade 3 After Cycle 8 (approx 168 days): 0"", ""  Grade 3 After 30 days or more after last cycle: 0""]",Entailment
1 patient in NCT01610284 had a cardiac related adverse event.,"[""Adverse Events 1:"", ""  Total: 146/573 (25.48%)"", ""  Anaemia 4/573 (0.70%)"", ""  Disseminated intravascular coagulation 0/573 (0.00%)"", ""  Neutropenia 1/573 (0.17%)"", ""  Thrombocytopenia 0/573 (0.00%)"", ""  Acute coronary syndrome 1/573 (0.17%)"", ""  Angina pectoris 1/573 (0.17%)"", ""  Atrial fibrillation 2/573 (0.35%)"", ""  Atrial flutter 0/573 (0.00%)"", ""  Cardiac arrest 1/573 (0.17%)"", ""  Cardiac failure 0/573 (0.00%)"", ""Adverse Events 2:"", ""  Total: 101/570 (17.72%)"", ""  Anaemia 3/570 (0.53%)"", ""  Disseminated intravascular coagulation 1/570 (0.18%)"", ""  Neutropenia 1/570 (0.18%)"", ""  Thrombocytopenia 1/570 (0.18%)"", ""  Acute coronary syndrome 0/570 (0.00%)"", ""  Angina pectoris 1/570 (0.18%)"", ""  Atrial fibrillation 0/570 (0.00%)"", ""  Atrial flutter 1/570 (0.18%)"", ""  Cardiac arrest 0/570 (0.00%)"", ""  Cardiac failure 1/570 (0.18%)""]",Contradiction
The most common adverse events in NCT00688740 and NCT00191815 is Neutropenia with a total of 3 cases across all cohorts.,"[""Adverse Events 1:"", ""  Total: 267/744 (35.89%)"", ""  Neutropenia *2/744 (0.27%)"", ""  Anaemia *1/744 (0.13%)"", ""  Leukopenia *1/744 (0.13%)"", ""  Thrombocytopenia *1/744 (0.13%)"", ""  Thrombotic thrombocytopenic purpura *1/744 (0.13%)"", ""  Atrial flutter *1/744 (0.13%)"", ""  Cardiac arrest *1/744 (0.13%)"", ""  Myocardial ischaemia *1/744 (0.13%)"", ""  Arrhythmia *0/744 (0.00%)"", ""  Cardiac failure congestive *0/744 (0.00%)"", ""Adverse Events 2:"", ""  Total: 67/736 (9.10%)"", ""  Neutropenia *1/736 (0.14%)"", ""  Anaemia *0/736 (0.00%)"", ""  Leukopenia *0/736 (0.00%)"", ""  Thrombocytopenia *0/736 (0.00%)"", ""  Thrombotic thrombocytopenic purpura *0/736 (0.00%)"", ""  Atrial flutter *0/736 (0.00%)"", ""  Cardiac arrest *0/736 (0.00%)"", ""  Myocardial ischaemia *0/736 (0.00%)"", ""  Arrhythmia *2/736 (0.27%)"", ""  Cardiac failure congestive *1/736 (0.14%)""]",Contradiction
"In total there were 32 cases of Febrile neutropenia in NCT00391092, and only one case of anemia.","[""Adverse Events 1:"", ""  Febrile neutropenia * 14/206 (6.80%)"", ""  Anaemia * 1/206 (0.49%)"", ""Adverse Events 2:"", ""  Febrile neutropenia * 18/215 (8.37%)"", ""  Anaemia * 1/215 (0.47%)""]",Contradiction
There are a total of 7 cases of Gastritis in NCT00274456 across both cohorts.,"[""Adverse Events 1:"", ""  Total: 14/76 (18.42%)"", ""  Neutropenia 10/76 (13.16%)"", ""  Febrile neutropenia 1/76 (1.32%)"", ""  Anaemia 0/76 (0.00%)"", ""  Thrombocytopenia 0/76 (0.00%)"", ""  Cardiopulmonary failure 0/76 (0.00%)"", ""  Optic ischaemic neuropathy 0/76 (0.00%)"", ""  Bowel peristalsis increased 1/76 (1.32%)"", ""  Colitis 0/76 (0.00%)"", ""  Diarrhoea 0/76 (0.00%)"", ""  Gastritis 0/76 (0.00%)"", ""  Nausea 0/76 (0.00%)"", ""Adverse Events 2:"", ""  Total: 12/76 (15.79%)"", ""  Neutropenia 2/76 (2.63%)"", ""  Febrile neutropenia 1/76 (1.32%)"", ""  Anaemia 0/76 (0.00%)"", ""  Thrombocytopenia 0/76 (0.00%)"", ""  Cardiopulmonary failure 1/76 (1.32%)"", ""  Optic ischaemic neuropathy 1/76 (1.32%)"", ""  Bowel peristalsis increased 0/76 (0.00%)"", ""  Colitis 1/76 (1.32%)"", ""  Diarrhoea 0/76 (0.00%)"", ""  Gastritis 0/76 (0.00%)"", ""  Nausea 1/76 (1.32%)""]",Contradiction
NCT00721630 and NCT00364611 recorded the exact same number of cases of nausea.,"[""Adverse Events 1:"", ""  Nausea  1/23 (4.35%)""]",Entailment
NCT02019277 and NCT00863655 recorded none of the same types of adverse events,"[""Adverse Events 1:"", ""  Total: 27/50 (54.00%)"", ""  Febrile neutropenia * 4/50 (8.00%)"", ""  Anaemia * 1/50 (2.00%)"", ""  Neutropenia * 1/50 (2.00%)"", ""  Cardiac failure * 1/50 (2.00%)"", ""  Diarrhoea * 1/50 (2.00%)"", ""  Gastritis * 1/50 (2.00%)"", ""  Nausea * 1/50 (2.00%)"", ""  Oesophagitis * 1/50 (2.00%)"", ""  Pyrexia * 7/50 (14.00%)"", ""  Mucosal inflammation * 1/50 (2.00%)"", ""  Drug hypersensitivity * 1/50 (2.00%)"", ""  Cellulitis * 2/50 (4.00%)""]",Contradiction
"histologically confirmed invasive ductal breast cancer would result in exclusion from NCT01581619, but not from NCT01008150.","[""Exclusion Criteria:"", ""  No histologic evidence of EIC""]",Contradiction
A single patient in NCT00129376 experienced a clinically significant inflammation of the back of the throat.,"[""Adverse Events 1:"", ""  Acute Pharyngitis * 1/63 (1.59%)""]",Entailment
"There are four types of adverse events in NCT00171314, for which no occurences are recorded.","[""Adverse Events 1:"", ""  Total: 47/254 (18.50%)"", ""  Anaemia 1/254 (0.39%)"", ""  Febrile neutropenia 1/254 (0.39%)"", ""  Lymphadenopathy 1/254 (0.39%)"", ""  Acute myocardial infarction 1/254 (0.39%)"", ""  Angina pectoris 0/254 (0.00%)"", ""  Angina unstable 0/254 (0.00%)"", ""  Bundle branch block left 0/254 (0.00%)"", ""  Cardiac failure 4/254 (1.57%)"", ""  Coronary artery disease 0/254 (0.00%)"", ""  Coronary artery stenosis 1/254 (0.39%)""]",Entailment
NCT02019277 and NCT00863655 recorded three of the same types of adverse events,"[""Adverse Events 1:"", ""  Total: 27/50 (54.00%)"", ""  Febrile neutropenia * 4/50 (8.00%)"", ""  Anaemia * 1/50 (2.00%)"", ""  Neutropenia * 1/50 (2.00%)"", ""  Cardiac failure * 1/50 (2.00%)"", ""  Diarrhoea * 1/50 (2.00%)"", ""  Gastritis * 1/50 (2.00%)"", ""  Nausea * 1/50 (2.00%)"", ""  Oesophagitis * 1/50 (2.00%)"", ""  Pyrexia * 7/50 (14.00%)"", ""  Mucosal inflammation * 1/50 (2.00%)"", ""  Drug hypersensitivity * 1/50 (2.00%)"", ""  Cellulitis * 2/50 (4.00%)""]",Entailment
"NCT01432886 is testing for the DLT of its interventions, whereas NCT02336737 is evaluating the efficacy of lymph node detection through the use of SentiMag and SiennaXP. ","[""Outcome Measurement: "", ""  Number of Participants With Detected Lymph Nodes"", ""  The proportion of lymph nodes detected intraoperatively by SentiMag and SiennaXP in relation the proportion of lymph nodes detected by the combination of Technetium Sulfur Colloid and Isosulfan blue dye""]",Entailment
Only patients who identify as female are eligible for NCT00129935 and NCT03136367.,"[""Inclusion Criteria:"", ""  Assigned female at birth;"", ""Exclusion Criteria:"", ""  Transgender men and women;""]",Contradiction
One patient in NCT00258960 experienced a grade 4 adverse event.,"[""Adverse Events 1:"", ""  Total: 16/48 (33.33%)"", ""  Febrile neutropenia grade 3 3/48 (6.25%)"", ""  Neutropenia grade 3 1/48 (2.08%)"", ""  Holocraneal cephalea 1/48 (2.08%)"", ""  Hypersensibility reaction grade 3 2/48 (4.17%)"", ""  Palmoplantar erythrodysesthesia grade 3, stomatitis grade 3 1/48 (2.08%)"", ""  Neutropenia grade 4, fever grade 1, oral mucositis grade 3 1/48 (2.08%)"", ""  Catheter - related infection grade 3 1/48 (2.08%)""]",Entailment
Patients with breast implants are always excluded from NCT00562718.,"[""  Patients having tissue expanders or implants placed prior to radiation may be enrolled at the physician's discretion""]",Contradiction
"NCT00259090 studies the impact of Fulvestrant, Anastrozole on Oestrogen Receptor H-score.","[""  Percentage Change From Baseline to Time of Surgery in Oestrogen Receptor (ER) H-score: Antitumour Effects of Fulvestrant, Anastrozole and a Combination of Both as Measured by the ER H-score.""]",Entailment
A higher number of patients in NCT00965523 suffured from infection compared to those in NCT01463007.,"[""Adverse Events 1:"", ""  Total: 1/41 (2.44%)"", ""  Infection  1/41 (2.44%)"", ""  Creatinine  1/41 (2.44%)"", ""  Hypokalemia  1/41 (2.44%)"", ""  Bicarbonate  1/41 (2.44%)"", ""  SGOT  1/41 (2.44%)"", ""  Alkaline Phosphatase value  1/41 (2.44%)"", ""  Hyperbilirubineamia  1/41 (2.44%)"", ""  Hypoalbuminemia  1/41 (2.44%)"", ""  Leukocytes  1/41 (2.44%)"", ""  Hemoglobin  1/41 (2.44%)"", ""  Neutrophils  1/41 (2.44%)"", ""  INR  1/41 (2.44%)"", ""  PTT  1/41 (2.44%)""]",Entailment
The most common adverse events in NCT00965523 where Infection and Stomatitis.,"[""Adverse Events 1:"", ""  Total: 14/81 (17.28%)"", ""  Neutropenia1/81 (1.23%)"", ""  Cataract1/81 (1.23%)"", ""  Ascites1/81 (1.23%)"", ""  Gastritis Hemorrhagic1/81 (1.23%)"", ""  Nausea1/81 (1.23%)"", ""  Stomatitis2/81 (2.47%)"", ""  Malaise1/81 (1.23%)"", ""  Oedema1/81 (1.23%)"", ""  Pain1/81 (1.23%)"", ""  Pyrexia1/81 (1.23%)"", ""  Infection2/81 (2.47%)"", ""  Upper Limb Fracture1/81 (1.23%)"", ""  Dehydration1/81 (1.23%)"", ""  Hypercalcemia1/81 (1.23%)""]",Entailment
"2 patients in NCT03165955 suffer from DVT, 0 in NCT00912340.","[""  Deep vein thrombosis 1/28 (3.57%)""]",Contradiction
In total more than 5 patients in NCT01095003 and NCT01702571 experienced Earache.,"[""Adverse Events 1:"", ""  Total: 107/383 (27.94%)"", ""  Anaemia 4/383 (1.04%)"", ""  Febrile neutropenia 7/383 (1.83%)"", ""  Haemoytique anaemia 0/383 (0.00%)"", ""  Leukopenia 1/383 (0.26%)"", ""  Neutropenia 6/383 (1.57%)"", ""  Thrombocytopenia 2/383 (0.52%)"", ""  Anginal pectoris 1/383 (0.26%)"", ""  Cardiomyopathy 0/383 (0.00%)"", ""  Ear pain 0/383 (0.00%)"", ""  Abdominal distension 1/383 (0.26%)"", ""  Abdominal pain 6/383 (1.57%)"", ""Adverse Events 2:"", ""  Total: 85/383 (22.19%)"", ""  Anaemia 3/383 (0.78%)"", ""  Febrile neutropenia 2/383 (0.52%)"", ""  Haemoytique anaemia 0/383 (0.00%)"", ""  Leukopenia 0/383 (0.00%)"", ""  Neutropenia 1/383 (0.26%)"", ""  Thrombocytopenia 1/383 (0.26%)"", ""  Anginal pectoris 0/383 (0.00%)"", ""  Cardiomyopathy 1/383 (0.26%)"", ""  Ear pain 1/383 (0.26%)"", ""  Abdominal distension 0/383 (0.00%)"", ""  Abdominal pain 3/383 (0.78%)""]",Contradiction
Informed consent is obligatory for entry in NCT02287675.,"[""Inclusion Criteria:"", ""  The subject must provide written informed consent with Health Insurance Portability and Accountability Act (HIPAA) authorization before participating in the study""]",Entailment
"Females over the age of 18, whose last period was 2 weeks prior are eligible for NCT01073865.","[""Inclusion Criteria:"", ""  Female 20 years and pre-menopausal.Pre-menopausal defined as 1) last menses within 1 year of randomisation, and 2) E2 10 pg/mL and FSH  30 mIU/mL within 4 weeks of randomisation.""]",Entailment
There only overlap between adverse events obeserved in NCT00371345 and NCT00475670 is the several case of Sepsis which occurred in both trials.,"[""Adverse Events 1:"", ""  Total: 20/70 (28.57%)"", ""  NAUSEA 2/70 (2.86%)"", ""  VOMITING 1/70 (1.43%)"", ""  DIARRHOEA 2/70 (2.86%)"", ""  ABDOMINAL PAIN 1/70 (1.43%)"", ""  ABDOMINAL PAIN LOWER 1/70 (1.43%)"", ""  FATIGUE 2/70 (2.86%)"", ""  PYREXIA 1/70 (1.43%)"", ""  OEDEMA PERIPHERAL 1/70 (1.43%)"", ""  GENERAL PHYSICAL HEALTH DETERIORATION 3/70 (4.29%)"", ""  PNEUMONIA 1/70 (1.43%)"", ""  SINUSITIS 1/70 (1.43%)"", ""  LOBAR PNEUMONIA 1/70 (1.43%)""]",Contradiction
All of the patients in cohort 1 of NCT00086957 experienced Leukopenia and Febrile neutropenia.,"[""Adverse Events 1:"", ""  Total: 2/2 (100.00%)"", ""  Febrile neutropenia * 2/2 (100.00%)"", ""  Haemorrhage NOS * 0/2 (0.00%)"", ""  Abdominal pain * 0/2 (0.00%)"", ""  Diarrhea * 0/2 (0.00%)"", ""  Melaena * 0/2 (0.00%)"", ""  Mucositis oral * 0/2 (0.00%)"", ""  Nausea * 0/2 (0.00%)"", ""  Vomiting * 0/2 (0.00%)"", ""  Catheter related infection * 0/2 (0.00%)"", ""  Infection NOS * 0/2 (0.00%)"", ""  Leukopenia * 1/2 (50.00%)""]",Contradiction
Intervention 2 of NCT01224678 resulted in a lower percentage in tumor diameter than intervention 1.,"[""Outcome Measurement: "", ""  Percent Change (Between Baseline and Month 12) in Mammographic Density by the Boyd Method Compared Between Arms"", ""  To evaluate change in mammographic density using the Boyd method after one year of vitamin D supplementation compared to placebo in premenopausal women. The percent change in breast density will be reported here."", ""  Time frame: 12 months"", ""Results 1: "", ""  Arm/Group Title: Placebo"", ""  Arm/Group Description: Patients receive oral placebo once daily for 12 months."", ""  Overall Number of Participants Analyzed: 46"", ""  Mean (Standard Deviation)"", ""  Unit of Measure: percent change  -3.4         (7.1)"", ""Results 2: "", ""  Arm/Group Title: Vitamin D"", ""  Arm/Group Description: Patients receive oral vitamin D (2000 IU) once daily for 12 months."", ""  Overall Number of Participants Analyzed: 40"", ""  Mean (Standard Deviation)"", ""  Unit of Measure: percent change  -1.4         (11.9)""]",Contradiction
Cohort 1 of NCT01901146 recorded the same number of instances of Neutropenic fever as Cohort 1 of NCT00209092.,"[""Adverse Events 1:"", ""  Febrile neutropenia 3/364 (0.82%)""]",Contradiction
several different mental health issues were observed in NCT01075100 and NCT00290758.,"[""Adverse Events 1:"", ""  Total: 10/48 (20.83%)"", ""  NEUTROPENIA 1/48 (2.08%)"", ""  THROMBOCYTOPENIA 0/48 (0.00%)"", ""  VOLUME BLOOD DECREASED 1/48 (2.08%)"", ""  FIBRILLATION ATRIAL 1/48 (2.08%)"", ""  HYPOTENSION 1/48 (2.08%)"", ""  ABDOMINAL PAIN 1/48 (2.08%)"", ""  APPETITE DECREASED 0/48 (0.00%)"", ""  DEHYDRATION 4/48 (8.33%)"", ""  DIARRHEA 4/48 (8.33%)"", ""  NAUSEA 3/48 (6.25%)"", ""  VOMITING 2/48 (4.17%)"", ""  FEVER 1/48 (2.08%)"", ""  RIGORS 0/48 (0.00%)"", ""Adverse Events 2:"", ""  Total: 5/53 (9.43%)"", ""  NEUTROPENIA 1/53 (1.89%)"", ""  THROMBOCYTOPENIA 1/53 (1.89%)"", ""  VOLUME BLOOD DECREASED 0/53 (0.00%)"", ""  FIBRILLATION ATRIAL 0/53 (0.00%)"", ""  HYPOTENSION 0/53 (0.00%)"", ""  ABDOMINAL PAIN 0/53 (0.00%)"", ""  APPETITE DECREASED 1/53 (1.89%)"", ""  DEHYDRATION 0/53 (0.00%)"", ""  DIARRHEA 0/53 (0.00%)"", ""  NAUSEA 1/53 (1.89%)"", ""  VOMITING 1/53 (1.89%)"", ""  FEVER 1/53 (1.89%)"", ""  RIGORS 1/53 (1.89%)""]",Contradiction
Patients with end-stage liver disease are excluded from NCT00429104 and NCT00878709.,"[""Exclusion Criteria:"", ""  Chronic active hepatitis or cirrhosis.""]",Contradiction
A total of 3 patients in NCT02115984 experience a Herpes related adverse event.,"[""Adverse Events 1:"", ""  Total: 57/57 (100.00%)"", ""  Dry eyes  13/33 (39.39%)"", ""  Heartburn  9/33 (27.27%)"", ""  Nausea after the CT (before day 7)  57/57 (100.00%)"", ""  Herpetic eruption  0/33 (0.00%)"", ""  Dry skin  15/33 (45.45%)"", ""  Alopecia  57/57 (100.00%)"", ""Adverse Events 2:"", ""  Total: 23/23 (100.00%)"", ""  Dry eyes  2/11 (18.18%)"", ""  Heartburn  2/11 (18.18%)"", ""  Nausea after the CT (before day 7)  23/23 (100.00%)"", ""  Herpetic eruption  3/11 (27.27%)"", ""  Dry skin  9/11 (81.82%)"", ""  Alopecia  23/23 (100.00%)""]",Entailment
Women of any age can participate in NCT01783444.,"[""Key Inclusion Criteria:"", ""  - Women with locally advanced, recurrent, or metastatic breast cancer along with confirmation of estrogen-receptor positive (ER+). Measurable disease defined as at least one lesion  10 mm by CT or MRI that can be accurately measured in at least one dimension (CT scan slice thickness  5 mm) OR  Bone lesions: lytic or mixed (lytic + blastic) in the absence of measurable disease as defined above."", ""  Key Exclusion Criteria:"", ""  - Patients who received more than one chemotherapy line. Patients with only non-measurable lesions other than lytic or mixed (lytic and blastic) bone metastasis.Previous treatment with exemestane, mTOR inhibitors, PI3K inhibitors or AKT inhibitors.""]",Entailment
None of the patients in Cohort 1 of NCT00193037 suffered from Hypotension.,"[""Adverse Events 1:"", ""  Hypotension 0/50 (0.00%)""]",Entailment
"None of the patients in NCT01250379 had Thrombocytopenia, heart failure, Pancytopenia, Acute coronary syndrome or Atrial fibrillation.","[""Adverse Events 1:"", ""  Cardiac failure * 1/238 (0.42%)"", ""  Thrombocytopenia * 0/238 (0.00%)"", ""  Pancytopenia * 0/238 (0.00%)"", ""  Acute coronary syndrome * 0/238 (0.00%)"", ""  Atrial fibrillation * 0/238 (0.00%)"", ""  Cardiac failure congestive * 0/238 (0.00%)""]",Contradiction
"NCT00950300 recorded a patient with chest pain, whereas NCT00615901 observed a patient with abdominal pain.","[""Adverse Events 1:"", ""  Angina pectoris * 1/298 (0.34%)""]",Entailment
"post-menopausal patients are excluded from NCT02455453, but eligible for NCT00429572.","[""Inclusion Criteria:"", ""  Recurrent or residual metastatic breast carcinoma"", ""  Zubrod performance status less than 2"", ""  18-60 years old"", ""  Related donor human leukocyte antigen (HLA)-compatible for allogeneic transplantation or unrelated HLA-compatible donor."", ""  No major organ dysfunction or active infection"", ""Exclusion Criteria: None""]",Contradiction
Patients with diabetes insipidusare not suitable for NCT00723398.,"[""Inclusion Criteria:"", ""  Postmenopausal status defined as history of at least 12 months without spontaneous menstrual bleeding or a documented hysterectomy and bilateral salpingo oophorectomy"", ""  Breast density greater than 25%"", ""  No hormone replacement therapy for at least six months prior to entry into this study"", ""  Non-smokers."", ""Exclusion Criteria:"", ""  History of stroke, pulmonary embolism or deep vein thrombosis"", ""  History of atherosclerotic heart disease"", ""  Presence of any known hypercoagulable state either congenital (e.g., protein S deficiency) or acquired (e.g., corticosteroid treatment)"", ""  Diabetes mellitus"", ""  Uncontrolled hypertension (BP 140/90)"", ""  Presence of a psychiatric condition that would interfere with adherence to the protocol.""]",Contradiction
NCT00468585 recorded several skin infections in their patients.,"[""Adverse Events 1:"", ""  Total: 2/4 (50.00%)"", ""  Atrial fibrillation 0/4 (0.00%)"", ""  Dehydration 1/4 (25.00%)"", ""  Fatigue (asthenia, lethargy, malaise) 1/4 (25.00%)"", ""  Pain - Back 1/4 (25.00%)"", ""  Urinary tract infection 0/4 (0.00%)"", ""  Dyspnea (shortness of breath) 0/4 (0.00%)"", ""  Pericardial effusion 0/4 (0.00%)"", ""  Thrombosis 0/4 (0.00%)"", ""  Skin infection 0/4 (0.00%)"", ""  Rash: hand-foot skin reaction 0/4 (0.00%)"", ""Adverse Events 2:"", ""  Total: 0/3 (0.00%)"", ""  Atrial fibrillation 0/3 (0.00%)"", ""  Dehydration 0/3 (0.00%)"", ""  Fatigue (asthenia, lethargy, malaise) 0/3 (0.00%)"", ""  Pain - Back 0/3 (0.00%)"", ""  Urinary tract infection 0/3 (0.00%)"", ""  Dyspnea (shortness of breath) 0/3 (0.00%)"", ""  Pericardial effusion 0/3 (0.00%)"", ""  Thrombosis 0/3 (0.00%)"", ""  Skin infection 0/3 (0.00%)"", ""  Rash: hand-foot skin reaction 0/3 (0.00%)""]",Contradiction
Patients in NCT02953860 receive less mg of Enzalutamide than Fulvestrant on a weekly basis.,"[""  Fulvestrant with Enzalutamide: 500mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC) and 160mg of Enzalutamide will be given PO daily. Patients will receive a tumor biopsy at the start of treatment and 4 weeks after the start of treatment, with an optional 3rd biopsy at the end treatment.""]",Contradiction
"There is one case of Cardiopulmonary failure in cohort 1 of NCT00274456, but none in cohort 1 of NCT00570921.","[""Adverse Events 1:"", ""  Total: 5/33 (15.15%)"", ""  Left Ventricular Thrombus * 1/33 (3.03%)"", ""  Nausea * 1/33 (3.03%)"", ""  Acute Cholecystitis * 1/33 (3.03%)"", ""  Renal Failure * 1/33 (3.03%)"", ""  Pneumonia * 1/33 (3.03%)""]",Contradiction
"Patients with HER2 positive tumors are excluded from NCT00944047, but may be included in NCT00228943.","[""Inclusion Criteria:"", ""  HER-2/neu 1+ or 2+ by immunohistochemistry""]",Contradiction
"2 patients, in cohort 1 of NCT02748213 was recorded as having an overactive pituitary gland.","[""Adverse Events 1:"", ""  Total: 52/112 (46.43%)"", ""  Febrile neutropenia * 16/112 (14.29%)"", ""  Neutropenia * 7/112 (6.25%)"", ""  Anaemia * 1/112 (0.89%)"", ""  Cardiac failure * 1/112 (0.89%)"", ""  Coronary artery disease * 1/112 (0.89%)"", ""  Left ventricular dysfunction * 1/112 (0.89%)"", ""  Pericardial effusion * 0/112 (0.00%)"", ""  Hyperthyroidism * 1/112 (0.89%)"", ""  Diarrhoea * 5/112 (4.46%)"", ""  Vomiting * 3/112 (2.68%)"", ""Adverse Events 2:"", ""  Total: 51/110 (46.36%)"", ""  Febrile neutropenia * 26/110 (23.64%)"", ""  Neutropenia * 7/110 (6.36%)"", ""  Anaemia * 1/110 (0.91%)"", ""  Cardiac failure * 0/110 (0.00%)"", ""  Coronary artery disease * 0/110 (0.00%)"", ""  Left ventricular dysfunction * 0/110 (0.00%)"", ""  Pericardial effusion * 1/110 (0.91%)"", ""  Hyperthyroidism * 0/110 (0.00%)"", ""  Diarrhoea * 0/110 (0.00%)"", ""  Vomiting * 1/110 (0.91%)""]",Contradiction
A Female patients with a bilateral mastectomy would be excluded from NCT00334542.,"[""  At least 1 healthy intact breast""]",Entailment
NCT01808573 Patients receiving Neratinib Plus Capecitabine had a Mean (95% Confidence Interval)  Progression Free Survival more than 2 months longer than patients administered with Lapatinib Plus Capecitabine.,"[""Outcome Measurement: "", ""  Centrally Assessed Progression Free Survival"", ""  Progression Free Survival (PFS), Measured in Months, for Randomized Subjects of the Central Assessment. The time interval from the date of randomization until the first date on which recurrence, progression (per Response Evaluation Criteria in Solid Tumors Criteria (RECIST) v1.1), or death due to any cause, is documented. For subjects without recurrence, progression or death, it is censored at the last valid tumor assessment. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Here, the time to event was reported as the restricted mean survival time. The restricted mean survival time was defined as the area under the curve of the survival function up to 24 months."", ""  Time frame: From randomization date to recurrence, progression or death, assessed up to 38 months. The result is based on primary analysis data cut."", ""Results 1: "", ""  Arm/Group Title: Neratinib Plus Capecitabine"", ""  Arm/Group Description: neratinib 240 mg orally, once daily with food, continuously in 21 day cycles, and capecitabine 1500 mg/m^2 daily in 2 evenly divided doses, orally with water within 30 minutes after a meal, taken on days 1 to 14 of each 21 day cycle."", ""  Overall Number of Participants Analyzed: 307"", ""  Mean (95% Confidence Interval)"", ""  Unit of Measure: months  8.8        (7.8 to 9.8)"", ""Results 2: "", ""  Arm/Group Title: Lapatinib Plus Capecitabine"", ""  Arm/Group Description: lapatinib 1250 mg orally, once daily, continuously in 21 day cycles, and capecitabine 2000 mg/m^2 daily in 2 evenly divided doses, orally with water within 30 minutes after a meal, taken on days 1 to 14 of each 21 day cycle."", ""  Overall Number of Participants Analyzed: 314"", ""  Mean (95% Confidence Interval)"", ""  Unit of Measure: months  6.6        (5.9 to 7.4)""]",Entailment
"Only one adverse event, a Breast abscess, is observed in patients from cohort 1 of NCT00759785.","[""Adverse Events 1:"", ""  Total: 1/25 (4.00%)"", ""  Diarrhoea 0/25 (0.00%)"", ""  Breast abscess 0/25 (0.00%)"", ""  Breast cellulitis 0/25 (0.00%)"", ""  Syncope 1/25 (4.00%)""]",Contradiction
The majority of patients in NCT01705691 suffered from Kidney stones.,"[""Adverse Events 1:"", ""  Total: 3/19 (15.79%)"", ""  Febrile neutropenia 1/19 (5.26%)"", ""  Colitis 1/19 (5.26%)"", ""  Pain in extremity 0/19 (0.00%)"", ""  Nephrolithiasis 0/19 (0.00%)"", ""  Pulmonary embolism 1/19 (5.26%)"", ""  Dyspnoea 0/19 (0.00%)"", ""  Haematoma 0/19 (0.00%)"", ""Adverse Events 2:"", ""  Total: 4/30 (13.33%)"", ""  Febrile neutropenia 1/30 (3.33%)"", ""  Colitis 0/30 (0.00%)"", ""  Pain in extremity 1/30 (3.33%)"", ""  Nephrolithiasis 1/30 (3.33%)"", ""  Pulmonary embolism 0/30 (0.00%)"", ""  Dyspnoea 1/30 (3.33%)"", ""  Haematoma 1/30 (3.33%)""]",Contradiction
"A patient has recently been receiving Tamoxifen to treat breast cancer, they are excluded from NCT02010021.","[""Exclusion Criteria:"", ""  Prior endocrine therapy for any histologically confirmed cancer is not allowed. Prior endocrine therapy that was administered  5 years ago for the prevention of breast cancer in patients with no history of breast cancer is allowed.""]",Entailment
Several patients in the Eribulin Mesylate group in NCT00337103 survived less than a year.,"[""Outcome Measurement: "", ""  Overall Survival (OS)"", ""  OS was measured from the date of randomization until the date of death from any cause, or the last date the participant was known to be alive. Participants who were lost to follow-up or who were alive at the date of data cutoff were censored. The censoring rules for OS were as follows: 1) if the participant was still alive at data cutoff, the date of data cutoff was considered the end date, and 2) if the participant was lost to follow-up before data cutoff, the date they were last known to be alive was considered the end date. Participants who survived past the end of the study were counted as in the full study period. If death occurred after data cutoff, the end date was to be censored at the time of data cutoff."", ""  Time frame: From date of randomization until date of death from any cause, assessed up to data cutoff date of 12 Mar 2012, or up to approximately 6 years"", ""Results 1: "", ""  Arm/Group Title: Eribulin Mesylate 1.4 mg/m^2"", ""  Arm/Group Description: Eribulin mesylate 1.4 mg/m^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days."", ""  Overall Number of Participants Analyzed: 554"", ""  Median (95% Confidence Interval)"", ""  Unit of Measure: days  484        (462 to 536)""]",Contradiction
"Adequate blood, kidney, and hepatic function are required to participate in NCT02536339, however this condition is not specified in NCT00213980.","[""Inclusion Criteria:"", ""  Postmenopausal women, Stage III or axillary node positive"", ""  Currently disease free of breast cancer and other invasive malignancies at the time of registration"", ""  No concurrent use of bisphosphonates"", ""Exclusion Criteria:"", ""Metastatic disease""]",Entailment
At least one patient in NCT00082641 suffered from impaired mobility.,"[""Adverse Events 2:"", ""  Hip fracture 1/12 (8.33%)""]",Entailment
Women of any age can participate in NCT00356148 and NCT01856543.,"[""Inclusion Criteria:"", ""  Women at any age with early stage breast cancer (stage I-II) and American Society of Anesthesiologists (ASA) score of I-II.""]",Contradiction
Men with Left ventricular ejection fraction > 50% are excluded from participating in NCT00331630.,"[""  LVEF  50% as measured by echocardiogram or MUGA scan"", ""  Male or female""]",Contradiction
1 patient in NCT00546104 suffered from a blood clot blocking their blood vessels.,"[""Adverse Events 1:"", ""  Total: 10/31 (32.26%)"", ""  Edema, limb 1/31 (3.23%)"", ""  Thrombosis1/31 (3.23%)"", ""  diarrhea1/31 (3.23%)"", ""  Pain 2/31 (6.45%)"", ""  Pain, back1/31 (3.23%)"", ""  Pain, extrimity limb 1/31 (3.23%)"", ""  Syncope 1/31 (3.23%)"", ""  Pain, chest/thorax1/31 (3.23%)"", ""  hyponatremia 1/31 (3.23%)"", ""  fever1/31 (3.23%)"", ""  AST 1/31 (3.23%)"", ""  infection1/31 (3.23%)"", ""  Anorexia 1/31 (3.23%)"", ""  Dyspnea 2/31 (6.45%)""]",Entailment
People who inherit undamaged variants of the BReast CAncer gene 1 or 2 are eligible for NCT01525589.,"[""Inclusion Criteria:"", ""  Known deleterious germline mutation of BRCA1/2 (Patients in Cohorts A and A1)""]",Contradiction
Patients with Cancer that has spread from a breast tumor to their bone marrow are excluded from NCT00004092.,"[""  No histologically proven bone marrow metastasis""]",Entailment
A patient with severe anginal syndrome but angiographically normal coronary arteries would be unable to participate in NCT00054275.,"[""  No New York Heart Association class III or IV heart disease"", ""  No unstable angina pectoris""]",Entailment
There were more cases of embolisms in cohort 2 of NCT00129935 than cohort 1.,"[""Adverse Events 1:"", ""  Total: 111/669 (16.59%)"", ""  Leukocytes *  [1]1/669 (0.15%)"", ""  Hemoglobin *  [1]1/669 (0.15%)"", ""  Hemoglobin *  [2]0/669 (0.00%)"", ""  CNS cerebrovascular ischemia *  [1]0/669 (0.00%)"", ""  CNS cerebrovascular ischemia *  [3]0/669 (0.00%)"", ""  Heart Failure *  [1]3/669 (0.45%)"", ""  Thrombosis/embolism *  [1]1/669 (0.15%)"", ""  Thrombosis/embolism *  [3]0/669 (0.00%)"", ""Adverse Events 2:"", ""  Total: 138/715 (19.30%)"", ""  Leukocytes *  [1]0/715 (0.00%)"", ""  Hemoglobin *  [1]0/715 (0.00%)"", ""  Hemoglobin *  [2]1/715 (0.14%)"", ""  CNS cerebrovascular ischemia *  [1]1/715 (0.14%)"", ""  CNS cerebrovascular ischemia *  [3]1/715 (0.14%)"", ""  Heart Failure *  [1]1/715 (0.14%)"", ""  Thrombosis/embolism *  [1]3/715 (0.42%)"", ""  Thrombosis/embolism *  [3]2/715 (0.28%)""]",Entailment
There were no patients in either cohort of NCT00022672 with a PFS exceeding 6 months.,"[""Outcome Measurement: "", ""  Progression Free Survival (PFS)"", ""  PFS was assessed by the investigator based on World Health Organization (WHO) criteria using radiographic tumor evaluations. Disease progression was defined as the appearance of any new lesion not previously identified or an estimated increase of 25% or more in existent bidimensionally or unidimensionally measurable lesions or progression of an existing non-measurable lesion. For bidimensionally measurable malignant lesions with an area of at least 2.0 centimeters squared (cm^2) an increase of 1.0 cm^2 was required and for unidimensionally measurable lesions of 1.0 cm or less an increase of 0.5 cm was required. PFS was defined as the number of days between date of randomization and date of documented disease progression or date of death. Kaplan Meier estimates of PFS are presented."", ""  Time frame: 24 Months, End of Study (Up to 5 years)"", ""Results 1: "", ""  Arm/Group Title: Trastuzumab + Anastrozole"", ""  Arm/Group Description: Trastuzumab 4 mg/kg loading dose intravenous (iv) over 90 minutes, followed by weekly doses of 2 mg/kg iv over 30 minutes plus 1 mg oral dose of anastrozole every day for 24 Months in the Main phase and in the Extension Phase."", ""  Overall Number of Participants Analyzed: 103"", ""  Median (95% Confidence Interval)"", ""  Unit of Measure: Months  24 Months: 4.8        (3.7 to 7)"", ""  End of Study: 5.8        (4.6 to 8.3)"", ""Results 2: "", ""  Arm/Group Title: Anastrozole"", ""  Arm/Group Description: 1 mg oral dose of anastrozole every day for 24 Months in the Main phase. In the Extension Phase participants could cross-over to also receive trastuzumab 4 mg/kg initial loading dose intravenous (iv) over 90 minutes, followed by weekly doses of 2 mg/kg iv over 30 minutes."", ""  Overall Number of Participants Analyzed: 104"", ""  Median (95% Confidence Interval)"", ""  Unit of Measure: Months  24 Months: 2.4        (2 to 4.6)"", ""  End of Study: 2.9        (2.1 to 4.5)""]",Contradiction
"One patient in NCT03012477 experienced a thromboembolic event, a condition associated with a high degree of morbidity and mortality. However, the most common adverse event was Anemia.","[""Adverse Events 1:"", ""  Total: 13/34 (38.24%)"", ""  Anemia 3/34 (8.82%)"", ""  Diarrhea 7/34 (20.59%)"", ""  Nausea 2/34 (5.88%)"", ""  Sepsis 1/34 (2.94%)"", ""  Urinary tract infection 1/34 (2.94%)"", ""  Alkaline phosphatase increased 1/34 (2.94%)"", ""  Neutrophil count decreased 2/34 (5.88%)"", ""  Dehydration 1/34 (2.94%)"", ""  Headache 1/34 (2.94%)"", ""  Thromboembolic event 1/34 (2.94%)""]",Contradiction
There were no cases of Multi-Organ Failure in both cohort 1 of NCT00454805 and cohort 1 of NCT00499122.,"[""Adverse Events 1:"", ""  Total: 27/41 (65.85%)"", ""  Febrile Neutropenia 4/41 (9.76%)"", ""  Neutropenia 1/41 (2.44%)"", ""  Deep Vein Thrombosis 1/41 (2.44%)"", ""  Pulmonary embolism 1/41 (2.44%)"", ""  Femoral Artery occlusion 1/41 (2.44%)"", ""  Abdominal Pain 2/41 (4.88%)"", ""  Constipation 1/41 (2.44%)"", ""  Fatigue 2/41 (4.88%)"", ""  Headache 1/41 (2.44%)"", ""  Nausea 1/41 (2.44%)"", ""  Cellulitis 1/41 (2.44%)"", ""  Muscular Weakness 1/41 (2.44%)""]",Entailment
"In total, across both cohorts of NCT00934856, there were at least 2 patients with a fever.","[""Adverse Events 1:"", ""  Total: 2/6 (33.33%)"", ""  Febrile neutropenia * 1/6 (16.67%)"", ""  Neutropenia * 0/6 (0.00%)"", ""  Thrombocytopenia * 1/6 (16.67%)"", ""  Diarrhoea * 0/6 (0.00%)"", ""  Pyrexia * 0/6 (0.00%)"", ""  Thrombosis in device * 1/6 (16.67%)"", ""  Fatigue * 0/6 (0.00%)"", ""  Mucosal inflammation * 0/6 (0.00%)"", ""  Device deployment issue * 0/6 (0.00%)"", ""  Hepatocellular injury * 1/6 (16.67%)"", ""  Cholecystitis * 1/6 (16.67%)"", ""Adverse Events 2:"", ""  Total: 2/6 (33.33%)"", ""  Febrile neutropenia * 1/6 (16.67%)"", ""  Neutropenia * 1/6 (16.67%)"", ""  Thrombocytopenia * 0/6 (0.00%)"", ""  Diarrhoea * 0/6 (0.00%)"", ""  Pyrexia * 0/6 (0.00%)"", ""  Thrombosis in device * 1/6 (16.67%)"", ""  Fatigue * 0/6 (0.00%)"", ""  Mucosal inflammation * 0/6 (0.00%)"", ""  Device deployment issue * 0/6 (0.00%)"", ""  Hepatocellular injury * 0/6 (0.00%)"", ""  Cholecystitis * 0/6 (0.00%)""]",Entailment
80% of patients in NCT00398567 did not suffer any adverse events.,"[""Adverse Events 1:"", ""  Total: 1/4 (25.00%)""]",Contradiction
Candidates with hyperparathyroidism are automatically excluded from NCT00656019 and NCT00328783.,"[""EXCLUSION CRITERIA:"", ""  History of parathyroid disease, hypercalcemia, or kidney stones.""]",Contradiction
"A female with Hemoglobin > 10.0 g/dl, Absolute neutrophil count 1,733/mm3, platelet count = 100,000/µl and total bilirubin > 1.6 x ULN are eligilbe for NCT00101400.","[""  Hemoglobin > 9.0 g/dl"", ""  Absolute neutrophil count (ANC) > 1,500/mm3"", ""  Platelet count = 100,000/\u00b5l"", ""  Total bilirubin =1.5 x the upper limit of normal.""]",Entailment
"Patients with any of the following conditions will be excluded from NCT00825734; grade 1 infection, unstable angina or a grade 4 hemorrhage within the last month.","[""  Exclusion Criteria"", ""  Uncontrolled intercurrent illness including (but not limited to)"", ""  ongoing or active infection >grade 2."", ""  Unstable angina (anginal symptoms at rest) or new onset angina"", ""  Pulmonary hemorrhage or bleeding event  grade 2 within"", ""  4 weeks of the first dose of study treatment, or any other"", ""  hemorrhage or bleeding event  grade 3 within 4 weeks of the"", ""  first dose of study treatment.""]",Contradiction
4 patients in NCT00258960 experienced a grade 3 or above adverse event.,"[""Adverse Events 1:"", ""  Total: 16/48 (33.33%)"", ""  Febrile neutropenia grade 3 3/48 (6.25%)"", ""  Neutropenia grade 3 1/48 (2.08%)"", ""  Holocraneal cephalea 1/48 (2.08%)"", ""  Hypersensibility reaction grade 3 2/48 (4.17%)"", ""  Palmoplantar erythrodysesthesia grade 3, stomatitis grade 3 1/48 (2.08%)"", ""  Neutropenia grade 4, fever grade 1, oral mucositis grade 3 1/48 (2.08%)"", ""  Catheter - related infection grade 3 1/48 (2.08%)""]",Contradiction
One patient in NCT00201864 had a WBC count far below normal.,"[""Adverse Events 1:"", ""  Total: 6/40 (15.00%)"", ""  Nausea 1/40 (2.50%)"", ""  Vomiting 1/40 (2.50%)"", ""  Chest pain 1/40 (2.50%)"", ""  Hypercalcemia 1/40 (2.50%)"", ""  Thromboembolism 2/40 (5.00%)""]",Contradiction
There is 1 case (1.45%) of thrombocytopenia in NCT02015676.,"[""Adverse Events 1:"", ""  Total: 26/69 (37.68%)"", ""  Thrombophlebitis * 1/69 (1.45%)"", ""  Anaemia NOS * 1/69 (1.45%)"", ""  Acute febrile neutrophilic dermatosis * 1/69 (1.45%)"", ""  Cardiac failure NOS * 2/69 (2.90%)"", ""  Ejection fraction decreased * 1/69 (1.45%)"", ""  Intestinal obstruction NOS * 1/69 (1.45%)"", ""  Diarrhoea NOS * 2/69 (2.90%)"", ""  Febrile neutropenia * 12/69 (17.39%)"", ""  Mucosal inflammation NOS * 1/69 (1.45%)""]",Contradiction
"Participants with HER2- primary liver tumors, confirmed by fluorescence in-situ hybridization are eligible for NCT00274768 and NCT00703326.","[""Inclusion Criteria:"", ""  Participant has histologically or cytologically confirmed adenocarcinoma of the breast that is now metastatic or locally-recurrent and inoperable with curative intent. Every effort should be made to make paraffin-embedded tissue or slides from the diagnostic biopsy or surgical specimen available for confirmation of diagnosis"", ""  Participants' primary and/or metastatic tumor is human epidermal growth factor receptor 2 (HER2)-negative by fluorescence in-situ hybridization (FISH) or chromogenic in-situ hybridization (CISH) or 0, 1+ overexpression by immunohistochemistry (IHC)""]",Contradiction
"In NCT00190671 cohort 2 had more patients with Leukopenia than cohort 1, whereas in NCT00455533 cohort 1 had more than cohort 2. Cohort 2 of NCT00190671 had the highest proportion of patients with leukopenia.","[""Adverse Events 1:"", ""  Leukopenia 0/42 (0.00%)"", ""Adverse Events 2:"", ""  Leukopenia 2/61 (3.28%)""]",Entailment
A minimum bodyweight of 50kg is required to participate in NCT00304096.,"[""  Body weight > 110 lbs (without clothes)""]",Entailment
The median TTP in cohort one of NCT00534417 is just under 27 months.,"[""Outcome Measurement: "", ""  Time to Progression (TTP)"", ""  Time to progression is defined as the time from treatment start until objective tumor progression. Progression is defined per Response Evaluation Criteria in Solid Tumors (RECIST)v1.0 guidelines as a measurable increase in the smallest diameter of any target lesion, progression of existing non-target lesions, or the appearance of 1 or more new lesions. The median time to progression is the parameter used to describe TTP."", ""  Time frame: TTP was measured from day 1 of treatment until time of progression (assessed every 8 weeks), up to 29 months."", ""Results 1: "", ""  Arm/Group Title: Capecitabine and Fulvestrant"", ""  Arm/Group Description: Capecitabine will be given on a continuous basis at a total dose of 1500 mg, given as 1000 mg po AM and 500 mg po PM in patients of body weight < 80 kg, and at a total dose of 2000 mg given as 1000 mg po bid in patients with a body weight of   80 kg."", ""  Fulvestrant will be given at 500 mg on Day 1 followed by 250 mg on Days 15 and 29, then 250 mg every 28 days."", ""  Overall Number of Participants Analyzed: 41"", ""  Median (95% Confidence Interval)"", ""  Unit of Measure: Months  26.94  [1]    (7.26 to NA)""]",Entailment
"Unlike NCT00479674, NCT01252290 does not record any instances of Anemia, Dyspepsia, Nausea or vomiting.","[""Adverse Events 1:"", ""  Total: 2/35 (5.71%)"", ""  Gastroesophageal reflux disease * 1/35 (2.86%)"", ""  Ductal carcinoma in situ * 1/35 (2.86%)""]",Entailment
NCT01086605 and NCT00570921 do not record any of the same adverse events.,"[""Adverse Events 1:"", ""  Total: 3/24 (12.50%)"", ""  Disseminated intravascular coagulation 0/24 (0.00%)"", ""  Death NOS 0/24 (0.00%)"", ""  Edema limbs 0/24 (0.00%)"", ""  Fatigue 0/24 (0.00%)"", ""  Hepatic failure 1/24 (4.17%)"", ""  Alanine aminotransferase increased 1/24 (4.17%)"", ""  Aspartate aminotransferase increased 1/24 (4.17%)"", ""  Blood bilirubin increased 0/24 (0.00%)"", ""  Ejection fraction decreased 1/24 (4.17%)"", ""Adverse Events 2:"", ""  Total: 9/22 (40.91%)"", ""  Disseminated intravascular coagulation 1/22 (4.55%)"", ""  Death NOS 1/22 (4.55%)"", ""  Edema limbs 1/22 (4.55%)"", ""  Fatigue 1/22 (4.55%)"", ""  Hepatic failure 0/22 (0.00%)"", ""  Alanine aminotransferase increased 0/22 (0.00%)"", ""  Aspartate aminotransferase increased 1/22 (4.55%)"", ""  Blood bilirubin increased 1/22 (4.55%)"", ""  Ejection fraction decreased 1/22 (4.55%)""]",Entailment
There were no cases of Pneumopathy in either NCT02402764 or NCT00490646.,"[""Adverse Events 1:"", ""  Total: 3/10 (30.00%)"", ""  Sinus tachycardia * 1/10 (10.00%)"", ""  Blurred vision * 1/10 (10.00%)"", ""  Memory impairment * 1/10 (10.00%)"", ""  Dyspnea * 2/10 (20.00%)""]",Entailment
"Emily has an Inoperable non-metastatic breast cancer, she is eligible for both NCT01644890 and NCT00996632.","[""Inclusion Criteria:"", ""  Inoperable breast cancer""]",Contradiction
Patients eligible for NCT02964234 must live in the USA.,"[""Inclusion Criteria:"", ""  Age 52-75 years old;"", ""  Identification as Latina/Hispanic/Chicana female;"", ""  Residence in Pilsen, Little Village, East Side or South Chicago;""]",Entailment
There were more cases of deteriorating mental health in NCT00323479 than NCT03078751.,"[""Adverse Events 1:"", ""  Total: 6/110 (5.45%)"", ""  Sudden death unexplained 1/110 (0.91%)"", ""  General body pain 1/110 (0.91%)"", ""  Lymphangitis 1/110 (0.91%)"", ""  Femur fracture 1/110 (0.91%)"", ""  Parathyroid adenoma 1/110 (0.91%)"", ""  Depression worsened 1/110 (0.91%)"", ""  Calculus urinary bladder 1/110 (0.91%)"", ""  Pneumopathy 1/110 (0.91%)""]",Entailment
"Patients with Myocardial Infarction,percutaneous transluminal coronary angioplasty or Deep vein thrombosis within the last 2 - 6 months are eligible for NCT01326481.","[""Exclusion Criteria:"", ""  Angina, MI, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, arterial embolism, pulmonary embolism, DVT, PTCA or CABG within the past 6 months""]",Contradiction
"Women with leptomeningeal metastases are unfortunately excluded from NCT00627978, as this would complicate the evaluation of neurologic and other adverse events.","[""  Exclusion Criteria"", ""  Patients with known and active brain and/or leptomeningeal metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.""]",Entailment
More than 3 patients in NCT01421472 suffered from adverse events associated with a low number of white blood cells.,"[""Adverse Events 1:"", ""  Febrile Neutropenia * 5/67 (7.46%)""]",Entailment
"Asian, white british and white irish women are eligible for NCT02692755, as long as they do not have uncontrolled or symptomatic brain metastases.","[""Inclusion Criteria:"", ""  Self-identified Black, African or African American women of  18 years of age with proven diagnosis of advanced adenocarcinoma of the breast (locoregionally recurrent or metastatic disease)"", ""Exclusion Criteria:"", ""  Current use of food or drugs known to be potent inhibitors or inducers of CYP3A4"", ""  Active uncontrolled or symptomatic brain metastases. Previously treated and clinically stable, as per Investigator's judgment, brain metastases are permitted.""]",Contradiction
"Adequate hematologic, renal, and hepatic function are required to participate in NCT02536339 and NCT00213980, however, patients with severe loss in cognitive function are still eligible.","[""Inclusion Criteria:"", ""  Postmenopausal women, Stage III or axillary node positive"", ""  Currently disease free of breast cancer and other invasive malignancies at the time of registration"", ""  No concurrent use of bisphosphonates"", ""Exclusion Criteria:"", ""Metastatic disease""]",Contradiction
"NCT00696072 uses Overall Survival (OS) as outcome measurement, which is different from Proportion of Participants With a Pathologic Complete Response Rate which is used for NCT01855828.","[""Outcome Measurement: "", ""  Proportion of Participants With a Pathologic Complete Response Rate"", ""  To estimate the pathologic complete response rate (pCR) when pertuzumab is added to weekly trastuzumab/paclitaxel followed by trastuzumab/5-fluorouracil, epirubicin and cyclophosphamide neoadjuvant chemotherapy in HER2-positive breast cancer. This study will assess pCR rates separately in ER+ and ER- cancers. Pathologic complete response is defined as no evidence of viable invasive tumor cells at the primary tumor site and axillary lymph nodes in the surgical specimen. Residual Disease (RD) is defined as: Any invasive cancer in the breast or axillary lymph nodes in the surgical specimen."", ""  Time frame: 20 weeks""]",Contradiction
NCT00320541 recorded more cardiac related adverse events than NCT01629615.,"[""Adverse Events 1:"", ""  Total: 17/50 (34.00%)"", ""  Fatigue  4/50 (8.00%)"", ""  Papulopustular rash  1/50 (2.00%)"", ""  Alanine aminotransferase increased  5/50 (10.00%)"", ""  Aspartate aminotransferase increased  4/50 (8.00%)"", ""  Alkalosis  1/50 (2.00%)"", ""  Anorexia  1/50 (2.00%)"", ""  Hyperglycemia  2/50 (4.00%)"", ""  Nervous system disorders - Other  1/50 (2.00%)"", ""  Dry skin  1/50 (2.00%)"", ""  Rash acneiform  1/50 (2.00%)""]",Contradiction
There were 2 cases of Angina in NCT02370238.,"[""Adverse Events 1:"", ""  Total: 13/61 (21.31%)"", ""  Anaemia 1/61 (1.64%)"", ""  Febrile neutropenia 1/61 (1.64%)"", ""  Cardiac failure congestive 0/61 (0.00%)"", ""  Pericardial effusion 0/61 (0.00%)"", ""  Constipation 1/61 (1.64%)"", ""  Intestinal perforation 1/61 (1.64%)"", ""  Stomatitis 0/61 (0.00%)"", ""  Non-cardiac chest pain 2/61 (3.28%)"", ""  Condition aggravated 1/61 (1.64%)"", ""  General physical health deterioration 1/61 (1.64%)"", ""Adverse Events 2:"", ""  Total: 12/60 (20.00%)"", ""  Anaemia 1/60 (1.67%)"", ""  Febrile neutropenia 0/60 (0.00%)"", ""  Cardiac failure congestive 1/60 (1.67%)"", ""  Pericardial effusion 1/60 (1.67%)"", ""  Constipation 0/60 (0.00%)"", ""  Intestinal perforation 0/60 (0.00%)"", ""  Stomatitis 1/60 (1.67%)"", ""  Non-cardiac chest pain 0/60 (0.00%)"", ""  Condition aggravated 0/60 (0.00%)"", ""  General physical health deterioration 1/60 (1.67%)""]",Contradiction
"NCT00645333 records several central nervous system related adverse events in its patients, whereas NCT00006110 does not.","[""  Autoimmune disorder *1/30 (3.33%)"", ""  Immune system disorder *1/30 (3.33%)""]",Contradiction
"Cohort 1 of NCT00493636 had a longer median, maximum and minimum pfs than cohort 2.","[""Outcome Measurement: "", ""  Progression Free Survival"", ""  [Not Specified]"", ""  Time frame: From the date of randomization to date of first documented disease progression (i.e., the date on which a radiologic procedure or clinical evaluation was performed) or the date of death due to any cause, if before progression, assessed up to 39 months."", ""Results 1: "", ""  Arm/Group Title: A (Sorafenib + Gemcitabine or Capecitabine)"", ""  Arm/Group Description: Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours); Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle; Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine)"", ""  Gemcitabine: Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle"", ""  Sorafenib: Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours)"", ""  Capecitabine: Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine)."", ""  Overall Number of Participants Analyzed: 81"", ""  Median (95% Confidence Interval)"", ""  Unit of Measure: Days  103        (83 to 128)"", ""Results 2: "", ""  Arm/Group Title: B (Placebo + Gemcitabine or Capecitabine)"", ""  Arm/Group Description: Placebo will be administered ( 2 tablets ) orally twice daily (approximately every 12 hours); Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle; Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine)"", ""  Gemcitabine: Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle"", ""  Placebo: Placebo will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours)"", ""  Capecitabine: Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine)."", ""  Overall Number of Participants Analyzed: 79"", ""  Median (95% Confidence Interval)"", ""  Unit of Measure: Days  81        (48 to 95)""]",Entailment
